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Abstract
This thesis examines the use of protein engineering to create antibody-based molecules 
for cancer treatment. The targeting unit used for these molecules was the single chain Fv 
antibody fragment MFE-23, which is directed against the tumour-associated marker 
carcinoembryonic antigen (CEA). It was hypothesised that implementation of molecular 
design features such as humanisation, high affinity, multivalency and mannose 
glycosylation to accelerate systemic clearance would result in the favourable in vivo 
performance of the molecules. Bioinformatic and recombinant approaches were applied to 
test this hypothesis.
First the molecular interaction between the MFE-23 and its cognate antigen, CEA, was 
investigated. A recombinant form of the N-terminal N-Al domain pair of CEA was 
expressed in bacteria and its specific interaction with MFE-23 was confirmed. Mass 
spectrometry in combination with proteolysis of the MFE-23/ CEA (N-Al) complex was 
used to obtain detailed sequence information on the putative region where MFE-23 binds to 
CEA, supporting structural predictions and the future design of MFE-23-based molecules.
A series of divalent MFE-based molecules were then created. These were genetically 
linked by polypeptide chains or human serum albumin (HSA). A humanised, high affinity 
version of MFE-23 (Ml Ob) was also investigated as part of the molecular design. In vivo 
studies demonstrated that the MIOb-HSA assemblies, termed HSAbodies, specifically 
localised to tumour cells whilst clearing rapidly from normal tissues, resulting in improved 
tumour: tissue ratios compared to an anti-CEA IgG and higher overall uptake in tumour 
compared to monovalent MFE-23. Glycosylation sites were engineered into the HSA 
linker, which resulted in accelerated systemic clearance, further improving tumour: tissue 
ratios. The combination of functional affinity and controllable clearance resulted in a 
superior CEA-targeting molecule. These results support the proposed hypothesis and 
suggest a clear therapeutic and diagnostic potential for HSAbodies in both native and 
glycosylated form.
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1.1 Cancer
Cancer is a collection of diseases characterised by abnormal cell growth which results 
in cells that have the ability to overrun the surrounding tissue, leading to the formation of 
secondary tumours (metastases) at other sites in the body. The stimuli that convert a 
normal cell into a cancerous cell are still not fully understood. What is clear is that their 
development (carcinogenesis) is a complex multi-step process resulting from the 
accumulation of errors in vital regulatory pathways of the genetic material of the cell. 
Carcinogenesis is initiated in a single cell, which then multiplies and acquires additional 
changes that give it a survival advantage over its neighbours, a phenomenon that continues 
during the cancer’s development. The proliferation of normal cells is regulated by both 
inhibitory (tumour suppressor) and stimulatory (proto-oncogenic) molecules (Fearon & 
Vogelstein, 1990). The conversion to a malignant genotype can result from amplification 
or over-activation of one of the two copies of a proto-oncogene or from loss or inactivation 
of both copies of a tumour suppressor gene. These initial errors may arise through genetic 
predisposition, viral attack, or through irradiative, chemical, or other carcinogenic 
mechanisms.
The process by which cancer cells escape from their local environment, invade their 
surroundings, and metastasise to remote sites in order to establish new tumours, represents 
the fundamental differences between benign and malignant growth. The metastatic process 
is unique to malignant tumours and a series of steps must be successfully completed to give 
rise to a metastatic tumour (Figure 1.1). First, malignant cells from a primary tumour 
invade adjacent blood vessels and lymphatics and embolise through the circulation in a 
process known as intravasation (Wyckoff et al, 2000). Second, the cells must survive 
immune detection in the circulation, stop and implant in the capillary bed of a new organ. 
Finally, the cells extravasate through the endothelium to establish themselves in the 
surrounding tissue and initiate maintenance of growth and vascularisation of the metastatic 
tumour (angiogenesis) (Fidler & Kripke, 1977; Fidler, 1978; Poste & Fidler, 1980; Fidler & 
Hart, 1982). Angiogenesis is initiated by increased secretion of mitogenic growth factors 
such as platelet-derived growth factor, fibroblast growth factor, and vascular endothelial 
growth factor (Folkman, 1992; Woodhouse et al, 1997; Chambers et al, 2000). Their
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Figure 1.1. The metastatic process, (a) Malignant cells from an established tumour site invade adjacent blood 
vessels and lymphatics and embolise through the circulation in a process known as intravasation. (b) The cells 
arrest in circulation and extravasate through the endothelium, where they establish themselves in the 
surrounding tissue and initiate angiogenesis for the formation o f a new metastatic site. Adapted from 
Chambers et al, 2002.
production is upregulated in cancer cells and in normal cells which are in regions of low 
oxygen (hypoxia).
1.1.1 Treatment of cancer
Cancer, which affects one in three of the population, represents the second most 
common cause of death in the western world (www.cancerresearchuk.org). The 
fundamental challenge in treating cancer has been to remove malignant cells without 
affecting normal cells, an approach that has not yet been realised. The objective of all 
current cancer treatments is to maximise the effects on the cancer whilst minimising the 
adverse side effects on normal tissues. These approaches are based on the prevention of 
proliferating cancerous cells (cytostatic effect) and the removal / or killing of cancerous 
cells (cytotoxic effect).
For established cancers, surgical removal of the tumour mass is the first approach, 
although cancers of blood cells, leukaemia, and solid tumours that have metastasised to
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inaccessible sites such as bone and brain are not amenable to this form of treatment. For 
this reason, adjuvant anti-cancer treatments were introduced, the majority of which are 
based on drugs designed to prevent cell growth.
Conventional chemotherapies rely on the altered proliferation rates of malignant cells 
compared to normal cells. They work by disrupting DNA synthesis and cell division 
through mechanisms common to all cells. However, this can lead to increased toxicities 
against normal cells that have rapid proliferation rates, such as those of the bone marrow, 
gastrointestinal tract, and hair follicles. Side effects that occur because of toxicity to these 
tissues can result in the administration of sub-curative doses being given, which in turn lead 
to the subsequent failure of the therapy as well as drug resistance and the development of 
metastatic disease.
Another widely used adjuvant treatment is radiotherapy. In this system, ionising 
radiations are directed at cells to generate reactive oxygen species. These, in turn, produce 
single and double DNA-strand breaks which result in cell death. However, cells differ in 
their inherent sensitivity to radiotherapy and this influences the responses obtained.
Tumour environment also affects the success of radiotherapy as hypoxic regions within the 
tumour are radioresistant (Sagar et al, 1983). Furthermore, doses of radiation that can be 
used are limited due to toxicity in normal cells, primarily in the bone marrow. However, 
the major limitation of using conventional radiotherapy is treating an essentially systemic 
disease with a local treatment and dissemination of cancer cells make it impossible to 
deliver radiation to cell deposits without also affecting large volumes of normal tissue. 
Furthermore, only known tumours can be treated leaving undetected metastases unaffected.
1.1.2 Selective targeting of cancer
Improvements to the selective toxicity of a cancer therapy can be achieved by either 
increasing the dose to cancerous tissues or decreasing the dose to normal tissues. Newer 
methods for the treatment of cancer are aimed at selectively targeting the therapeutic 
moiety to the cancer cells by exploiting differences between normal and malignant cells.
For example, one approach is to prevent the growth of new tumour sites through
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interruption of angiogenesis, a vital step in the metastatic process that is specific to cancers 
and governed by its own control mechanisms (Klohs & Hamby, 1999).
Another method to selectively deliver therapies to cancer cells is to use antibodies as 
mediators of cytotoxicity by stimulating the natural effector mechanisms of the host, or by 
blocking receptors. They can also be used as vehicles for the delivery of drugs, toxins, or 
radionuclides. The antibody acts as a 'guided missile' to selectively deliver the ‘payload’ to 
cancer cells or cancer associated cells such as tumour vasculature. A major advantage of 
antibodies over other forms of treatment is their selectivity. The therapeutic moiety is 
cleared from normal cells but retained in diseased cells through the antibodies’ association 
with molecular markers, either uniquely expressed or over-expressed on target cells relative 
to normal tissues, or by accessibility of antigen through the abnormal morphology as a 
result of tumour spread. Furthermore, due to the antibodies’ ability to recognise tumour- 
associated antigens that are expressed at higher densities on malignant cells than on normal 
cells, the antibody, and the therapeutic moiety it is targeting, is concentrated at the site of 
malignant tissue relative to other tissues.
1.2 Antibodies and their use in cancer therapy
The idea that antibodies could be used to discriminate between cancerous and normal 
tissues was proposed as early as 1890 by Behring (MacNalty et al, 1954). Soon after in 
1895, further investigations by Hericourt and Richet showed that patients responded to 
treatment with serum from animals that had been immunised with an osteosarcoma.
Several years later, Ehrlich described antibodies as ‘magic bullets’ for their ability to seek 
out and destroy their target without any detrimental effect to the host (Ehrlich, 1913). 
However, widespread use of antibodies for cancer targeting was limited until 1975 when 
the potential to generate unlimited supplies of monoclonal antibodies raised against specific 
antigen became available due to the development of hybridoma technology (Kolher & 
Milstein, 1975).
Initial studies using murine antibodies as cancer therapeutics encountered many 
problems and as a result, treatment with unmodified antibodies had few successful clinical 
outcomes. These early clinical disappointments may be attributed to several factors. In
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most cases, small quantities of material were administered, which were not sufficient to 
produce a therapeutic response. The antibodies had very short half-lives and were often 
highly immunogenic, resulting in human anti-mouse antibodies (HAMA) after repeated 
treatments (Shawler et al, 1985; Miller et al, 1983; Schroff et al, 1985; Khazaeli et al, 
1994). The importance of antibody specificity for antigen was underestimated and this, 
together with inappropriate targets, contributed to unsatisfactory therapies. In addition, the 
antibodies showed poor tumour penetration and retention (Jones et al, 1986). To 
overcome these limitations, alternative strategies were developed to improve the tumour 
targeting potential of antibodies. The tumour microenvironment was investigated to 
elucidate the mechanisms restricting antibody penetration and the search for new tumour- 
associated antigens was initiated {see 1.4). In addition, the antibodies themselves were 
manipulated to improve specificity and reduce immunogenicity {see 1.3).
1.2.1 Antibody structure
In order to deal with the vast assortment of antigenic molecules presented, the immune 
system has evolved a method of producing antigen recognition molecules, which share 
certain effector functions whilst at the same time having an immense diversity of antigen 
specificities. Antibodies, produced by B-lymphocytes and forming the soluble receptor of 
B-cell recognition of antigen, are bi-functional molecules comprised of an antigen-binding 
half and an immunological effector half, and form an integral part of the immune defence 
system.
The antibody molecule has a basic four-peptide structure of two heavy (H) and two 
light (L) polypeptide chains (Porter, 1962; Edelman, 1975; Poulik 1961). The five classes 
of immunoglobulin IgM, IgG, IgD, IgA and IgE are defined by differences in their heavy 
chains (isotypes); p, y, 6, a , e respectively. The heavy chain also determines the subclass 
of an immunoglobulin. For example, there are four human IgG subclasses; IgGl, IgG2, 
IgG3, IgG4, with heavy chains termed yl, y2, y3, and y4 respectively, whose heavy chains 
differ slightly but are all of the same y-isotype. There are also two light chain isotypes, k  
and X. Antibodies of each isotype differ in size, charge, amino acid sequence, and 
carbohydrate content as well as in function.
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As a targeting molecule, by far the most widely used class of antibody is IgG (Figure 
1.2a). In the IgG format, the H and L chains consist of two antiparallel P-sheets linked 
together by an intramolecular disulphide bond (Poljak, 1973), characteristic to all 
immunoglobulin-fold molecules (Williams & Barclay, 1988). The heavy and light chains 
are further divided into variable (V) and constant (C) regions (Dreyer & Bennet, 1965; 
Hilschmann & Craig, 1965) and are folded into globular domains (Poljak, 1973). The V 
regions, located at the amino-terminus of both the heavy and light chains, comprise the 
antigen-binding face of the antibody. This unique surface for the specific recognition of 
antigen is formed by six hypervariable loops, termed complementarity-determining regions 
(CDRs), three of which are located in the VH domain and three of which are in the Vl 
domain, and is highly variable in length and sequence (Wu & Kabat, 1970; Kabat & Wu, 
1971). Intervening sections of the V domains form the framework regions (FR). The 
effector functions of the antibody (e.g. complement fixing and immunoglobulin receptor 
binding motifs) are found in the carboxy-terminal C regions.
The IgG molecule has an exposed hinge region that is extended in structure due to the 
high proline content, making it vulnerable to proteolytic attack. The distinct protein 
domains of the antibody molecule, referred to as antibody fragments, can thus be isolated 
by protease digestion (Porter, 1958). Protelytic cleavage with the enzyme papain releases 
two identical fragments (Fab) containing the VL-CL and V h-C hi (Fd region) segments 
linked together by disulphide bonds, each with a single antigen-binding site, and a third 
crystallisable fragment (Fc), comprised of the Cm and Ch3 regions, which lacks the ability 
to bind antigen (Figure 1.2b). Digestion with another protease, pepsin, cleaves the Fc from 
the remainder of the molecule to leave a large molecule, F(ab’)2, which retains the divalent 
antigen-binding properties of the parent antibody (Figure 1.2c).
The smaller Fv (fragment variable) region is composed of the Vl and Vh regions only 
(Inbar et al 1972; Figure 1.2d) and when in a recombinant form, the two regions are 
artificially joined together using a neutral linker and expressed as a single Fv polypeptide 
chain (scFv; Huston et al, 1988; Bird et al, 1988). A more detailed description of the
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Figure 1.2. Schematic representation o f  the structure o f an immunoglobulin (IgG) and antibody fragments produced by proteolytic cleavage, (a) The basic structure o f  the antibody 
is comprised o f  two heavy (H) and two light (L) chains. These are further divided into variable (V) and constant (C) domains. The VH and V L (shown in green and blue respectively) 
regions comprise the antigen-binding face o f  the antibody, which is formed by the CDR loops (shown as orange and red stripes). A close-up o f  the VH and VL structure (MFE-23 x- 
ray crystal structure; Boehm et al, 2000) shows the CDR region in more detail. Effector functions are found in the C-domains. Disulphide bonds are depicted as SS. (b) Proteolysis 
o f  the IgG with papain releases the Fab fragment, which is comprised o f  the VL-CL and Vh-Chi regions linked together by a disulphide bond, (c) Proteolysis o f  the IgG with pepsin 
results in the removal o f  the Ch2 and CH3 regions to obtain the F (ab ’)2  molecule, which retains the divalent-binding o f  the parent molecule, (d) The Fv region contains the V L and VH 
regions only. Adapted from Delves & Roitt, 2000.
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molecular design of engineered antibody fragments can be found in section 1.3 of this 
chapter.
The close study of antibody structure over the past four decades, together with the 
advent of crystallography techniques, has enabled the rational design of antibodies as 
targeting molecules. Of particular importance has been the understanding of the antibody’s 
relationship with antigen, in terms of antibody diversity and recognition of antigen.
1.2.2 Antibody diversity
The enormous diversity that is necessary to generate antibodies that can interact with 
any antigen is created in two stages, through combinatorial rearrangement (Figure 1.3) and 
somatic hypermutation. Combinatorial rearrangement occurs during the early 
differentiation of the B cell, yielding an estimated 109 distinct B-cell clones producing 109 
different antibody molecules (Tonegawa, 1983). Clusters of genes on three different 
chromosomes encode k , X and heavy Ig chains respectively. There are only approximately 
one-hundred variable (V) gene segments in each cluster but each one of these is able to 
undergo recombination with a number of small joining (J) minisegments and, for heavy 
chains of Ig, several diversity (D) minigene segments. There is a single gene encoding 
each constant region. The recombination of the V, J, and D segments is done in a precise 
order. First, the heavy chain D genes rearrange with the J genes, followed by the V genes 
rearranging with the DJ genes. Then, if a functional heavy chain results, the light chains 
rearrange by first attempting to join the k  gene, or if this is unproductive or cannot pair with 
the heavy chain, the X gene (Cook & Tomlinson, 1995; Tonegawa, 1983).
Whilst this recombination strategy allows a relatively small number of gene segments 
to encode an extremely large number of variable regions, additional diversity is provided 
through alternative mechanisms. During rearrangement, imprecision in the joining of the V, 
D and J gene segments may occur as well as the addition of random nucleotides and of 
small DNA encoded duplications around the diversity region (Weigert et al, 1980; Hay, 
1996). The combination of different Ig heavy and light chains may also introduce increased 
variability, as can the rearrangement of V genes for ‘receptor editing’(Gay et al, 1993;
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Figure 1.3. Immunoglobulin gene rearrangement. The diverse antigen specificities o f the immunoglobulins 
are generated by gene rearrangements during early B-cell development, (a) To produce a heavy chain, 1 o f  25 
diversity (D ) gene segments are randomly rearranged next to 1 o f  6 joining (J) gene segments. This is 
followed by the rearrangement o f  1 o f 50 variable ( V) gene segments next to the already assembled DJ  
segment. Different B-cells will rearrange a different segment in each pool with further diversity brought 
about through imprecise joining o f the V, D  and /  gene segments and by the addition o f  random nucleotides 
and o f small DNA encoded duplications around the diversity region. The constant (C) region gene is spliced 
next to the assembled VDJ segment and the heavy-chain primary RNA transcript is processed into mRNA. 
This mRNA encodes for a heavy chain which will be expressed on the surface o f  early stage (pre)-B cells 
together with a surrogate light chain, which is encoded by genes that do not undergo rearrangement. As the 
B-cell matures, the light-chain genes undergo rearrangement in a similar manner to those for the heavy-chain. 
(b) The genes for the two light chains kappa (k) and lambda (A.) are located on two separate chromosomes and 
include V and J gene segments, but not D. To produce these chains, the V and /  segments rearrange next to 
one another followed by a C  region. The resulting light chain replaces the surrogate paired to the completed 
heavy-chain, producing a mature antibody. Adapted from Delves & Roitt, 2000.
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Radic, 1993; Namazee & Hogquist, 2003). Genetic recombination events are also used in 
the class switching of immunoglobulin genes (Casellas, 1998). In this process, switch 
sequences comprised of tandem repeats of highly conserved short DNA sequences found 
before each C gene segment (except C8) mediate further rearrangement of the VDJ gene 
segments to different C gene segments (e.g. from Cp to C y3). This maintains antigen 
specificity whilst changing the isotype of antibody produced (e.g. from IgM to IgG3).
To further generate diversity antibodies undergo a process of somatic hypermutation. 
This involves the antigen driven introduction of mutation into V regions of activated B- 
cells, preferentially within the CDRs, for affinity maturation (Gearhart et al, 1981; Berek & 
Milstein, 1987; Mian et al, 1991; Neuberger et al, 1998; Wabl et al, 1999). B-cells 
expressing affinity-matured antibodies are then selected and expanded.
1.2.3 Recognition of antigen
The effective identification of the antibody/antigen interface can greatly enhance the 
rational design of antibodies with improved binding to antigen. This interaction occurs 
through multiple non-covalent bonds between amino acids on the antigen and in the 
antibody-binding site. These include hydrogen bonds, electrostatic, Van der Waals and 
hydrophobic interactions, which result in a considerable binding energy that increases as 
intermolecular distances decrease (Janin & Chothia, 1990; Webster et al, 1994).
Biochemical and crystallographic studies have shown that the thermodynamically 
favourable conditions of antibody binding to antigen are accompanied by a decrease in free 
energy (Braden et al, 1998). The interaction is stabilised by water molecules, which fill 
cavities where the geometric complementarity is imperfect and ensure that all hydrogen 
bond donors and acceptors are compensated (Bhat et al, 1994). Small ‘hot spot’ regions are 
often found (Jin & Wells, 1994) within the binding site, which account for a large fraction 
of the interaction energy, a common phenomenon in biological recognition (Clackson & 
Wells, 1995).
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It has been observed that antibodies to native proteins do not usually react strongly 
with peptides having the same primary sequence, as the majority of antibodies recognise 
topographic (surface) epitopes that depend upon confirmation of the native molecule.
These epitopes, termed conformational, usually consist of amino acid residues far apart in 
the primary sequence, which are brought together by the folding of the peptide chains in the 
native protein, although conformational epitopes may be formed by continuous amino acid 
sequences. Epitopes that are not dependent on the folding of the protein are called non- 
conformational. It has been proposed that antibody binding sites generally fall into three 
topographical classifications: (i) cavity or concave and moderately concave, which mostly 
bind small molecules, (ii) grooved or ridged which mostly bind peptides, and (iv) planar 
that mostly bind protein (Wang et al, 1991; MacCallum et al, 1996; Figure 1.4).
Arguably, the most important performance criterion for antibodies is the strength of its 
binding to antigen, or its affinity. This can be defined through the equilibrium binding 
constant of the antibody/antigen binding interaction. This interaction is described as:
* o n
Antibody + Antigen ^  ^  Antibody + Antigen
^off
Where kon is the association of the antibody onto the antigen, and k0ff is the dissociation of 
the antibody off the antigen. The dissociation constant, IQ = &0ff/ kon is a measurement of 
the antibody’s affinity for an antigen and is monovalent in nature.
Multivalency is the ability of an antibody or array of antibodies to bind to several 
antigen determinants at the same time, which increases the strength of binding between the 
antibody and its antigen. When there are more than one potential antigen binding faces on 
the antibody, there is a ‘bonus’ effect in which the binding of antigen to antibody by 
multiple links is always greater than the sum of the individual antibody bonds. Thus, the 
affinity effect is amplified and the molecule is described as binding with functional affinity 
or avidity (Karush, 1970).
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(a) (b) (c)
Figure 1.4. Illustration o f antibody-combining site topographies, (a) Example o f a cavity binding site, which mostly bind small molecules, using an anti-fluorescein 
antibody (Herron et al, 1989). (b) Example o f a groove binding site, which mostly bind peptides, using an anti-peptide antibody (Stanfield et al, 1990). (c) Example o f  a 
planar binding site, which mostly bind protein, using an anti-lysozyme antibody (Padlan et al, 1989). The antigen is shown in dark gray at the top o f  the figure (i) and 
the antibody is shown in light gray in the centre o f  the figure with the antigen binding site surface shown in dark gray (ii). The bottom figure shows the antigen binding 
site o f  the antibody face on (iii). Taken from Searle et al, 1995.
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1.2.4 Treatment of cancer with antibodies
Since the development of hybridoma technology almost 30 years ago, monoclonal 
antibodies have been used to target cancer cells and their ability to specifically localise to 
tumour tissue in vivo offers a variety of therapeutic approaches for cancer imaging and 
therapy. Several strategies have been explored to improve the in vivo efficacy of 
antibodies. These include the enhancement of effector functions, direct or indirect arming 
of the antibody with a variety of cytotoxic agents, and pre-targeting of antibodies to 
decrease toxicity to normal tissues.
One way in which antibodies have been exploited as therapeutic agents for cancer 
therapy is by stimulating the natural effector mechanisms of patients. This is achieved 
through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC), which mimic the host immune responses. This approach has been used 
in clinical trials with varying degrees of success. A large number of clinical trials in the 
early 1980’s were centred on the effects of unmodified monoclonal antibodies for 
haematological malignancies such as B-cell lymphoma (Nadler et ol, 1980), chronic 
lymphatic leukaemia (Miller et al, 1983), and acute lymphoblastic leukaemia (Ritz et al, 
1981). However, responses were usually only transient, with leukaemic cells in the blood 
returning to pre-treatment levels within 24-48 hours.
More recently, some clinical success has been seen with antibodies directed against 
CD52 (Campath Iff®) and CD20 (Rituxan®; Zevalin®) for the treatment of chronic 
lymphocytic leukaemia (Hale et al, 2002) and Non-Hodgkins lymphoma (Coiffier, 2003; 
Press et al, 2001), respectively, although overall responses were modest. For example, in a 
Phase III clinical trial using Rituxan® in patients with Non-Hodgkins lymphoma, the overall 
response rate was 50% (McLaughlin et al, 1998). However, these results are still higher 
than those seen with other unmodified antibodies and are believed to be due to the high 
levels of expressed target antigens on the cancer cell membranes.
Another approach using unmodified antibodies is to interact with transmembrane 
signalling pathways of growth factors on cancer cells. A widely-used anti-cancer antibody, 
Herceptin®, acts on the growth factor receptor HER-2/neu, which is overexpressed in a
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large portion of breast cancers, by modulating the signalling capacity of the target molecule 
(Baselga et al, 2001). However, response rates were again low (15%) in a Phase III clinical 
study (Cobleigh et al, 1999).
These findings indicate that the use of antibodies alone as therapeutic agents is limited. 
This may be due to antigen heterogeneity and the inability of the antibodies to target all 
tumour cells. This results in inefficient mediation of cytotoxicity and the resurgence of 
malignant cells. Superior therapy can be achieved however, when antibodies are combined 
with cytotoxic chemotherapies and/or radiotherapy. For example, dramatic improvements 
in the overall response rates have been seen when Herceptin® or Rituxan® are combined 
with various chemotherapies and radiotherapies and Zevalin® with 90Yttrium (Wiseman et 
al, 2000; Witzig et al, 2000; White et al, 2003; Emmanuouilides, 2003).
To increase their direct cytotoxicity, antibodies have been linked to a variety of toxic 
agents. Many anti-cancer drugs have been conjugated to monoclonal antibodies for 
selective delivery to tumour (Garnett, 2001). However, clinical success has been limited 
due to low levels of the drug at the tumour site as a result of the amount of drug the 
antibody can carry or loss of drug potency and antibody binding after conjugation. An 
alternative strategy is the use of immunotoxins. In this approach, antibodies are conjugated 
to toxins usually of plant or bacterial origin. Commonly used toxins include ricin toxin, 
diphtheria toxin, and Pseudomonas exotoxin, which have been chemically or genetically 
altered to prevent non-specific binding to normal tissues. Because of the potent nature of 
these toxins, very few molecules are needed for effective cell killing. However, this 
therapy requires monoclonal antibodies which are internalised to allow the toxin to work. 
Relatively few surface antigens have been identified for this application but despite this 
limitation, immunotoxins have shown some promise in clinical trials, mainly directed 
against haematological malignancies (Ghetie et al, 1997; Kreitman et al, 2000; Pai et al, 
1996; Multani et al, 1998; Dinndorf et al, 2001; Grossbard et al, 1999; Frankel et al, 2002; 
Schnell et al, 2000; Kreitman et al, 2001). For example, in one study anti-CD22 antibodies 
conjugated to Pseudomonas exotoxin resulted in an 81% response rate (Kreitman, 2001). 
However, a major drawback with this form of therapy is that it exhibits high levels of 
systemic toxicity, often involving vascular leak syndrome due to damage to the 
endothelium (Baluna & Vitetta, 1997; Schindler et al, 2001). These toxicity problems may
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be overcome by the development of antibodies fused to toxic enzymes. Conjugation of 
antibodies to a variety of enzymes has shown potent cell-killing in animal models (Newton 
et al, 1996; Deonarain & Epenetos, 1998; Linardou et al, 2000; Newton & Ryback, 2001).
Antibody targeting of radioactivity has been extensively used for both the detection
(RAID) and therapy (RAIT) of cancer deposits. In a therapeutic approach, antibodies are
linked to radionuclides that can cause DNA strand breaks and other effects which result in
cell kill. In addition, radiotherapy contributes to a bystander effect as many of the
commonly used radionuclides are cytotoxic over many cell diameters. The two most
widely used therapeutic radionuclides are the p-emitters 13 iodine (131I) and90Yttrium (90Y).
131I is readily available, inexpensive and provides y-emissions for imaging. However,
dehalogenation of the radionuclide and a reduced residence time in tumour due to
conventional conjugation techniques of this radionuclide to antibodies can be problematic
(Goldenberg, 2002). In contrast,90Y has a long residence time in tumour and a higher
1^1energy and particle range than I, which makes it particularly suited for irradiation of 
larger tumours. However, a stable attachment to the antibody is required as unbound 
radioyttrium can accumulate in bone (Williams et al, 1996; Govindan et al, 1998; 
Goldenberg, 2002).
Recently, RAIT has had encouraging results in the management of hematopoietic 
cancers (DeNardo et al, 1999; Seitz et al, 1999; Ilidge & Johnson, 2000; Schulz et al, 2000; 
Vose et al, 2000; Kaminiski et al, 2000; Press et al, 2000; Wiseman et al, 2000; Witzig et 
al, 2000; Juweid et al, 2000; Postema et al, 2003). However treatment of the more 
radioresistant solid tumours has not been as successful. Nevertheless, some encouraging 
results in the treatment of small-volume or micrometastatic disease have been reported 
(Goldenberg, 2002). The major limitation in delivering effective tumour radiation doses is 
antibody accumulation in normal clearance tissues. Multiple administrations and 
combinations with other treatment modalities have proved necessary, particularly for solid 
tumours.
To overcome some of the toxicity problems seen with antibody therapy, cytotoxic 
agents, such as radionuclides or prodrugs, may be specifically targeted to cancer cells 
through a series of steps. Pre-targeting strategies typically require the antibody unit to
32
localise to the tumour site, followed by the clearance (often assisted by a clearing agent) of 
non-bound antibody. The cytotoxic agent is then administered, and upon capture by the 
antibody, selectively delivers it cytotoxic effect at the tumour site. This system is 
particularly attractive for RAIT and chemotherapy as it has the potential to significantly 
decrease systemic toxicity. The most popular antibody pre-targeting techniques include 
hapten/antibody (Reardan et al, 1985; Goodwin et al, 1986; Kraeber-Bodere et al, 2003) 
and biotin/avidin (Hnatowich et al, 1987, 1994; Paganelli et al, 1988; Sharkey et al, 1997; 
Goodwin et al, 1988; Axworthy et al, 2000; Breitz et al, 1999,2000; Knox et al, 2000; 
Graves et al, 2003), although DNA/DNA (Bos et al, 1994) and prodrug/ enzyme 
(Bagshawe et al, 1988) systems have also been used. Bispecific antibodies have also been 
employed in pre-targeting approaches (Barbet et al, 1999; Bardies et al, 1996; Gautherot et 
al, 2000).
There are currently five licensed antibodies for the treatment of cancer (Grillo-Lopez 
et al, 2002; Leyland-Jones, 2002; Sievers & Linenberger, 2001; Ferrajoli et al, 2001; Table 
1.1). Monoclonal antibodies and immunoconjugates have proved effective against 
lymphomas but relatively ineffective against carcinomas, and this is reflected in that four of 
the five approved antibodies are targeted to malignant lymphomas. The main problem is 
the impermeability of tumours to macromolecules as typically only 0.001-0.01% of the 
injected dose of an antibody localises to each gram of tumour in humans (Epenetos et a l 
1986). The poor tumour penetration of murine monoclonal antibodies (due to size), 
coupled with their longer circulating half-lives (thereby increasing the toxicity to other 
tissues), and their innate immunogenicity (murine antibodies and fusion proteins) have been 
addressed in the engineering of recombinant antibody fragments.
1.3 Engineering recombinant antibody fragments for anti-cancer targeting
The advent of genetic engineering in the late 1980’s has enabled an almost unlimited 
supply of antibody-based molecules with the potential for cancer targeting. This is due 
largely to the development of cloning, expression, and selection systems which facilitate
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Table 1.1. FDA approved antibodies for the treatment of cancer
Antibody (US trade name*) Target Type Mechanism Target Date Refs
Rituximab
(Rituxan®)
CD20 Chimeric IgGl ADCC, CDC, directly induces apoptosis NHL 1997 1
Trastuzumab
(Herceptin®)
HER2/neu Humanised IgGl Inhibition of HER2-mediated tumour cell proliferation and 
migration
HER2-Breast cancer 1998 2
Gemtuzumab ozogamicin 
(Mylotarg®)
CD33 Humanised IgG4 IT delivering calicheamicin, resulting in DNA strand breaks 
and apoptosis
AML 2000 3
Alemtuzumab
(Campath®)
CD52 Humanised IgGl ADCC, CDC CLL 2001 4
Ibritumomab tiuxetan 
(Zevalin™)
CD20 Murine IgGl RI using conjugated ^ Yttrium, ADCC,CDC, apoptosis NHL 2002 5
♦The suffixes of the generic name of antibodies are assigned as follows: murine antibodies are ‘omab’, chimeric antibodies are ‘xuuab’, humanised antibodies are ‘zumab’, and fully 
human antibodies are ‘umab’. CD20: B-cell surface antigen; HER2/neu: ERBB2 growth factor receptor, CD33: sialo-adhesion molecule, leukocyte differentiation antigen; CD52: B- 
cell antigen. NHL: Non-Hodgkin’s lymphoma; HER2-Breast cancer. Breast cancer bearing HER2 receptors; AML: acute myeloid leukaemia; CLL: B cell chronic lymphocytic 
leukaemia; IT: immunotoxin; RI: radioimmunoconjugate; !Grillo-Lopez, 2002;2 Leyland-Jonea, 2002; Severs & Linenberger, 2001; ^errajoli, 2001; 5Goldenberg, 2001.
Compiled from Glennie & van de Winkel, 2003; Trikha et al, 2002; Allen, 2002).
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not only the rapid and simple production of recombinant antibody-based molecules but also 
the swift implementation of design features resulting in antibodies with the characteristics 
of choice (e.g. affinity, avidity, size).
1.3.1 Monovalent Ig fragments
The first attempts at engineering recombinant antibodies was through digestion of whole 
IgG to obtain smaller fragments such as Fab and F(ab’)2  (see 1.2.1). As part of the rational 
development of novel antibody-based molecules, attempts were made to produce the 
smallest antigen-binding portion of the antibody. This resulted in an array of small, 
monovalent molecules capable of binding antigen.
1.3.1.1 Variable heavy chain fragment
The smallest antibody-derived domain that can bind antigen with reasonable affinity is 
a single Vh chain (Figure 1.5a). Vh chains are normally very unstable and prone to 
aggregation in vivo because the largely hydrophobic area that normally forms the interface 
with the Vl domain is exposed to the solvent (Muyldermans, 2001). However, one class of 
VH chains (VHH domains), derived from camelids and sharks, are naturally found without 
a light chain, yet exhibit high antigen affinities (Hamers-Casterman et al, 1993). Sequence 
and structural analysis of camelid Vh chains has led to the rational design of mutations in 
human Vh chains that rendered it stable in the absence of a Vl chain (Desmyter et al, 1996; 
Decanniere et al, 1999; Davies & Riechman, 1994, 1996; Kortt et al, 1995). Alternatively, 
a naturally stable murine Vh domain has been engineered to associate with different 
antigens (Reiter et al, 1999). Although still a relatively new approach in antibody 
engineering, these molecules have a great potential to form the building blocks of future 
antibody-based targeting molecules.
1.3.1.2 Single chain Fv
In general, both the Vh and Vl domains are necessary for high antigen affinity and 
stability. Vh and Vl chains can be expressed as separate polypeptides in bacteria where 
they assemble into Fv fragments (Skerra & Pluckthun, 1988). However, in this form the
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two chains are held together by noncovalent interactions and are prone to dissociation and 
aggregation. The two chains can be covalently assembled by the engineering of interchain 
disulphide bonds (dsFv; Brinkmann et al, 1993; Reiter et al, 1993, Webber et al, 1995) but 
these are difficult to produce in large volumes and the bond can be reduced under mild 
conditions. By far the most widely used combination of the Vh and Vl chains is the single 
chain Fv antibody fragment (scFv; Figure 1.5b). In this format, the Vh and Vl chains are 
genetically tethered together using a flexible, polypeptide linker (Huston et al, 1988; Bird 
et al, 1988). The two variable domains can be connected as either Vh -linker- Vl or VL -  
linker- Vh, the former being the most common. The order of the two domains can affect 
expression efficiency, stability, and the tendency to form spontaneous dimers with each 
other in solution. The choice of linker can have pronounced affects on the soluble 
expression, folding and stability of a scFv. Several linkers joining the two domains have 
been investigated. The most common linker used is based on the (Gly4 Ser)3 motif (Huston 
et al, 1988). The success of this linker is attributed to its neutral charge and flexibility, 
which is evident in its general applicability for a variety of scFvs. Other linkers have been 
selected to join the two domains together for improved function based on structural 
consideration, screening of linker libraries or natural linker sequences from multi-domain 
polypeptides (Bird et al, 1988; Whitlow et al, 1993; Pantoliano et al, 1991; Tang et al, 
1996; Deonarain et al, 1997; Hennecke et al, 1998).
Their routine use in display technologies as well as their relatively small size (~27 
kDa) and suitability for recombinant expression and purification make scFv an ideal 
platform for antibody-based therapies. Initial pre-clinical and clinical studies with scFv 
alone however, were disappointing as they showed rapid clearance and persistent uptake in 
kidney, resulting in low overall accumulation in the tumour (Colcher et al, 1990; Milenic et 
al, 1991; Yokota et al, 1992, 1993; Adams et al, 1993; Begent et al, 1996; Larson et al, 
1997; Pavlinkova et al, 1999). This has been overcome by using scFv as building blocks in 
larger molecules. ScFv have been fused to toxins (Kreitman & Pastan, 1998; Di Paolo et 
al, 2003), enzymes (Michael et al, 1996; Bhatia et al, 2000; Ryback & Newton, 2001; 
Kousparou et al, 2002; de Graaf et al, 2002), viral coat proteins (Konishi et al, 1998; Khare 
et al, 2001), cytokines (Yang et al, 1995; Scherf et al, 1996; Cooke et al, 2002; Heuser et 
al, 2003; Shi et al, 2003), drugs (Sun et al, 2003) and have formed the basis of a variety of 
multivalent antibodies (see 1.3.2).
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1.3.1.3 Fab fragment
In addition to scFvs, the other commonly used recombinant antibody fragments are 
Fabs. Fabs consist of the V l-C l and V h-C hi chains linked together by disulphide bonds 
(Figure 1.5c). Although the expression of Fab requires the association of two chains, it 
often occurs quite efficiently in bacteria (Carter et al, 1992; Skerra, 1994). However, the 
presence of two chains complicates genetic manipulation and the large-scale production of 
these molecules. Furthermore, Fab fragments are still relatively small (~55 kDa) and 
exhibit the same limitations as scFv, namely rapid clearance and renal uptake. As with 
scFv, Fab fragments have been more successful as the targeting arm of larger molecules 
(Buchegger et al, 1990, 1996; Behr et al, 2000; Casey et al, 2002; Donda et al, 2003; 
Pastorino et al, 2003).
1.3.2 Multivalent Ig fragments
The small size and monovalent binding of the first engineered antibody fragments 
resulted in poor tumour retention and high renal uptake. Therefore, monovalent antibody 
units such as scFv and Fab have been engineered into multimeric constructs using a variety 
of chemical and genetic cross-linkages. These have exhibited superior in vivo targeting 
characteristics over their smaller, monovalent counterparts (Adams et al, 1993; Whitlow et 
al, 1993; Wu et al, 1996; Adams et al, 1998; Beresford et al, 1999; Goel et al, 2000; 
Nielsen et al, 2000; Goel et al, 2001; Yazaki et al, 2001).
1.3.2.1 Spontaneous multimerisation
ScFvs often form dimers and higher molecular weight species because of pairing of the 
Vh chain of one scFv with the Vl chain of another (Holliger et al, 1993; Adams et al, 1993; 
Essig et al, 1993; Schodin & Kranz, 1993; Whitlow et al, 1993; Atwell et al, 1999; Figure 
1.6a). The formation of multimers appears to be determined primarily (but not exclusively) 
by the length of the linker joining the two variable domains (Holliger et al, 1993; Whitlow 
et al, 1994; Desplancq et al, 1994). Linkers greater than 15 amino acids result 
predominantly in the formation of monomers, those of between 5-12
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(a) VHH domain (b) scFv fragment (c) Fab fragment
1.
}
Figure 1.5. Monovalent antibody fragments. Examples o f  the ribbon structure is shown for (a) VHH domain (-15  kDa; Cab-Ca05 antibody; PDB code 1F2X; 
Decanniere et al, 2000), (b) scFv fragment (-27  kDa; MFE-23 antibody; PDB code lqok; Boehm et al, 2000) and (c) Fab fragment (-55 kDa; A5B7 antibody; PDB 
code 1CL0; Banfield et al, 1997). CDR loops are shown in red (VH) and orange (VL).
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amino acids form dimers (diabodies) (Holliger et al, 1993,1996; Perisic et al, 1994; Atwell 
et al, 1996; Kortt et al, 1997), and those of between 0-1 amino acids form trimers 
(triabodies) (Kortt et al, 1997; Iliades et al, 1997; Pei et al, 1997) and tetramers 
(tetrabodies) (Dolezal et al, 2000).
In addition, the order of the domains can affect their tendency to form multimers 
(Pluckthtin, 1997; Dolezal et al, 2000). This occurs because the Vh and Vl domains are 
related by a rotation of about 170° (instead of 180°), about the pseudo two-fold axis 
(parallel to the Vr/Vl interface) (Huston et al, 1988; Padlan, 1994; Pluckthun, 1997). 
Consequently, the Vl C-terminus is further away from the Vh N-terminus than the VH C- 
terminus is from the Vl N-terminus. This leads to predominantly monomeric species in the 
V h -V l orientation, and dimeric species in the V h -V l orientation when the same linker 
(Gly4 Ser)3 is used to join them together (Huston et al, 1991). These molecules have shown 
high functional affinity and have been veiy successful in pre-clinical studies (Wu et al, 
1996; Adams et al, 1998, 2000; Nielsen et al, 2000; Power et al, 2001; Yazaki et al, 2001). 
Moreover, association of a domain from one scFv with a domain from a second scFv with 
different antigen specificity results in antibody fragments which can bind two different 
epitopes (Holliger et al, 1996, 1997, 1999; Zhu et al, 1996; Kontermann et al, 1997; 
FitzGerald et al, 1997; Kipriyanov et al, 1999; Denton et al, 1999).
1.3.2.2 Tandem, covalently and chemically-linked molecules
Rather than relying on the tendency of scFvs to self-associate, multimeric recombinant 
antibodies can be generated using protein engineering techniques. These include 
connecting two scFv using a polypeptide linker (Mallender & Voss, 1994; Neri et al, 1995; 
Beresford et al, 1999; Figure 1.6b) or by disulphide bridges formed through COOH- 
terminal cysteine residues (Cumber et al, 1992; Huston et al, 1994; Kipriyanov et al, 1994; 
Breitling & Dubel, 1997; FitzGerald et al, 1997; Schmiedl et al, 2000), which can be 
further stabilised through chemical cross-linking (King et al, 1994).
A divalent scFv may be generated by incorporating a free cysteine residue into the 
sequence, allowing cross-linking (Adams et al, 1993; Kipriyanov et al, 1994; McCartney et 
al, 1995). In vivo studies using this format have shown improved localisation to tumour
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(Adams et al, 1995). One of the simplest methods of generating multivalent antibody 
fragments is to link two scFv as a single polypeptide chain. This has the advantage over 
disulphide and chemically linked scFv in that the molecule is encoded as a single gene and 
there is no need to perform additional chemical modification of the molecule following 
expression. Divalent molecules based on polypeptide linkers have shown improved 
tumour: tissue ratios in vivo (Goel et al, 2000). Furthermore, divalent tandem scFv have 
shown spontaneous dimerisation, producing tetramers with further tumour targeting 
improvements (Goel et al, 2000). Another unique application of tandem scFv is to link two 
scFv which bind to adjacent, non-overlapping epitopes on the same antigen (Neri et al, 
1995).
1.3.2.3 Multimerisation molecules
Another approach to obtain multimeric antibody fragments is to link them together 
using molecules which tend to self-associate. This may be accomplished using short 
polypeptides that have a strong tendency to associate in a defined fashion, particularly helix 
bundles (Pack & Pluckthun, 1992; Pack et al, 1995) or coiled-coil structures such as 
leucine-zippers (Kostelny et al, 1992; Pack & Pluckthun, 1992), constant domains 
(McGregor et al, 1994; Hu et al, 1996; Figure 1.6c) and molecules which are 
homomultimeric, such as p53 (Pack & Pluckthun, 1992), steptavidin (Diibel et al, 1995; 
Cloutier et al, 2000; Yang et al, 2000), and TNFa, (Yang et al, 1995; Scherf et al, 1996; 
Cooke et al, 2002). These have shown encouraging targeting in pre-clinical studies, with 
prolonged circulating half-lives over their monovalent counterparts (Haunschild et al, 1995; 
Hu et al, 1996; Wu et al, 2000; Willuda et al, 2001; Yazaki et al, 2001).
1.3.3 Addressing Immunogenicitv
Systemic administration of murine monoclonal antibodies can lead to immune 
responses in the form of HAMA usually directed against the constant regions of the Ig 
although anti-idiotypic responses have also been detected. This has led to the development 
of chimeric, humanised, and fully human antibodies. A chimeric antibody combines the 
variable fragments of a murine antibody with the human constant regions. An antibody can
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(a) Diabody (-60 kDa) (b) Tandem scFv (-60 kDa) (c) Minibody (-80 kDa)
Figure 1.7. Multivalent antibody fragments. Schematic examples o f  multivalent scFv assemblies represented by a (a) diabody, (b) tandem scFv, (c), minibody. VH is 
shown in green, VL in blue, Ch3 in pink. Linkers are shown as black lines.
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be further humanised by transferring just the CDR loops to a human framework. 
Additionally, fully human antibodies have been made by using transgenic mice with human 
immunoglobulin genes (Mendez et al, 1997; Nagy et al, 2000; O’Connell et al, 2002). This 
has been further developed by the display of fully human antibody libraries on the surface 
of phage (Knappik et al, 2000). Antibodies have also been ‘resurfaced’ to present a more 
human Fv framework (Pedersen et al, 1994; Roguska et al, 1994). Four of the five 
antibodies approved for clinical use are chimaeras or fully human.
1.3.4 Recombinant antibody production
Several practical considerations must be taken into consideration when designing 
antibody-based molecules, in terms of ease and expense of expression and potential for 
large-scale production. Mammalian cell lines including hybridomas and recombinant CHO 
and COS cell lines can be used to obtain high levels of antibody fragments (Yazaki et al, 
2001; de Graaf et al, 2002). However, despite the high titres that can be achieved with 
mammalian expression systems, the costs and long production times are prohibitive for 
many applications. Therefore, alternative expression systems have been sought.
One of the critical advances in the manipulation of antibody fragments was the 
development of bacterial expression systems. Since that time, antibodies (or antibody 
fragments) have been expressed in a wide variety of hosts, both prokaryotic (Skerra & 
Pluckthun, 1988; Better et al, 1988), and eukaryotic (Horwitz et al, 1988; Kousparou et al, 
2002; FitzGerald et al, 1997; Wang et al, 1998; Freyre et al, 2000; Goel et al, 2000; Powers 
et al, 2001; Shi et al, 2003; Gurkan & Ellar, 2003; Medzihradszky et al, 2003; Yang et al, 
2003). In addition, alternative systems such as insect cells (Hsu et al, 1994; Kretzschmar et 
al, 1996; Potter et al, 1993; Yang et al, 2000; Choo et al, 2002) and plants (Eto et al, 2003; 
McCormick et al, 2003; Kathuria et al, 2003) have been applied. These systems confer 
different characteristics on the resulting proteins (e.g. glycosylation) and are a vital 
parameter in the design of antibody-based molecules. The two most commonly-used 
systems are bacteria and yeast, although plant systems are gaining commercial popularity, 
only limited by the space available to grow them.
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The first reports of recombinant antibodies synthesised in bacteria were published in 
1984, involving modest expression in Escherichia coli of an entire IgG antibody (Cabilly et 
al, 1984). Fv domains were initially expressed in E. coli (Skerra & Pluckthun, 1988) and 
the first scFv were produced by refolding of bacterially expressed protein (Huston et al, 
1988). Antibody fragments can be produced in E. coli by refolding from inclusion bodies 
or by secretion of functional protein to the bacterial periplasm. Bacterial cultures are easily 
scaled-up for large-scale fermentation (Pack et al, 1993; Horn et al, 1996; Zhu et al, 1996; 
Bayly et al, 2002). Although still favoured for the expression of small antibody fragments, 
the inability of bacteria to add post-translational modifications (e.g. glycosylation, 
phosphorylation) and the often modest yields of larger molecules obtained can limit their 
use.
Alternative expression systems were developed for the increased production of 
antibody fragments which could incorporate post-translational modifications to mature 
proteins. Yeast such as Saccharomyces cerevisiae and Pichia pastor is have long been used 
for the production of heterologous proteins and their methods are well characterised 
(Cereghino & Cregg, 2000). Yeast has many of the advantages of higher eukaryotic 
expression systems including protein processing, folding and posttranslational 
modifications, while being as easy to manipulate as E. coli. Expression in yeast is faster, 
easier and less expensive than other eukaryotic systems and generally gives higher 
expression levels. Although not mammalian, yeast glycosylations have been well 
characterised, consisting of the high mannose type (Bretthauer & Castellino, 1999). To 
date, several engineered antibody fragments have been produced in yeast (Lou et al, 1996; 
Eldin et al, 1996; FitzGerald et al, 1997; Wang et al, 1998; Boado et al, 2000; Freyre et al, 
2000; Goel et al, 2000; Powers et al, 2001; Shi et al, 2003; Gurkan & Ellar, 2003; 
Medzihradszky et al, 2003; Yang et al, 2003), with yields of up to 1.2 g/L reported (Freyre 
et al, 2000).
1.3.5 Display technologies for the selection of recombinant antibodies
Cloning the genes of antibodies was greatly simplified by a number of advancements 
in the field of genetic engineering. First was the production of antibody fragments in
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bacteria, as discussed in the previous section (Better et al, 1998; Skerra & Plucktiin, 1988). 
Second was the isolation of antibody gene libraries from pools of B lymphocytes using 
polymerase chain reaction (PCR; Orlandi et al, 1989). Third was the development of phage 
display technology (McCafferty et al, 1990), allowing for the improvement of natural 
antibodies by mimicking immune selection in vitro.
Since its inception, several display technologies have been developed using a variety 
of host systems. These include phage systems (McCafferty et al, 1990), in vitro display on 
ribosomes (He & Taussig, 1997; Hanes & Pluckthun, 1999; Roberts, 1999), and cell 
surface systems displaying antibody fragments on the surface of bacteria (Daugherty et al, 
1998) or yeast (Boder & Wittrup, 1997). However, they all share the common trait of the 
original display format; recovery of both the mature protein and its genetic information by 
linking the genotype directly to the phenotype (Figure 1.7).
1.3.6 Directed evolution for improved recombinant antibodies
In vitro methods of generating diversity have been developed for the improvement of 
targeting molecules, which successfully mimic the in vivo process. This may be achieved 
using large libraries of antibody genes and selecting for binding to a desired target. 
Selection against low amounts of target gives rise to higher affinity antibodies, and rational 
mutagenesis of the sequence can increase this effect further. Several scFv and Fab 
fragments against therapeutically relevant antigens have been affinity improved over 1000- 
fold with these methods (Yang et al, 1995; Schier et al, 1996; Pini et al, 1998; Wu et al, 
1998; Hanes et al, 2000).
A number of strategies have been used to modulate antibody/ antigen interactions and 
the inherent stability of the antibody fragment. These can be divided into rational and 
evolutionary approaches (Worn & Pluckthun, 2001). Rational approaches use structure- 
based knowledge or sequence statistics to predict affinity or stabilising mutations that are 
introduced by site-directed mutagenesis or into a framework that serves as a recipient of a 
CDR library. Examples of rational approaches include the extension of the heavy chain 
CDR loops to introduce addition contacts between antibody and antigen (Lamminmaki et
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(b) Ribosome •*** .  . » * • * ,
mRNA
Ribosome
(c) Cell-surface
Figure 1.7. Antibody display technologies for the linking o f phenotype and genotype, (a) In phage display 
the antibody is fused to a minor coat protein o f  the filamentous phage with the DNA encoded inside the 
phage, (b) In ribosome display, mRNA and proteins are linked by the ribosome, (c) In cell surface display 
the antibody is displayed in the outer surface o f  bacterial or yeast cells with the genetic information encoded 
on a plasmid inside the celL Adapted from Maynard & Georgiou, 2000.
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al, 1999), grafting CDR loops onto a stable framework (Jung & Pluckthun, 1997; Willuda 
et al, 1999; Worn et al, 2000), increasing the intrinsic domain stability (Steipe et al, 1994; 
Frisch et al, 1996; Wirtz & Steipe, 1999; Willuda et al, 1999; Knappik et al, 2000), and 
increasing the stability of the Vh-Vl  interface (Tan et al, 1998). Evolutionary strategies 
include the construction of randomised library generated using error-prone PCR or DNA 
shuffling (Fromant et al, 1995; Stemmer, 1994), chain shuffling (Kang et al, 1991; Marks 
et al, 1992; Jespers et al, 1994), screening of libraries in which one or more CDR loops are 
subjected to combinatorial mutagenesis and then undergo selection pressure for high 
affinity (e.g. in the presence of less and less antigen each round) or stability (e.g. following 
removal of conserved intradomain disulphide bonds; carried out at 37°C; Braisted & Wells, 
1996; Ruan et al, 1998; Jung et al, 1999 ).
1.4 Factors influencing antibody targeting
There are several limitations in current antibody targeted therapies. These limitations 
can be attributed to (i) the innate immunogenicity of the antibody-based molecule, leading 
to hypersensitivity reactions and in some cases anaphylactic shock, preventing repeated 
therapy; (ii) undesirable pharmacokinetics of the antibody-based molecule, increasing 
toxicity to normal tissues; and (iii) sub-optimal tumour localisation, resulting in lowered 
therapeutic dose to the tumour. Many of these factors have been addressed by the 
engineering of antibody fragments, however in order to make the necessary changes to the 
antibody, the physiological parameters governing its success as a targeting agent must be 
addressed. These include improvements to the therapeutic ratio by altering 
pharmacokinetics and neutralising immunogenicity, improvements to tumour localisation 
and penetration by enhancing functional affinity, stability and size, and adapting to 
physiological factors such as tumour architecture and target antigen expression by the 
manipulation or destruction of tumour vasculature, and the enhancement of target antigen 
expression.
The heterogeneity of antibody distribution in tumours and their poor localisation is a 
consequence of the tumour microenvironment. This is attributed to the chaotic nature of 
blood vessels and blood flow and the altered convection and diffusion within the interstitial
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space, which create potential physical barriers to the delivery of therapeutic agents to 
malignant cells in vivo (Curti, 1993). Antibodies enter the tumour vasculature and distribute 
through the vascular space, from where they are transported across the microvascular wall, 
and through the interstitial space (Jain, 1987). High interstitial pressures cause the 
formation of pressure gradients from the centre of the tumour to the periphery and occurs 
due to the absence of functioning lymphatics in tumours (Jain & Baxter, 1988). The 
elevated pressure hinders convection, which is the primary route for delivery of 
macromolecules and consequently antibodies can enter the tumour solely by diffusion. The 
time scale of diffusion is proportional to distance squared, so a large molecule, such as an 
IgG, diffuses 1 mm in 54 hours whereas smaller molecules such as antibody fragments 
diffuse into the tumour more rapidly (Baxter & Jain, 1988; Jain & Baxter, 1988).
The choice of tumour-associated antigen is an important factor influencing the success 
of antibody targeting. There are several characteristics which have been exploited for 
selective targeting (Urban & Schreiber, 1992). These include overexpression on 
malignant cells (e.g. CD20, CD22), or expression on surfaces of the membrane that are not 
typical (e.g. CEA). Inappropriately displayed or alternatively spliced isoforms (e.g. ED-B 
fibronectin) of antigens, differentiating antigens, or those with atypical glycosylations (e.g 
Tag-72, Mucins) have also been targeted. Point mutations (e.g. Her2) or deletions (e.g. 
epidermal growth factor) to the genes of some antigens on malignant cells make them good 
targets. An alternative approach to destroy solid tumours using antibody-based therapeutics 
is to target the vasculature of the tumours rather than the tumour cells themselves by 
directing antibodies against targets such as vascular endothelial growth factor or its receptor 
(Brekken et al, 1998; Mordenti et al, 1999; Zhu et al, 1999; Zhang et al, 2002; Afanasieva 
et al, 2003; Yang et al, 2003: Ran et al, 2003) and fibronectin (Neri et al, 1997; Tarli et al, 
1999; Viti et al, 1999).
1.5 Carcinoembryonic antigen as a tumour-associated target
The discovery of carcinoembryonic antigen (CEA) in 1965 by Gold and Freedman 
(Gold & Freedman, 1965) and its subsequent cloning (Oikawa et al, 1987; Beaucheman et 
al, 1987; Zimmermann et al, 1987; Kamarck et al, 1987), closely followed by that of non­
specific crossreacting antigen (NCA or CEACAM6; Barnett et al, 1988; Neumaier et
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al, 1988; Tawaragi et al, 1988), biliary glycoprotein (BGP or CEACAM1; Hinoda et al, 
1988; Barnett et al, 1989, 1993) and pregnancy-specific glycoprotein (PSG; Khan et al,
1992) revealed a new family of glycoproteins belonging to the immunoglobulin 
superfamily (Paxton et al, 1987). This family was mapped to 29 genes and pseudogenes 
located along chromosome 19 (Kamarck et al, 1987; Zimmermann et al, 1988; Neumaier et 
al, 1988; Inazawa et al, 1989) and are collectively known as CEA Gene family Members 
(CGMs). There is a high degree of similarity between gene family members with 80-90% 
identical nucleotide sequences (Arakawa et al, 1990; Berling et al, 1990).
The products of the CEA gene family subgroup are highly glycosylated via asparagine 
residues which represent up to 50% of their total molecular weight. They all contain a 108 
amino acid IgV -like domain at the N-terminus (N domain) followed by up to six IgC-like 
domains of either 93 amino acids (type A domain) or 85 amino acids (type B domain). 
These proteins can be further subdivided based on their amino acid sequences into two 
groups, PSGs and CEA and CEA cross-reacting proteins. The CEA and CEA cross­
reacting proteins are classified by their membrane association as linked via either a 
glycophosphatidyl inositol (GPI) moiety or a hydrophobic transmembrane domain (Figure 
1.8).
CEA has a molecular weight of 180 kDa, half of which is attributed to the 
glycosylations (GlcNAc-asparagine linkage of the high mannose type; Yamashita et al, 
1987, 1989) at the 28 potential sites in the CEA sequence (Beauchemin et al, 1987). 
Molecular modelling (Bates et al, 1992) and X-ray and neutron solution scattering (Boehm 
et al, 1996) of CEA has verified that its Ig-like domains form an extended, monomeric, zig­
zag structure of 27-33 nm in length and 8 nm in width. The 7 Ig-like domains consist of 
one V-type fold domain (N) followed by three repeated C2-type fold domains containing an 
A and B type sub-domain (A1B1, A2B2, A3B2) that are about 80-82% homologous at the 
nucleotide sequence and 67-70% homologous at the amino acid sequence levels, with the 
first 67 amino acids of each A subdomain showing 89-96% nucleotide sequence identity 
(Beauchemin et al, 1987). There are no cysteines in the N domain and two cysteines in 
each A and B domain, which form intra-domain disulphide bonds. CEA is attached to the 
membrane via a GPI moiety (Takami et al, 1988; Hefta et al, 1988; Sack et al, 1988, Jean 
et al, 1988).
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(a) CEACAMl(BGP) (b) CEACAM3(CGM1) (c) CEACAM4(CGM7) (d) CEACAMS(CEA) (c) CEACAM6(NCA) (f) CEACAM7(CGM2) (g) CEACAM8(CGM6)
Figure 1.9. Schematic o f carcinoembryonic antigen family members, (a) CEACAM 1 (Biliary glycoprotein; BGP) is made up o f four domains with 19 potential 
carbohydrate sites and contains a hydrophobic transmembrane domain, (b) CEACAM3 (CGM1) and (c) CEACAM4 (CGM7) are both comprised one domain and are 
linked to the cell surface via a transmembrane domain. They encode 2 and 4 glycosylation sites, respectively, (d) CEACAM5 (CEA) contains 7 domains linked to the 
cell surface via a glycophosphatidyl inositol (GPI) moiety. CEA has the most potential carbohydrate chains with 28 potential sites, (e) CEACAM6 (NCA) has three 
domains with 12 potential sites o f  glycosylation and GPI linkage, (f) CEACAM7 (CGM2) is a two-domain protein linked to the surface via a GPI moiety and containing 
7 glycosylation sites, (g) CEACAM8 (CGM6) is comprised o f  three domains containing 11 glycosylation sites and a GPI linkage. Old nomenclature is shown in 
parentheses. Carbohydrates are depicted as black lines and linkages to the cell surface as green lines. Adapted from http://cea.klinikum.uni-muenchen.de/.
Originally classified as a protein expressed only in fetal tissue (Gold & Freedman, 
1965), CEA has now been identified as present in several normal tissues (Bordes et al,
1973; Fritsche & Mach, 1977; von Kleist et al, 1972; Mach & Pusztaszeri, 1972). These 
tissues are primarily epithelial in origin, including cells of the colon, stomach, tongue, 
esophogus, cervix, sweat glands, and prostate and CEA is therefore more accurately 
defined as a differentiation antigen first expressed in mature endothelial cells at the onset of 
early fetal life (Zimmermann et al, 1988). While presence of CEA itself does not indicate 
malignancy, the distribution of CEA does. In normal tissue, CEA is restricted to the apical 
surface of the cell (Ahnen et al, 1982; Fantini et al, 1989). In contrast, cancerous cells will 
express CEA over the entire surface (Hammarstrom et al, 1999), allowing for the selective 
targeting of antibodies directed against tumours expressing CEA. In colorectal tumours, 
CEA has been observed intracellularly (Itzkowitz et al, 1986), extracellularly bound to the 
entire surface of non-polarised epithelial cells (Benchimol et al, 1989), and as a solubly- 
secreted product. This loss of polarity is used as an indicator of disease for colon cancer 
(Seregni et al, 1992; Graham et al, 1998).
The protein and mRNA levels of CEA have been found to be higher in colon 
tumours relative to their normal surrounding tissues (Boucher et al, 1989), although they do 
not always correlate (Hauck & Stanners, 1991). The increase in protein and mRNA levels 
has also be confirmed in a variety of other sites, including gastric tract (Sheahan et al,
1990), breast (Zimmermann et al, 1988), lung (Sheibani et al, 1986), pancreas (Albers et al,
1988), skin (Banks & Cooper, 1991), ovary (Athanassiadou et al, 1994) and cervix 
(Sanders et al, 1993). Furthermore, cytokines such as IFN-y and TNF-a generally increase 
mRNA levels and cell-surface expression of CEA in colon carcinoma cell lines (Takahashi 
et al, 1993; Kantor et al, 1989; Hauck & Stanners, 1991) and it is predicted that they would 
initiate the active release of proteins as well.
The function of CEA is still not fully understood. Studies in human tumour cell lines 
grown in vitro have shown it plays an important role in homophilic (CEA/CEA) and 
heterophilic (CEA/NCA/BGP) cell adhesion (Benchimol et al, 1989). For CEA, the 
homophilic interaction takes place between the V-like N domain and the C-like A3 domain 
(although it may bind to other A-type domains in the absence of the A3) of an anti-parallel 
CEA molecule in a double-reciprocal symmetrical fashion (Zhou et al, 1990, 1993). These
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intercellular adhesion properties have given important leads into normal function and 
malignant transformation. It is clear that it is involved in the tissue architecture of the cell, 
and an overexpression of CEA may perturb other cell-cell and cell-substrate interactions, 
thus causing the cell to lose its tissue orientation and its reception of normal signals for 
differentiation, leaving cells susceptible to further oncogenic lesions (Benchimol et al,
1989).
In normal physiology, CEA plays a role in the innate immune defence, protecting the 
colon, upper alimentary tract, urinary bladder and skin (sweat glands) from microbial 
attack. By binding and trapping microorganisms, CEA prevents them from reaching down 
the microvilli of the epithelial cells and invading the cell, presumably with the aid of 
cytokines which may also promote the release of the protein/microorganism complex. 
Studies have shown that CEA is able to interact with fimbriated bacteria (Leusch et al, 
1990, 1991; Sauter et al, 1991,1993) and several bacterial proteins have been isolated 
which bind specifically to CEA, the most characterised of which are the Opacity class of 
proteins on the surface of Neisseria gonorrhea and Neisseria meningitis (Virji et al, 1996, 
1999, 2000; Chen et al, 1997; Gray-Owen et al, 1997).
CEA has also been implicated in the invasion and development of hepatic metastases 
arising from colorectal cancers (Tibbetts et al, 1993; Hostetter et al, 1990; Jessup et al,
1993). This occurs through binding to an 80kDa receptor on the surface of liver Kupffer 
cells and its subsequent internalisation and transport to the liver (Toth et al, 1989). Further 
studies have shown that Kupffer cells recognise and bind CEA via a pentapeptide sequence 
located between the N and Al domains of CEA (Thomas & Toth, 1990; Thomas et al, 
1992), and this interaction elicits the secretion of a series of cytokines by Kupffer cells 
(Gangopadhyay et al, 1996). Release of these cytokines in the hepatic sinusoid may 
stimulate the hepatic endothelium to express adhesion molecules, promoting tumour cell 
adhesion and growth in liver. In addition, CEA blocks differentiation and contributes to 
tumourigenesis in several systems (Eidelman et al, 1993; Screaton et al, 1997).
Several distinct epitopes have been identified on CEA (Bjemer et al, 2002) and 
multiple monoclonal antibodies have shown good localisation for diagnostic (Goldenburg 
et al, 2000) and clinical (Riva et al, 1991; Juweid et al, 1996; Behr et al, 1997, 1999; Wong
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et al, 1999; Buchegger et al, 2000) use. Smaller antibody fragments have been engineered 
from anti-CEA monoclonal antibodies (Abraham et al, 1995; Wu et al, 1996) and have 
shown excellent in vivo targeting properties (Wu et al, 1996; Wu et al, 2000; Yazaki et al, 
2001). Antibody fragments directed against CEA have also been successfully isolated from 
phage libraries (Chester et al, 1994; Osbourn et al, 1996). The phage-derived scFv MFE- 
23 directed CEA (Chester et al, 1994) has been widely applied as a cancer targeting agent 
(Table 1.2). Clinical trials with MFE-23 have shown effective targeting of CEA-expressing 
colorectal carcinoma for RAID (Begent et al, 1996) and radioimmunoguided surgery 
(Mayer et al, 2000). However, as exhibited by other scFv fragments in vivo, MFE-23 is 
rapidly cleared from the circulation and its monovalent nature is not sufficient for 
prolonged tumour retention (Begent et al, 1996). MFE-23 has shown that it is readily 
amenable to fusion with a variety of effector proteins, resulting in a longer circulating half- 
life and improved in vivo behaviour. MFE-23 has been used in bispecific antibodies 
(Holliger et al, 1999; FitzGerald et al, 1997) as the targeting arm in antibody-directed 
prodrug therapy (ADEPT; Michael et al, 1996; Bhatia et al, 2000; Medhiraszky et al,
2003), antibody-guided enzyme nitrile therapy (AGENT; Kousparou et al, 2002), and 
redirected cytotoxic T lymphocyte responses (Darcy et al, 1998), cytokine delivery (Cooke 
et al; 2002), and retroviral infection for gene delivery (Konishi et al, 1998).
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Table U .  MFE-23-based molecules for cancer targeting
Antibody name ‘Payload’ Application Avidity for Recombinant Ref.
CEA expression host
MFE-23 ‘"I, ‘“ I, “ P, ™Tc Imaging monomer E. coli 1-5
MFE-CP CPG2 enzyme ADEPT dimer E. coli, P. pastoris 6-8
MFE-23-TNFa TNFa cytokine Targeted cellular cytotoxicity trimer E. coli 9
MFE-linamarase Linamarase enzyme AGENT monomer S. cerevisiae 10
MFE-23-RV pENv retrovirus Targeted retroviral gene delivery monomer \\f2 packaging cells 11
a-CEA-a-CEA Cy7 fluorescent dye Imaging dimer E. coli, P. pastoris 12
a-CEA- a-CD3 Anti-CD3 antibody Redirection/activation CTL monomer E. coli, P. pastoris 12,13
MFE-23-B7 Anti-CD3 antibody Redirection/activation CTL monomer E. coli 13
MFE-23-FCyR Chimeric FCy 
receptor
Redirection/activation CTL monomer Mammalian cells 14
ADEPT: antibody direoted enzyme prodrug therapy; AGENT: antibody guided enzyme nitrile therapy; CTL: cytotoxic T lymphocyte; CD3: human T-cell co-receptor. 
Chester eta l, 1994;2Begentefa/, 1995; Patrick et al, 1998; 4Pietersz eta l, 1998; fla y er  et al, 2000; ^Napier et al, 1996; 7Bhatia et al, 2000 ; ^edzihradszky et al, 
2003; 9Cookee/o/, 2001; 10Kousparou et al, 2002; "Konishi et al, 1998; 12FitzGerald et al, 1997; 13Holliger et al, 1999; 14Darcy eta l, 1998.
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1.6 Aims
This thesis examines the use of protein engineering to create antibody-based molecules 
with improved cancer targeting properties. An ideal antibody-based cancer-targeting agent 
would be one which was non-immunogenic and localised quickly to the tumour and 
remained in the tumour whilst clearing rapidly from normal tissues. Towards meeting these 
ideals, bioinformatics and recombinant techniques are applied to create divalent antibody- 
based molecules for targeting CEA using MFE-23 as a building block.
Specific aims of this study were:
1) To characterise the molecular interaction between MFE-23 and its cognate
antigen CEA in order to guide the structure-based design of divalent molecules
2) To construct divalent forms of MFE-23 in tandem using a polypeptide linker
3) To develop divalent MFE-23-based molecules using human serum albumin as a
linker
4) To investigate the affect of glycosylation on the pharmacokinetic properties of
the constructed divalent molecules
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Chapter 2
Materials and Methods
55
2.1 Materials and suppliers
All experiments were done in accordance with COSHH and Royal Free & University 
College Medical School guidelines for good laboratory practice. Radioactive work was 
done in accordance with Royal Free & University College Medical School Radiation 
Protection guidelines. All animal work was carried out in accordance with the guidelines 
of the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) and the 
Animal (Scientific Procedures) Act 1986.
2.1.1 Chemicals and reagents
All chemicals were of AnalaR grade and purchased from VWR-BDH Ltd (Gillingham, 
Dorset, UK) or Sigma-Aldrich Company Ltd (Poole, Dorset, UK), unless otherwise stated. 
Components of microbial culture media were purchased from Difco (UK) unless otherwise 
stated. Buffers, solutions and antibiotics were prepared using distilled de-ionised water 
(dFLO; Elga, UK), unless otherwise stated. Individual buffer components are given in 
Tables 2.1-2.6.
2.1.2 Glassware and disposables
All glassware used was washed with tap water and detergent followed by rinsing with 
dl-kO. All plasticware was purchased from VWR-BDH Ltd (Gillingham, Dorset, UK), 
unless otherwise stated.
2.1.3 Electrophoresis consumables
For agarose gel electrophoresis, Agarose MP was supplied from Roche Diagnostics 
(Lewes, East Sussex, UK). DNA Molecular Weight Markers II (Hind Ill-digested X DNA) 
and IX (Hae Ill-digested cpxl74 DNA) were purchased from Roche Diagnostics Ltd 
(Lewes, East Sussex, UK). Figure 2.1 shows sizes of standards.
56
Table 2.1 Buffers for DNA manipulation
BUFFER FORMULA
Tris-borate (TBE) buffer stock (10X) 100 mM Tris, 10 mM Boric acid, 1.25 mM EDTA
Tris-acetate (TAE) buffer stock (50X) 40 mM Tris, 1 mM EDTA, pH 8.0
Direct purification buffer for DNA isolation 50 mM KC1,10 mM Tris-HCl pH 8.8,1.5 mM MgCl2, 0.1% 
Triton X®-100
Mini-prep Cell resuspension solution 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, 100 pg/ml RNAse 
A
Mini-prep Cell Lysis Solution 0.2 M NaOH, 1 %SDS
Mini-prep Neutralisation Solution 4.09 M guanidine hydrochloride, 0.759 M potassium acetate, 
2.12 M glacial acetic acid, pH 4.8
Mini-prep Column Wash Solution 60% ethanol, 60 mM potassium acetate, 8.3 mM Tris-HCl, 
0.04 mM EDTA, pH 8.0
Resuspension Buffer PI 50 mM Tris-HCl, pH 8.0,10 mM EDTA, 100 pg/ml RNAse 
A
Lysis Buffer P2 200 mM NaOH, 1% (w/v) SDS
Neutralisation Buffer P3 3 M potassium acetate, pH 5.5
Equilibration Buffer QBT 750 mM NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) ethanol, 
0.15% (v/v) Triton® X-100
Wash Buffer QC 1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) ethanol
Elution Buffer QF 1.25 M NaCl, 50 mM Tris-HCl, pH 8.5,15% (v/v) ethanol
DNA agarose gel loading buffer (10X) 2.7 ml glycerol, 0.3 ml TBE buffer (lOx), 1% SDS, 1 ml 0.5 
M EDTA, pH 8.0
PCR ‘master’ mix 1000 pi 10 x PCR buffer, 250 pi each 2.5 mM dATP, dCTP,
(taken from Amersham reagents) dGTP, d lTP, 6.5 ml sterile dH20
1 x NEBuffer 2 (NEBiolabs Ltd, UK) 10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM 
dithiothreitol (pH 7.9)
1 x NEBuffer 4 (NEBiolabs Ltd, UK) 20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM 
potassium acetate, 1 mM dithiothreitol (pH 7.9)
1 x Buffer H (Roche Diagnostics, UK) 10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM 
dithioerythritol (pH 7.5)
1 x Buffer M (Roche Diagnostics, UK) 10 mM Tris-HCl, 10 mM MgCl2, 100 mM NaCl, 1 mM 
dithioerythritol (pH 7.5)
1 x Ligase buffer (NEBiolabs Ltd, UK) 50 mM Tris-HCl (pH 7.0), 10 mM MgCl2, 10 mM 
dithiothreitol, 1 mM ATP, 25 pg/ml bovine serum albumin
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Table 2.2 Buffers for protein manipulation
BUFFER FORMULA
2 x SDS-PAGE loading buffer 1.25 mM Tris-HCl, pH 6.8; 20& (v/v) glycerol; 2% 
(v/v) p-mercaptoethanol; 0.1% (w/v) bromophenol 
blue; 0.1% (w/v) SDS
1 x SDS-PAGE running buffer 25 mM Tris-HCl; 192 mM glycine; 0.1%( w/v) SDS
1 x transfer buffer 25 mM Tris-HCl; 192 mM glycine; 20% (v/v) 
methanol
1 x N-terminal transfer buffer 10 mM CAPS, pH 11.0; 10% (v/v) methanol
Coomassie gel stain 0.1% (w/v) Coomassie Blue R-250; 45% (v/v) 
methanol; 10% (v/v) glacial acetic acid
Coomassie gel destain 30% (v/v) methanol; 10% (v/v) glacial acetic acid
Native lysis buffer for soluble pellet extraction 50 mM NaH2P 0 4, pH 8.0; 300 mM NaCl
Table 2.3 Microbial culture media for bacterial expression
MEDIA FORMULA
2 X TY broth 16 g tryptone, 10 g yeast extract, 5 g NaCl. Complete to 1 L with 
dH20. Autoclave.
For 2 X TY Agar, add 15 g/L agar prior to autoclaving.
Luria Bertani Broth (LB ) 10 g tryptone, 5 g yeast extract, 10 g NaCl. Complete to 1 L with 
dH20. Autoclave.
For LB Agar, add 15 g/L agar prior to autoclaving.
Low salt LB 10 g tryptone, 5 g yeast extract, 5 g NaCl. Complete to 1 L with 
dH20. Autoclave.
For Low salt LB Agar, add 15 g/L agar prior to autoclaving.
NZY+ Broth 10 g NZ amine (casein hydrolysate), 5 g yeast extract, 5 g NaCl. 
Complete to 1 L with dH20. Autoclave. Add 12.5 ml each of 1 M 
MgCl2, 1 M M gS04 and 20 ml o f 20% glucose prior to use. Filter 
sterilise.
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Table 2.4 Microbial culture media and solutions for yeast expression
MEDIA FORMULA
Yeast Extract Peptone Dextrose Medium Dissolve 10 g yeast extract and 20 g peptone in 900 ml dH20.
(YPD) Autoclave. When cool add 100 ml 20% glucose solution. Store at
(2% peptone; 1% yeast extract; 2% 4°C.
dextrose) For YPD agar add 20 g/L agar prior to autoclaving.
YPD with sorbitol (YPDS) Dissolve 10 g yeast extract, 20 g peptone and 182.2 g sorbitol in
(2 % peptone; 1% yeast extract; 2% 900 ml dH20. Autoclave. When cool add 100 ml 20% glucose
dextrose; 1M sorbitol) solution. Store at 4°C.
For YPDS agar add 20 g/L agar prior to autoclaving.
Minimal Dextrose Medium (MM) agar Add 15 g agar to 800 ml dH20 and autoclave. Cool and add 100
(1.34% Yeast Nitrogen Base with ml 13.4% YNB, 2 ml 0.02% biotin, 100 ml 20% glucose. Pour
ammonium sulphate and without amino plates immediately and store at 4°C.
acids (YNB); 4 x 10'5% biotin; 2%
dextrose
Minimal Methanol Medium (MM) agar Add 15 g agar to 800 ml dH20 and autoclave. Cool and add 100
(1.34% YNB; 4 x 10'5% biotin; 0.5% ml 13.4% YNB, 2 ml 0.02% biotin, 100 ml 5% methanol. Pour
methanol) plates immediately and store at 4°C.
Buffered Methanol-complex Medium Dissolve 10 g yeast extract and 20 g peptone in 900 ml dH20.
(BMMY) (1% yeast extract; 2 % Autoclave. When cool add 100 ml 1M potassium phosphate
peptone; 100 mM potassium phosphate, buffer, pH 6.0,100 ml 13.4% YNB, 2 ml 0.02% biotin, 100 ml
pH 6.0; 1.34% YNB; 4 x 10‘5% biotin; 5% methanol. Store at 4°C.
0.5% methanol)
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Table 2.5 Microbial culture media and solutions for yeast fermentation
MEDIA FORMULA
YEPD medium/glucose primary culture Dissolve 4 g peptone, 4 g yeast extract, 3 g glucose into 230 ml
medium dH20. Autoclave.
Basic salt medium Dissolve 5.4 g CaS04,87.6 g K2S 0 4, 70.2 g M gS04: 7H20, 54 g 
(NH4)2S 0 4and 300 ml Glycerol into 5.0 L dH20. Autoclave.
Sodium hexametaphosphate Dissolve 150 g in 1 L dH20. Filter sterilise.
Secondary culture medium 300 ml basic salt medium 30 ml sodium hexametaphosphate, 1 
ml trace elements (see Table 2.6). Filter sterilise.
Fermentation medium 4.7 L basic salt medium, 1 L sodium hexametaphosphate, 1 ml 
anti-foam, 24 ml trace elements. Autoclaved in fermentor.
Limited glycerol feed 300 ml glycerol, 300 ml dH20. Autoclave. Add 7 ml sterile trace 
elements.
Limited methanol feed 2 L methanol, 24 ml sterile trace elements.
Dissolve the trace elements (PTM1; Invitrogen Ltd, UK) in the amounts and order shown 
below. Store at RT.
Table 2.6 Trace elements formulation
Component MW Concentration used (mM)
CuSO4.(H20)5 249.7 24
Nal 149.9 0.53
MnSO4.H20 169 17.8
Na2MoO4.(H20)2 241.9 0.83
CoC12.(H20)6 237.9 2.1
ZnC12 136.3 147
FeSO4.(H20)7 278 234
H3B03 61.83 0.32
H2S04 98.07 188
D-biotin 244.3 1.64
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Figure 2.1 DNA standards used in agarose gel electrophoresis. The separation o f  the DNA standards is 
shown a 1% agarose gel and their sizes are indicated.
Pre-cast Tris-Glycine SDS-PAGE minigels (10 or 15 well, 8 % or 12% polyacrylamide, 
1 mm thick) and protein molecular weight markers (Multimark®; See Blue®, See Blue2® 
Mark 12®) were obtained from Invitrogen Ltd (Paisley, UK). Sequencing grade 0.45-pm 
polyvinylidene difluoride (PVDF) membrane and chromatography filter paper was 
purchased at Bio-Rad Laboratories Ltd (Hemel Hampstead, U.K.). Figure 2.2 shows MW.
SeeBlue M ultim ark Marie 12 SeeBlue Plus2
250 k D a(l)—
98 kDa (2)—
64 kDa (3)—
50 kDa (4)-------
36 kDa (5)____
30 kDa (6)—
16 kDa (7)-------
6 kDa (8)____
4 kDa (9)-------
250 kDa (1 
148 kDa (2b]
60 kDa (3)
42kDa (
30 kDa (6)
22 kDa (5b) 
17 kDa (7) 
6 kDa (8) 
4 kDa (9)
200 kDa ( 1 ) ____
1163 kDa (2c)
250 kDa ( 1 ) -------
la * *
97.4 kDa (2 b ) ------ 148 kDa (2b) _
66J kihi ( 2 )  
e c  A l ,n «  f \ \ 98 kDa ( 2 ) ____0 0 .4  Kl/9 (j) 1
64 kDa (3) _
36^  kDa ( 6 a ) ------ 50kDa (4)
31 ld>a (5) 36 kDa (5)
21.5 kDa (7 a ) ------ 22 kDa (6)
14.4 kDa (7)
6 kDa (8) !ii 16 kDa (7) ~n 6 kDa (8)
Figure 2.2. Apparent molecular weights o f  SeeBlue, Multimark, Mark 12 and SeeBlue Plus2 markers 
subjected to SDS-PAGE (4-20% Tris-Glycine). Molecular weight markers correspond as follows: (1) 
Myosin; (2)BSA; (2b) Phosphorylase B; (2c) P-galactosidase; (3) Glutamic Dehydrogenase; (4) Alcohol 
Dehydrogenase; (5) Carbonic Anhydrase; (5b) Myoglobin red; (6) Myoglobin; (6a) Lactate Dehydrogenase; 
(7) Lysozyme; (7a) Trypsin inhibitor, (8) Aprotinin; (9) Insulin. Taken from Invitrogen catalogue.
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MW calibrants for gel filtration chromatography were purchase from Bio-Rad 
Laboratories (UK). Their components are as follows: thyroglobulin (5.0 mg; 670 kD), 
bovine gamma globulin (5.0 mg; 158 kD), chicken ovalbumin (5.0 mg; 44 kD), equine 
myoglobin (2.5 mg; 17 kD) and vitamin B12 (5.0 mg; 1.35 kD).
2.1.4 Expression vectors
The bacterial expression vector pUCl 19HIS was a kind gift from the MRC Laboratory 
of Molecular Biology, Cambridge, UK. The bacterial expression vector pUCl 19myc/CEA 
(N-Al) was constructed by Dr. Kerry A. Chester and Prof. Robert Hawkins. Briefly, The N 
and Al domains of CEA were isolated from a human normal colon cDNA library 
constructed in the lambda ZAP vector using primers ‘Ndomain Ncol back’ (5’- 
ACGTACTCGCGGCCCAACCGGCCATGGCCAAGCTCACTATTGAATCC-3’) and 
‘Aldomain Notl forward’ (5’-
GATATGAGATACTGCGGCCGCATAGAGGACATTCAGGATGACTG-3’). 
Amplification was performed by 5 cycles of PCR under the following conditions: 
denaturation at 94°C for 1 minute, annealing at 50°C for 1 minute, and extension at 74°C 
for 1 minute. The reactions were further amplified for 25 more cycles as follows: 
denaturation at 94°C, annealing at 65°C, and extension at 74°C for 1 minute. The primers 
append Ncol and Notl sites to the 5’ and 3’ ends of the PCR fragment respectively and 
these were used to digest the subsequent PCR fragment for insertion into the similarly 
digested pUCl 19-based bacterial expression vector. The yeast expression vector pPICza- 
A was obtained from Invitrogen (Paisley, UK). The pRSMlOb was obtained from Dr. 
Chrystalin Graff and Dr. Dane Wittrup (MIT, Cambridge, USA).
2.1.5 Primers and enzymes
Custom-designed oligonucleotide primers were ordered from Sigma-Genosys Ltd 
(Poole, Dorset, UK). They were purified by SDS-PAGE and were received lyophilised and 
resuspended in sterile dH2 0  to a stock concentration of 100 pM and stored at -20°C. M l3 
sense (GTTTCCCAGTCACGAC) and anti-sense (CAGGAAACAGCTATGAC) primers
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were obtained from Sigma-Genosys Ltd (Poole, UK). The 5’
(GACTGGTTCCAATTGACAAGC) and 3’ AOX1 (TACTATTGCCAGCATTGCTGC) 
primers were obtained from Invitrogen Ltd (Paisley, UK). All other primer sequences are 
given in the Results chapters.
Restriction enzymes were obtained from New England Biolabs (Hitchin, 
Hertfordshire, UK), unless otherwise stated. Sequencing-grade trypsin was obtained from 
Roche Diagnostics (Lewes, East Sussex, UK).
2.1.6 Microbial strains
The bacterial strain TGI was a kind gift from Dr. Robert Hawkins (Cancer Research 
UK Department of Medical Oncology, Paterson Institute of Cancer Research, Manchester, 
UK). XLl-Blue was obtained from Stratagene (Cambridge, UK). TOPI OF’ and the wild- 
type yeast strain X-33 were obtained from Invitrogen (UK). Genotypes are given in Table
2.7.
Table 2.7 Microbial genotypes
STRAIN GENOTYPE Transformation vector and use
TGI supE thi-1 A(lac-proAB) A(mcrB-hsdSM)5(rkmk)  
/F ’ traD36 proAB lacPZAMIS]
pUCl 19-based vectors used for 
DNA propagation and protein 
expression in bacteria
TOPIOF’ F’ {proAB, laclq, /acZAM15, Tn/0, (TetR)} mcrA, 
A(mrr-hsdRMS-mcrBC), <D80/acZAM15, AlacX14, 
deoR, recA l, X araD\2>9, A{ara-leu)1691, galU, 
galK, /7?5L(StrR), endAl, nupG
pPICZaA-based vectors used for 
DNA propagation
XLl-Blue rec A l endAl gyrA96 thi-1 h sdR ll supE44 relA l 
[F’ proAB lacP lac ZAM15 Tn/0 (TetR)]
pPICZaA-based vectors used for 
repair o f nicks in mutated plasmid 
DNA
X-33 Wild-type pPICZaA-based vectors used for 
protein expression in Pichia pastoris
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2.1.7 Proteins
Carcinoembryonic antigen (CEA) was obtained from laboratory stocks isolated by the 
perchloric acid method (Keep et al, 1978) from human colorectal tumour liver metastases, 
followed by affinity-purification on an anti-CEA IgG A5B7 column. Perchloric acid- 
isolated CEA was also kindly donated by Dr. Graeme Denton and Professor Alan Perkins 
(Nottingham University).
Human serum albumin (>99% Essentially Fatty Acid free, Globulin free) and bovine 
serum albumin were obtained from Sigma-Aldrich Ltd. Sterile heat inactivated, stabilised 
HSA 4.5% B.P. for radiolabelling experiments was purchased from Immuno Ltd (Norfolk, 
UK).
2.1.8 Antibodies
The murine anti-CEA scFv, MFE-23, was originally selected from a combinatorial 
phage display library produced from mice immunised with CEA (Chester et al, 1994). All 
references to MFE-23 are to the bacterially-expressed hexahistidine-tagged form, unless 
otherwise stated. MFE-23 was purified by IMAC (see 2.2.3.1) from induced E. coli cells 
transformed with pUCl 19/MFE-23 HIS following protocols from Casey et al (1995). The 
murine anti-CEA IgG A5B7 (bulk purified from a hybridoma) was obtained from clinical- 
grade laboratory stocks generated by Celltech (Slough, UK).
Laboratory stocks of polyclonal antibodies were raised against MFE-23 by 
immunisation of a rabbit with purified MFE-23. Antibodies against CEA were obtained 
from immunisation of rabbit or goat with CEA. Rabbit anti-HSA and mouse anti-cmyc tag 
clone 9E10 were purchased from Sigma Ltd (UK). Mouse tetrahis (anti-HIS) antibody was 
obtained from Qiagen (Crawley, West Sussex, UK).
The conjugated antibodies goat anti-rabbit horse radish peroxidase (HRP) and rabbit 
anti-goat HRP were purchased from Sigma Ltd (UK). Sheep anti-mouse HRP was 
obtained from Amersham Biosciences Ltd (Chalfont St Giles, Buckinghamshire, UK).
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2.1.9 Animals
TO outbred albino mice were obtained from Harlan Ltd (Bicester, UK). Nude MF1 
mice (nu/nu) were obtained from an in-house breeding colony.
2.2 Methods
2.2.1 DNA manipulation and molecular biology techniques
2.2.1.1 Polymerase Chain Reaction (PCR)
PCR amplifications were carried out using the GeneAmp kit from Applied Biosystems 
(Roche Diagnostics Ltd, UK), unless otherwise stated. The reaction buffer was 10 mM 
Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM MgC12, 0.001% (w/v) gelatine. The four 
deoxynucleoside triphosphates (dNTPs) were diluted from their original stock 
concentrations of 10 mM to 1.25 mM in sterile d ^ O  as a mixture, and used at a working 
concentration of 0.2 mM. Oligonucleotide primers at a stock concentration of 100 pM 
were diluted to 10 pM as a working dilution. AmpliTaq® DNA polymerase was at a stock 
concentration of 5 U/pl. PCR was carried out on a Biometra Personal Cycler.
PCR for subcloning
Plasmid DNA was subjected to PCR for the incorporation of restriction sites to 
facilitate subcloning into expression plasmids. All PCR reactions were carried out in 100 
pi final volumes, completed with sterile dH2 0 , unless otherwise stated. PCR reactions 
were performed as follows (individual PCR reactions are outlined in Appendix 1): 5 pi (5 
ng) template plasmid DNA, 10 pi dNTP mix, 2 pi each oligonucleotide (final conc. 0.2 
pM), 10 pi 10 X PCR reaction buffer, 0-12 pi 25 mM MgCfe, 0.5 pi AmpliTaq® DNA 
polymerase, completed to 100 pi with sterile dH2 0 . Amplification was carried out by 30 
cycles of PCR as follows: denaturation at 94-95°C for 1-2 min, annealing (according to
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specific primer melting temperatures) at 50-72°C for 1-2 min, extension at 72°C for 1-2 
min, followed by a final extension at 72°C for 7-10 min.
PCR screening o f bacterial colonies
Individual bacterial colonies were picked using sterile, plastic loops (VWR) from 2 X 
TY agar plates and added to 20 pi aliquots of reaction mixture. To make this mixture, 425 
pi of PCR ‘master mix’ (see Table 2.1), containing 10 x PCR buffer, dNTP mixture and 
dFfeO, was combined with 25 pi each of Ml 3 sense and anti-sense primers (final conc. 0.2 
pM) and 4.75 pi AmpliTaq® DNA polymerase. Amplification was carried out by 30 cycles 
of PCR as follows: 94°C for 1 min, 50°C for 1 min, 72°C for 1 min.
PCR screening o f yeast colonies
Individual yeast colonies were picked using sterile, plastic loops (VWR) from YPDS 
plates and added to 50 pi of PCR ‘master mix’ (see Table 2.1). The tubes were heated at 
99°C for 10-15 min, at which time lpl of each oligonucleotide primer (final conc. 0.2 pM) 
was added to each tube, along with 0.5 pi AmpliTaq® DNA polymerase. Amplification 
using 5’ and 3’ AOXl primers was carried out by 30 cycles of PCR as follows: 95°C for 1 
min, 54°C for 1 min, 72°C for 1 min, with a final extension of 7 min. Amplification using 
specific primers was carried out by 30 cycles of PCR as follows: 95°C for 1 min, 70°C for 
1 min, 72°C for 1 min.
PCR for site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene, Cambridge, UK) using a set of complementary primers 
overlapping the region to be mutated. Melting temperatures (Tm) of the primers to 
determine annealing temperatures in PCR amplifications were estimated using the 
following equation:
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Tm=81.5 + 0.41(%GC) -675/N-%mismatch [Equation 2.1]
where N is the primer length in bases, and % GC and % mismatch are whole numbers.
Amplification was carried out according to manufacturer’s protocols in 600 ,ul snap-fit 
thin-walled tubes (Bio-Rad Laboratories, UK). Briefly, 5 pi (5 ng) of template plasmid 
DNA was added to 5 pi 10 X reaction buffer (consisting of 100 mM KC1, 100 mM 
(NHO2 SO4 , 200 mM Tris-HCl (pH 8 .8 ), 20 mM MgS04, 1% Triton® X-100,1 mg/ml 
nuclease-free bovine serum albumin), 1 pi dNTP mix, 1.25 pi each oligonucleotide (125 
ng), and sterile dt^O  to 50 pi. One micolitre of PfuTurbo® DNA polymerase (2.5 U/ pi) 
was then added to each reaction. Reactions were incubated at 95°C for 30 s followed by 
12 cycles of PCR as follows: 95°C for 30 s, 55°C for 1 min, 6 8 °C for 2 min/kb plasmid 
length (reaction times were between 12-13.2 min).
2.2.1.2 Agarose gel electrophoresis
Agarose gel electrophoresis was performed using 1% horizontal slab gels containing 
5 pg ethidium bromide and run in an Hi-Set mini horizontal electrophoresis unit (Anachem, 
UK). For analytical gels, 0.5 mg of agarose MP (Roche Diagnostics, UK) was added to 50 
ml 1 X TBE buffer (see Table 2.1) and the slurry was dissolved by heating in the 
microwave. After slight cooling (so that it was comfortable to hold), 5 pi of ethidium 
bromide was added and the mixture was poured into the gel forming unit with appropriate 
well formers to set. 10 x DNA loading buffer (1 pi; see Table 2.1) was added to 10 pi of 
DNA sample and loaded into wells, alongside 10 pi of DNA Molecular Weight Markers 
(250 n g ). Electrophoresis was carried out in 1 X TBE buffer with 0.2 pg/ml ethidium 
bromide at a constant voltage of 50 mV using the Pharmacia LKB-GPS 200/400 power 
pack (Pharmacia, UK) until desired separation. Bands were visualised using a UVP 
transilluminator (Genetic Research Instrumentation Ltd, Essex, UK) at 312 nm. Gels were 
photographed using a DS34 polaroid direct screen instant camera (Genetic Research 
Instrumentation Ltd. Essex, UK) with black and white Polaroid film type 667.
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For gel purification, NuSieve low melting temperature agarose was resuspended in 1 X 
TAE buffer (see Table 2.1) with 5 pg ethidium bromide and run at a constant voltage of 30 
mV.
2.2.1.3 DNA isolation and preparation
Purification o f PCR product
PCR products were purified using the Wizard® PCR Preps DNA purification system 
(Promega, Madison, WI, USA) as directed by the manufacturer. Up to 300 pi of sample 
was transferred to a fresh 1.5 ml microcentrifuge tube and 100 pi of Direct purification 
buffer (see Table 2.1) was added, followed by 1 ml of Purification resin (glassbeads). The 
mixture was vortexed three times over 1 min and applied to a Wizard PCR prep mini­
column using a 2 ml syringe. The minicolumn was washed with 2 ml 80% isopropanol 
(v/v) using a 2 ml syringe, and centrifuged at 10,000 x g  for 2 min. Bound DNA was 
eluted by the addition of 50 pi dFfeO for 1 min followed by centrifugation of the column for 
2 0  s at 1 0 , 0 0 0  xg .
Purification o f DNA fragments from agarose
DNA fragments isolated from agarose gels (using a sterile scalpel) were transferred to
1.5 ml microcentrifuge tubes and melted at 70°C for 5-10 min in the presence of 1 ml of 
Purification resin. Tubes were mixed every minute until gel fragments were completely 
melted. DNA was then extracted using the Wizard® PCR Preps DNA purification system 
as above.
Plasmid preparation
Plasmids were isolated from bacterial cultures using two systems. For small-scale 
production (10-20 pg) of DNA, the Wizard Plus SV DNA Miniprep Kit (Promega, 
Southampton, UK) was used. For larger-scale production, the Qiagen Midi (up to 100 pg) 
and Maxi (up to 500 pg) Plasmid prep kits were used (Qiagen, UK). A single bacterial
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colony transformed with plasmid DNA was used to inoculate 2 ml of the appropriate 
medium (2 X TY or LB for pUCl 19 vectors, low salt LB for pPIC vectors; see Table 2.3) 
containing glucose and antibiotic (ampicillin, final conc. of 100 pg/ml for pUCl 19 vectors; 
Zeocin™, final conc. of 25 pg/ml for pPIC vectors) in a sterile, 50 ml polypropylene tube. 
The culture was then grown to confluency at 37°C in an orbital shaker (Innova 4000 
incubator shaker, New Brunswick Scientific) at 250 rpm. For maxiprep cultures, the entire 
2  ml starter culture was used to inoculate 2 0 0  ml fresh medium (containing antibiotic) 
contained in a sterile, 2L conical flask and grown overnight (approximately 16 h) at 37°C 
in an orbital shaker at 250 rpm. For midiprep cultures, 0.3 ml of the starter culture was 
used to inoculate 30 ml fresh medium (containing antibiotic) contained in a sterile, 250 mL 
conical flask and grown overnight as before. For miniprep cultures, the 2 ml cultures were 
started in the evening and grown overnight as before.
One millilitre of miniprep culture was pelleted in a microcentrifuge tube at full speed 
(14,000 x g) for 1 min at room temperature. Supernatant was poured off and cells were 
resupended in 250 pi Cell Resuspension Solution (see Table 2.1) by vortexing, followed by 
the same amount of Cell Lysis Solution (see Table 2.1). The tube was mixed by inversion 
and incubated until a clear lysate had formed, at which point 10 pi of Alkaline Protease 
Solution (1.32 M potassium acetate, pH 4.8) was added and the mixture was incubated at 
room temperature for 5 min. At this time, 250 pi of Neutralisation Solution (see Table 2.1) 
was added, mixed by inversion and immediately centrifuged at 14,000 x g  for 1 0  min at 
room temperature. The supernatant was transferred to a spin column and centrifuged at 
14,000 x g  for 1 min. The column was washed with 750 pi of Column Wash Solution (see 
Table 2.1) by centrifugation at 14,000 x g  for 1 min, followed by another wash with 250 pi 
of Column Wash Solution. The column was dried by centrifugation at 14,000 x g for 2 min 
and DNA was eluted into a fresh 1.5 ml microcentrifuge tube using 50 pi of Nuclease-Free 
H2O by centrifugation at 14,000 x g  for 1 min. DNA was stored at -20°C.
Maxi- and midi-prep overnight cultures were pelleted by centrifugation at 6,000 x g, 
4°C for 15 min. The bacterial pellets were resuspended in 10ml (maxi-prep) or 4 ml (midi­
prep) cold Resuspension Buffer PI (see Table 2.1), followed by the same amount of chilled 
Lysis Buffer P2 (see Table 2.1), mixed by inversion and incubated for 5 min at room
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temperature. At this time, 10ml (maxi-prep) or 4 ml (midi-prep) of Neutralisation Buffer 
P3 (3 M potassium acetate, pH 5.5) was added, mixed by inversion and incubated on ice for 
15 min.
The suspension was centrifuged at 20, 000 x g , 4°C for 30 min and promptly removed. 
Qiagen-tip 500 (maxi-prep) or 100 (midi-prep) columns were equilibrated with 10ml 
(maxi-prep) or 4 ml (midi-prep) of Equilibration Buffer QBT (see Table 2.1) by gravity, 
followed by the supernatant. The columns were washed with 2 x 30 ml (maxi-prep) or 2 x 
10 ml (midi-prep) applications of Wash Buffer QC (see Table 2.1) and the DNA was eluted 
with 10 ml (maxi-prep) or 5 ml (midi-prep) of Elution Buffer QF (see Table 2.1).
The DNA was precipitated with 0.7 volumes of isopropanol equilibrated to room 
temperature and centrifuged immediately at 15, 000 x g, 4°C for 30 min. The supernatant 
was promptly removed and the DNA pellet was washed with 5 ml (maxi-prep) or 2 ml 
(midi-prep) 70% (v/v) ethanol by centrifuging at 15,000 x g, 4°C for 5 min. The 
supernatant was carefully decanted off and the DNA pellet was air-dried for approximately 
5 min before resuspension in between 0.1-0.5 ml sterile dH2 0 .
Phenol/chloroform extraction and DNA precipitation
An equal amount of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) saturated with 
10 mM Tris, pH 8.0, ImM EDTA (Sigma-Aldrich Lt., Poole, UK) was added to sample, 
vortexed for 1 min and centrifuged for 1 min (14,000 x g) at room temperature. The 
aqueous phase was then carefully transferred to a clean tube. This was repeated until a 
clear interface between the aqueous and organic phases was achieved.
DNA was precipitated by the addition of 1/10 volume of 3 M sodium acetate, pH 6.0 
and 2.5 volumes 100% ethanol followed by incubation at -20°C from 1 h to overnight. 
Precipitated DNA was recovered by centrifugation (14, 000 x  g) for 30 min at 4°C. The 
pellet was then washed with 500 pi 80% (v/v) ethanol by centrifugation (14, 000 x  g) for 10 
min at 4°C, air-dried and resuspended in an appropriate volume of sterile dH2 0 .
70
DNA quantitation
The concentration of DNA was calculated by measurement of the optical density (OD) 
at 260 nm on a spectrophotometer (CECIL CE2041 2000) using a quartz cuvette. OD 
readings taken of sample diluted in dFfeO to 1:1000 and 1:500 were used to estimate the 
concentration of double-stranded DNA using the following formula (Sambrook et al,
1989):
DNA concentration = (OD260 x 50 x dilution factor) pg/ml [Equation 2.2]
where an OD260 of 1.0 is equivalent to approximately 50 pg/ml.
DNA concentration was also roughly estimated by the direct comparison of the 
brightness of bands on agarose gels (ethidium bromide fluorescence) with bands of DNA 
markers of known concentration.
2.2.1.4 Restriction digestion
Final concentrations of restriction enzymes were calculated based on the amount 
necessary to digest 1 pg coiled DNA. The volume of restriction enzyme added never 
exceeded 1/10 of the total reaction mixture volume. For double digestions, a compatible 10 
x reaction buffer (see Table 2.1) was used where at least one of the enzymes maintained 
100% activity. Individual digestion conditions are given in Appendix 1.
Vector and insert preparation for subcloning
Double-digestion was performed on insert and plasmid DNA to facilitate cloning.
Two hour restriction digestion reactions were performed at 37°C as follows, unless 
otherwise stated: 10 pg plasmid DNA (approx. 10 pi) or 50 pi Wizard® -purified insert 
DNA (maximum approx. 5 pg) was added to 12 pi 10 X reaction buffer (according to 
enzyme), 0-10 pi BSA (final concentration 100 pg/ml; according to enzyme), 5 pi each
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enzyme (50 units each of a combination of Not /, Xba I, or Xho I) and completed to 120 pi 
with sterile dH20.
Digestions with Sfi I were performed overnight (-16 h) at 50°C as follows: 10 pg 
vector DNA (approx. 10 pi) or 50 pi Wizard® -purified insert DNA (approx. 5 pg) was 
added to 20 pi 10 X reaction buffer M (Roche Diagnostics Ltd, UK), 4 pi Sfi 7(4 units; 
Roche Diagnostics Ltd, UK), and completed to 160 pi with sterile dH20. This was 
followed by digestion with the relevant second restriction enzyme {Not I, Xho I, or Xba I) 
for 2 h at 37°C. To the Sfi I digestion was added 20 pi 400 mM Tris-HCl, 10 pi 1 M NaCl, 
5 pi of the relevant enzyme (50 units; Roche Diagnostics Ltd, UK), and 5 pi sterile dH20.
Screening o f vector DNA for correct insert
Two microlitres of miniprep DNA was double-digested at 37°C for 2 h in the presence 
of 1 pi 10 x reaction buffer (according to enzyme), 0.5 pi each restriction enzyme {Not I, 
Xho I, or Xba I) and 6  pi sterile dH20. A master mix containing 10 x reaction buffer, 
restriction enzymes and sterile dH20 were made and 8  pi was aliquoted to tubes, at which 
time 2 pi mini-prep DNA was added. Control digestions were performed alongside mini­
prep reactions using parent plasmid DNA (1 pg) as well as an ‘uncut* control with no 
enzyme added to the reaction.
Linearisation ofplasmids for homologous recombination with X-33 yeast genome
pPICZa-A based plasmids containing insert DNA were linearised for transformation 
into the X-33 yeast genome. 10 pg (approx. 10 pi) of plasmid DNA was digested with 4 pi 
Pme I (40 units; New England Biolabs) for 2 h at 37°C in the presence of 5 pi 10 X 
NEBuffer 4 (see Table 2.1), 5 pi BSA (10 x BSA; final concentration 100 pg/ml), and 
completed to 50 pi with sterile dH20. Reactions were stopped by heat inactivation at 65°C 
for 20 min and digested DNA was purified by phenol xhloroform extraction and 
precipitated (see 2.2.1.3).
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Digestion o f methylated, non-mutated parental DNA template during site-directed 
mutagenesis
PCR reactions following amplification with specific oligonucleotide primers 
incorporating the required mutation (see 2.2.1.1) were cooled to < 37°C by incubation on 
ice for 2 min. The reactions were then digested following manufacturer’s protocols 
(Stratagene Quickchange® Site-Directed Mutagenesis Kit, Stratagene Ltd, Cambridge,UK). 
Briefly, 1 pi of Dpn 1(10 U/pl) was added directly to amplification reactions and mixed 
gently by pipetting. The reaction was spun down in a microcentrifuge for 1 min and 
immediately incubated at 37°C for 1 h.
2.2.1.5 Ligation reactions
A range of between 5:1 and 3:1 molar ratio of insert:vector was used for ligations. 
Ligations were performed at 16°C for 4 h to overnight in a Biometra personal cycler as 
follows, unless otherwise stated: 100 ng digested, agarose gel-purified vector DNA; 100- 
200 ng digested, Wizard® -purified insert DNA; 2 pi 10 X Ligase buffer (see Table 2.1);
0.5 pi (400 U/pl) T4 DNA ligase; sterile dH2 0  to 20 pi. A control ligation was performed 
by omitting insert in the reaction to determine self-ligation efficiency of the digested vector.
2.2.1.6 DNA sequencing
Automated DNA sequencing was carried out by Cytomyx (Cambridge, UK) on a 
MegaBACE 100 Capillary DNA sequencer (Amersham) using DYEnamic ET dye 
terminator chemistry and Thermo Sequenase II DNA Polymerase. Reactions were 
performed using 0.5-1 pg DNA template at 250 ng/pl and sequencing primers at 5 pmol/pl. 
Sequences were analysed using Chromas VI.45 software supplied by Cytomyx.
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2.2.1.7 Plasmid transformation o f bacterial cells
Preparation o f electro-competent bacterial cells
Single colonies of E. coli cells (e.g. TGI) were used to inoculate 10 ml 2 X TY (see 
Table 2.3) medium and the culture was incubated overnight at 37°C, 250 rpm. Overnight 
culture was diluted 1/100 into 1 L of 2 X TY medium and grown at 37°C, 250 rpm until 
OD600 reached 0.6, at which time the culture was chilled on ice for 30 min. The culture was 
then centrifuged for 15 min at 4000 x  g, 4°C and the pellet was resuspended in 1 L ice-cold 
sterile H2O. The resuspended cells were centrifuged again, and resuspended in 500 ml ice- 
cold sterile H2O. This process was repeated with 20 ml ice-cold sterile 10% (v/v) glycerol 
in H20, followed by a final centrifugation and respension in 3 ml ice-cold sterile 10% (v/v) 
glycerol in H2O. Cells were aliquoted to 100 pi and either stored on ice for immediate use 
or snap frozen in liquid nitrogen, followed by storage at -80°C.
Electroporation o f electro-competent bacterial cells
If frozen, the electrocompetent cells were thawed on ice. In a chilled 0.5 ml 
microcentrifuge tube, 50 or 100 pi of cells were mixed with 1-2 pi ligation mixture or 
diluted plasmid DNA (1 ng/pl in dl-^O) by gentle pipetting and incubated on ice for 1 min. 
The mixture of cells and DNA was transferred to an ice-cold, sterile 0.2 cm disposable 
cuvette (BioRad Laboratories, Hertfordshire, UK) and pulsed once for 4-5 ms in the 
electroporator (BioRad MicroPulser™, Bio-Rad Laboratories Ltd., Hemel Hampstead, 
U.K.). The apparatus was set to 2.5 kV, 25 pFD, and 200Q. One millilitre of 2 x TY (see 
Table 2.3) was immediately added to the pulsed cells and the culture was incubated for 1 h 
at 37°C with no agitation. At that time, 100 pi of culture was plated out onto 2 x TY agar 
plates (see Table 2.3) containing 100 pg/ml ampicillin and incubated at 37°C overnight.
Heat shock transformation
Transformations of circular, nicked dsDNA incorporating mutations were performed 
according to manufacturer’s protocols (Strategene QuikChange® Site-Directed Mutagenesis
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Kit). Briefly, 1 pi of Dpn I-treated DNA sample (see 2.2.1.4) was added to 50 pi of XL1- 
Blue supercompenent cells (Stratagene), which had been gently thawed on ice and 
aliquoted into prechilled polypropylene tubes (Falcon® 2059). The transformation 
reactions were gently mixed and incubated on ice for 30 min, at which time they were heat 
pulsed for 45 s at 42°C in a water bath and then incubated a further 2 min on ice. Five- 
hundred microlitres of NZY* broth (see Table 2.3) preheated to 42°C was added and the 
transformation reaction incubated at 37°C for 1 hwith shaking at 225 rpm. The entire 
transformation reaction (250 pi) was spread over two Low-salt LB agar plates (see Table 
2.3) containing 25 pg/ml Zeocin™. Plates were incubated at 37°C overnight.
2.2.1.8 Plasmid transformation o f yeast cells
Preparation o f electro-competent yeast cells
Yeast wild-type X-33 strain was prepared for electroporation following protocols by 
Invitrogen (UK). Five millilitres of YPD media (see Table 2.4) was inoculated with X-33 
cells picked from agar stabs (EasySelect™ Pichia Expression Kit; Invitrogen, UK) and the 
inoculated culture was grown overnight at 30°C, 250 rpm in an orbital shaker. The next 
day, 500 ml YPD was inoculated with 0.5 ml overnight culture and grown at 30°C, 250 rpm 
until an OD600 of between 1.3-1.5 (~16 h).
Cultures were centrifuged at 1,500 x g  for 5 min at 4°C and pellets resuspended in 500 
ml ice-cold sterile dFLO. Cells were centrifuged as before, followed by resuspension of 
the pellet in 250 ml ice-cold sterile CIH2O. The cells were centrifuged as before and the 
pellet resuspended in 20 ml ice-cold sterile 1 M sorbitol. The process was repeated once 
more and cells resuspended in 1 ml ice-cold sterile 1 M sorbitol. The cells were stored on 
ice and used the same day.
Electroporation o f electro-competent yeast cells
Eighty microlitres of freshly prepared X-33 electrocompetent cells were added to 10 pi 
of linearised plasmid DNA (see 2.2.1.4) and incubated on ice for 1 min. Cells were
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transferred to a pre-chilled 0.2 pm cuvette (Biorad) and pulsed once using the pre-set ‘Pic’ 
setting on BioRad MicroPulser™ (Bio-Rad Laboratories Ltd., Hemel Hampstead, U.K.) for 
5 ms at 2000 V. One millilitre of ice-cold, sterile 1 M sorbitol was immediately added to 
the mixture, the contents of the cuvette were transferred to a sterile 15 ml tube and the cells 
were incubated at 30°C for 2 h with no shaking. Transformed cells were spread onto YPDS 
plates (see Table 2.4) containing Zeocin™ (100 pg/ml) in 10, 25, 50,100, and 200 pi 
aliquots and incubated at 30°C for 4-5 days until colonies formed. At this time, ten clones 
were picked and streaked onto fresh YPDS Zeocin™ plates and incubated for 2-3 days until 
colonies formed.
Confirmation o f the methanol utilisation phenotype
Single colonies of Zeocin™-resistant transformants were spread in a regular pattern 
using a sterile plastic loop onto minimal methanol (MM) and then minimal dextrose (MD) 
plates {see Table 2.4). Ten colonies were spread per plate and incubated at 30°C for 2-4 
days, at which time they were scored. Mut+ strains grow normally on both plates, whereas 
Muts strains grow normally on MD plates but show little to no growth on MM plates.
2.2.2 Protein expression
2.2.2.1 Protein expression in bacterial cells
Single TGI bacterial colonies transformed with pUCl 19-based plasmid DNA were 
used to inoculate small starter cultures (5-10 ml) of 2 X TY with 100 pg/ml ampicillin and 
0.1% glucose (2 X TYAG) and grown until confluent (2-3 h) at 37°C, 250 rpm. For small 
scale expression, this culture was induced using P-D-thiogalactoside (IPTG) to a final 
concentration of 1 mM when OD600 had reached 0.9 and grown overnight at 30°C, 225-250 
rpm. For large scale expression, the culture was diluted 1:100 into 500 ml 2 X TYAG in a 
2L conical flask (total culture volume 4 L) and grown until an OD6oo=0.9 (2-3 h) at 37°C, 
250 rpm. At this time, the culture was induced as before and grown overnight at 30°C,
76
225-250 rpm. Glycerol stocks were made for high expressers by mixing 900 jil of culture 
with 100 pi sterile glycerol, followed by storage at -80°C.
Expression o f the CEA (N-Al) domains in a captured complex with purified MFE-23
Five millilitre cultures of 2xTY medium containing 100pg/ml ampicillin and 2% 
glucose were inoculated with individual bacterial colonies containing the CEA (N-Al)/ 
pUCl 19 myc construct and grown at 37°C with agitation until an OD6oo=0.9 (2-3 h). 
Cultures were pelleted at 4,000 x g  for 10 min, resuspended in fresh media containing 100 
pg/ml ampicillin and IPTG (1 mM final conc.), and induced for 2 h at 30°C with agitation. 
At this time either 100 pg purified MFE-23, 1 ml of inducing MFE-23 culture (see above), 
or 200 pi of expressed MFE-23 supernatant was added to the inducing CEA (N-Al) culture 
and the cells were further induced overnight for 16 h at 30°C with agitation. The overnight 
culture was centrifuged at 4,000 x g  for 10 min and the supernatants containing CEA (N- 
Al)/ MFE-23 complex were retained for analysis.
For large-scale expression, 5 ml cultures of 2xTY medium containing 100 pg/ml 
ampicillin and 2% glucose were inoculated with individual colonies and grown at 37°C 
with agitation until confluent (2-3 h). The culture was diluted 1:100 in 2 x 500 ml of 
2xTY medium containing 100 pg/ml ampicillin and 2% glucose and grown at 37°C with 
agitation until an ODeoo^O^ (2-3 h). The culture was pelleted at 11,300 x g  for 30 min, 
resuspended in 2 x 500 ml fresh media containing 100 pg/ml ampicillin and IPTG (1 mM 
final conc.), and the cells were induced for 2 h at 30°C with agitation. At this time, purified 
MFE-23 was added at a concentration of 5 pg MFE-23/1 ml of culture and further induced 
overnight for 16 h at 30°C with agitation.
Harvest o f bacterial supernatants containing expressed protein
Small-scale, overnight culture was centrifuged at 4,000 x  g  for 10 min at room 
temperature and supernatant was decanted into sterile, polypropylene tubes. Large-scale, 
overnight culture was centrifuged at 11,300 x g  for 1 h, and then passed through 0.45 pm 
and 0.2 pm disposable Nalgene filters (Millipore UK). The filtered supernatant (up to 4 L) 
was concentrated to a final volume of 150 ml on an Amicon CH2 ultrafiltration system
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(Millipore, U.K.), consisting of an RA2000 stirred-cell reservoir and an SI Y10 spiral 
cartridge with molecular weight cut-off of 10 kDa. EDTA was added to 1 mM and the 
concentrated supernatant was then pressure-dialysed against Dulbecco’s phosphate buffered 
saline, pH 7.2, without calcium chloride (PBS).
Extraction o f soluble protein from bacterial cell pellet
Bacterial cell pellets stored at either -20°C or -80°C were thawed on ice for 15 min and 
resuspended in Lysis buffer (see Table 2.2) at 2-5 ml/g wet weight. The lysis buffer was 
supplemented with 1 mM PMSF (phenylmethanesulfonyl fluoride; 100 mM stock in 
isopropanol) and a protease inhibitor cocktail for hexahistidine-tagged proteins (AEBSF, 
bestatin, pepstatin A, E-64; Sigma, UK) at 1 ml/20g wet weight. Lysozyme (Sigma- 
Aldrich Ltd, Poole, UK) was added to 1 mg/ml and the cells were incubated on ice for 30 
min. Lysed cells were sonicated (Kerry Ltd, UK) in 5 s bursts with 10 s rest periods 
between each burst until visibly less viscous, followed by centrifugation at 10,000 x g  for 
30 min at 4°C. The supernatant was filtered through 0.2 pm Nalgene vacuum filters 
(Millipore) and immediately purified.
2.2.2.2 Protein expression in yeast
Individual colonies were picked from YPDS plates (YPDSZ; see Table 2.4) containing 
100 pg/ml Zeocin and inoculated into 5ml BMGY medium (see Table 2.4) and grown until 
an OD600 of 2-5 at 30°C, 250 rpm (approximately 16 h). Overnight cultures were 
centrifuged for 5 min at 3,000 x g  (room temperature) and pellets were resuspended in 
BMMY (see Table 2.4) with the addition of 1 % casamino acid, pH 6.0 medium to a final 
OD600 = 1 (approximately 50 ml). Cultures were expressed at 30°C, 250 rpm with the 
addition of 100% methanol for a final concentration of 0.5% (v/v) every 24 h for a total of 
96 h. At this time cultures were centrifuged for 10 min at 3,000 x g  and supernatants were 
filtered through 0.2 pm Nalgene filters and stored at either 4°C for immediate purification 
or at -80°C. Glycerol stocks were made for high expressers by mixing 900 pi of culture 
with 100 pi sterile glycerol, followed by storage at -80°C.
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Seed lot preparation for P. pastoris fermentation
Fresh YPDSZ plates were prepared in a laminar flow cabinet under sterile conditions. 
Single colonies growing on YPDSZ plates were streaked out onto the freshly prepared 
YPDZ plates in the cabinet and grown at 30°C until colonies formed (1-2 days) in an empty 
incubator which had been sprayed with 80% (v/v) ethanol in sterile dtfeO. In the cabinet, 
colonies were picked from the fresh YPDSZ plates and used to inoculate 50 ml sterile 
YPDZ. The culture was grown at 30°C, 250 rpm in an empty incubator which had been 
sprayed with 80% (v/v) ethanol until an OD600 = 15-25 (approximately 48 h). At this time 
the culture was centrifuged in a sterile centrifuge tube for 10 min at 3,000 x g  and moved 
into the cabinet. The pellet was resuspended in 25 ml sterile YPD and dispensed in 1 ml 
aliquots into cryovials (Nunc) for storage at -80°C.
Fermentation o f  P. pastoris X-33 cells
Fermentations of P. pastoris X-33 cells were performed with the help of Dr. Berend 
Tolner (Department of Oncology) using a Bioflo 3000 Batch/Continuous Bioreactor (New 
Brunswick Scientific, Edison, NJ, USA). One frozen vial containing 1 ml of seed lot was 
used to inoculate a 250 ml primary culture of YEPD Glucose medium {see Table 2.5) and 
the culture was grown overnight at 30°C at 180 rpm (OD6oo= 12). Concomitant with this, 
fermentation medium was prepared by mixing 5 L basic salt medium (see Appendix 1) in 
the fermentor and 1 L sodium hexametaphosphate {see Table 2.5).
Five millilitres of the primary culture was used to inoculate a 0.2 pm filter-sterilised 
(Nalgene Ltd., UK) secondary culture comprised of 300 ml basic salt medium, 30 ml 
sodium hexametaphosphate, and 1 ml trace elements (AMRESCO; see Table 2.5). The 
secondary culture was grown overnight at 30°C at 180 rpm (OD6oo= 5 ). The 10 L 
fermentor, with remaining basic salt medium, was autoclaved and the remaining sodium 
hexametaphosphate was added, along with 1 ml anti-foam (Sigma-Aldrich Ltd., UK) and 
24 ml trace elements. The fermentor pH was set to 5.0, regulated by a base solution of 
100% NH4OH and an acid solution of 10% ortho phosphoric acid. The dissolved oxygen
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probe was set to 40%. The run was started upon addition of the complete secondary starter 
culture.
A limited glycerol feed (made up of an autoclaved mixture of 300 ml 100% glycerol 
with 300 ml water and 7 ml trace elements) was started immediately upon a sharp increase 
in dissolved oxygen (approximately 23-24 h) and the pH was reset to 6.5. One hour after 
the start of the limited glycerol feed, 11 ml of limited methanol feed (made up of 2000 ml 
methanol and 24 ml trace elements) was directly injected into the fermentor. Flow rates of 
glycerol and methanol feeds were altered during the run and are given in Table 2.8. The 
fermentation run was stopped after approximately 72 h post inoculation, at which time the 
cells were harvested by centrifugation at 11,300 x g  for 1 h. Cleared supernatants were 
filtered through 0.2 pm Nalgene vacuum filters (Millipore UK) and either immediately 
purified or stored at -80°C.
Time post limited feed 
start 
(h)
Flow rate glycerol 
(ml/h)
Flow rate methanol 
(ml/h)
0 120 0
1.0 120 0
1.5 100 0
2.0 80 0
2.5 60 0
3.0 40 0
3.5 20 0
4.0 0 10
6.0 0 20
8.0 0 30
10.0 0 42-45
Table 2.8. Flow rates for addition of glycerol and methanol during yeast fermentation
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2.2.3 Protein purification
2.2.3.1 Immobilised metal affinity chromatography (IMAC)
Ni-NTA-coated magnetic beads
The MagneHIS™ Protein Purification System (Promega, Madison, WI, USA) was 
used for immunoprecipitation studies following manufacturer’s protocols. Briefly, 
MagneHIS™ Ni-particles were vortexed to a uniform suspension and 30 pi was added to 1 
ml culture supernatant (3 pg MFE-23, CEA (N-Al), or MFE-23/CEA (N-Al), or 2 x TY), 
mixed by pipetting and incubated for 10 min at room temperature. The MagneHIS™ Ni- 
particles were isolated from the supernatant by insertion of the tube into a magnetic particle 
concentrator stand (Dynal, Oslo, Norway) for approximately 30 s, after which the 
supernatant was carefully removed with a pipette. The tube was removed from the magnet 
and the MagneHIS™ Ni-particles were resuspended in 150 pi 20 mM imidazole/PBS. The 
tube was placed in the magnetic stand and wash solution removed as before. This wash step 
was repeated two more times (total of three washes).
One millilitre of culture supernatant (MFE-23, CEA (N-Al), or 2 x TY) was added to 
pre-coated MagneHIS™ Ni-particles and washed as before. After the final wash, the 
particles were resuspended in 25 pi dH2 0  and 25 pi 2 x SDS-PAGE reducing buffer (see 
Table 2.2).
Small-scale IMAC purification
Small-scale purifications of hexahistidine-tagged proteins were performed on culture 
supernatants (10 ml) or solublised cell pellets (from 10 ml cultures) using the Ni-NTA spin 
column kit (Qiagen, UK) as directed by manufacturers. Briefly, spin columns were pre­
equilibrated with 600 pi of the appropriate buffer (2 x TY for supernatants; lysis buffer for 
cell pellets) and centrifuged at 700 x g  for 2 min in a microcentrifuge. Supernatants or 
solubilised cell pellets were then applied to the pre-equilibrated columns and centrifuged as 
before. Flow-through was collected and columns were washed 3 x 600 pi Wash buffer (50 
mM sodium phosphate buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole) by centrifugation
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as before. Bound proteins were eluted with 2 x 200 pi Elution buffer (50 mM sodium 
phosphate buffer, pH 8.0,300 mM NaCl, 250 mM imidazole) by centrifugation as before.
Large-scale IMAC purification
The large-scale IMAC purification of hexahistidine-tagged proteins was performed 
on an AKTA FPLC™ system (Amersham Pharmacia Biosciences, Little Chalfont, U.K.) at 
a flow rate of 10 ml/min. An XK-26/20 column (Amersham Biosciences, Little Chalfont, 
U.K.) was prepared with 53 ml of Chelating Sepharose™ Fast Flow matrix (Amersham 
Biosciences, Little Chalfont, U.K). The packed matrix was charged with metal ions using 2 
x column volumes of 0.1 M CuSC>4 , unbound ions were washed off with 2 x column 
volumes of dH2 0 , and the matrix was equilibrated with 2 x column volumes of PBS with 
the addition of 1M NaCl (PBSN). The filtered supernatant, containing 1 M NaCl, was 
loaded onto the column (150ml concentrated bacterial supernatants; 1L yeast supernatants) 
and unbound protein was washed off with 4 x column volumes of PBSN. Bound protein 
was recovered in 7 ml fractions by competitive elution using 4 x column volumes of 40 
mM Imidazole in PBSN to remove non-specific binders, followed by the same volume of 
200 mM Imidazole in PBSN. The column was regenerated using 2 x column volumes of 
100 mM EDTA to strip the metal ions. Peak fractions were pooled and dialysed against 
PBS (4L) for 20 hours at 4°C with four buffer exchanges.
Purification of bacterial supernatants containing CEA (N-Al) complexed to MFE-23 
was performed as above with the concentration of NaCl lowered from 1 M to 200 mM in 
all buffers.
2.2.3.2 CEA affinity chromatography
Affinity chromatography was carried out on Sepharose-4B gel matrix (Amersham 
Biotech) covalently coupled to CEA (Casey et al, 1995). Filtered supernatants were 
passed through the column under gravity flow and the flow-through was reapplied up to 
three times. Unbound material was washed off with PBS (4 column volumes), and CEA- 
bound proteins eluted with 4 column volumes 50mM diethylamine (DEA), pH 11.0, in 1 ml
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fractions buffered with 200 pi 1M NaPC>4 , pH 8.0. Fractions containing the highest OD280 
were pooled and dialysed against PBS (4 L) for 20 h at 4°C with four buffer changes.
2.2.3.3 Size-exclusion chromatography
Proteins were separated by gel filtration using an AKTA FPLC™ system (Amersham 
Biosciences, Little Chalfont, U.K.) with a 2 ml injection loop. A HiLoad™ Superdex 200 
column (16/60, 150 ml; Amersham Biosciences, UK) was used to separate proteins larger 
than -100 kDa. Proteins were filter sterilised (0.2 pm; Acrodisc, UK) and injected onto the 
column at a constant flow rate of 1.5 ml/min PBS. Fractions (2 ml) were collected 
immediately after the void volume (40 ml) for a total of 120 ml. Peak fractions were 
pooled and concentrated (see 2.2.3.4).
For resolution of smaller proteins, a Superdex 75 (16/60,120ml; Amersham 
Biosciences, UK) was used. Filter sterilised proteins were injected onto the column at a 
constant flow rate of 2 ml/min PBS. Fractions (2 ml) were collected immediately after the 
void volume (34 ml) for a total of 100 ml. Peak fractions were pooled and concentrated (see 
2.2.3.4).
For calibration, the Gel Filtration Standard kit (Bio-Rad, UK) was prepared and 
applied to column as directed by manufacturers.
2.2.3.4 Protein concentration
For small volumes, Microcon YM3 columns (3 kDa molecular weight cut-off; 
Millipore, UK) were used. Up to 500 pi of protein was applied to the column and 
centrifuged at 10,000 x g  for 30 min intervals until the desired concentration was reached. 
For volumes up to 15 ml, proteins were concentrated using Centriprep (Millipore) columns 
(YM3; molecular weight cut-off 3,000 Da or YM10; molecular weight cut-off 10,000 Da) 
by centrifugation at 3,000 x g  at 4°C for 30 min intervals until the desired concentration 
was reached. For volumes up to 50 ml, an Amicon stirred-cell fitted with a pre-wetted 
YM10 (10 kDa molecular weight cut-off) membrane (Millipore, UK) was applied. The
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Amicon concentrator was placed on a magnetic stirrer at 4°C and proteins were 
concentrated by pressurised N2 (BOC gases).
2.2.4 Protein characterisation
2.2.4.1 Protein quantitation
The concentration of proteins was determined using the following equation:
A28o= £ 2 8 0  x c x l  [Equation 2.3]
where A280 is the absorbance at 280 nm of protein samples measured in quartz cuvettes on a 
Cecil CE2041 2000 series spectrophotometer, £280 is the extinction coefficient (0.1%, 280 
nm, 1 cm path length) of the protein calculated based on the protein primary amino acid 
sequence using the Expasy Protparam web tool
(http://www.expasv.ch/tools/nrotparam.htmB. c is the protein concentration, / is the 
pathlength of the cuvette (cm). For MFE-23, £280=1.9; for MFE-23-MFE-23, £280=1 -9; for 
HSAbody, £280=1.1.
2.2.4.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
Electrophoresis of proteins was performed using the discontinuous buffer system 
(Laemmli, 1970) under reducing conditions. Samples were prepared by the addition of 2 x 
SDS-PAGE reducing buffer (see Table 2.2) followed by denaturation at 95°C for 5 min. 
Samples were loaded onto 8% or 12% Tris-Glycine pre-cast mini-gels (Invitrogen, Paisly, 
U.K.) and separated on an XCell II™ Mini-Cell system (Invitrogen) in 1 x SDS-PAGE 
Running buffer (see Table 2.2) on an automated program of 90 min at 35 mA (125V, 5 W) 
using a PowerEase® 500 power supply (Invitrogen). Following electrophoresis, proteins 
were stained with Coomassie blue or subjected to Western blotting (see 2.2.43'). Gels were 
stained for 2-16 h at room temperature and coomassie-stained proteins were visualised after 
destaining (1 h to overnight) with repeated Destain solution changes. Gels were rinsed 3 
times in dFbO for 15 min each, followed by 15 min incubation in Gel drying solution
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(Invitrogen) in preparation for drying using the Invitrogen Gel drying kit. The Gel drying 
solution was used to wet two plastic sheets (Invitrogen) and the gel was sandwiched 
between them and left to dry in a drying rack for 2  days at room temperature.
2.2.4.3 Western blot analysis
Following electrophoresis, proteins were transferred to sequencing grade 0.45-pm 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories Ltd., Hemel 
Hampstead, U.K.), which had been treated with methanol. Gels were sandwiched with the 
PVDF membrane between several sheets of pre-wetted chromatography filter paper 
(Whatman, Maidstone, UK) and submerged in an XCell II Blot Module (Invitrogen, Paisly, 
U.K.) filled with 1 x Transfer buffer (see Table 2.2). Proteins were transferred using an 
automated program of 90 min at 125 mA (25 V, 17 W).
Following electro-transfer, PVDF membranes were either stained for 5 min in 
Coomassie blue or blocked in 5% (w/v) Marvel skimmed milk powder (Marvel, UK) in 
PBS/0.02% NaN3 for at least 1 h. Coomassie-stained proteins were visualised after 
destaining with repeated destain solution changes. At this time, stained PVDF membranes 
were air-dried. For lectin blotting, the blocking buffer used was 1% (w/v) gelatine 
dissolved in dH2 0 .
The blocked blots were washed in PBS, and then incubated on a rocker at room 
temperature for 1 h in the appropriate primary antibody diluted in 1% (w/v) Marvel/PBS.
At the end of the incubation, blots were washed with 3 x 0.1% (v/v) Tween-20 in PBS, then 
3 x PBS, followed by incubation on a rocker at room temperature for 1 h in the appropriate 
secondary horseradish peroxidase (HRP)-conjugated antibody diluted in 1% (w/v) 
Marvel/PBS. Following incubation, the blots were washed as before and proteins 
visualised with DAB substrate solution (0.25 mg/ml 3, 3’-Diaminobenzidine 
tetrahydrochloride, 0.5 pl/ml H2O2 in d^O). The reaction was stopped by rinsing of the 
membrane in dH2 0 . Antibodies and the dilutions used are given in Table 2.9. For lectin 
blotting, the incubation buffer used was 0.05% (v/v) Tween-20 in PBS.
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Table 2.9 Antibody dilutions
Primary antibody (dilution) Secondary antibody (dilution)
Tetra His; Qiagen (1/1000) Sheep anti-mouse-HRP; Amersham 
(1/500)
Anti-cmyc 9E10; Sigma (1/1000) Sheep anti-mouse-HRP; Amersham 
(1/500)
Anti-MFE-23 rabbit sera (1/1000) Goat anti-rabbit-HRP; Sigma (1/1000)
Anti-CEA goat sera (1/500) Rabbit anti-goat-HRP; Sigma (1/1000)
Anti-CEA rabbit sera (1/500) Goat anti-rabbit-HRP; Sigma (1/1000)
Anti-HSA rabbit sera (1/1000) Goat anti-rabbit-HRP; Sigma (1/1000)
2.2.4.4 Enzyme-linked Immunosorbent Assay (ELISA)
ELISA were performed on 96-well microtitre plates (Costa, High Wycombe, UK) 
coated for 2 h with 100 pi PBS, CEA (2 pg/mL) or MFE-23 (5 pg/mL) diluted in PBS. 
Wells were washed 2 x with PBS and blocked with 250 pi 5% (w/v) Marvel/PBS/0.02% 
NaN3 from 2-16 h. Samples were applied to both CEA-, MFE-23-, or PBS-coated wells in 
duplicate. One hundred microlitres of sample (neat supernatants or purified proteins 
diluted in PBS) were applied to wells and incubated for 1 h, followed by washing with 4 x 
PBS/0.1% (v/v) Tween-20 and 3 x PBS. Wells were then incubated for 1 h with 100 pi 
primary antibody diluted in 1% (w/v) Marvel/PBS. Following incubation with primary 
antibody, wells were washed as before and incubated for 1 h with 100 pi HRP-conjugated 
secondary antibody diluted in 1% (w/v) Marvel/PBS. Wells were washed as above and 100 
pi OPD (O-phenylenediamine dihydrochloride; 0.4 mg/ml dissolved in phosphate citrate 
buffer, pH 5.0) was added. Reactions were stopped with 50 pi 4 M HC1 and the 
absorbances were measured at 490 nm using an Opsys MR™ Microplate Reader (Dynex 
Technologies). Antibody dilutions are given in Table 2.9.
2.2.4.5 N-terminal sequencing
Purified proteins were separated by SDS-PAGE (see 2.2.4.2) and transferred to PVDF 
membrane (see 2.2.4.S) using a running buffer consisting of 10 mM CAPS/10% (v/v) 
methanol in place of the Tris-based transfer buffer. Proteins transferred to PVDF 
membranes were stained with Coomassie blue (see 2.2.4.2) and the air-dried membrane 
was sealed in a plastic bag to prevent contamination. N-terminal sequencing was carried
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out on excised protein bands from the membrane by Dr. Jeff Keen at the BioMolecular 
Analysis Facility, School of Biochemistry and Molecular Biology, University of Leeds. 
Five to ten cycles of Edman degradation were performed using an Applied Biosystems 
Procise 494 high-throughput gas-phase/liquid pulse sequencer (Perkin-Elmer, Roche 
Diagnostics Ltd).
2.2.4.6 Analysis o f N-linked glycans
Peptide-N-glycosidase F  treatment
One hundred microlitres of purified protein (approximately 100 pg) was denatured 
with 0.5% SDS, 0.1% p-mercaptoethanol at 95°C for 5 min and allowed to cool. Triton-X 
(final concentration 1 %) was added and the protein solution was diluted with sodium 
phosphate buffer, pH 7.5 to a final concentration of 50 mM. At this time, 2 pi Peptide-N- 
glycosidase F (PNGase F; 1 U/pl in 100 mM sodium phosphate, 25 mM EDTA, pH 7.2; 
Roche Diagnostics) was added and the digestion mixture was incubated at 37°C for 1-2 h.
Protein (approximately 100 pg) was digested under native conditions by the addition 
of sodium phosphate buffer, pH 7.5 to a final concentration of 50 mM and 10 pi PNGase F. 
Digestion mixtures were incubated at 37°C for 16-18 h. Deglycosylation was assessed by 
SDS-PAGE and Western blot analysis {see 2.2.4.2 and 2.2.4.3).
DNA-sequencer-adapted FACE (DSA-FACE)
Glycosylation was further analysed by Professor Roland Contreras and Dr Wouter 
Vervecken at the Unit of Fundamental and Applied Molecular Biology (Department of 
Molecular Biology, Ghent University and Flanders Interuniversity Institute for 
Biotechnology, Ghent, Belgium) using DSA-FACE. DSA-FACE was performed following 
protocols detailed in Callewaert et al (2001). Briefly, 5 pg of protein was deglycosylated in 
a 96-well Multiscreen-IP microtitre plate (Millipore, USA) following Papac et al (1998) 
using PNGase F. The free glycans were fluorescently-labelled using 8 -amino-1,3, 6 - 
pyrenetrisulfonic acid (APTS), followed by gel filtration on Sephadex G-10 columns to 
remove excess APTS. A rhodamine-labelled internal standard was spiked into N-glycan
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solutions and the mixture was resolved by PAGE (12%) on an Applied Biosystems 377A 
gel-based DNA-sequencer (3500 V; 3 h; 23°C; Perkin-Elmer; Roche Diagnostics). A lane 
containing APTS-labelled malto-oligosaccharide was used as a reference (Kobata, 1994). 
Results were analysed using Genescan 3.1 software (Roche Diagnostics).
2.2.4.7 Surface enhanced laser desorption ionisation (SELDI) mass spectrometry
Mass spectrometry data was acquired using the SELDI ProteinChip® Biology System 
II (Ciphergen Biosystems Inc, Fremont, CA) and ProteinChip® Software 3.0. All 
experiments were done at room temperature unless otherwise stated.
One hundred microlitres of cleared cell supernatant or 1-5 pi (approximately 2 pmol) 
of purified protein was applied to a Normal Phase ProteinChip® Array (NP20; Ciphergen 
Biosystems Inc, Fremont, CA) and allowed to diy. Spots were washed 2-3 times 20 pi 
dFfeO followed by the immediate addition of 1 pi Sinapinic acid (SPA; trans-3,5- 
dimethoxy-4-hydroxycinnamic acid; Ciphergen Biosystems Inc, Fremont, CA) at 5 mg/ml 
in 50% acetonitrile / 0.1% trifluoroacetic acid. The external calibration of masses was 
carried out by applying 0.5-1 pi Protein All-In-One MW Standard (Ciphergen Biosystems) 
to a blank spot. This gives a molecular mass accuracy of within 0.05% (ProteinChip® 
Software Operation Manual 3.0). One hundred spectra were collected and averaged per 
spot in acquisitions where the UV laser intensity was set to 10.
For SELDI-affinity mass spectrometry, an IMAC3 ProteinChip® Array (Ciphergen 
Biosystems Inc, Fremont, CA) was prepared by washing spots with 5 pi of 100% 
acetonitrile followed by 1 pi of 50% (v/v) acetonitrile. Five microlitres of 50 mM NiS0 4  
was immediately loaded onto each spot and the chip was incubated for 30 min in a 
humidity chamber at room temperature. The humidity chamber consisted of an empty 
plastic pipette tip box half-filled with dE^O. When the lid was placed back on firmly it was 
sufficiently sealed to prevent drying of the chip for several hours. Spots were washed with 
PBS containing 200 mM NaCl, then 5 pi 50 mM NiSC>4 was reapplied and the chip was 
incubated for 30 min in the humidity chamber at room temperature.
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One microlitre of protein (~ 100 pg/ml) or 200 mM imidazole/PBS/200 mM NaCl was 
added to spots and incubated for 1 h in the humidity chamber. After washing as before, 5 pi 
modified sequencing-grade trypsin (Roche Molecular Biochemicals, Mannheim, Germany) 
was added at enzyme:substrate ratios of 1:20 or 1:100 in 25 mM ammonium bicarbonate, 
pH 8.0, The digestion times varied from 30-60 min at 37°C (in a humidity chamber). Spots 
were washed as before with a final wash of dH2 0  after which spots were dried and 1 pL a- 
cyano-4-hydroxycinnamic acid (5 mg/ml in 50% acetonitrile / 0.1% trifluoroacetic acid; 
Ciphergen Biosystems Inc, Fremont, CA) was applied. The external calibration of masses 
was carried out by applying 0.5-1 pi of Peptide All-in-One MW Standard Kit (Ciphergen 
Biosystems) to a blank spot. One hundred spectra were collected and averaged per spot in 
acquisitions where the UV laser intensity was set to 10.
The proteolytic peptide fragments were identified from their observed masses using 
the Protein Analysis Worksheet and the MS-Digest programs (web addresses: 
http://prowl.rockefeller.edu and http://prospector.ucsf.edu) (Clauser et al, 1999). The 
parameters of the MS-Digest program on the inputted CEA (N-Al) sequence were set to 
check for peptides containing oxidised methionine and pyro-glutamic acid and the number 
of maximum missed enzyme cleavages was set to 5.
2.2.4.8 BIAcore binding interaction studies
Experiments were performed on a BIAcore X system (BIAcore AB, Uppsala, Sweden) 
(at a constant temperature of 25°C) controlled by BIAcore Control V3.0 software (see 
Appendix 3). HBS-EP buffer (10 mM HEPES, pH7.0, 150 mM NaCl, 3.4 mM EDTA, 
0.005% surfactant P20) was used as the running buffer, unless otherwise stated.
Preparation o f chips
Recombinant CEA (N-Al) domains produced in P. pastoris (Y.C. Lee, Department of 
Oncology) were immobilised to CM5 biosensor chips by amine coupling following 
manufacturers’ protocols (Amine Coupling Kit; BIAcore). Briefly, 35 pi of a 1:1 mixture 
(final concentration of 0.1 M) of EDC (N-ethyl-N’-(3-diethyl-aminopropyl)-carbodiimide) 
and NHS (N-hydroxysuccinimide) was injected over the carboxymethylated matrix surface
89
of flow cell 2 (FC2) on the sensor chip at a flow rate of 5 pl/min. Five microlitres of CEA 
(N-Al) (0.3 mg/ml) was added to 95 pi of 10 mM sodium acetate, pH 4.0 and 15 pi 
aliquots were injected onto the activated surface until the desired amount was immobilised. 
The surface was blocked using 35 pi 1 M ethanolamine, followed by washing with 10 mM 
HC1, The immobilisation process was repeated on FC1, substituting HBS buffer for protein 
to create a reference cell.
Binding studies
To test avidity, analytes (diluted to 100 nM in HBS-EP buffer) were passed over the 
ligand immobilised at 1200 RU, 780 RU or 120 RU) at a flow rate of 10 pl/min. Binding 
(association) was allowed to take place for 5 min, followed by a 5 min delay 
(disassociation) and finally a wash. CEA (diluted to 100 nM in HBS-EP buffer) was then 
injected and allowed to bind to the immobilised ligand-captured analyte for 5 min, followed 
by a 5 min delay and wash. Surfaces were regenerated using a 2 x 1 min pulses of 10 mM 
HC1.
Analysis o f sensorgrams
BIAevaluation software V3.0 (BIACore) was used to analyse the sensorgrams.
Binding curves and their components were fit to the Bivalent Analyte binding model and 
assessed by the returned residual plots, log plots and Chi values.
2.2.5 Protein radiolabelling
All radioiodinations were carried out in the iodination suite of the Department of 
Nuclear Medicine, Royal Free Hospital in a laminar flow hood. Radioiodination using 
Iodo-gen® was performed according to Fraker and Speck (1978) using a ratio of 1:5 (5 
mCi/mg; ~185 MBq/mg). One hundred microlitres of pre-chilled protein (100-500 pg in 
PBS, pH 7.5) was added to Pre-coated Iodination tubes (Pierce, UK), followed by the 
appropriate volume of Na125I (Amersham Biosciences) and allowed to react for 10-20 min 
at room temperature. During this time the tube was tapped gently every 5 min to facilitate
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mixing. Radiolabelled protein was removed from the Iodogen tube to stop the reaction and 
placed in microcentrifuge tube. The Iodogen tube was rinsed with 100 pi PBS and this was 
added to the radiolabelled sample. The radiolabelled protein was loaded onto a PD-10 
column (Sephadex G-25M; Amersham Biosciences) primed with 25 ml PBS/0.1% HSA 
(BPL, UK) and eluted with PBS/0.1% HSA in 7 x 1 ml fractions. The amount of 
radioactivity in the Iodogen tube, microcentrifuge tube, PD-10 column and 7 fractions was 
measured using a dose calibrator (Capintec CRC-10, Southern Scientific, Worthing, UK) 
set for 125I. Fractions containing the highest counts (fractions 3 and 4) were taken for 
further study.
2.2.6 Characterisation of radiolabelled protein
2.2.6.1 Thin layer Chromatography (TLC)
Strips of supported silica gel polyester backed 250 pm TLC plates (Whatman, UK) 
were cut to approximately 10 cm x 3 cm and 1-3 pi of radiolabelled material was applied to 
the centre of the strip about 1 cm from the base. The sample was left to dry for a few 
seconds and the strip was carefully inserted into a 150 ml lidded pot containing 80% (v/v) 
methanol, filled so the solvent was beneath the sample on the strip (approximately 0.5 cm). 
The solvent was allowed to move up the strip until about one cm from the top, at which 
time the strip was removed from the pot. The percent of incorporated radiolabel was 
determined by phosphor image analysis (see 2.2.6.5) of the nitrocellulose strip. The percent 
of free (migrating with the solvent front) and antibody-bound (retained at the bottom of the 
strip) radiolabel was calculated.
2.2.6.2 Immunoreactivity studies
A mini-CEA affinity column was used to determine immunoreactivity of radiolabelled 
protein. Six microlitres of radiolabelled sample was diluted in 300 pi PBS and applied 
(under gravity) to a CEA-Sepharose (300 pi bed volume see 2.2.2.3) pre-equilibrated with 
PBS. The column was washed three times with 2 ml PBS followed by specific elution of
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three times 2 ml 50 mM DEA. This was followed with three washes with 2 ml 3M 
ammonium thiocyanate. Non-specific binding to the Sepharose-4-B matrix was tested 
using an uncoupled Sepharose column (300 pi bed volume) under the same conditions. 
The radioactivity in each fraction was measured for 1 minute on a COBRA II autogamma 
multidetector sample Gamma Counter (Packard, UK). The percentage binding of the 
radiolabelled antibody was estimated using the following equation:
Percentage binding =   X 100 [Equation 2.4]
Total
where Bound is the radioactive counts for the three elutions, and Total is the total 
radioactive counts for the washes and elutions.
2.2.6.3 SDS-PAGE analysis o f radiolabelled protein
Radiolabelled samples were resolved on 8 % Tris-Glycine 10 well pre-cast mini-gels 
(see 2.2.4.2). Gels were wrapped in cling film and exposed to phosphor plates for up to 
two weeks at room temperature and then digitised (see 2.2.6.5).
2.2.6.4 Size-exclusion chromatography o f radiolabelled protein
Radioiodinated proteins were analysed on a Superose 12 (XK 16/60) column run at a 
flow rate of 2 ml/min (in PBS) using the Millipore-Waters 650E system. Two hundred 
microlitres of radiolabelled protein ( 6  pi diluted in 300 pi PBS) was injected and 1 ml 
fractions were collected after 2 0  ml (void volume) had passed through the column. 
Radioactivity levels for all fractions were counted for 1 min in a COBRA II autogamma 
Packard Gamma Counter. Counts were plotted against volume (ml) to give the radioactive 
profile.
2.2.6.5 Phosphorlmaging
For phosphorimaging, Molecular Dynamics Storage Phosphor Screens (Amersham 
Biosciences) in Molecular Dynamics exposure cassettes were used. Immediately prior to 
use, screens were exposed to white light for 12 min using a Molecular Dynamics Image
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Eraser (Amersham Biosciences) to eliminate accumulated background and residual signal 
from previous use. Samples were exposed to phosphor plates at room temperature from 15 
min to two weeks, according to their level of radioactivity, after which they were digitised 
using a Molecular Dynamics Storm 860 Phosphorlmager (Amersham Biosciences). 
Radioactivity was quantified using Molecular Dynamics ImageQuant 5.0 software 
(Amersham Biosciences).
2.2.7 In vivo studies
All animal work was carried out with the help of Mr. Robert Boden (Department of 
Oncology) in the Comparative Biology Unit at the Royal Free Hospital. Throughout the 
experiment, mice were given food and water ad libitum, the water supplemented with 0 .1% 
potassium iodide to block thyroid uptake of iodine. Groups of four mice were used for all 
tissue samples and time points.
2.2.7.1 LS-174T colorectal tumour xenografts
A human colon adenocarcinoma cell line LS-174T, expressing CEA (Tom et al, 1976), 
was used to develop a xenograft model by subcutaneous implantation of small tumour 
pieces (~1 mm3) in the left flank of male nude mice (MF1 (nu/nu) cross) and were used at 
2-3 months old weighing 20-25 g at the start of the experiment. Subsequent passaging was 
performed under halothane anaesthesia by continuous subcutaneous implantation of the 
original xenograft (1 mm3). Mice were used 3 weeks after passaging when the mean 
tumour volume was approximately 0.5-1.0 cm3. Studies have shown that MFE-23 
routinely localises to implanted LS-174T xenografts (Chester et al, 1994; Casey et al, 1995; 
Verhaar et al, 1995) and that this tumour secretes low levels of CEA into the circulation 
(Philben e/a/, 1986).
2.2.7.2 Biodistribution studies o f radiolabelled proteins
One hundred microlitres of 125I-labelled protein was injected intravenously via the tail 
vein of non-tumour-bearing male TO mice or nude MF1 mice bearing LS-174T xenografts
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(see 2.2.7.1). At 1, 4,24 and 48 h post administration, mice were anaesthetised and bled 
via the retro-orbital venous sinus, at which point they were sacrificed. Tumour-bearing 
mice had an additional time point at 30 min, with blood taken from the 48 h cohorts.
Tissues (liver, kidney, lung, spleen, colon, muscle) and tumour were removed and placed in 
pre-weighed tubes. Tubes containing tissue samples were weighed, 7 M KOH was added 
to cover tissues (~2 ml) and samples were digested overnight. After complete digestion, 
samples were gently vortexed and gamma radioactivity was counted for 1 min on a 
COBRA II auto-gamma Packard Gamma Counter. Five tubes containing 10 pi of injected 
antibody diluted in 990 pi PBS were prepared and counted alongside tissue samples as 
standards.
The results were expressed as a percentage of injected dose (radioactive counts) per 
gram of tissue (%ID/g). No correction was performed for radioactive decay in 
biodistribution experiments. Correction for radioactive decay was not performed on the 
results of the biodistribution experiments. Differences in %ID/g between the proteins were 
tested for statistical significance using the Mann-Whitney U test.
2.2.8 Structural investigations
The crystal structures of MFE-23 (PDB code lqok), HSA (PDB code la06), A5B7 Fab 
fragment (PDB code 1CLO) and the solution scattering a-carbon model of CEA (PDB code 
le07) were used for subsequent structural analyses using Rasmol 2.7.1 software 
(http://www.umass.edu/microbio/rasmol: Sayle & Milner-White, 1995).
Analysis of the crystal structures of HSA and MFE-23 and their potential assembly 
was performed on INSIGHT II software (Biosym/MSI, San Diego, U.S.A.) on Silicon 
Graphics 02  and Octane Workstations with the help of Dr. Nicholas Whitelegg.
Analysis of the crystal structure of MFE-23 and the homology model of CEA was 
perfomed using INSIGHT II software (Biosym/MSI, San Diego, U.S.A.) on Silicon 
Graphics 02  and Octane Workstations in conjunction with Crystal Eyes stereo glasses with 
the help of Professor Steve Perkins. The predicted model for the complex (including all the
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sidechains and carbohydrate residues in CEA) was taken from Boehm & Perkins (2000). 
The residue sidechain solvent accessibilities of MFE-23 and CEA were calculated using a 
probe of 1.4 A to represent a water molecule in the COMPARER program (Lee & 
Richards, 1971; Sali & Blundell, 1990). Contacts in the complex were identified by 
differences in the accessibilities from the unbound proteins.
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A study o f the molecular interaction between MFE-23 and its 
cognate antigen, carcinoembryonic antigen
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3.1 Introduction
The molecules designed and generated for this thesis all use the scFv MFE-23 as a 
targeting arm. An understanding of the binding interaction between antibody and antigen is 
desirable to guide the molecular design of engineered antibody-based molecules.
Therefore, the first aim of this thesis was to characterise the interaction of MFE-23 with its 
cognate antigen CEA. CEA is a member of the IgG superfamily and is comprised of one 
V-type fold domain (N) followed by six C2-type fold domains (A, B) (see 1.5). Structural 
investigations based on the homology model of CEA (Boehm et al, 1996) and the crystal 
structure of MFE-23 (Boehm et al, 2000) have proposed that MFE-23 binding may occur at 
the N and Al domains of CEA (Boehm & Perkins, 2000). The aim of this chapter was to 
test this hypothesis experimentally and to identify the MFE-23-binding epitope on CEA.
First, recombinant CEA (N-Al) domains were expressed in E. coli. The ability of 
MFE-23 to bind the CEA (N-Al) domains was then tested using three experimental 
techniques. First, the immunoreactivity of MFE-23 for bacterially-expressed CEA (N-Al) 
was assessed by ELISA. Second, the formation of an immune complex between the 
proteins was tested by immunoprecipitation studies, and third, by co-purification using 
immobilised metal affinity chromatography (IMAC) via the hexahistidine tag on MFE-23.
To further characterise the interaction, the MFE-23 epitope sequence was mapped 
using proteolysis in combination with surface enhanced laser desorption/ionisation-affinity 
mass spectrometry (SELDI-AMS) (Figure 3.1). In this process protein complexes are 
bound directly to activated metal (ProteinArray®) chip surfaces and digested in situ with 
proteolytic enzymes. Non-reactive peptides are washed away and the remaining bound 
peptides are identified by mass spectrometry. SELDI-AMS has been successfully applied to 
characterise protein complexes (Hinshelwood et al, 1999) and antibody/antigen interactions 
(Spencer et al, 2000) and was predicted to be amenable to the epitope mapping of the MFE- 
23/ CEA (N-Al) interface.
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(a) Sam ple applied to chip and proteins retained
(c) Unbound sam ple 
w ashed  aw ay100 pm2
(d) Laser desorption
bound fragm ents
ProteinChip Array 
inity C apture Surface
(e) Identification 
of
peptide fragm ents
on surface by affinity capture
(b) In situ digestion
Figure 3.1. Epitope mapping by SELDI-AMS. (*) Sample is applied to chip and protein o f interest is 
retained by affinity capture (e.g. antigen captured by antibody), (b) On-chip sample is digested with 
proteolytic enzymes, resulting in an array o f peptides, (c) Unbound peptides are washed away and (d) bound 
peptides (epitopes) subjected to laser desorption, (e) Molecular weights o f peptide are identified by mass 
spectrometry.
32  Results
3.2.1 Production of soluble CEA (N-l) domains
The pUCl 19myc/CEA (N-Al) bacterial expression vector was sequenced across the 
cloning junctions to confirm that the entire CEA (N-Al) insert was intact and in frame. 
Details of the cloning sites, DNA and amino acid sequences of CEA (N-Al) within the 
pucl 19myc vector are shown in Figure 3.2. To test the expression in E. coli of CEA (N-Al) 
domains, small-scale cultures of pUCl 19/CEA (N-Al) transformed TGI cells were 
induced using IPTG as described in section 2.2.2.1. The cleared supernatants were 
subjected to SDS-PAGE under reducing conditions and Western blot analysis using a 
polyclonal anti-CEA antibody confirmed low yields of protein at the expected molecular 
weight (-24 kDa) (Figure 3.3 a). The immunoreactivity of the expressed product with MFE- 
23 was confirmed by ELISA (Figure 3.3b). These results represent the first experimental
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Figure 3.2. Details o f  the cloning sites, DNA and amino acid sequence o f CEA (N -A l) within the bacterial 
expression plasmid pU Cl 19myc. The vector contains a COOH-terminal c-myc tag, an isopropyl P-D- 
thiogalactoside (IPTG) inducible lac promotor and a pelB leader sequence directing soluble protein to the 
bacterial periplasmic space from where the heterologous protein is released into the supernatant. CEA (N- 
A l)  was cloned between the Nco I and Not I restriction sites (DNA sequence underlined), downstream o f the 
pelB leader sequence (amino acid sequence underlined) and directly upstream o f the c-myc tag (amino acid 
sequence underlined) and stop codon. Non-CEA (N -A l) sequences are italicised.
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(a)
M
CEA
(N-A1)
250 kDa
148 kDa
60  kDa 
4 2  kDa
30 kDa
22  kDa 
17 kDa
4/6  kDa
~ 24  kD
(b)
neg. control
Figure 3 3 . Analysis o f  bacterially-expressed CEA (N -A l) domains, (a) Western blot analysis. Bacterial 
culture supernatants containing CEA (N -A l) domains were separated by SDS-PAGE (12% Tris-Glycine) and 
transferred proteins were visualised by anti-CEA antibodies alongside molecular weight marker (Multimark, 
see Figure 2.2 for MW; lane M). (b) Immunoreactivity. Bacterial culture supernatants containing CEA (N- 
A l)  domains were applied to MFE-23-coated wells. CEA (1 pg/ml) and culture medium (negative control) 
were applied as controls. Following washing, bound CEA (N -A l) domains were detected using anti-CEA 
antibodies. Proteins were tested in triplicate and their means were plotted, together with one standard 
deviation (bars). Samples were blanked against wells coated in PBS.
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evidence of the specific interaction between MFE-23 and CEA (N-Al).
Purifying bacterially-expressed CEA (N-Al) domains proved to be problematic. First 
attempts to purify the domains by anti-CEA affinity chromatography were unsuccessful, 
resulting in low yields of mainly degraded product (data not shown). Furthermore, there 
was no histidine tag available on the CEA (N-Al) domains, which prevented the use of 
IMAC. To overcome this, an alternative approach was taken to purify CEA (N-Al) in 
complex with MFE-23. This was achieved by adding MFE-23 directly to E. coli cells 
expressing CEA (N-Al) domains to test whether it was able to form an immune complex 
with CEA (N-Al) during expression. Small-scale expression of CEA (N-Al) was 
performed either alone or in the presence of purified MFE-23 and the supernatants from 
both expressions were subjected to SDS-PAGE under reducing conditions. Western blot 
analysis using anti-CEA (Figure 3.4a) or anti-MFE-23 (Figure 3.4b) antibodies confirmed 
bands at the expected molecular weight in both cases, indicating the addition of MFE-23 
did not detrimentally affect the expression of CEA (N-Al).
(a) (b)
M M
250 kDa
98 kDa 
64 kDa 
50 kDa
36 kDa 
16 kDa
6 kDa 
4 kDa
Figure 3.4. Analysis o f  bacterially-expressed CEA (N -A l) in the presence o f MFE-23. SDS-PAGE (12% 
Tris-Glycine) and Western blot analysis, using (a) anti-CEA and (b) anti-MFE-23 antibodies, o f bacterial 
supernatants containing CEA (N-A1) expressed alone (lane 1) or with MFE-23 (lane 2). Molecular weight 
marker in lane M (SeeBlue, see Table 2.2 for MW).
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Figure 3.5. Analysis o f  CEA (N -A l) domains expressed as a bacterial co-culture with MFE-23. SDS-PAGE 
(12% Tris-Glycine) and Western blot analysis, using (a) anti-CEA and (b) anti-MFE-23 antibodies, o f 
bacterial supernatants containing CEA (N -A l) expressed as a co-culture with MFE-23 (lane 2). MFE-23 (4 
ug; lane 1) was spiked with Molecular weight marker (SeeBIue).
In further experiments, small-scale expressions were conducted to determine if MFE- 
23 and the CEA (N-Al) domains formed an immune complex when expressed 
simultaneously as a co-culture. A culture of bacterial cells expressing MFE-23 was added 
to a culture expressing CEA (N-Al), and the two proteins were induced together overnight. 
Expression of both proteins was assessed by SDS-PAGE and Western blotting using anti- 
CEA (Figure 3.5a) and anti-MFE-23 antibodies (Figure 3.5b). The results were in good 
agreement with those found for the CEA (N-Al) domains expressed in the presence of 
purified MFE-23, showing that the co-culture expression method was also effective in 
yielding similar amounts of CEA (N-Al).
3.2.2 Assessment of an immune complex formed between MFE-23 and CEA (N-Al)
The ability of MFE-23 to capture CEA (N-Al) in an immune complex was tested by 
immunoprecipitation studies. Ni-NTA-coated magnetic beads saturated with MFE-23
102
(a) (b)
M l  2 3 4 5 6 7 8 9  M 1 2 3 4 5 6 7 8 9
Figure 3.6. Evaluation o f  MFE-23-immunoprecipitated CEA (N -A l) domains. SDS-PAGE (12% Tris- 
Glycine) and Western blot analysis o f MFE-23-immunoprecipitated CEA (N -A l) domains as detected by (a) 
anti-CEA or (b) anti-MFE-23 antibodies. MFE-23 was coupled to Ni-NTA magnetic beads, via the 
hexahistidine tag, in excess and the beads were washed thouroughly with 10 mM imidazole. The MFE-23- 
saturated beads successfully captured CEA (N -A l) from bacterial supernatant (lane 5), CEA (N -A l) from 
bacterial supernatant containing MFE-23 (lane 6), and whole CEA (lane 7). Control beads saturated with 
culture medium were not able to capture CEA (N -A l) (lane 3), nor were there non-specific bands from MFE- 
23-saturated beads reacted with culture medium (lane 4). CEA (N -A l) supernatant (lane 1), CEA (N- 
Al)/M FE-23 supernatant (lane 2), CEA (4 gg; lane 8), and MFE-23 (4 gg; lane 9) were run alongside the 
molecular weight marker (Multimark; lane M).
coupled via the hexahistidine tag were used to capture CEA (N-Al) domains from bacterial 
supernatant expressed either alone or in the presence of MFE-23. Following washing of the 
beads, the CEA (N- Al)/MFE-23-bead complex was resolved directly by SDS-PAGE and 
proteins were detected by anti-CEA (Figure 3.6a) and anti-MFE-23 antibodies (Figure 
3.6b). The presence of bands at the expected molecular weight for CEA (N-Al) and MFE- 
23 confirmed that the MFE-23 pre-coated beads successfully recovered the CEA (N-Al) 
domains directly from supernatant. Control experiments, in which Ni-NTA beads coated 
with culture medium (instead of MFE-23) were unable to capture CEA (N-Al) domains, 
supported the hypothesis that CEA (N-Al) was isolated from bacterial supernatant by 
MFE-23. These results again confirm the specific interaction of MFE-23 with the CEA 
(N-Al) domains.
The feasibility of purifying the immune complex via the hexahistidine tag on MFE-23 
was tested by IMAC purifications on 1L bacterial culture supernatants of CEA (N-Al) 
expressed in the presence of purified MFE-23. The UV trace is shown in Figure 3.7. Peaks 
corresponding to increases in UV absorbance readings were observed following loading of
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the matrix with copper ions, and following application of the culture supernatant. A large 
peak was seen for the removal of non-specifically bound proteins during the column wash, 
followed by a smaller peak corresponding to eluted hexahistidine-tagged protein. SDS- 
PAGE and Western blotting using anti-CEA (Figure 3.8a) and anti-MFE-23 (Figure 3.8b) 
antibodies confirmed the presence of both proteins in the 200 mM imidazole-eluted 
fractions, suggesting that the immune complex was maintained throughout the purification 
procedure resulting in the co-purification of CEA (N-Al) with MFE-23. These results 
established that IMAC was a viable method for the purification of the CEA (N-A1)/MFE- 
23 complex and that the hexahistidine tag on MFE-23 could be exploited for epitope 
mapping studies on the immune complex.
Elution volume (ml)
Figure 3.7. UV trace showing IMAC purification o f  CEA (N -A l)/ MFE-23 from bacterial supernatant. 
Chelating Fast-flow Sepharose was charged with copper ions, washed with dH20 and equilibrated with PBS 
containing 200 mM NaCl. Samples containing expressed protein were loaded onto the column following 
addition o f  200 mM  NaCl and non-speciflcally-bound proteins were washed off with 40 mM imidazole in 
PBS/ 1M  NaCl. Hexahistidine-tagged protein was eluted using 200 mM imidazole in PBS/ 1 M  NaCl. 
Fractions (7 ml; red dotted lines) were taken starting at the 40 mM imidazole wash. Fractions corresponding 
to the 200 mM imidazole-eluted protein were pooled, dialysed against PBS and concentrated.
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Figure 3.8. Analysis o f  MFE-23/ CEA (N -A l) IMAC purification. SDS-PAGE (12% Tris-Glycine) and 
Western blot analysis showing IMAC purification o f CEA (N -A l) in complex with hexahistidine-tagged 
MFE-23, as detected by (a) anti-CEA and (b) anti MFE-23 antibodies. Bacterial culture supernatant (lane 1) 
was concentrated and loaded (lane 2) onto a copper-chelated Sepharose column. Non-specifically bound 
proteins were washed off with PBS and 40 mM imidazole (lanes 3-6). Hexahistidine tagged MFE-23, in 
complex with CEA (N -A l), was eluted with 200 mM imidazole (lanes 7-13). MFE-23 (5 pg) was spiked into 
the molecular weight marker as a control (Seeblue; lane M).
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3.2.3 Epitope mapping the CEA (N-A1VMFE-23 interface
Epitope mapping studies were carried out on the IMAC-purified CEA (N-Al)/MFE-23 
complex using SELDI-AMS. The immune complex was captured by an IMAC 
ProteinArray® chip via the hexahistidine tag on MFE-23. The captured proteins were 
digested in situ with trypsin, non-binding peptides were washed away and the remaining 
peptides were identified by MS. Repeated experiments consistently identified three MFE- 
23 reactive CEA (N-Al) domain peptides in a molecular weight range of 4300 to 11300 Da 
(Figure 3.9). Based on analysis of the CEA amino acid sequence using PAWS sequence 
identification software, the observed peptide masses and their assignments were as follows. 
The peak at m/z 4316.6 was assigned to Asp [127-164] Arg in CEA, which is within 0.1% 
(1434.3 ppm) of its calculated average mass o f4322.8 Da (Figure 3.9ai). That at m/z
5355.1 was assigned to Asp [127-173] Arg in CEA, which is within 0.3% (2588.9 ppm) of 
its calculated average mass of 5369.0 Da (Figure 3.9bi). That at m/z 10405.0 was assigned 
to Glu [65-156] Arg in CEA, which is within 0.1% (643.5 ppm) of its calculated average 
mass of 10411.7 Da (Figure 3.9ci). Control spots based on digests of MFE-23 alone 
showed no similar masses to those seen in the presence of CEA, and the observed peaks at 
m/z 4352.8, 5516.9 and 11401.5 were assigned to sequences arising from tryptic digestion 
of MFE-23 (Figure 3.9aii, 3.9bii and 3.9cii). In conclusion, all three proteolytic fragments 
that originated from the CEA (N-Al) domains correspond to sequences found in the A1 
domain to within an accuracy of 0.1-0.3% (difference of 643.5 - 2588.9 ppm; Table 3.1). 
All three peptides contained the common 30-residue CEA sequence Asp [127-156] Arg 
(Figure 3.10).
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Figure 3.9. SELDI-AMS epitope mapping mass spectra o f  trypsin digested (i) CEA(N-Al)/M FE-23 complex 
or (ii) MFE-23 alone. CEA(N-Al)-specific peaks were identified at (ai) mass 4316.6 Da corresponding to Asp 
[127-164] Arg in CEA, (bi) mass 5355.1 Da corresponding to Asp [127-173] Arg, (ci) mass 10405.0 Da 
corresponding to Glu [65-156] Arg. Peaks at 4352.8 Da, 5516.9 Da, and 11041.5 Da were also detected and 
corresponded to peaks observed on control spots containing trypsin digested MFE-23 (ai-iii).
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Table 3.1. Observed masses o f the peptides identified by SELDI-AMS that remain associated with MFE- 
23 and their assignment to CEA (N-Al) peptides calculated by PAWS.
Observed mass 
(Da)*
Calculated mass 
(Da)
% Difference 
(A ppm)
Sequence of CEA
4316.6 4322.8 0.1 (1434.3) D [127-164] R
5355.1 5369.0 0.3 (2588.9) D [127-173] R
10405.0 10411.7 0.1 (643.5) E [65-156] R
“The mass values correspond to the experiments shown in Figure 3.9.
Investigation on the potential interaction of MFE-23 at this site was performed using 
the crystal structure for MFE-23 (Boehm et al, 2000) and the predicted complex of MFE-23 
with CEA based on surface accessibilities of residues in the CEA/MFE-23 complex and the 
two free proteins(Boehm & Perkins, 2000) (Figure 3.11 a). These showed that the surface- 
exposed amino acid side-chains of four CEA peptides became buried in the predicted 
complex with MFE-23, corresponding to CEA residue Glu [5-20] Leu (lost surface area of 
118 A2) and Arg [64-76] Gin (loss of 78 A2) in the N domain, and Tyr [142-150] Ser (loss 
of 67 A2) and Lys [180-193] Asp (loss of 123 A2) in the Al domain. The observed surface 
area changes in the Tyr [142-150] Ser peptide are in full agreement with the occurrence of 
this sequence in all three of the CEA(N-Al)-derived peptides identified by SELDI-AMS 
(Figure 3.11b).
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KLTIESTPFNVAEGKEVLLLVHNLPQHLFGY SWYKGERVD 
GNROIIGYVIGTOOATPGPAYSGREIIYPNASLLIONIIONDT 
GFYTLHVIKSDLVNEEATGOFRVYPELPKPSISSNNSKPVED 
KDA VAFTCEPETODA TYL WWVNNOSLP VSPR L O LSN GN RTL 
TLFNVTRNDT ASYKCETQNPV S ARRSDS VILNVLY
Figure 3.10. Position o f  SELDI-AMS-identified peptides in the CEA (N -A l) amino acid sequence. The 
PAWS program was used to determine all possible peptides resulting from cleavage o f the CEA (N -A l) 
sequence by trypsin. Peptide masses obtained by SELDI-AMS are then crosschecked against these and listed 
together with their placement in the protein sequence, which is graphically represented by lines, (a) Grahic 
representation o f  CEA (N -A l) amino acid sequence with the placement o f  MFE-23-binding peptides resulting 
from tryptic digestion o f  CEA (N -A l) complexed with MFE-23 represented by solid lines and (b) listed 
below with their exact placement in the sequence, (c) Amino acid sequence o f  CEA(N-A1) domains. The 
peptide sequences identified by SELDI-AMS are underlined. The peptides all contain the common sequence 
Asp [127-156] Arg (italicised).
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Figure 3.11. Structural representation o f  the predicted model o f  the CEA (N-Al)/M FE-23 complex. The 
backbone structures o f MFE-23 and the CEA N and A l domains are shown in grey and the four CEA peptides 
predicted to make contact with MFE-23 are highlighted in blue, (a) The complex is viewed from the side, 
where the H I, H2 and H3 loops o f  MFE-23 (red) are seen to make contact with the CEA-N domain, and the 
L I, L2 and L3 loops (orange) make contact with the CEA-A1 domain, (b) The view in (a) is rotated by 90° in 
order to view the MFE-23 binding pocket face-on. The SELDI-AMS-identified 30-residue peptide Asp [127- 
156] Arg is shown in red and the Tyr [142-150] Ser CEA peptide within the 30-residue peptide identified by 
SELDI-AMS is highlighted in blue.
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3.3 Discussion
In order to guide the design of divalent MFE-23-based targeting molecules, the 
interaction between MFE-23 and its cognate antigen CEA was investigated. Recombinant 
domains of CEA corresponding to the N-terminal N-Al domain pair were first chosen to 
study this relationship based on previous structural observations. The use of recombinant 
CEA domains was advantageous because it overcame the sometimes difficult process of 
obtaining the pure and homogeneous supplies of CEA from human tissue which are needed 
for accurate molecular interaction studies. Whole CEA is generally isolated from 
colorectal tumour tissue by perchloric acid treatment, which removes the protein from its 
GPI linkage, followed by affinity chromatography (Keep et al, 1978). This often results in 
CEA samples which are heterogeneous in nature, with varying size, charge and 
glycosylation (Kimball & Brattain, 1978; Thomas et al, 1990). Furthermore, CEA obtained 
from tumour tissues may also be contaminated with other CEA family members, as 
CEACAM1 and CEACAM6 are also expressed in colorectal carcinomas (Hammarstrom,
1999).
The CEA (N-Al) domains were successfully expressed in E. coli although overall 
expression levels of CEA (N-Al) were low and only detectable after expression conditions 
were optimised. These findings are supported by reports of recombinant bacterially- 
expressed CEA domains as fusion proteins with B-galactosidase (Kuroki et al, 1992) or 
CMP-KDO synthetase (Hass et al, 1991) or in insoluble bacterial inclusion bodies (Krop- 
Watorek et al, 1998) resulting in low expression and poor antigen activity, presumably due 
to improper folding and lack of glycosylation (Hass et al, 1991).
Despite the low expression levels of CEA (N-Al) obtained, their specific interaction 
with MFE-23 was confirmed by ELISA, immunoprecipitation and co-purification studies. 
The immunoreactivity of MFE-23 with the bacterially-expressed domains represents the 
first experimental evidence that MFE-23 binding to CEA occurs at the N-Al N-terminal 
pair. To our knowledge, this is also the first report of bacterially-expressed soluble CEA 
domains maintaining antigenic activity.
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Attempts to purify the domains by anti-CEA affinity chromatography were 
unsuccessful and the CEA (N-Al) domains were not amenable to direct purification by 
IMAC due to lack of the hexahistidine tag. As an alternative purification method, MFE-23 
was added directly to E. coli cultures expressing CEA (N-Al) domains to test whether it 
was able to form an immune complex with CEA (N-Al) during expression. This achieved 
two things: 1) only the immunoreactive portion of the expressed CEA (N-Al) product was 
isolated, and 2) the histidine tag of MFE-23 was utilised for purification without the need 
for re-cloning of the CEA (N-Al) domains. The addition of MFE-23 to CEA (N-Al) 
expressing cells, in either a purified form or as an expressing bacterial co-culture, did not 
compromise the soluble expression of CEA (N-Al). Moreover, the small-scale MFE-23 
co-culture strategy by-passed the need for prior purification of MFE-23. Further 
optimisation of this method will be needed to obtain sufficient amounts of both proteins for 
further investigations. However, the preliminary results reported here show, in principle, 
that this approach may be applicable to the simultaneous isolation of antigen and antibody 
from crude supernatants.
The specific interaction between the two proteins was demonstrated by the successful 
capture of the CEA (N-Al) domains by MFE-23 in immunoprecipitation studies. 
Imunoprecipitation of protein complexes is a widely-used approach for the characterisation 
of protein: protein interactions and has been successfully applied to the study of 
antibody/antigen relationships (Domenech et al, 2003; Chisaka et al, 2003; Carnahan et al, 
2003). For the study of the interaction between MFE-23 and CEA (N-Al), the IMAC 
technology (Porath, 1992; Porath et al, 1975) was exploited to capture MFE-23 via the 
hexahistidine tag. Ni-NTA-coated magnetic beads were saturated with hexahistidine- 
tagged MFE-23 and used to capture CEA (N-Al) domains directly from bacterial culture 
supernatants. The successful precipitation of CEA (N-Al) domains as a result of a specific 
interaction with MFE-23 was evidenced by the inability of control beads containing no 
MFE-23 to capture the domains. CEA (N-Al) domains expressed in the presence of MFE- 
23 were also immunoprecipitated by MFE-23-coated beads. This may be due to binding of 
the CEA (N-Al)/MFE-23 complex to un-coupled Ni-NTA (via the MFE-23), the binding of 
un-complexed CEA (N-Al) in the supernatant to MFE-23-coated beads, or the competition 
of bead-bound MFE-23 with MFE-23 in complex with CEA (N-Al) in solution. In both
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cases the immunoprecipitation of CEA (N-Al) via a specific interaction with MFE-23 was 
clearly demonstrated.
The addition of MFE-23 to the inducing culture facilitated the co-purification of the 
immune complex by IMAC using the hexahistidine-tag on MFE-23, providing pure 
material for epitope mapping studies and again demonstrating the specific formation of an 
immune complex between MFE-23 and the CEA (N-Al) domains. The purification of the 
CEA (N-Al)/MFE-23 complex was performed on a copper-chelated Sepharose column 
automated by FPLC, which provided a controlled procedure. The CEA (N-Al) domains 
were eluted with MFE-23 by competition with a high concentration of imidazole (200 mM) 
for the copper ions immobilised on the matrix. Faint bands were also detected for CEA (N- 
Al) in the wash fractions, which may be due to the pH change caused by the addition of 
low concentrations of imidazole (40 mM). Buffering the pH of the buffers to neutral 
should reduce this slight loss of protein. However, the majority of the CEA (N-Al) protein 
was specifically eluted with the majority of the MFE-23 protein, indicating that its removal 
from the column was through association with the scFv.
It was not possible to determine the affinity of the recombinant CEA (N-Al) domains, 
although the relatively stable complex formed between MFE-23 and CEA (N-Al) during 
immunoprecipication and purification studies suggests that their interaction was not easily 
dissociated. Kinetic investigations on the binding of MFE-23 to bacterially-expressed CEA 
(N-Al) domains would be needed to confirm that the affinity was not compromised. 
However, these studies would require reasonable amounts of purified CEA (N-Al), which 
has, to date, been difficult to obtain.
Detection of the expressed CEA (N-Al) domains and their interaction with MFE-23 
was monitored by SDS-PAGE and Western blot analysis using polyclonal antibodies raised 
against either CEA (N-Al) or MFE-23. This method is suitable for the qualitative 
assessment of proteins; however poor transfer of the protein to the membrane or poor or 
non-specific binding of the antisera may occur, and the results are not quantitative. To 
overcome these limitations, further work should be directed at more sensitive techniques 
for the visualisation and confirmation of the protein bands (e.g. silver staining, protein
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sequencing). In addition, quantitative data may be obtained for the interaction between 
CEA (N-Al) and MFE-23 using methods such as radioimmunodetection.
Having identified that MFE-23 bound to recombinant N-Al domains, the precise 
epitope protein sequence was partially mapped using mass spectrometry (MS) combined 
with proteolytic digestion. This approach was taken because conventional methods for 
mapping an antibody-binding site on an antigen rely on peptide libraries (Benjamin et al, 
1984), which can limit the identification of epitopes to continuous amino acid sequences 
(Berzofsky et al, 1985). To overcome this limitation, several groups turned to the direct 
mapping of both continuous and conformational epitopes using partial proteolysis of 
immune complexes. This approach was supported by the findings that: i) antibodies are 
partially resistant to proteolytic degradation; ii) antigenic sites are protected from 
proteolytic enzymes in immune complexes; iii) immune complexes do not dissociate upon 
proteolyis (Eisenberg et al, 1982; Jemmerson et al, 1986; Moelling et al, 1980; Schwyzer et 
al, 1980). Ambiguity problems arising from peptide analysis after proteolysis of immune 
complexes by SDS-PAGE (Sheshberadaran et al, 1988) or high performance liquid 
chromatography (HPLC) (Jemmerson et al, 1986) led to the use of MS (Suckau et al, 1990; 
Van de Water et al, 1997; Yi & Skalka, 2000) for the identification of peptides resulting 
from proteolysis of the immune complex.
SELDI-AMS has several advantages over existing MS epitope mapping techniques, 
which can be expensive, time consuming and labour intensive (Van de Water et al, 1997). 
Because the SELDI-AMS is based on a specialised metal chip surface, the entire procedure 
from binding of the complex to the surface to the MS analysis can be done in situ. The 
experimental time is much reduced in SELDI-AMS as the removal of non-binding antigen 
fragments is done by washing the chip, rather than by the lengthy separations used in 
matrix-assisted laser desorption/ionisation mass spectrometry. SELDI-AMS also enables 
the study of proteins in crude supernatants or incompatible buffers as non-binding proteins 
or salts can be washed away. Very little starting material is required as the remaining 
antibody-associated peptides are laser desorped from the chip-bound antibody in the mass 
spectrometer, resulting in limited sample loss. Furthermore, an interface has been 
developed to analyse samples on a ProteinChip® Array further using laser desorption
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ionisation-tandem mass spectrometry, enabling the direct sequencing of peptides identified 
by SELDI-AMS (Reid et al, 2002; Merchant et al, 2000).
For epitope mapping studies, the immune complex was captured by an IMAC 
ProteinArray® chip via the hexahistidine tag on MFE-23. Previous epitope mapping studies 
using SELDI-AMS were performed by covalently coupling purified ligand to the 
preactivated surface of chips via carbonyl diimidazole chemistry (Hinshelwood et al, 1999; 
Spencer et al, 2000). Following immobilisation of the ligand, purified antigen was allowed 
to bind the resulting complex was then digested in situ. Due to the difficulties in obtaining 
purified CEA (N-Al) domains and the success of using the hexahistidine tag on MFE-23 
for the purification of the immune complex and for the immobilisation of MFE-23 onto Ni- 
NTA beads for immunoprecipitation studies, it was predicted that the tag could be further 
exploited for epitope mapping studies. To our knowledge, this is the first application of the 
IMAC chip surfaces for the capture of immune complexes and their subsequent 
characterisation (Dr. Kathryn Chapman, Ciphergen Biosystems Inc, personal 
communication).
Using SELDI-AMS, three peptides were identified which were assigned to the MFE- 
23 epitope on CEA (N-Al). Although the observed masses were identified to be within 
0.1-0.3% of the actual masses defined by the protein sequence analysis software, these 
corresponded to 643-2588 ppm, which is slightly outside the mass accuracy for external 
calibration on the SELDI-AMS (0.1 %; 1000 ppm). The slight mass inaccuracy of two of 
the three identified peptides is presumed to be caused by errors in calibration parameters. 
However, no other proteolytic peptides matches could be found for the SELDI-AMS- 
identified peptides and repeated experiments consistently gave similar results.
Furthermore, the analysis of control spots containing digested MFE-23 or trypsin alone 
confirmed that the SELDI-AMS-identified peptides did not originate from them. In 
conclusion, although the calibration was off by a range of between 500-1500 ppm, there 
were no peptides better matched to these masses, and the alignment of the peptides with the 
predicted model indicated that they may form a part of the MFE-23 epitope. Further 
mapping studies using alternative enzymes will help to clarify the epitope of MFE-23 
binding to CEA (N-Al).
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All three SELDI-AMS-identified peptides contained the common 30-residue CEA 
sequence Asp [127-156] Arg and the placement of this peptide was mapped in the CEA 
homology model. Comparison with structural predictions of the CEA (N-Al)/MFE-23 
complex confirmed that the SELDI-AMS-identified sequence corresponded to one of the 
predicted MFE-23-binding sites Tyr [142-150] Ser, determined by the surface 
accessibilities of surface-exposed CEA amino acid side-chains. The observed surface area 
changes at this position are in full agreement with the SELDI-AMS-identified peptide, with 
the peptide becoming buried in the predicted complex with MFE-23. The SELDI-AMS 
results support that the N-terminal N and Al domains of CEA had been correctly predicted 
as the MFE-23 binding site. The prediction for the complex suggests that CEA Tyr [142- 
150] Ser makes contacts primarily with the LI loop of MFE-23. Further experiments will 
be needed to refine the orientation of MFE-23 within its binding pocket on CEA (N-Al).
The results reported in this thesis represent the most detailed analysis of an antibody 
binding site on CEA. Previously, antigenic regions on CEA have been classified into 
several non-overlapping groups, termed GOLD epitopes, which were defined by 
monoclonal antibody binding (Bjemer et al, 2002). Indeed, most efforts to epitope map 
anti-CEA antibodies have been limited to CEA domains only, and not precise amino acid 
sequences (Hass et al, 1991; Hefta et al, 1992,1998; Ikeda et al, 1992; Kuroki et al, 1992; 
Nasu et al, 1999; You et al, 1998; Zhou et al, 1993). To date, apart from the preliminary 
results described here, only one predicted epitope has been reported for an anti-CEA 
antibody. The binding site of the monoclonal antibody A20 was assigned to a linear region 
(8 residues) on the N-domain (Taheri et al, 2000) and was determined based on the ability 
of this antibody to block CEA-mediated intercellular adhesion (Zhou et al, 1993). Another 
linear epitope (5 residues) at the N-Al interface was reported for a receptor expressed on 
the surface of Kupffer cells (Thomas & Toth, 1990; Thomas et al, 1992), which have been 
shown to specifically bind CEA (Toth et al, 1982; Toth et al, 1985). This region was 
identified by overlapping synthetic peptides and was confirmed by the rapid accumulation 
of the injected pentapeptide (conjugated to albumin) in the liver and its subsequent uptake 
inhibition by CEA.
The difficulties in producing recombinant forms of CEA and overcoming the stability 
problems associated with heterogeneous glycosylation are expected to have contributed to
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the paucity of protein interaction data. This may also be the reason that no x-ray 
crystallography information has been available, despite the determination of the primary 
structure of CEA more than 10 years ago (Beauchemin et al, 1987; Oikawa et al, 1987; 
Paxton et al, 1987; Zimmermann et al, 1987). CEA has 28 potential glycosylation sites, 
most of which are occupied, and it is known that glycosylated proteins are generally 
difficult to crystallise due to the chemical heterogeneity and conformational flexibility of 
sugar chains (Baker et al, 1994; Wyss & Wagner, 1996). Despite this, structures of several 
glycosylated proteins have been reported, although the proteins all contained short sugar 
chains (Casasnovas et al, 1999; Kwong et al, 2000; Sondermann et al, 1999). More 
recently, the structure of a glycosylated, recombinant form of the two-domain CEACAM1 
molecule was solved, representing the first report of a crystal structure for a CEA family 
member (Tan et al, 2002). Optimisation of the bacterial expression methods described in 
this chapter, and the potential for co-culture with MFE-23, may provide sufficient material 
for crystallisation studies. These would enable in-depth structural characterisation of the 
CEA (N-Al)/MFE-23 interface and give invaluable information for the design of improved 
MFE-23-based targeting molecules. The assignment of the MFE-23 binding pocket on 
CEA to the N-terminal N-Al domain pair obtained from the preliminary studies outlined in 
this chapter, however, have given a better understanding of the interaction between MFE- 
23 and CEA. These results correspond to practical design guidelines and have been useful 
in the development of the divalent MFE-23 molecules described in this thesis.
3.4 Summary
The aim of this chapter was to characterise the MFE-23 binding site on CEA. To 
study this interaction, a recombinant form of the N-terminal N-Al domain pair of CEA was 
expressed in bacteria and its immonoreactivity with MFE-23 was confirmed. Further 
evidence of their specific interaction was demonstrated by the successful capture of CEA 
(N-Al) by MFE-23 in immunoprecipitation studies, and by co-purification of the immune 
complex using IMAC via the hexahistidine tag on MFE-23. Finally, the binding 
relationship between MFE-23 and CEA (N-Al) was directly characterised by the partial 
mapping of the MFE-23 epitope on CEA (N-Al). This was accomplished using SELDI- 
AMS in conjunction with proteolysis, resulting in detailed sequence information on the 
putative region where MFE-23 binds to CEA. These results have guided the design of 
MFE-23 dimers developed in subsequent chapters.
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Chapter 4
Design, production and characterisation o f tandem 
MFE-23-based molecules
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4.1 Introduction
When compared to whole antibodies, small antibody fragments exhibit better tumour 
penetration and faster clearance, resulting in improved pharmacokinetics. However, the 
first generation of engineered antibody fragments proved disappointing as the absolute 
uptake of these molecules by tumours was low, mainly due to their monovalent binding and 
rapid elimination (Colcher et al, 1990; Milenic et al, 1991; Adams et al, 1993; Wu et al, 
1996; Larson et al, 1997; Beresford et al, 1999; Begent et al, 1996; Mayer et al, 2000). 
Furthermore, these small molecules were found to persistently accumulate in the kidney, 
making this the dose-limiting organ. In order to overcome these limitations, larger, 
multivalent scFv-based molecules have been developed. These have shown superior 
tumour targeting capabilities compared to their monovalent counterparts (Adams et al,
1993; Whitlow et al, 1994; Wu et al, 1996; Adams et al, 1998; Beresford et al, 1999; Goel 
et al, 2000; Nielsen et al, 2000; Goel et al, 2001; Yazaki et al, 2001). This has been 
attributed to a gain in synergistic binding to antigen combined with a longer circulating 
half-life due to an increase in molecular weight, resulting in improved cumulative levels in 
the tumour and reduced renal uptake. The excellent tumour localisation of MFE-23 in 
patients demonstrated its suitability for future clinical use (Begent et al, 1996; Mayer et al,
2000). However, its monovalent nature and high renal uptake limits its therapeutic 
potential as a scFv alone. Therefore, it was hypothesised that increasing the avidity of 
MFE-23 would improve its in vivo performance and clinical application. The aim of this 
chapter was to test this hypothesis by designing divalent forms of MFE-23.
A number of approaches have been taken to increase the valency and size of scFv 
molecules (see 1.3.2). These include formation of multimers by constraining intradomain 
linker lengths (Holliger et al, 1993, 1996; Adams et al, 1996; Wu et al, 1996; Kortt et al, 
1997; Iliades et al, 1997), or joining scFv together using polypeptide linkers (Mallender & 
Voss, 1994; Neri et al, 1996; Beresford et al, 1999), strategically placed cysteine residues 
(Cumber et al, 1992; Kipriyanov et al, 1994), chemical cross-linkers (King et al, 1994) and 
molecules which tend to self-associate (Kostelny et al, 1992; Pack & Pluckthun, 1992; 
Dubel et al, 1995; McGregor et al, 1994; Hu et al, 1996; Alt et al, 1999).
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The approach taken here was to develop tandem MFE-23 joined together using a 
flexible polypeptide linker. In the previous chapter, the MFE-23 binding site on CEA was 
assigned to the N-terminal N-Al domain pair and detailed sequence information was 
obtained on the putative epitope. This enabled the calculation of optimal linker lengths for 
divalent MFE-23 binding to CEA. Based on these results, a bacterial expression vector was 
designed to facilitate the production of divalent, chelating, or bispecific MFE-23-based 
anti-CEA molecules. The vector was constructed by cloning a ‘reversed’ version of MFE- 
23 (in the Vl-Vh orientation) downstream of a hydrophilic linker and restriction sites for 
insertion of a second scFv to produce a genetically fused dimer in the V h-V l-V l-V h 
format. The feasibility of generating tandem molecules in this arrangement was tested by 
cloning MFE-23 into the expression vector to produce an MFE-23 dimer.
4.2 Results
I
4.2.1 Structural analysis to guide design of dimeric MFE-23
Based on the putative MFE-23 epitope on CEA determined in the previous chapter, the 
minimum distances spanning across two MFE-23/CEA complexes were measured to guide 
the design of minimum linker lengths for the production of dimeric MFE-23 molecules.
The homology model of CEA (Boehm et al, 1996) and the x-ray crystallography structure 
of MFE-23 (Boehm et al, 2000) were used to make these measurements. Two CEA 
molecules with MFE-23 docking at the CEA (N-Al) domains (Chapter 3) were aligned 
side-by-side so that there were no interactions between the oligosaccharide chains (Figure 
4.1a). The closest distances between the two CEA molecules to prevent steric hindrance 
was calculated to be ~ 10 A. This distance was then used to determine the minimum 
potential linker lengths between two MFE-23 molecules which would allow dimeric 
binding based on the closest possible distance between two CEA molecules on a cell 
membrane. An enlarged view of the MFE-23 docking site on the CEA (N-Al) domains is 
shown in Figure 4. lb. Distances between the Vl C-terminus of one scFv and the Vh and 
V l  N-termini of the second scFv were measured to be -53 A and ~63 A, respectively. This 
corresponds to linkers of between —17-21 amino acids in length based on average amino 
acid lengths (Richards, 1974).
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~<10 A
Vl-Vl:~ 6 3 A
Figure 4.1. Structural representation o f MFE-23 in complex with CEA showing predicted distances needed between two MFE-23 molecules to facilitate dimeric binding 
to CEA. (a) Two homology models o f CEA containing oligosaccharide chains at all 28 potential sites were aligned and the minimum distances needed between them to 
prevent steric hindrance or carbohydrate interaction was calculated to be -10  A. The x-ray crystallography structure o f MFE-23 was docked at the N-terminal N and A l 
domains pair o f CEA based on prediction made in Chapter 3. (b) An enlarged view o f the MFE-23 docking site. The distances from the C-terminus o f VL from one 
scFv to the N-terminus o f the VH or VL on the second scFv were measured to be -53 A and -63  A, respectively. Figure provided by Professor Steve Perkins, as detailed 
in Chapter 2.
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4.2.2 Feasibility of reversing MFE-23 domains (V t - V h )
Based of several possible tandem scFv formats, it was decided to produce dimeric anti- 
CEA scFv as genetically-fused Vh-Vl-Vl-Vh constructs. To establish whether the 
(Gly4Ser)3 intra-domain linker was sufficiently long to allow proper folding of the domains 
in the reversed orientation, the distances spanning the C-terminus of Vh and the N-terminus 
of V l  (V h -V l orientation) and the C-terminus of V l  and the N-terminus of V h (V l-V h  
orientation) were measured using the x-ray structure of MFE-23 (Boehm et al, 2000). 
Calculated distances for MFE-23 in the V h -V l orientation (30.2 A) and MFE-23 in the V l-  
V h (35.5 A) showed an increase of -  5 A when the domains were ‘reversed’ (Figure 4.2). 
This confirmed that the 15 residue (Gly4 Ser)3 intradomain linker used in the original V h -V l  
format was sufficiently long to allow proper folding of MFE-23 (V l-V h ) , as a distance of 
-29-36 A require linkers of 10-15 residues (Huston et al, 1991).
To determine whether MFE-23 (V l-V h) retained its activity for CEA, the rearranged 
Vh and Vl domains of MFE-23 were subcloned into the bacterial expression plasmid 
pUCl 19 HIS using the primers in Table 4.1. The cloning strategy to accomplish this is 
detailed in Figure 4.3. Primer pairs annealing to the V l and V H domains respectively were 
used to isolate the individual domains and introduce a new (Gly4 Ser)3  intra-domain linker 
with altered codon usage to the original linker in order to prevent transcriptional errors due 
to repetitive nucleotides when in the dimer format (linker sequence is given in Figure 4.3). 
Overlapping and complementary regions on the primers were annealed together and gaps in 
the sequences were filled in using the Klenow fragment enzyme. The Vl-Vh domains were 
then amplified and cloned into the pUCl 19HIS vector for bacterial expression.
Orientation of cloned constructs was tested by Pst I fingerprinting (Figure 4.4). Four 
E. coli transformants of MFE-23 (V l-V h) were screened and comparison of their Pst I 
digestion patterns with MFE-23 showed the expected differences in digestion. Pst I 
digestion of MFE-23 resulted in a drop-out band of -230 bp. For MFE-23 (V l-V h)  an 
extra band at -  318 bp was observed as expected. These results showed the domains were 
successfully reversed and this was confirmed by DNA sequencing.
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(a) W L
(b) VL-VH
Figure 4 2 . Structural representations o f MFE-23 in (a) VH-VL and (b) VL-VH orientations. VH is shown in 
green, VL in cyan. N-termini are highlighted in blue and C-termini in red. Distances (dotted lines), spanning 
from the C-terminus o f  VH to the N-terminus o f  V L for the V H-VL orientation (30.2 A), and the C-terminus of 
VL to the N-terminus o f  VH for the VL-VH (35.52 A) are given. MFE-23 structure generated in Rasmol {see 
Chapter 2).
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Primer name Sequence 5’-3’
V Hsense AGTGGTGGCGGAGGGTCAGGTGGCGGAGGTTCTGCCCAGGTGAAACTGCA
GCAGTC
V H anti-sense ATAAGAATGCGGCCGCT GAGGAGACGGTGACCGTGGTC
V L sense CATGCCATGGCAGAAAATGTGCTCACCCAGTCTCCA
V L anti-sense ACCTGACCCTCCGCCACCACTCCCACCTCCTGACGCCCGTTTCAGCTCCAG
CTTG
Table 4.1. Oligonucleotide primers for constructing ‘reversed’ MFE-23. Sequences annealing to template are 
in bold. Restriction sites are underlined. Linker sequences are italicised.
(a)
VH sense VL sense
VH anti-sense VL anti-sense
/i \ Nco I ----1(b) , VL
(c)
Nco I
k VL
L2
v
L 2 _ J
■ c z z s s z z z a - ^ o ,
Not I
VII i l l i
T C AGGAGGT GGGAGT GGT GGCGG AGGGT C AGGT GGCGG AGGTTCT
Figure 4 3 .  Construction o f ‘reversed’ MFE-23. (a) Two sets o f  primers, annealing to VH and VL 
respectively, were used to (b) switch the two domains and insert a new (GLY4SER)3 linker (L2) between 
them. The codon usage o f the new intra-domain linker was altered from the original to prevent transcriptional 
errors due to repetitive nucleotides when in the dimer format, (c) Gaps in the sequence where filled in using 
the large Klenow fragment according to Clackson et a l (1991). The ‘reversed’ MFE-23 sequence was 
amplified by PCR using VL sense and VH antisense primers and cloned into pU C l 19HIS using the Nco I and 
Not I restriction sites. Details o f  the cloning conditions are given in Appendix 1.
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Figure 4.4. Confirmation o f  reversed domain orientation o f MFE-23 (Vl- V h). Four transformants o f  MFE-23 
( V l- V h)  were screened by Pst I digestion (lanes 3-6) alongside MFE-23 in the original orientation (lane 2). 
Uncut MFE-23 (Vl-Vh) plasmid DNA is in lane 1 and DNA markers are in lanes M l (X Hind HI) and M2 (<p 
X I74 Hae HI). Bands at the expected size were observed for Pst I digested MFE-23 (— 3.3 kb plasmid band, 
-2 3 0  bp drop-out band) and MFE-23 (Vl-Vh) (3.3 kb plasmid band, —318 bp and ~230 bp drop-out bands).
To test the bacterial expression of MFE-23 (V l-V h ) in comparison to MFE-23 in the 
original orientation, individual clones of is. coli TGI cells transformed with puCl 19HIS/ 
MFE-23 (V l-V h)  or puCl 19HIS/MFE-23 were induced overnight using IPTG. SDS- 
PAGE revealed expressed product in yields (-20 mg/L) and molecular weight (-27 kDa) 
similar to the original MFE-23 scFv, although MFE-23 (VL-VH) migrated slightly faster 
than MFE-23 on SDS-PAGE (Figure 4 .5 ) . Furthermore, CEA activity of the MFE-23 (V l- 
V h) was retained, showing that the two domains of MFE-23 were able to be switched 
without loss of immunoreactivity (Figure 4 .6 ). Retention of MFE-23 (V l-V h)  to CEA- 
coated wells was detected using both anti-MFE-23 and anti-HIS antibodies, showing that 
the full-length protein was expressed and contained the COOH-terminal hexahistidine tag.
The availability of the COOH-terminal hexahistidine tag for isolation of MFE-23 (V l- 
V h) from bacterial culture supernatants was tested by small-scale IMAC purification. This 
resulted in yields and immunoreactivity similar to the original MFE-23 scFv, as detected by 
SDS-PAGE and Western blotting using anti-MFE-23 antibodies (Figure 4.7). Some loss of 
protein was visible in the wash fractions for both proteins, resulting from saturation of the 
column or loss of hexahistidine tag from a small proportion of the expressed scFv.
However, the majority of the protein was recovered, and these results indicated that moving 
Vh to the COOH-terminal position of the scFv did not affect the accessibility of die
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Figure 4.5 Bacterial expression o f MFE-23 (VL-VH). Supernatants from bacterial cultures expressing MFE-23 
or MFE-23 ( V l- V h)  were separated on SDS-PAGE (12% Tris-Glycine) and proteins at the expected 
molecular weight for MFE-23 (lane 2) and MFE-23 (V l-V h)  (lane 3) were visualised by Coomassie blue 
staining. Lane 1 was left blank and molecular weight marker (Multimark) was loaded into lane M.
(a)
MFE-23 (VL-VH) negative controlMFE-23
(b) 0.12 
0.1 
a o.o8s
0.06 -j 
0.04 
0.02 
0 -I
MFE-23 M FE-23 (VL-VH) negative control
Figure 4.6. Immunoreactivity o f MFE-23 (V l- V h) . Bacterial culture supernatants containing MFE-23 (V l-  
V h)  or MFE-23 were applied to CEA-coated wells, alongside culture supernatant only (neg. control). 
Following washing, bound scFv was detected using (a) anti-MFE-23 and (b) anti-HIS antibodies. Samples 
were tested in duplicate and values were subtracted against ‘blank’ wells coated with PBS. Data is 
representative o f repeated experiments.
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Figure 4.7. Analysis o f  MFE-23 (VL-VH) IMAC purification. SDS-PAGE (12% Tris-Glycine) and Western 
blot analysis using anti-MFE-23 antibodies o f  small-scale IMAC purifications o f  (a) MFE-23 (VL-VH) and (b) 
MFE-23. Following application o f  the bacterial supernatants to Ni-NTA mini spin columns (lanes 1 ,6), non­
binding proteins were washed o ff (lanes 2-3, 7-8) and hexahistidine tagged-proteins were freed from the 
column by competitive elution (lanes 4-5, 9-10). Molecular weight markers are in lanes M l (Seeblue) and M2 
(Multimark).
hexahistidine tag. Therefore, MFE-23 (Vl-Vh) in the COOH-terminal position of the 
subsequent dimer should not affect its subsequent purification using IMAC.
4.2.3 Construction of an expression vector for dimeric and chelating tandem MFE-23
A bacterial expression vector for the production of tandem scFv was designed to 
facilitate dimeric and chelating binding to CEA. This was generated by cloning MFE-23 
(V l-V h) downstream of restriction sites for insertion of a second scFv in the original V h-V l 
orientation and a flexible 18 residue linker (Neri et al, 1995) to join them together. Details 
of the oligonucleotide primers and cloning strategy are given in Table 4.2 and Figure 4.8, 
respectively. Primers annealing to pUCl 19HIS/ MFE-23 (V l-V h) were used to append 
part of the 18 residue linker to the 5’-end and an Eco RI site to the 3’-end for cloning into 
pUCl 19HIS. A third primer was then introduced, complementary to the 5’-linker primer 
and containing a Not I site, and gaps in the sequence were filled in using the Klenow
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Primer name Sequence 5 ’-3’
Tandem 1 sense TCAGA CGGAAAAGCGTCTGGTGGCTCCGCGTCAGGCGGTGAAAAT 
G TG C TC A C C C A G TC TC C A
Tandem 2 anti-sense CCGGAATTCTTATTAATGGTGATGATGGTGATGTCTAGATGAGG
A G A C G G TG A C C G TG G TC
Tandem 3 anti-sense GCCACCAGACGCmTCCGTCTGAGCCGGAGGAAGAACCTGCGGC 
CGCT AAACT AT
Table 4.2. Oligonucleotide primers for construction o f  tandem MFE-23. Sequences annealing to template are 
in bold. Restriction sites are underlined. Linker sequences are italicised.
Tandem 1 sense
(a)
(b)
I VL |L21 VH _
Tandem 2 anti-sense
i>
*—I VL IL2 |  VH
Tandem 3 anti-sense
(C)
(d)
(e)
I I VL |L21 VH tHISfe
Tandem 3 anti-sense n  Tandem 2 anti-sense
Not I Eco RIi h
I L 31 VL <L2t VI1 |H l s i
]\/co |  Not 1 | Xba I Eco RI
VH |L 1| VL /  L3 1 VL |L 2 | VH I f f l s l
VH |L1 | VL^j Non-CEA specific scFv
Selection from anti-CEA 
library
Figure 4.8. Construction o f  a bacterial expression vector for divalent and chelating forms o f  MFE-23. (a)
PCR was performed on MFE-23 (V l -Vh) using an anti-sense primer annealing to the VH domain o f  MFE-23 
(Vl-Vh) to replace the existing Not I site with an Xba  I site, hexahistidine tag and Eco RI site for cloning into 
pU Cl 19HIS/MFE-23 and a sense primer to remove the existing Nco I site at the 5 ’- end o f MFE-23 (Vl -Vh) 
and insert a complementary sequence to (b) a third primer for the generation o f  an 18 amino acid linker (L3). 
Gaps were filled in using the Klenow fragment enzyme to produce an inter-domain linker sequence as 
follows: Gly-Ser-Ser-Ser-Gly-Ser-Asp-Gly-Lys-Ala-Ser-Gly-Gly-Ser-Gly-Ser-Gly-Gly. (c) The PCR product 
was amplified, (d) digested with Not I and Eco RI and (e) cloned into a similarly digested pU C l 19HIS/MFE- 
23. The final construct contains Nco I and Not I sites for easy subcloning o f  a non-specific scFv for bispecific 
binding or an anti-CEA scFv library for selection o f  a chelating binder. Details on the cloning conditions are 
given in Appendix 1.
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fragment enzyme. The resulting product was cloned into pUCl 19HIS/MFE-23 using the 
Not I and Eco RI sites to produce an MFE-23 dimer as follows: VH-(Gly4Ser)3-VL-Ala-Ala- 
Ala-GIy-Ser-Ser-Ser-Gly-Ser-Asp-Gly-Lys-Ala-Ser-Gly-Gly-Ser-Ala-Ser-Gly-Gly-VL- 
(Gly4Ser)3-VH. Twenty-one amino acid residues span the C-terminus of the Vl of the first 
scFv and the N-terminus of the VL of the second scFv, corresponding to the Not I cloning 
site and the linker. This length is equivalent to -63 A, which was predicted to be the 
minimal length for this orientation (,see 4.2.1).
4.2.4 Production of a divalent tandem MFE-23 molecule
To test the expression levels of divalent MFE-23, small-scale bacterial expressions on 
four E. coli transformants were performed. SDS-PAGE on culture supernatants confirmed 
the successful expression of tandem MFE-23 at the predicted size (-54 kDa) for all four 
transformants (Figure 4.9). The best expresser (clone 3) was tested for CEA 
immunoreactivity by ELISA. Results confirmed that the expressed product was still able to 
interact with CEA, as bound protein was detected using anti-MFE-23 antibodies following 
washing (Figure 4.10).
M 1 2 3 4
250 kDa 
98 kDa 
64 kDa
50 kDa
36 kDa 
16 kDa
4/6 kDa
Figure 4.9. Bacterial expression o f tandem MFE-23. Bacterial culture supernatants from four transformants 
(lane 1-4) expressing tandem MFE-23 were separated by SDS-PAGE (12 % Tris-Glycine) and proteins at the 
predicted MW (-54  kDa) were visualised by Coomassie blue staining. Molecular weight marker (Seeblue) is 
in lane M.
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Figure 4.10. Immunoreactivity o f  tandem MFE-23. Bacterial culture supernatants containing expressed 
tandem MFE-23 or MFE-23 were applied to CEA-coated wells, alongside culture medium only (negative 
control). Following washing, bound scFv was detected using anti-MFE-23 antibodies. Proteins were tested in 
duplicate and values were subtracted from ‘blank’ wells coated in PBS. Data is representative o f repeated 
experiments.
The achievability of isolating tandem scFv via the COOH-terminal hexahistidine was 
tested by small-scale IMAC purifications. Two methods were tested; isolation directly 
from bacterial culture supernatants and from solublised cell pellets. Both methods resulted 
in low yields of tandem MFE-23, with barely detectable levels of proteins detected by SDS- 
PAGE and Western blotting using anti-MFE-23 antibodies (Figure 4.11). Initial protein 
loads onto the columns were visibly low, with no detectable band at the predicted MW for 
the culture supernatant prep. A stronger band was visible for the solublised cell pellet, 
presumably due to concentration of the protein due to the method of preparation. However, 
a band corresponding to the tandem MFE-23 was visible in the column wash fraction, 
suggesting either saturation of the column or some loss of the hexahistidine tag from 
expressed protein. Strong bands were also detected in the load and flow-through samples 
at lower MW species. These may correspond to bacterial host proteins which cross-react 
with the polyclonal antibody used for detection or to breakdown products resulting from 
proteolytic digestion of the tandem MFE-23. These were not detected in the eluted product, 
and although low yields were detected, IMAC purification resulted in relatively pure 
protein.
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Figure 4.11. SDS-PAGE (12% Tris-Glycine) and Western blot analysis using anti-MFE-23 antibodies o f  IMAC-purified tandem MFE-23 isolated from (a) bacterial 
culture supernatant and (b) soluble cell pellet. Following application o f the samples to Ni-NTA mini spin columns (lane 1), non-binding proteins were washed off (lane 
2) and hexahistidine tagged-protein was freed from the column by competitive elution (lanes 3-4). Molecular weight marker (Multimark) is in lane M.
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To test whether larger-scale production would improve recoveiy yields, 4 L culture 
volumes of expressed tandem MFE-23 were evaluated. Bacterial culture supernatant and 
solublised cell pellets were subjected to IMAC purification controlled by FPLC. The UV 
traces for both sample preparations purified by IMAC are shown in Figure 4.12. Peaks 
corresponding to increases in UV absorbance readings were observed for loading of the 
matrix with copper ions, followed by sample load. A large peak was seen for the removal 
of non-specifically bound proteins during the column wash, followed by a smaller peak 
corresponding to eluted hexahistidine-tagged protein. A larger sample load peak was
£
.5
£
Figure 4.12. UV traces showing IMAC purification o f tandem MFE-23 from (a) bacterial supernatants and 
(b) soluble cell pellets. Chelating Fast-flow Sepharose was charged with copper ions, washed with dH20 and 
equilibrated with PBS containing 1 M NaCl. Samples containing expressed protein were loaded onto the 
column following addition o f  1 M  NaCl and non-specifically-bound proteins were washed off with 40 mM 
imidazole in PBS/ lM N aC l. Hexahistidine-tagged protein was eluted using 200 mM imidazole in PBS/ 1 M  
NaCl. Fractions (7 ml; red dotted lines) were taken starting at the 40 mM imidazole wash. Fractions 
corresponding to the 200 mM imidazole-eluted protein were pooled, dialysed against PBS and concentrated.
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Figure 4.13. Evaluation o f  large-scale tandem MFE-23 IMAC purification. Final products were subjected to 
SDS-PAGE (12% Tris-Glycine) and Western blot analysis using (a) anti-MFE-23 and (b) anti-HIS 
antibodies. Tandem MFE-23 was purified by IMAC from bacterial culture supernatant (lane 2) or solublised 
cell pellet (lane 3). MFE-23 (-5  pg) is in lane 1, molecular weight marker (Multimark) in lane M. Two 
dominant bands o f  co-purifying protein were detected at -30  kDa and -2 2  kDa.
observed for the solublised cell pellet compared to the supernatant, presumably due to the 
concentration of protein during preparation. Following concentration of the eluted peak, 
SDS-PAGE and Western blot analysis using anti-MFE-23 and anti-HIS confirmed the 
isolation of tandem MFE-23 using both of these methods (Figure 4.13).
In this case, the final yields of tandem MFE-23 recovered from the soluble cell pellet were 
lower (~ O.lmg/L) than those obtained from the supernatant (~ 0.3 mg/L), which is not 
consistent with the results seen for small-scale purification. In addition, two dominant co- 
purifying proteins were also detected by anti-MFE-23 antibodies at MW corresponding to 
-30 kDa and -22 kDa. The -30 kDa contaminant band was also detected by anti-HIS 
antibodies in protein purified from the soluble cell pellet, giving a stronger signal by 
Western blot analysis than the tandem MFE-23 protein, which were barely detectable.
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Figure 4.14. Gel filtration chromatography profile o f  tandem MFE-23. IMAC-purified tandem MFE-23 
isolated from bacterial culture supernatants (-0 .2  mg) was applied to a Superdex 75 column at a flow-rate o f 
1.5 ml/min in PBS. A very poor UV trace was observed, with an unsteady baseline. A broad peak 
corresponding to the predicted MW o f  the tandem MFE-23 was detected (Peak 1), as well as a peak similar in 
MW to the breakdown product at ~30 kDa (Peak 2). Smaller peaks corresponding to low MW species were 
also detected. Elution volumes o f MW calibrants are indicated at top o f  figure, along with their MW.
The feasibility of removing the co-purifying proteins from the tandem MFE-23 
samples was tested by size-exclusion chromatography. However due to the low protein 
concentration applied to the column, a poor UV profile was observed (Figure 4.14). 
Nevertheless, two distinct peaks were visible corresponding to the MW of tandem MFE-23 
(-54 kDa) and the contaminant proteins (-20-30 kDa) based on calibration of the column 
with proteins of known MW. Analysis of the two peaks by SDS-PAGE and Western blot 
using anti-MFE-23 antibodies confirmed that the contained the tandem MFE-23 and -30 
kDa contaminant protein, respectively (Figure 4.15). Interestingly, the first fraction from 
the lower MW peak contained low levels of tandem MFE-23, suggesting it was not 
efficiently separated at this elution volume. However, upon concentration of the pooled 
peak corresponding to the tandem MFE-23, a single faint band at the expected molecular 
weight was visible, confirming the successful removal of the lower MW proteins (Figure 
4.16a). Furthermore, CEA ELISA confirmed the protein retained its immunoreactivity 
(Figure 4.16b).
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Figure 4.15. Evaluation of gel filtration chromatography of tandem MFE-23 by SDS-PAGE (12% Tris-Glycine) and Western blot analysis. Following application of 
IMAC-purified tandem MFE-23 (lane 2) to a Sephadex 75 size-exclusion column, fractionated proteins (lanes 3-10) were detected by anti-MFE-23 antibodies. Bands at 
the expected MW for tandem MFE-23 were not detected in the high MW peak fractions (lanes 3-4) but were detected in peaks corresponding to -54 kD (lanes 5-6) and 
-30 kD (lanes 7-8). Co-purifying protein was detected in peak fractions corresponding to -30 kD (lanes 7-10). MFE-23 (5pg; lane 1) was also detected, alongside the 
molecular weight marker (Multimark; lane M).
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Figure 4.16. Evaluation of concentrated tandem MFE-23 purified by IMAC and size-exclusion 
chromatography. Pooled fractions were concentrated and (a) subjected to SDS-PAGE (12% Tris-GIycine) and 
Western blot analysis using anti-MFE-23 antibodies. Very low levels of tandem MFE-23 protein was 
detected (-0.2 pg; lane 1), when compared to MFE-23 (1 pg; lane 3) and molecular weight marker 
(Multimark; lane M). Lane 2 is blank, (b) Immunoreactivity o f the final product was tested by CEA ELISA. 
Pooled and concentrated tandem MFE-23 was applied to wells coated with CEA and following washing, 
bound proteins were detected using anti-HIS and anti-MFE-23 antibodies. Proteins were tested in duplicate 
and values were subtracted from ‘blank’ wells coated in PBS. Purified MFE-23 (1 mg/ml) or PBS (neg. 
control) were used as controls. Data is representative of several experiments.
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4.3 Discussion
The aim of this chapter was to develop divalent forms of MFE-23 in order to improve 
its tumour targeting potential by increasing avidity. Guided by the putative MFE-23 
epitope on CEA predicted from epitope mapping studies performed in the previous chapter, 
tandem scFv were designed using a flexible linker to join them together. To develop these 
molecules, a bacterial expression vector was produced by cloning MFE-23 in the reversed 
orientation ( V l- V h)  alongside restriction sites for insertion of a second scFv. To test the 
feasibility of producing tandem scFv using this vector, an MFE-23 dimer was generated by 
cloning MFE-23 into the expression vector to produce a molecule in the V h-V l-V l-V h 
format.
Increasing the avidity of scFv molecules may be achieved using a variety of linkers 
{see 1.3.2). For the purposes of this study, simplistic dimeric MFE-23 molecules were 
designed by connecting two scFv using a flexible polypeptide chain. This format was 
chosen for the production of MFE-23-based dimers because of its potential application for 
the production of a variety of MFE-23-based molecules. First, as developed in this chapter, 
the expression vector may be used to produce tandem MFE-23 dimers. The use of 
polypeptide linkers to increase avidity has been successfully applied to several scFv 
(Mallender et al, 1994; Beresford et al, 1999; Goel et al, 2000). For example, the avidity of 
the scFv generated from the CC49 IgG, directed against the sialyl-Tn epitope of tumour- 
associated glycoprotein-72 has been increased by linking two CC49 scFv using a 20- 
residue polypeptide linker (Pantoliano et al, 1991; Beresford et al, 1999). This resulted in 
favourable tumour localisation compared to the monovalent version (Beresford et al, 1999).
A second application of the tandem scFv expression vector is the production of 
chelating recombinant antibodies (CRAbs; Neri et al, 1995). This may be achieved by 
cloning a second anti-CEA scFv alongside MFE-23 (V l-V h) . CRAbs were originally 
developed to produce high affinity molecules with divalent binding to adjacent, non- 
overlapping epitopes simultaneously on the same antigen (Neri et al, 1995). In this case, 
the crystal structure of the two scFv used by Neri et al had previously been determined in 
complex with their antigen (Harper et al, 1987; Smith-Gill et al, 1984; Amit et al, 1986; 
Padlan et al, 1989) and their epitopes were well-defined. This structural information was
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used to guide the design of a hydrophilic linker to facilitate tandem binding of the two scFv 
to their cognate antigen, resulting in up to a 100-fold gain in affinity for the antigen. It was 
hypothesised that the tandem scFv vector described in this chapter may be applied to the 
generation of such a molecule by cloning an anti-CEA phage display library alongside 
MFE-23 ( V l- V h)  and screening for (in the presence of MFE-23) an adjacent, non­
overlapping scFv. Furthermore, as the epitope has been partially mapped for MFE-23 
(Chapter 3), the binding site of the second scFv could then be determined and the inter-scFv 
linker further optimised for simultaneously binding to CEA.
A third approach using this format is the construction of bispecific scFv, in which a 
scFv with specificity for another antigen is cloned into the vector alongside MFE-23 to 
produce a molecule with the ability to bind to two distinct antigens. Bispecific antibodies 
have become exceeding applied in the recruitment of effector molecules or the direction of 
cytotoxic agents to the tumour site in pre-targeting strategies (Segal et al, 2001). The 
simple tandem format may be particularly suitable for the generation of these molecules 
and has already been successfully applied to construct antibody molecules with two 
specificities (Mallender & Voss, 1994; Gruber et al, 1994; Kurucz et al, 1995; Mack et al, 
1995; Kipriyanov et al, 1999; Schmiedl et al, 2000). Furthermore, MFE-23 has been shown 
it is effective as a bispecific antibody when in the diabody format (FitzGerald, et al, 1997; 
Holliger et al, 1999) and the tandem approach may provide a more stable alternative.
A further application of this scFv format is the investigation of molecular size and 
avidity on tumour localisation and retention. Because increasing the valency of an antibody 
also increases the molecular weight, which in turn reduces the clearance rate and 
subsequently increases tumour uptake, the relative effect of these characteristics is not 
understood. The tandem scFv format would allow the direct comparison of size and avidity 
as a non-antigen binding scFv may be cloned alongside its active counterpart. An ideal 
candidate to test this is the MFE-23 derivative, NFE, which has abolished binding to CEA 
(Read et al, 1995). This scFv was produced by a single point mutation in the CDR H3 loop 
of MFE-23 and retains a similar shape, charge and MW to the wild-type version with no 
detectable antigen binding.
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A bacterial expression vector was designed for divalent and chelating scFv by the 
insertion of cloning sites and a flexible linker, based on the 18-residue hydrophilic linker 
used by Neri et al (1995), upstream of MFE-23 in 'reverse' orientation (V l- V h). The 
feasibility of using the tandem format for divalent MFE-23 binding to CEA was confirmed 
by structural analysis on the predicted binding site of MFE-23. Two CEA homology 
models were studied alongside each other to identify the minimum distances possible 
between them without steric inhibition or oligosaccharide interactions. MFE-23 was then 
modelled in the putative epitope at the N-terminal CEA (N-Al) domains (Chapter 3) and 
distances between the C-terminus of the first scFv VL and the N-terminus of the second 
scFv Vl was measured to be ~63 A, which corresponds to a ~21 residue linker to join two 
MFE-23 together. With the addition of a cloning site following the N-terminal scFv, the 
total residue number spanning from the C-terminus of the first Vl to the N-terminus of the 
second Vl was 21 mer.
The two domains of MFE-23 were reversed in the C-terminal scFv position as it was 
predicted that this would prevent the association of the Vh from one scFv with the Vl from 
the other. This has been recently supported by a study comparing the effect of domain 
order on tandem scFv (Kipiyanov et al, 2003). The authors reported that a bispecific 
tandem scFv in the V h- V l- V h-V l format could fold to form the functional (scFv)2 as well 
as fold head-to-tail with the formation of a non-functional (scFv)2 , whereas a tandem scFv 
in the V h-V l- V l- V h resulted exclusively in the functional form. Measurement of the 
distances between the two domains of MFE-23 in both orientations revealed a ~5 A 
increase for the ‘reversed’ MFE-23. This is consistent with other scFv molecules in the V l- 
V h format (Huston et al, 1991). Reorientation of the V h and V l domains of MFE-23 did 
not affect expression yields, purification by hexahistidine tag or activity for CEA.
Although the MFE-23 (Vl-Vh) molecule was not fully characterised, in terms of CEA 
affinity and heterotypic interactions, it may be a useful molecule for future applications, for 
example in the formation of spontaneous dimers (diabodies), which this orientation tends to 
favour due to constraints on the intra-domain linker.
The tandem scFv vector was first tested by cloning MFE-23 alongside MFE-23 (V l-  
V h)  to produce a bivalent MFE-23 molecule. Unfortunately, expression of tandem MFE-23 
in E. coli resulted in very low yields and the over-expression of bacterial contaminating
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proteins. N-terminal sequencing confirmed these co-purifying proteins originated from the 
host E. coli expression system and corresponded to E. coli tagatose-bisphosphate aldolase 1 
and FKBP-type peptidyl-prolyl cis-trans isomerase (data not shown). It has been suggested 
that these proteins are over-expressed in E. coli when heterologous proteins are not well 
expressed (Nicola O’Reilly, Cancer Research UK Peptide and Protein Isolation Unit, 
personal communication). In addition, analysis of their amino acid sequences revealed they 
were both histidine-rich, accounting for their co-purification by IMAC. Although the co- 
purifying proteins were successfully removed by gel filtration chromatography, very low 
yields of the tandem scFv were recovered. Exhaustive attempts to isolate tandem MFE-23 
from both bacterial culture supernatants and solublised cell pellets using various expression 
and purification conditions did not improve overall protein yields (data not shown). 
Unfortunately, low recovery did not allow further investigation of the molecules, as 
substantial quantities of material is needed for characterisation studies.
Although MFE-23 expresses at high yields in bacteria (~20 mg/L; Chester et al, 1994) 
this is not the case for most antibody fragments. Poor expression of scFv in bacteria is 
generally attributed to incorrectly folded protein retained in the inner cell membrane or in 
insoluble inclusion bodies (Chadd & Chamow, 2001). Extraction of proteins from 
insoluble compartments of the bacterial cell requires denaturation of the sample, followed 
by tedious refolding techniques (Huston et al, 1991). This approach generally necessitates 
the antigen affinity-purification of resulting proteins as a substantial amount of the refolded 
material will not retain immunoreactivity. Improvements in the yield of soluble production 
of heterologous protein can be made by the addition of proteins with chaperone-like 
refolding activity (Lin et al, 2001; Bessette et al, 2001; Joly et al, 1998; Bothmann & 
Pluckthun, 2000; Levy et al, 2001). As an E. coli isomerase was identified as being 
overexpressed in this study, it is unlikely that the addition of more chaperone-like proteins 
would increase yields of the tandem MFE-23. Of course, it is possible that the little amount 
of tandem scFv detected is actually a result of this protein enhancing, rather than 
suppressing, expression. The production problems encountered for expression of tandem 
MFE-23 may be overcome by changing to a more robust expression system. The 
methylotropic yeast Pichia pastoris has been successfully applied to the expression of 
tandem scFv (Goel et al, 2000), diabodies (FitzGerald et al, 1997), and scFv-fusion 
proteins (Powers et al, 2001; Gurkan & Ellar, 2003; Medzihradszky et al, 2003). Critically,
140
it has been shown to successfully produce proteins which had been previously difficult to 
express in bacteria (Freyre et al, 2000; Gurkan et al, 2003; Shi et al, 2003). Because of the 
poor protein yields obtained from bacterial production of tandem MFE-23, alternative 
methods of increasing the avidity of MFE-23 were investigated. The production of divalent 
versions of MFE-23 from P. pastoris is described in the next chapter.
4.4 Summary
The aim of this chapter was to increase the avidity of MFE-23 for improved tumour 
targeting. A bacterial expression vector was designed by cloning a ‘reversed’ version of 
MFE-23 (V l- V h)  downstream of an 18 residue linker and restriction sites for insertion of a 
second anti-CEA scFv. Expression levels and immunoreactivity of MFE-23 (V l-V h)  was 
first tested in an E. coli system, resulting in similar protein yields and activity for CEA as 
the original MFE-23 scFv. To test the tandem scFv format, MFE-23 was cloned into the 
plasmid to produce a divalent molecule. However, subsequent expression resulted in low 
yields of protein and purification of the molecule by IMAC resulted in heterogenous 
products, with the bulk of the purified protein associated with two contaminating proteins. 
These co-purifying proteins were identified by N-terminal sequencing as originating from 
the bacterial host and were histidine-rich, accounting for their co-purification. Size- 
exclusion chromatography on the purified product successfully removed the contaminant 
but low recovery prevented further study of these molecules. Following these results, 
alternative formats and expression systems for the production of divalent versions of MFE- 
23 were investigated in the following chapters.
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Chapter 5
Design and in vivo performance o f divalent MFE-23-based 
molecules incorporating high affinity, humanised MFE-23- 
derivatives linked together by human serum albumin
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5.1 Introduction
The previous chapter described the design and production of a divalent form of MFE- 
23 in order to improve its tumour targeting potential. Unfortunately, poor bacterial 
expression of the resulting tandem MFE-23 prevented further investigation of this 
molecule. In order to improve protein yields, the methylatropic yeast Pichia pastoris was 
chosen to express divalent forms of MFE-23. P. pastoris has been widely used for the 
high-level expression of antibody-based molecules (FitzGerald et al, 1997; Wang et al, 
1998; Freyre et al, 2000; Goel et al, 2000; Powers et al, 2001; Shi et al, 2003; Gurkan & 
Ellar, 2003; Medzihradszky et al, 2003; Yang et al, 2003) and has all the advantages of 
higher eukaryotic systems such as protein processing, protein folding and post-translational 
modifications (Cereghino & Cregg, 2000). This system has shown successful expression of 
relatively large, soluble antibody fusion proteins (FitzGerald et al, 1997; Goel et al, 2000; 
Powers et al, 2000; Smith et al, 2001; Gurkan & Ellar, 2003; Medzihradszky et al, 2003), 
which allowed a more sophisticated design strategy to be implemented for the production 
of divalent MFE-23 molecules than was previously employed with E. coli.
It was hypothesised that to improve the in vivo performance of MFE-23, its favourable 
tumour localisation could be combined with the longer tumour retention times and systemic 
clearance of larger antibody fragments by engineering a divalent MFE-23 molecule, closer 
in size and form to a human IgG. The aim of this chapter was to test this hypothesis by 
designing ‘humanised’ MFE-23 dimers incorporating human serum albumin (HSA) as a 
backbone to link the two scFv together. HSA is a non-immunogenic serum protein which 
has been extensively used to increase the circulating half-life of proteins (Sheffield et al, 
2001; Marques et al, 2001; Syed et al, 1997; Yeh et al, 1992; Paige et al, 1995; Mao & 
Poznansky, 1989; Poznansky et al, 1988). To further improve the in vivo potential of the 
divalent molecules, a humanised, high affinity version of MFE-23 (Ml0b) was used. Ml0b 
was created by replacing amino acid sequences in the framework region of MFE-23 to 
present a more ‘human’ surface (Graff, 2002), based on structural similarities to a 
crystallised human antibody (Boehm et al, 2000). Following humanisation mutations, one 
round of affinity maturation was performed, resulting in one amino acid mutation in CDR 
loop 2 in the Vl domain of MFE-23, corresponding to a 200-fold slower off-rate (Kd=0.08 
nM) than MFE-23. This molecule was used as the building block for subsequent MFE-23-
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based dimers linked together using HSA or HSA-derivatives. Following expression in P. 
pastoris, the resulting proteins were characterised in terms of their protein integrity, 
immunoreactivity and avidity for CEA. The in vivo biodistribution and tumour localisation 
properties of the ‘HSAbody’ were then investigated in comparison with a similarly sized 
molecule, the anti-CEA IgG, A5B7 which has been used to target CEA-expressing 
tumours in mice (Mayer et al, 2003; Pedley et al, 2002; Casey et al, 1998) and in humans 
(Dawson et al, 1991; Lane et al, 1994).
5.2 Results
5.2.1 Structural investigations for the design of MIOb-HSA assemblies
The changes made previously to the amino acid sequence of MFE-23 to create a 
humanised, high affinity version (MlOb) are shown in Figure 5.1 (Graff, 2002). Their 
placement in the MFE-23 crystal structure (Boehm et al, 2000) is also shown. In total, 28 
humanisation changes were made to the framework regions of MFE-23. One additional 
mutation was made in CDR loop 2 of V l, corresponding to Ser [50] Leu based on Kabat 
numbering (Kabat et al, 1991). In addition, the Lys-Arg site at the C-terminus of MFE-23 
(directly before the histidine tag) was altered to Lys-Ala to prevent possible proteolytic 
cleavage at this site.
To guide the design of MFE-23-HSA assemblies the x-ray structures of MFE-23 
(Boehm et al, 2000) and HSA (He & Carter, 1992) were used to predict a simplistic 
potential model of an MFE-23-HSA dimer (Figure 5.2). In this model, the CDR loops of 
both scFv are pointing outward and in opposite directions, and represents the most 
extended possible structure for the assembly. Using this model, the distance spanning the 
molecule from one set of Ml 0b CDR loops to the second was determined to be ~150 A, 
which is similar to that for IgG molecules (Harris et al, 1992; Colman 1976; Sarma et al, 
1971). When moved by 90°, the width of the potential molecule was measured to be ~73 
A, and the height to be ~80 A. The calculated distances were not expected to hinder MFE- 
23 binding to its epitope on the CEA (N-Al) domains (Chapter 3). Minimum distances 
between the MFE-23 molecules and HSA to prevent steric interactions between the side
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(a)
(b)
Ml Ob QVKLEQSGAEVVKPGASVKLSCKASGFNKDSYMHWLRQGPG
MFE-23 QVKLQQSGAELVRSGTSVKLSCTASGFNIKDSYMHWLRQGPE
MlOb QRLE WIG WTDPENGDTE Y APKF QGKATFTTDT SANT A YLGLS SL
MFE-23 QGLEWIGW1DPENGDTEYAPKFQGKATFTTDTSSNTAYLQLSSL
MlOb RPEDTAVYYCNEGTPTGPYYFDYWGQGTLVTVSSGGGGSGGG
MFE-23 TSEDTAVYYCNEGTPTGPYYFDYWGQGTTVTVSSGGGGSGGG
MlOb GSGGGGSENVLTQSPSSMSASVGDRVNIACSASSSVSYMHWFQ
MFE-23 GSGGGGSENVLTQSPAIMSASPGEKVTn’CSASSSVSYMHWFQ
MlOb QfCPGKSPKLWIYLTSNLASGVPSRFSGSGSGTDYSLTISSMQPED
MFE-23 QKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAED
MlOb AATYYCQQRSSYPLTFGGGTKLEIKA-AAHHHHHH
MFE-23 A AT YYCQQRSSYPLT FGAGTKLE LKR-AAA HI IHHHH
Figure 5.1. Mutations made to MFE-23 to generate a humanised, high affinity version termed MlOb. (a) X- 
ray crystal structure o f  MFE-23 shown with humanisation mutations in blue. The affinity mutation is 
identified in red in CDR L2. MFE-23 is positioned with the CDR loops facing upwards, (b) Amino acid 
sequence alignment o f  M lOb and MFE-23. Humanisation mutations are identified in blue. Affinity mutation 
is identified in red. The CDR loops are highlighted in grey.
Ser [Vl50J Leu
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-73 A
Figure 5.2. Molecular measurements o f a potential MFE-23-HSA assembly when viewed (a) from the front and (b) rotated by 90°. Distances are given in angstrom. 
MlOb VH domains are shown in green and VL in cyan. HSA is shown in purple. The spacer regions between MlOb and HSA are depicted as dotted lines (magenta). 
MFE-23 and HSA structures generated in Rasmol (see Chapter 2).
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chains of exposed residues were calculated to be -5  A between the C-terminal of the Vl 
domain of MFE-23 and the N-terminal of HSA, and -10 A between the C-terminal of HSA 
and the N-terminal of the Vh domains of MFE-23. These correspond to -  1-2 amino acid 
residue and -  3-4 amino acid residue spacers, respectively, based on average amino acid 
volumes (Richards, 1974). These distances were used in the design of subsequent 
constructs.
5.2.2 Construction of a dimeric Pichia pastoris expression vector
A plasmid was constructed for the expression of divalent scFv genetically linked 
together by HSA. Plasmid pPHSAl for the expression of divalent scFv-HSA fusions was 
based on the P. pastoris expression vector pPICza-A (Invitrogen, UK). This vector 
contains the signal sequence from the S. cerevisiae a-factor prepro peptide (Cregg et al, 
1993; Scorer et al, 1993) for secretion of the solubly-expressed heterologous protein under 
the control of the strong, methanol-inducible Paoxi promoter (Ellis et al, 1985; Koutz et al, 
1989; Tschopp et al, 1987).
A three-step approach was taken for the construction of pPHSAl. First, to 
accommodate insertion of genes directly downstream of the leader sequence and remove 
the existing c-myc affinity tag, the multiple cloning site (MCS) of pPICza-A was 
redesigned using pUCl 19/MFE-23 HIS as a template and the oligonucleotide primers 
shown in Table 5.1. This resulted in a new plasmid, pPICOl, details of which are given in 
Figure 5.3. The new MCS contains AT10 I and Sfi I sites at the 5’-end of MFE-23 to 
facilitate cloning flush and in frame with the signal sequence and a Not I site, hexahistidine 
tag, stop codons in all three frames and an Xba I site at the 3’-end of MFE-23.
Primer name Sequence 5’-3’
pPIC MFE-23 sense CCGC7CG/1GAAAAGAGAGGCTGAAGCGGCCCAGCCGGCCATGGCC
pPIC MFE-23 anti-sense CTAG7CT404TTAATTAATTAATGGTGATGATGGTGATGTGCGGCCGCCC
G TTTC A G C TC C A
Table 5.1. Oligonucleotide primers for construction o f the P. pastoris expression vector pPICOl based on an 
MFE-23 template. Sequences annealing to MFE-23 are shown in bold. Restriction endonuclease sites used to 
clone the resulting PCR product into pPICZaA, creating a new MCS, are shown in italics.
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Next, MlOb or HSA were cloned into the expression vector pPICOl via SJi I and Not I 
sites appended by the oligonucleotide primers detailed in Table 5.2. Previous studies done 
on HSA reported the successful recombinant production of its three, structurally similar 
domains (Kjeldsen et al, 1998; Dockal et al, 1999). These were also investigated as 
potential linkers for divalent molecules to create a range of molecules with varying 
molecular weight. The HSA subdomains were inserted into the pPICOl plasmid, 
designated by overlapping regions comprised of amino acids Asp [1-197] Arg for HSA 
Domain 1 (Dl), Gly [189-385] Gin for HSA domain 2 (D2) and Val [381-585] Leu for 
HSA Domain 3 (D3) based on boundaries identified by Dockal et al (1999). 
Oligonucleotide primers for isolation of HSA domains are given in Table 5.2.
pPICOl M FE-23
ATTCGAAACG ATG AGA TTT CCT TCA ATT TTT ACT GCT GTT TTA TTC GCA GCA
TCC TCC GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA
Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala
a-factor signal sequence
CAA ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA GGG GAT TTC
Gin lie Pro Ala Glu Ala Val lie Gly Tyr Ser Asp Leu Glu Gly Asp Phe
GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTT
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe
Xho 1
ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA TCT CTC
H e Asn Thr Thr lie Ala Ser l i e Ala Ala Lys Glu Glu Gly Val Ser Leu
Kex2 signal cleavage Sfi 1
GAG AAA AGA”GAG GCT GAA GCG GCC CAG CCG GCC ATG GCC. CTG AAA CGG
Glu Lys Arg Glu Ala^Glu Ala^Ala Gin Pro Ala M e t Ala
Ste13 signal cleavage
Not I polyhistidine tag Pac I Xba I
GCG GCC GCA CAT CAC CAT CAT CAC CAT TAA TTAATTCTAGAACAAAAACT 
Ala Ala Ala His His His His His His ***
Figure 5.3. DNA and amino acid sequences o f multiple cloning sites o f  pPICOl plasmid for P. pastoris 
expression. The MCS o f  pPICZa-A was redesigned to accommodate insertion o f open reading frames 
directly downstream o f the a-factor signal sequence (shown with amino acid residues underlined), using 
MFE-23 as a template. The DNA sequences o f restriction sites are underlined. Changes to pPICZa-A are 
shown in bold.
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P rim er nam e Sequence 5 ’-3 ’
M 1 Ob sense GTTATTACTCGCGGCCC4GCCGGCC/17GGCCCAAGTTAAACTGGAACAGTCC
G G TG C
M l Ob anti-sense AT AGTTTT GCGGCCGCCTTG ATTTC C A A CTT CG T T C C  A CCCC
wHSA sense GTTATTACTCGCGGCCOIGCCGGCCATGGCCGATGCACACAAGAGTGAGGTT
G C TC
wHSA anti-sense ATAGTTTAGCGGCCGCTAAGCCTAAGGCAGCTTGACTTGCAG
D1 anti-sense ATAGTTTAGCGGCCGCTCTCTGTTTGGCAGACGAAGCCTTC
D2 sense GTrATT ACTCGCGGCCCAGCCGGCCATGGCCGGGAAGGCTTCGTCTGCCAAA 
CAG
D2 anti-sense ATAGTTTAGCGGCCGCCTGAGGCTCTTCCACAAGAGGTTTAA
D3 sense GTTATTACTCGCGGCCC4GCCGGCCATGGCCGTGGAAGAGCCTCAGAATTTA
ATCAAAC
Table 5.2. Oligonucleotide primers for insertion o f M l Ob, HSA and HSA domains into pPICOl expression 
vector. Restriction sites are italicised and sequences annealing to template are in bold.
Finally, the pHSAl vector was generated to facilitate the insertion of an HSA linker 
between two Ml Ob scFv genes. To accomplish this, two Ml Ob ‘pieces’ were produced for 
insertion into the pPSHl plasmid containing HSA (or HSA subdomains) using 
oligonucleotide primers outlined in Table 5.3. Details of the cloning strategy are given in 
Figure 5.4. The spacers between the two scFv and the HSA linker were designed to be 
between ~21 A and ~ 10 A, respectively (based on the structural investigations in 5.2.1) 
and corresponded to restriction sites used in the cloning process. First, primer pairs 
annealing to Ml Ob were used to append Xho I/ Sfi I sites to create the ‘N-terminal’ scFv, 
and Not I / Xba I sites to create the ‘C-terminal’ scFv. The ‘C-terminal’ Ml Ob was then 
cloned into the pPICOl plasmid containing D1 or D3 via the Not 1/ Xba I sites. The ‘N- 
terminal’ piece was then inserted into these newly-constructed plasmids via Xho 1/ Sfi I 
restriction sites to generate Vl -Vh-D1/D3-Vh-Vl . D1 was then replaced with HSA or D2 
via Sfi 1/ Not I digestion. The full set of constructs is listed in Table 5.4.
Prim er nam e Sequence 5 ’-3 ’
M l Ob Xho I sense CCGCTCG/1GAAAAGAGAGGCTGAAGCTATGCAAGTTAAACTGGAACAG
TC C G G TG C
M 1 Ob S/H  anti­
sense
CATGGCCATGGCCGGC7GGGCCGCAGCCTTGATTTCCAACTTCGTTCCA
C
M l Ob Not I sense ATTGCGG CCGCACAA GTTAAACTGGAACAGTCCGG TGC
M l Ob Xba I anti­
sense
CTAGrCT4G^TTAATTAATTAATGGTGATGATGGTGATGGGCTGCAGCCT
TG A TTTCC A A C TT
Table 5.3. Oligonucleotide primers for construction o f  pPHSAl P. pastoris expression vector. Restriction 
sites are italicised and sequences annealing to MFE-23 template are in bold.
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MlObXho I sense
(a)
(b)
T*vh t H  v r n
MIObS/? I anti-sense
MIObMrt I sense
Xho I
o factor D1
I VII I  L |i T T
MlOb Xba I anti-sense
O
Not I Xba I
 L
HIS 6
mm 'jMmm
(C)
V
^  Afto I ^  I 
I / f«  factor signal^* D1
a factor signal
Not I I
y  VH | L |  VL | ms<
Not I Xba I
- I  L,I ms 6 |
^  xho I Sfi I Not I I
M - f n - n r - i T - M  llil ■  ' I 1 I f”  f ” " H
(d)
.Via IXho I Sfi I Not I |
[ | ) |a  factor lignall VH f L} VTT~^BFf P l '^ T ^ ^ F *  I L t ^  HHIS6 1
Xho I
Q f c te *  W - VH I L I
I Not I
k. UVH t L | VL B r n s t ' l
AAQPAMA AAA
(e)
D2
■ DT T D2
Figure 5.4. Construction strategy for production o f HSAbodies. (a) Oligonucleotide primers were used to append Xho I and Sfi I or Not I and Xba  I restriction sites onto 
MlOb. (b) Resulting PCR product digested with Not I and Xba  I was then subcloned into similarly digested pPICOl/Dl or pPIC01/D3. Following successful cloning (c), 
Xho I and Sfi I digested MlOb was cloned into the newly constructed plasmids, resulting in (d). Amino acid spacer sequences, corresponding to restriction sites, are 
given, (e) HSA or D2 were then subcloned into (d) using Sfi I and Not I sites. Construction details are given in Appendix 1.
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C onstruc t nam e Linker M W  (kDa)
MIOb-HSA-MlOb (HSAbody) WT HSA —120
M IOb-Dl-M lOb HSA Domain 1 -7 7
M10b-D2-M10b HSA Domain 2 -7 6
M10b-D3-M10b HSA Domain 3 -7 7
Table 5.4. List o f  constructs containing MlOb joined to HSA-based linkers. The linkers used and their 
predicted MW are given.
5.2.3. Test expressions of MIOb-HSA assemblies in Pichia pastoris
The P. pastoris expression and secretion levels of MFE-23, MlOb, and HSA domains 
were first evaluated independently by small-scale expressions (50 ml) for each pPICOl 
transformant. Because protein expression in P. pastoris from integrated pPICZa-derived 
plasmids can vary depending on site of integration and copy number, several transformants 
for each construct were screened. Culture supernatants (96 h expression) were subjected to 
SDS-PAGE under reducing conditions, followed by Western blot analysis antibodies 
directed against the COOH-terminal histidine tag. Results show that a new protein band 
appears at the expected MW for the scFv (~27 kDa) and HSA domains (Dl, -22 kDa; D2, 
-22 kDa; D3, -23 kDa; Figure 5.5) when compared to the pPICzaA control transformant. 
Anti-HIS antibodies detected expressed product for all constructs, confirming the presence 
of the full-length protein containing a C-terminal hexahistidine tag. The HSA proteins 
were well expressed, with secreted levels estimated to be -10 mg/L for D3 and up to -400 
mg/L for D2. The yields seen for the HSA domains are comparable to previously reported 
expression of the HSA domains in P. pastoris (Dockal et al, 1999). As expected, no bands 
were visible for the empty vector, nor was there evidence of other expressed protein in the 
supernatant. This is consistent with observations that P. pastoris secretes very low levels 
of native proteins (Barr et al, 1992).
Expression yields for both MFE-23 and MlOb were estimated to be -10 mg/L. Protein 
bands were detected at a slightly higher molecular weight than expected when compared to 
bacterially-expressed MFE-23. This was attributed to incomplete cleavage of the a-factor 
secretion signal sequence and has been reported for other proteins expressed from P. 
pastoris (You et al, 1998; FitzGerald et al, 1997; Powers et al; 2001). Furthermore,
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M l  2 3 4 5 6 7  8 M 10 11 12 13 14 15 16 17 M
250 kDa
148 kDa
60 kDa 
42 kDa
30 kDa 
22 kDa 
17 kDa 
4/6 kDa
18 19 20 21 M
Figure 5.5. Evaluation o f P. pastoris expressed (96 h) transformants. SDS-PAGE (12% Tris-Glycine) and Western blot analysis using anti-HIS antibodies detected the 
presence o f  bands at the expected MW for MFE-23 (-27  kD; lanes 2-4), D1 (-22.4 kD; lanes 5-7), D2 (-22.9 kD; lanes 8, 9, 11), D3 (-23.3 kD; lanes 12-14), and MlOb 
(-27  kD; lanes 18-21). No bands were detected for the pPICZaA control expression (lanes 15-17). Purified MFE-23 (2 pg) was used as a control (lanes 1 and 10) 
alongside the MW marker (Multimark; lane M).
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MlOb MFE-23 bMFE-23 neg control
Figure 5.6. Immunoreactivity o f P.pastoris-expressed MFE-23 and MlOb. Yeast culture supernatants (96 hr) 
containing MFE-23 or MlOb domains were filtered and proteins in the supernatant were applied to CEA- 
coated wells, alongside purified bacterially-expressed MFE-23 (bMFE-23; 1 pg/ml) and culture medium only 
(negative control). Following washing, bound proteins were detected using anti-HIS antibodies. Proteins were 
tested in duplicate and values were subtracted from ‘blank’ wells coated in PBS. Data is representative o f  
repeated experiments.
expression in P. pastoris did not affect the immunoreactivity of the scFv, as determined by 
CEA ELISA (Figure 5.6). These results indicated that the scFv and HSA domains were 
amenable to expression in P. pastoris.
Next, P. pastoris expression of the HSAbody was investigated. Culture supernatants 
(96 h expression) of four yeast transformants were subjected to SDS-PAGE and Western 
blot analysis confirmed the presence of protein bands at the predicted MW (-120 kDa) for 
two of the four expressed clones (Figure 5.7). The scFv, HSA and COOH-terminal 
hexahistidine units were all detected with specific antibodies, confirming the presence of 
full-length protein. Lower MW species were also detected by both anti-MFE-23 and anti- 
HSA antibodies. The two transformants with visible protein bands as detected by Western 
blot analysis were further tested by CEA ELISA. This indicated that fusion of MlOb with 
HSA resulted in expressed product reactive with CEA (Figure 5.8).
Test expression of the dimers generated by fusion to HSA domains resulted in 
detectable protein bands for two of the three constructs (Figure 5 .9). Four transformants for 
each construct were expressed (96 h) and culture supernatants were subjected to SDS- 
PAGE. Expressed proteins were visualised by anti-histidine, anti-MFE-23 and anti-HSA 
antibodies. Protein bands at the predicted MW (-77 kDa) were visible for Ml Ob dimers
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Figure 5.7. Evaluation o f  HSAbody expression (96h) in P. pastoris. Culture supernatants were subjected to 
SDS-PAGE (12 %  Tris-Glycine) and Western blot analysis using (a) anti-HIS, (b) anti-MFE-23, and (c) anti- 
HSA antibodies detected the presence o f  a band at the predicted MW (-120 kD) in two o f the four 
transformants expressed (lanes 1-4).
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anti-HSA 
anti-HIS
MFE-23 HSA neg. control
F igure 5.8. Immunoreactivity o f P. pastoris expressed HSAbodies. The two transformants visualised by 
SDS-PAGE to contain a protein band at the predicted MW were tested by CEA ELISA. Yeast culture 
supernatants (96 h) were applied to wells coated with CEA (2 ng/pl) and following washing, proteins 
remaining associated with CEA were detected using anti-HIS or anti-HSA antibodies. Controls were 
performed using bacterially-expressed MFE-23 (MFE-23; 10 pg/ml), fatty-acid free HSA (10 pg/ml) and 
yeast culture media (neg. control). Proteins were tested in duplicate and values were subtracted from ‘blank’ 
wells coated with PBS. Data is representative o f  repeated experiments.
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250 kDa
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Figure 5.9. Expression o f  MlOb dimers using HSA domains as linkers. Culture supernatants (96 h) were 
subjected to SDS-PAGE (12% Tris-Glycine) and Western blot analysis using (a) anti-HIS, (b) anti-MFE-23, 
and (c) anti-HSA antibodies. Protein bands at the predicted MW were seen for M IOb-Dl-M lOb (-77  kD; 
lanes 2-5) and M10b-D2-M10b (-77  kD; lanes 9-13), but not for M10b-D3-M10b (-78 kD; lanes 6-8). A 
band for the control, MFE-23 (-2 7  kD; lane 1), was also detected for anti-HIS and anti-MFE-23, but not anti- 
HSA. MW marker (Mulimark) is in lane M.
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Figure 5.10. Immunoreactivity o f P. pastoris -expressed MlOb dimers using HSA domains as a linker. Four 
transformants for each construct were expressed (96 h) and culture supernatants containing MlOb dimers 
utilising HSA D1 (clones 1-4), D2 (clones 5-8) or D3 (clones 9-12) as linkers were filtered and applied to 
CEA-coated well. Controls o f yeast culture supernatant containing expressed MFE-23 and culture medium 
only (negative control) were applied alongside test samples. Following washing, bound proteins were 
detected using anti-HIS antibodies. Samples were tested in duplicate and values were subtracted against 
‘blank’ wells coated with PBS. Data is representative o f  repeated experiments.
linked together using D1 and D2, but not D3. However, CEA ELISA confirmed the 
presence of CEA-binding proteins for all three constructs (Figure 5.10). Lower MW 
species were also detected by anti-MFE-23 and anti-HSA antibodies in Western blot 
analysis, corresponding to ~ 60 kDa and ~ 40 kDa.
5.2.4 Large-scale production of the HSAbodv
The best expressor from the test expressions was produced on a large-scale by 
fermentation of P. pastoris wild-type X-33 cells. Purification of the fermented material 
(1L) was expedited using the COOH-terminal hexahistidine tag of the construct. The UV 
trace showing purification of the fermentation supernatant by IMAC is shown in Figure 
5.11. Following application of copper ions to the matrix, a large sample load peak was
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Figure 5.11. UV trace showing EMAC purification o f  HSAbody from P. pastoris fermentation supernatant. 
Chelating Fast-flow Sepharose was charged with copper ions, washed with dH20 and equilibrated with PBS 
containing 1 M NaCl. The supernatant containing expressed protein was loaded onto the column following 
addition o f 1 M NaCl and non-specifically-bound proteins were washed off with 40 mM imidazole in PBS/ 
1M NaCl. Hexahistidine-tagged protein was eluted using 200 mM imidazole in PBS/ 1 M  NaCl. Fractions (7 
ml; red dotted lines) were taken starting at the 2000 mM imidazole elution. Fractions corresponding to the 
protein peak were pooled, dialysed against PBS and concentrated.
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Figure 5.12. SDS-PAGE and Western blot analysis o f IMAC purified HSAbody. Eluted proteins were 
pooled, dialysed, concentrated and subjected to SDS-PAGE (12% Tris-Glycine). Proteins were visualised by 
(a) commassie staining, (b) anti-HIS, (c) anti-MFE-23, and (d) anti-HSA antibodies. Protein bands at the 
predicted MW (-120 kDa) are indicated by an arrow. Lower MW species were also detected
observed, followed by a peak corresponding to non-specifically bound proteins washed off 
using 40 mM imidazole. Competitive elution with 200 mM imidazole resulted in a peak 
representing hexahistidine-tagged proteins. Protein yields after purification was ~5 mg/L. 
The purity and integrity of the final protein was analysed by SDS-PAGE and Western blot 
analysis. As shown in Figure 5.12, the HSAbody appeared at the predicted MW (~120 
kDa) when probed for the scFv, HSA and histidine tag units. The protein was substantially 
pure, however a number of smaller co-purifying bands ranging from ~94 kDa- ~27 kDa 
were detected. These may represent breakdown products that also bind to IMAC.
Further purification steps were explored to remove the lower MW species. Isolation of 
the CEA-reactive portion of the IMAC-purified product was achieved by affinity 
chromatography. However, although relatively low levels of protein loss were observed, 
suggesting the majority of the IMAC-purified protein was reactive with CEA, this method 
of purification was not successful in removing the co-purifying species. Figure 5.13 shows 
SDS-PAGE and Western blot analysis of the CEA-affinity purification.
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Figure 5.13. Analysis o f CEA-affinity chromatography. Following IMAC purification, the HSAbody was immediately loaded onto a CEA-Sepharose colume (lane 1), 
unbound proteins were collected (lane 2) and the column was washed with PBS (lanes 3-5). CEA binding proteins were eluted with 50 mM DEA (lanes 6-8) and the 
column was washed with 3 M ammonium thyocyanate (lane 9). The elution peaks were pooled and dialysed against PBS, followed by concentration. Proteins were 
detected by (a) coomassie staining, (b) anti-HIS, (c) anti-MFE-23, and (d) anti-HSA antibodies.
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Further attempts to remove these proteins by gel filtration chromatography were also 
unsuccessful. The IMAC and CEA-purified HSAbody was applied to a Sephadex-200 
column for size-exclusion chromatography and fractions were monitored by SDS-PAGE 
and Western blot analysis using anti-MFE-23 and anti-HSA antibodies. Figures 5.14 and 
5.15 show the UV trace for the gel filtration and the SDS-PAGE analysis, respectively. 
Three broad peaks were observed for the gel-filtrated HSAbody, corresponding to MW 
ranges of > -600 kDa, -120 kDa, and -  27 kDa when compared to protein standards of 
known MW. The two smaller peaks are in good agreement with the predicted MW of the 
HSAbody and co-purifying protein as detected by SDS-PAGE. When die peak fractions 
were subjected to SDS-PAGE, the presence of the co-purifying proteins was observed in all 
three peaks. This suggested that the high MW peak was a result of aggregation of the 
HSAbody, and that the lower-MW species were associating with the full-length protein 
under native conditions.
15* kD 17 kD44 kD
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Figure 5.14. UV trace showing gel filtration chromatography o f  the HSAbody. IMAC and CEA-affinity 
purified HSAbody (1 mg) was applied to a Sepharose 200 column at a flow rate o f 1.5 ml/mm in PBS 
following calibration o f  the column with proteins o f  known molecular weight. Three broad peaks were 
observed, corresponding to high M W  proteins (Peak 1), HSAbody (Peak 2), and low MW proteins (Peak 3). 
Fractions (2 ml; pink dotted lines) were taken across all peaks and subjected to SDS-PAGE. Elution volumes 
o f MW  calibrants are indicated at top of figure, along with their MW.
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Figure 5.15. Evalutaion o f gel filtration chromatography o f  the HSAbody. Fractions across all three peaks 
were subjected to SDS-PAGE (8% Tris-Glycine) and Western blot analysis and proteins were detected by (a) 
coomassie blue staining, (b) anti-MFE-23 and (c) anti-HSA antibodies. Peak fractions are indicated above 
gels. Lane M contains molecular weight marker (Multimark), lane 1 contains MFE-23 (4 pg), lane 2 contains 
HSA (4 pg), lanes 3 and 4 contain IMAC-purified samples o f HSAbody.
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5.2.5 Characterisation of co-purifving proteins
SELDI-MS was applied to determine the MW of the native and co-purifying proteins 
(Figure 5.16). Peaks were observed at 120.1+H kDa, 93.6+H kDa, 60.6+H kDa, and 
26.9+H kDa, as well as a broad peak ranging from 40.6-52.9+H kDa. The masses of these 
peaks are in good agreement with those observed from gel filtration chromatography and 
SDS-PAGE analysis, and for the predicted MW of the HSAbody.
In order to characterise the co-purifying species further, the two dominant bands 
(-94 kDa and -27 kDa) were N-terminally sequenced. Repeated sequencing of the -94 
kDa species resulted in several sequences of overlapping regions of Ala-Gln-Pro-Gln-Pro- 
Ala, Met-Al a-Asp-Al a-Hi s-Lys-Ser-Gl u-Val - Ala, Ala-Asp-Ala-Asp-Ala-His-Lys-Ser-Glu- 
Val-Ala, and Asp-Ala-His-Lys-Ser-Glu-Val-Ala. These correspond to the region between 
the C-terminus of die N-terminal MlOb Vl domain and the N-terminus of the HSA linker. 
The position of this region in the sequence of the HSAbody is shown in Figure 5.17. 
Estimation of the MW of a protein resulting from an N-terminus at this position is -93.9 
kDa, which is in good agreement with the SELDI-observed peaks. Sequencing of the -27 
kDa peak resulted in two sequences. The first sequence, Gln-Val-Lys-Ala-Ala-Ala, 
corresponds to the N-terminus of the Vh of MlOb. This may relate to the N-terminal MlOb 
ScFv, which would be freed after cleavage at the HSA linker (determined in sequencing of 
the 94 kDa band). It may also relate to the C-terminal MlOb scFv, which would also have a
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Figure 5.16. SELDI-MS spectra showing MW o f  the HSAbody and co-purifying proteins. Purified protein 
was spotted onto a NP20 normal phase chip, washed with dH20 and laser desorbed following application o f 
SPA. External calibration was performed using the All-in-One Protein standards. MW  o f peaks are indicated.
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£4£4M-QVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQRLEW
IGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTG
PYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSASVGDRVNIAC
SASSSVSYMHWFQQKPGKSPKLWIYLTSNLASGVPSRFSGSGSGTDYSLTISSMQPE
DAATYYCQQRSSYPLTFGGGTKLEIKAAAQPAMADAHKSEVAHRFKDLGEENFK
ALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLC
TVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHD
NEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDEL
RDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTK
VHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVEND
EMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA
KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNA
LLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLC
VLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSE
KERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEG
KKLVAASQAALGLAAAQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWL
RQGPGQRLE WIG WIDPEN GDTE Y APKF QGK ATFTTDTS ANT A YLGLS SLRPEDT AV
YYCNEGTPTGPYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMS
ASVGDRVNIACSASSSVSYMHWFQQKPGKSPKLWIYLTSNLASGVPSRFSGSGSGT
DYSLTISSMQPEDAATYYCQQRSSYPLTFGGGTKLEIKAAAHHHHHH
Figure 5.17. Amino acid sequence o f  the HSAbody showing N-terminal sequencing results. Sequences 
obtained from Edmann degradation o f  the two dominant co-purifying bands are shown in bold. They 
correspond to regions at the N-terminus o f  the MlOb VH domain and the region between the N-terminal MlOb 
and the HSA linker. In addition, sequences relating to incomplete cleavage o f  the signal sequence were 
returned for the ~27 kDa fragment and the whole length protein.
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MW of -  27 kDa. The second sequence found for the -  27 kDa protein, Glu-Ala-Glu-Ala- 
Met, corresponds to incomplete cleavage of the signal sequence. This sequence is also 
obtained when the full-length protein (-120 kDa) is N-terminally sequenced. An N- 
terminus starting with this sequence results in a protein of MW of 120.1 kDa as determined 
by PAWS sequence analysis software and is in perfect agreement with the SELDI-MS data. 
Taken together, these results indicate that the region between the N-terminal MlOb and 
HSA is sensitive to spontaneous degradation and results in a smaller, N-terminal fragment 
(-27 kDa) and a larger, C-terminal fragment (-94 kDa), and that the kex signal sequence is 
not being efficiently removed during expression.
5.2.6 Analysis of avidity
In order to establish the presence of two CEA-reactive scFv units, the avidity of the 
HSAbody was tested by surface plasmon resonance using Biacore. Because of the high 
affinity of MlOb for CEA (K d=  0.08 nM), it was not possible to compare the off-rates 
between monomer and dimer directly using this technique. Therefore, a sandwich assay 
was developed in which one antibody unit of the HSAbody was allowed to interact with 
immobilised antigen and then challenged with antigen in solution to determine if both 
antibody units were able to interact with antigen.
Results showed a large binding curve for the HSAbody when passed over the antigen 
immobilised to the chip surface (Figure 5.18), followed by a small binding curve when the 
antigen was introduced in solution (Figure 5.19). Control experiments with monomer 
(MlOb) did not result in a binding interaction with CEA in solution, neither was a binding 
curve detected when CEA was passed over the chip surface. The experimental data for 
binding of the HSAbody to the immobilised antigen was fit to a bivalent binding model. 
Figure 5.20 shows the results of the fit. Residues of +/- 2 for the association and 
dissociation phases indicated this was a reasonable fit to the model, as did the Chi2 value of 
0.263. The individual components of the model curve (i.e. monovalent binding at surface 
or bivalent binding at surface) were then analysed. These were returned as predominantly 
divalent binding at the immobilised surface, suggesting very little of the HSAbody was 
capable of binding antigen in solution.
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F igure 5.18. BIAcore sensorgram showing HSAbody binding to antigen. The HSAbody (blue line) and MlOb (green line) were (a) passed over a CEA (N -A l) chip 
(1200 RU immobilised) at 10 ml/min (association 1), and (b) monitored for retained binding to antigen on chip surface (dissociation 1) before washing, (c) CEA was 
then passed over captured HSAbody or MlOb (association 2) and (d) monitored for retained binding to antigen in solution (dissociation 2) for retained binding.
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F igure 5.19. BIAcore sensorgram showing magnified view o f HSAbody binding to CEA in solution. The HSAbody (blue line) and MlOb (green line) were captured by 
CEA (N -A l) immobilised to the chip surface {see Figure 5.18) and then challenged with CEA in solution. The two curves were aligned for comparison purposes, (a) 
Response units o f  CEA passed over captured HSAbody or MlOb and (b) response units o f retained antigen during dissociation. Note the low response units on the y- 
axis.
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Figure 5.20. Bivalent binding model o f HSAbody binding to antigen, (a) The HSAbody binding data (red line) was fit to a bivalent analyte model (black line) in 
BIAevaluation software. Residuals o f  the curve fit are shown for the association and dissociation phases in (b). The circles represent the experimental data along the fit, 
represented at a line across zero. The predicted individual components o f the modelled binding curve are shown in (c). The total binding curve is shown as a black line, 
the contribution o f a monovalent binding (AB) interaction at the chip surface is shown as a green line and that for a bivalent binding (AB2) interaction is shown as a 
cyan line. The contribution o f buffer (bulk and drift) is shown as a red line.
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5 .2.7 Assessment of radiolabelled HSAbodv
The IMAC and CEA-purified HSAbody was radiolabelled with Na-125I and 
radiolabelling efficiency, protein integrity and immunoreactivity were confirmed. Thin 
layer chromatography (TLC) indicated that > 97% of the total radioactivity was associated 
with protein. In size-exclusion studies, the majority of the radioactivity eluted as a single 
peak at the expected MW for the HSAbody (-120 kDa; Figure 5.21) with a slight 
‘shoulder’. A smaller peak corresponding to breakdown products (-27 kDa) was also 
observed. These results are consistent with profiles observed for the unlabelled protein and 
were not predicted to be a result of radioiodination.
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Figure 5.21. Radioactive profile showing gel filtration chromatography o f  ,25-I labelled HSAbody. The 
radiolabelled protein was injected onto a Superose 12 size-exclusion and the radioactivity for each fraction (1 
ml) was plotted against the elution volume. The elution volumes o f  the molecular weight standards are 
indicated at the top o f  the figure.
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Immunoreactivity studies of the radiolabelled protein performed on a CEA affinity 
column indicated > 65% of the radioactivity was reactive with CEA. Negligible binding 
was detected on the control column containing Sepharose matrix only (<5%). 
Electrophoresis followed by phosphor image analysis of the radiolabelled protein and CEA 
affinity chromatography fractions confirmed that the majority of the radioactivity was 
specifically eluted and associated with a band corresponding to the full length protein 
(Figure 5.22). The characterised breakdown products (-94 kDa, -27 kDa) were also 
detected, but the individual contributions of these proteins accounted for < 20% of the total 
radioactivity.
1 2 3 4 5 6 7
Figure 5.22. Digitised SDS-PAGE analysis o f ,25I-labelled HSAbody. The final radiolabelled product was 
loaded onto a CEA-affinity column (lane 1), non-specific proteins were washed off (lanes 2-4), and CEA- 
reactive proteins were eluted from the column (lanes 5-7). Samples were subjected to SDS-PAGE (8% Tris- 
Glycine) and exposed to phosphor storage plates for 1 week. Radioactivity was detected on a Phosphorlmager 
and quantified.
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Table 5.5. Biodistribution o f  125I-labelled HSAbody (% ID/g) in non-tumour bearing m ice
1 h 4 h 24 h 48 h
Blood 13.85 ±4.15 11.06 ± 1.02 2.31 ±0.74 1.09 ±0.19
Liver 3.53 ± 0.64 2.68 ±0.15 0.56 ±0.21 0.22 ±0.14
Kidney 5.64 ± 0.44 3.84 ±0.85 0.85 ± 0.29 0.54 ± 0.09
Lung 4.75 ±0.51 4.27 ±0.95 1.03 ±0.55 0.53 ±0.10
Spleen 2.69 ± 0.64 1.79 ±0.09 0.37 ±0.13 0.23 ± 0.03
Colon 1.17 ± 0.31 1.07 ±0.05 0.22 ± 0.06 0.12 ±0.01
Muscle 0.44 ±0.07 0.40 ± 0.04 0.13 ±0.04 0.07 ±0.01
5.2.8 In vivo pharmacokinetic, biodistribution and tumour localisation studies
The in vivo properties of the HSAbody were investigated in mouse models. In order to 
determine appropriate time points for studies in xenograft-bearing models, preliminary 
pharmacokinetic and biodistribution studies were performed in non-tumour bearing mice. 
Table 5.5 contains the biodistribution data. Figure 5.23 shows the mean values (n=4) of the 
biodistribution results as a percent injected dose per gram (%ID/g) at 1, 3, 24, and 48 h post 
injection. Rapid clearance was observed from all tissues within 24 h following intravenous 
administration with radiolabelled HSAbody (2.8 MBq; 10 pg). Blood levels at 1 h were 
13.85 ± 4.15, dropping to 2.31 ± 0.71 %ID/g at 24 h. One hour liver, kidney and spleen 
levels were 3.53 ± 0.64, 5.64 ± 0.44, and 2.69 ± 0.64, respectively, dropping to 0.56 ± 0.21 
%ID/g, 0.85 ± %ID/g, and 0.37 ±0.13 %ID/g, respectively after 24 h. By 48 h, only 1.09 ± 
0.19 %ID/g was retained in blood and less than 1 %ID/g in liver (0.22 ±0.14 %ID/g), 
kidney (0.54 ± 0.09 %ID/g) and spleen (0.23 ± 0.03 %ID/g).
As there was less than 1 %ID/g by 48 h in all tissues, these same time points were 
chosen for subsequent tumour localisation and biodistribution studies in tumour-bearing 
mice. In order to represent the data more accurately, (because of the inter-mouse variation 
within each group), the individual data for these biodistribution studies are given, rather 
than the mean and standard deviation of each group (see Table A2.1). Biodistribution 
results for each time point following intravenous administration with radiolabelled
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F igure 5.23.Biodistribution o f 125I-labelled HSAbody in non-tumour bearing mice. Tissues were taken 1 ,4 , 24 and 48 h following intravenous injection o f  radio labelled 
protein (1.12 MBq; 4 pg). The mean %ID/g is shown as columns with 1 standard deviation as bars.
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HSAbody or an anti-CEA IgG A5B7 are represented as %ID/g tissue and tissue: blood 
ratios (%ID/g tissue divided by %ID/g blood) in Figures 5.24-5.27. At 1 h (Figure 5.24), 
higher levels in the tumour (8.74,42.39, 59.25, and 64.39 %ID/g) and blood (48.14,48.88, 
53.91, 54.83 %ID/g) were observed for A5B7 than for the HSAbody (6.11, 17.99, 18.19, 
and 63.57 %ID/g in tumour; 25.28,26.19, 26.44, and 38.13 %ID/g in blood). However, 
tumour: blood ratios were similar, at 0.15, 0.78, 1.23, and 1.29 for A5B7 and 0.16, 0.68, 
0.71, and 2.42 for the HSAbody. Similar results were seen at 4 h (Figure 5.25), with 
comparable tumour: blood levels for both proteins (0.39, 0.61, 0.96, and 1.57 for A5B7 and 
0.55, 0.94, 1.58, 1.84 for the HSAbody) but higher overall antibody uptake for A5B7 in 
tumour (16.10, 28.21, 28.39, and 55.66 %ID/g compared to 6.82, 8.42, 9.03, and 26.02 
%ID/g for HSAbody) and blood (29.42, 35.43,40.33, and 46.00 %ID/g compared to 4.88, 
7.23, 15.12, and 16.40 %ID/g for HSAbody).
Maximum levels of HSAbody in the tumour were observed at 24 h (Figure 5.26), with 
8.97, 21.46, 28.81 and 38.80 %ID/g. Blood levels were 0.47, 3.02, 4.96 and 5.76 %ID/g, 
resulting in tumour: tissue ratios of 3.72, 5.80, 12.82 and 18.91. For the same time point, 
the tumour levels for A5B7 were 33.88, 39.28, 44.78 and 49.93 and 18.94 %ID/g and blood 
levels were 12.33, 14.74, 17.42, and 21.36 %ID/g, resulting in tumour: blood ratios of 1.83, 
2.29, 2.56 and 4.04. This represents ~ 4 fold increase in the tumour: blood ratios for the 
HSAbody over A5B7. HSAbody levels for liver (0.89, 1.58, 1.60 and 2.19 %ID/g), kidney 
(1.12, 1.78,2.24 and 3.19 %ID/g) and spleen (0.63, 0.95, 1.45 and 2.37 %ID/g) at 24 h 
were lower than A5B7. The same tissues at 24 h for A5B7 were 4.66, 5.25, 6.40 and 9.17 
%ID/g, 3.39, 4.53, 5.14 and 5.79 %ID/g, and 2.21, 3.01, 3.80 and 4.06, respectively.
Tissue: blood ratios {see Table A2.2) for these organs at 24 h were calculated to be 0.27, 
0.44, 0.52, and 1.89; 0.38, 0.59, 0.64, 2.36 and 0.25, 0.31, 0.57 ani 1.34 for liver, kidney 
and spleen, respectively. These are comparable to those seen for A5B7 (0.29, 0.31, 0.42, 
0.52 for liver, 0.27, 0.27,0.30, 0.33 for kidney, and 0.17, 0.19, 0.20, 0.21 for spleen). 
Tumour: liver (9.99, 13.10,13.37 and 24.41), kidney (7.97, 9.02, 9.56, and 21.72) and 
spleen (10.15, 14.08, 14.73, and 40.76) for the HSAbody at 24 h were slightly raised 
compared to A5B7 for the same tissues (4.88, 6.133, 7.25 and 9.50; 7.47, 7.63, 7.73, and 
14.70; 9.65, 11.22, 11.77 and 22.58, respectively; see Table A2.3).
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Figure 5.24. Biodistribution o f  125I-labelled HSAbody and A 5B7 in LS-174T xenografts in tissues taken 1 h
post intravenous injection o f  radiolabelled protein (HSAbody: 2.0 MBq, 20 pg; A5B7: 2.68 M Bq, 20pg).
Individual data is represented as (a) overall uptake (%ID/g) and (b) Tissue: blood ratios.
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Figure 5.25. Biodistribution o f  125I-labelled HSAbody and A 5B 7 in LS-174T xenografts in tissues taken 4 h
post intravenous injection o f  radiolabelled protein (HSAbody: 2.0 MBq, 20 pg; A5B7: 2.68 M Bq, 20 pg).
Individual data is represented as (a) overall uptake (%ID/g) and (b) Tissue: blood ratios.
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Figure 5.26. Biodistribution o f  l25I-labelled HSAbody and A 5B 7 in LS-174T xenografts in tissues taken 24 h
post intravenous injection o f  radiolabelled protein (HSAbody: 2.0 M Bq, 20 pg; A 5B7: 2.68 MBq, 20pg).
Individual data is represented as (a) overall uptake (%ID/g) and (b) Tissue: blood ratios.
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Figure 5.27. Biodistribution o f  125I-labelled HSAbody and A 5B7 in LS-174T xenografts in tissues taken 48 h
post intravenous injection o f  radiolabelled protein (HSAbody: 2.0 M Bq, 20 pg; A5B7: 2.68 MBq, 20pg).
Individual data is represented as (a) overall uptake (%DD/g) and (b) Tissue: blood ratios.
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By 48 h (Figure 5.27), the levels of HSAbody in tumour and blood had dropped, with 
0.21, 0.49, 0.50 and 6.01 %ID/g in tumour and less than 0.22 %ID/g in blood (0.08, 0.08, 
0.13 and 0.22 %ID/g). At the same time point, the %ID/g levels in tumour and blood for 
A5B7 IgG were 18.94, 35.85,45.02 and 50.03, and 3.16, 4.52, 8.84 and 19.45, respectively. 
These resulted in tumour: blood ratios of 2.20, 2.44, 6.25, and 44.85 and 1.84, 5.65, 5.99, 
and 9.93 for the HSAbody and A5B7, respectively. Liver (0.14, 0.29, 0.33,0.42 %ID/g), 
kidney (0.21, 0.49, 0.51, 0.55 %ID/g) and spleen (0.17, 0.21, 0.26, 0.31 %ID/g) levels for 
the HSAbody at 48 h were lower than A5B7 (2.29, 2.58, 6.96, 7.23 %ID/g for liver; 1.11, 
1.17,2.83, 6.11 %ID/g for kidney; 0.75, 0.83, 1.95, 2.89 %ID/g for spleen).
5.3 Discussion
Because of the production problems encountered in the previous chapter for the 
generation of tandem MFE-23 joined by a flexible linker, a new approach was taken for the 
assembly of MFE-23 dimers. First, the expression system was changed to a eukaryotic 
system to allow for higher protein yields and a more sophisticated molecular design. 
Second, a larger linker was chosen to join the two MFE-23 together, one which would 
increase the MW of the protein to improve its circulating half-life without affecting its 
specific tumour localisation and CEA binding. Third, the molecule was ‘humanised’ by the 
incorporation of a human linker and a humanised MFE-23 variant. Fourth, the tumour 
targeting potential was further increased by the inclusion of a high affinity derivative of 
humanised MFE-23. These design implementations resulted in -4-fold improvement in 
tumour: blood ratios at 24 h in mouse models when compared to a molecule of similar size 
and avidity, the anti-CEA IgG A5B7.
The yeast P. pastoris has several advantages as a heterologous protein expression 
system. Production of recombinant proteins in this system results in efficient protein 
processing, folding and post-translational modifications such as glycosylation. Expression 
of the heterologous protein is tightly regulated by the A OXl promoter, (Cregg et al, 1993), 
which is strongly repressed in cells grown on carbon sources (e.g. glucose) but induced 
over 1000-fold when cells are transferred to medium containing methanol as the sole 
carbon source (Cereghino et al, 2000). The heterologous protein can be secreted into the
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culture supernatant using the S. cerevisiae a-factor secretion signal (Cregg et al, 1993; 
Scorer et al, 1993), which serves as the first step in purification of the protein as very low 
levels of native host proteins are secreted (Digan et al, 1988; Barr et al, 1992; Larouche et 
al, 1994). A major advantage is that P. pastoris is readily fermented to high cell densities 
for large-scale protein production (Cregg & Higgins, 1995) and this process has been 
successfully applied to the production of many recombinant proteins (Cereghino et al,
2002; http://www.kgi.edu/html/noncore/facultv/cregg.htm). Furthermore, several scFv 
(Eldin et al, 1997; Luo et al, 1997a, 1997b; Fischer et al, 1999; Boado et al, 2000; Freyre et 
al, 2000; Goel et al, 2000; Wang et al, 2001; Shi et al, 2003; Gurkan et al, 2003) and scFv- 
fusion proteins (Luo et al, 1996; Fitzgerald et al, 1997; Smith et al, 2001; Gurkan & Ellar, 
2003; Medzihradszky et al, 2003) have been produced at high yields in this system and 
proteins which had been previously difficult to express in bacteria were successfully 
produced in P. pastoris (Freyre et al, 2000; Gurkan et al, 2003; Shi et al, 2003).
Apart from the removal of antibodies from the circulation as a result of an immune 
response the rate of clearance is determined primarily by the molecular weight of the 
antibody, although molecular shape and charge are also involved (Lote, 1992). Small 
antibodies (< ~60 kDa) are cleared from the circulation by the glomerular filter in the 
kidney (Morgenson & Soiling, 1977; Silbemagl, 1988). Accordingly, small molecules 
exhibit the fastest half-life in circulation. As the antibody size increases, so does the 
restriction to filtration (Sumpio & Hayslett, 1985), resulting in longer circulating half-lives. 
Consequently, smaller antibody fragments that clear quickly give both lower tumour and 
normal tissue levels and subsequently reduced normal tissue exposure. In contrast, large 
antibodies show good tumour localisation but also give more exposure to normal tissues.
An increase in the MW of smaller antibodies can improve their tumour targeting 
potential by increasing their circulating half-lives and reducing renal accumulation. This 
has been achieved by conjugation to monomethanoxy-polyethylene glycol (PEG; Chapman 
et al, 1999,2002), HSA (Smith et al, 2001), and by combining an increase in molecular 
size with an increase in avidity (Hu et al, 1996; FitzGerald et al, 1997; Beresford et al,
1999; Goel et al, 2000; Powers et al, 2001). The approach taken here was to use HSA as a 
linker, ostensibly replacing the Fc domain of an IgG. This was predicted to achieve the
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dual effect of increasing the circulating half-life of MFE-23 and increasing avidity by using 
HSA as a backbone linking two scFv together.
HSA is a non-glycosylated protein abundant in normal serum (40-50 g/L) with a half- 
live in humans similar to that of an IgG molecule (2-3 weeks; Peters, 1985; Waldmann & 
Strober, 1969). Furthermore, it has been widely applied to increase the circulation of small 
drugs (Wunder et al, 2003; Burger et al, 2001; Hartung et al, 1999; Stehle et al, 
1997;Wunder et al, 1998; Stehle et al, 1999; Dosio et al, 2001), proteins (Sheffield et al, 
2001; Marques et al, 2001; Syed et al, 1997; Yeh et al, 1992; Paige et al, 1995; Mao & 
Poznansky, 1989; Poznansky et al, 1988;) and more recently, antibody fragments (Smith et 
al, 2001). There is also some evidence that HSA is preferentially taken up by tumour tissue 
(Andersson et al, 1991; Clorius et al, 1995; Wunder et al; 1997; Stehle et al, 1997; 
Guerdoud et al, 1994; Sinn et al, 1990). Recombinant HSA has been produced in P. 
pastoris for clinical use (Yoshitomi pharmaceutical industries) and this has overcome the 
dangers of using HSA from human sources (e.g. prion contamination). HSA has been 
found to consist of three homologous domains, probably formed through gene 
multiplication (Brown, 1976). Truncated versions of HSA have shown altered clearance to 
the whole molecule in animal models (Sheffield et al, 2000) and these differences in 
circulation may be exploited to create another method of modulating the clearance of MFE- 
23 dimers. Furthermore, HSA domains have been successfully produced in yeast (Dockal 
et al, 1999; Kjeldsen et al, 1998), and were shown to retain the structural and ligand- 
binding properties of whole HSA. These offer an attractive alternative as linkers to the 
whole length protein for the production of molecules with varying size and clearance. 
Although Ml0b dimers using HSA domains as linkers were not further investigated in this 
thesis, their successful expression demonstrated the feasibility of their future application.
A humanised, high affinity derivative of MFE-23 was chosen as the scFv unit in these 
molecules. The partial humanisation of MFE-23 was accomplished by resurfacing the Fv 
framework (Graff, 2002), based on the structural similarity of MFE-23 to another 
crystallised human antibody (Boehm et al, 2000). Subsequent affinity maturation resulted 
in a scFv with a 100-fold improvement in the affinity and a 200-fold improvement in the 
off-rate compared to the wild-type MFE-23 (Graff, 2002). Furthermore, the amino acid 
sequence for this scFv is coded using yeast optimum codons, making it an ideal candidate
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for expression in P. pastoris. The successful shake-flask expression of Ml Ob (and MFE- 
23) in P. pastoris resulted in yields slightly less than those normally found for bacterial 
expression (-10 mg/L compared to 20-25 mg/L) but confirmed that the humanised, high 
affinity scFv was amenable to production in P. pastoris. These levels are consistent with 
soluble expression of Ml Ob in S. cerevisiae (Graff, 2002). Stabilising mutations on the 
Ml Ob scFv have resulted in increased soluble expression (Graff, 2002). This scFv may be 
easily cloned into the HSAbody expression vector for improved protein yields.
A series of divalent constructs were developed by genetically linking two Ml 0b 
molecules together using HSA and HSA domains. These were successfully produced by 
small-scale P. pastoris expression, with estimated protein yields ranging from 10-30 mg/L. 
Moreover, all of the expressed proteins retained their activity for CEA. The subsequent 
fermentation of Ml 0b dimers using whole HSA as a linker, followed by IMAC and CEA- 
affmity purification, resulted in protein yields of ~4 mg/ L. However, a variety of methods, 
under both native and reducing conditions, indicated the presence of lower molecular 
weight species in the final product, corresponding to a MW range of between 94 and 27 
kDa. The co-purifying proteins were detectable by anti-HIS, anti-MFE-23 and anti-HSA 
molecules, suggesting they were smaller fragments of the whole protein.
Gel filtration chromatography was not able to separate the lower molecular weight 
proteins from the final product. This may be a result of poor separation by the 
chromatography column, as the MW region separating proteins between 158 kDa and 40 
kDa is quite narrow (Figure 5.14; Figure 5.21). Further separation of the HSAbody on 
columns of varying separation ranges may successfully remove these lower MW species, 
although at the cost of severely diminished final protein yields. Another explanation for the 
presence of these breakdown products resolving at higher MW ranges is the association of 
these proteins as larger protein species when in a native state. It may be that following 
proteolysis of the proteins, they remain in their original conformation, eluting at the 
predicted MW for the whole length protein and only separating under the stringent 
environment of reducing SDS-PAGE. Examination of their migration on non-reducing 
SDS-PAGE gels may help to explain these results.
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N-terminal sequencing of the two prevalent proteins (~94 kDa and ~27 kDa) 
confirmed that they originated from the HSAbody, corresponding to HSA-MlOb and Ml Ob 
sub-units. This suggested that the full-length protein was cleaved between the N-terminal 
Ml Ob and HSA linker. Analysis of this region revealed the presence of Lys residues, 
which may account for cleavage at this site by protelytic enzymes expressed by P. pastoris. 
Proteolysis of P. pastoris-expressed protein has been reported for several proteins (Piefer & 
Jonsson, 2002; Romanos et al, 1992; B. Tolner, Dept, of Oncology, personal 
communication). Optimisation of media pH and application of protease deficient strains 
may decrease the proteolysis of heterologous proteins expressed in P. pastoris (Brankamp 
et al, 1995; McGrew et al, 1997; Rosenfeld et al, 1996). Furthermore, as the sequences of 
these lower MW species have been determined, the potentially vulnerable regions may be 
eliminated by site-directed mutagenesis. N-terminal sequencing also indicated that the S. 
cerevisiae secretion signal was not efficiently cleaved from the full-length protein. This 
has been observed for several scFv-based molecules expressed in P. pastoris and showed 
no effect on the overall integrity of these recombinant proteins (Ridder et al, 1995; Eldin et 
al, 1997; FitzGerald et al, 1997; Powers et al, 2001; Gurkan et al, 2003). If necessary, 
these addition amino acids can be easily removed by mild protease treatment (FitzGerald et 
al, 1997).
The susceptibility of the HSAbody to preteolytic cleavage ex vivo may have 
implications on it stability in vivo. 125I-labelled HSAbody resolved as the predominant peak 
by size-exclusion chromatography and was still immunoreactive against CEA. This 
indicated that the protein remained intact following radioiodination and protein stored at 
4°C for one week showed similar profiles (data not shown). Further assays will need to be 
performed to determine the stability of the radiolabelled protein in vivo (e.g. stability or 
protein and radiolabel in serum at 37°C).
Avidity of the molecules was confirmed by surface plasmon resonance using BIAcore. 
This technique is widely used to measure the kinetic interactions between antibodies and 
their cognate antigen. BIAcore is particularly suited to the measurement of avidity, as the 
intrinsic affinity can be assessed by binding studies using soluble antigen (Karlsson, 1994; 
Nieba et al, 1996). The high affinity of the scFv Ml 0b for CEA (K d=  0.08 nM) however, 
made it difficult to assess the gain in avidity when in the HSAbody format using off-rates
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alone. This was overcome by developing a sandwich assay to test the antigen binding of 
the discrete scFv units of the HSAbody. Using this method, a large binding curve was 
observed for the HSAbody to the immobilised antigen, in this case recombinant CEA (N- 
A l) produced in P. pastoris. A small binding curve was then detected, corresponding to 
HSAbody binding to antigen in solution. In these experiments considerable optimisation of 
the experimental conditions is needed to favour a monovalent binding interaction at the 
surface, leaving the second scFv free to bind antigen in solution. High analyte 
concentrations on low density surfaces promote this type of interaction. For the chip 
surface used in these experiments (1200 RU), binding kinetic models predicted that the 
majority of the analyte would bind divalently to the surface antigen (-98%). Regardless of 
this, a small portion of molecules was still able to bind antigen in solution, as evidenced by 
the binding curve seen for the HSAbody when introduced to antigen in solution, but not the 
monomer. In an attempt to force a monovalent interaction at the surface, two more sensor 
chips were tested with moderate (780 RU) and low (170 RU) antigen densities. However, 
binding models predicted a similar interaction at the surface (-89%) for the moderate chip 
and similar results were observed (data not shown). Although in theory the low antigen 
density is the optimal chip surface for these assays, several attempts to bind antigen at low 
levels resulted in an inactivated surface. Considerable optimisation will be needed to 
obtain an amplification of the binding curve for antigen in solution. Nevertheless, the 
observation of two binding curves suggests the presence of a divalent molecule. 
Furthermore, for these assays recombinant CEA (N-Al) was immobilised to the surface of 
sensor chips and captured antibody was then challenged with CEA in solution. The binding 
curves for these experiments not only confirm that the MFE-23 subunits of the HSAbody 
specifically interact with CEA (N-Al), as determined in Chapter 3, but suggest that their 
interaction is stable and of high affinity, as the addition of whole CEA in solution resulted 
in a second binding event with ‘free’ scFv and not in competitive elution and loss of the 
HSAbody from the chip surface.
A direct comparison of the in vivo biodistribution and tumour localisation of divalent 
anti-CEA molecules was performed for the HSAbody and A5B7 IgG in tumour xenograft 
models grown in nude mice. The HSAbody showed rapid tumour accretion with low non­
specific uptake in normal tissues. At 24 h, overall uptake in tumour was only slightly less 
than the IgG and the %ID/g for the HSAbody was -  8-fold greater than the highest levels
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reported for MFE-23 (mean of 3.2 %ID/g; Verhaar et al, 1995) and even greater for those 
seen with the humanised MFE-23 (hMFE; Graff, 2002) and a stabilised, higher affinity 
variant of MlOb (sm3E; Graff, 2002), which had levels of 0.63 ± 0.22 %ID/g and 1.00 ± 
1.09 %ID/g, respectively (data not shown). High tumour: kidney ratios were seen for the 
HSAbody at this time point, constituting a ~6-fold improvement over the scFv and showing 
their high renal accumulation was overcome. Overall uptake in liver, kidney and spleen 
were lower for the HSAbody than A5B7, and improved tumour: tissue ratios were obtained 
for these organs. Critically, the HSAbody exhibited a ~4-fold higher tumour: blood ratio at 
24 h than the IgG A5B7 (12.82, 5.8, 18.91 and 3.72 versus 4.04, 2.29, 1.83 and 2.5), and 
equivalent ratios as MFE-23 (11:1, Chester et al, 1994; 13:1, Verhaar et al, 1995) and 
MFE-23 variants (10:1; data not shown). These findings, taken with the dose levels for 
each molecule in tumour at this time point, constitute a considerable improvement in the 
tumour localisation and retention of the HSAbody in comparison with MFE-23 and high 
affinity MFE-23 variants.
The behaviour of the HSAbody in vivo is comparable to that seen for other engineered 
multivalent scFv-based molecules of similar size. For example, dose levels of 10.5 %ID/g 
at 24 h were reported for tetravalent scFv in tandem (-120 kDa), representing a 35:1 
tumour: tissue ratio (Goel et al, 2000; Goel et al, 2001; Batra et al, 2002). Another 
example of the effect of size and avidity on the tumour localisation properties of scFv is the 
engineering of minibodies (-80 kDa; Hu et al, 1996). Two formats, the LD (a genetic 
fusion of the scFv with the human IgGl CH3 domain) and Flex (a genetic fusion of the 
scFv with the human IgGl hinge region and an addition 10 amino acid linker) minibodies 
both exhibited rapid and high tumour uptake, with 8 %ID/g and 29 %ID/g at 24 h, 
respectively. These corresponded to tumour: blood ratios of 44:1 and 14: 1, respectively. 
High tumour: blood ratios were also reported for a CH2 domain-deleted antibody (-125 
kDa), with -  18 %ID/g in tumour compared to -1 %ID/g in blood at 24 h (Reff & Heard, 
2001). Data for the HSAbody cohorts at 24 h showed a range of 38.80, 28.21, 8.97 and 
21.46 %ID/g accumulation in the tumour, producing tumour: blood ratios of 12.82, 5.80, 
18.91 and 3.72, respectively. This places the pharmacokinetic properties of the HSAbody 
within the range seen for other engineered scFv-based molecules of comparable size and 
avidity. Based on the preliminary pharmacokinetic properties exhibited by the HSAbody, it 
is proposed that this molecule may be suitable as a vehicle for the delivery of therapeutic
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and diagnostic radionuclides. Furthermore, its smaller size, faster clearance and higher 
tumour: tissue ratios compared to A5B7 indicate that the HSAbody may be a superior 
reagent to the murine IgG, which is currently used in antibody-targeted imaging and 
therapy in patients.
The ability to radiolabel antibodies provides an important clinical reagent for both 
tumour imaging (RAID) and therapy (RAIT). The efficacy of a radionuclide is governed 
by its physical properties, the nature of the radiation emission, and its fate after antibody 
metabolism in vivo. The antibody/radionuclide molecule is influenced by target tumour 
location, size, morphology and pathophysiology. Therefore, it is important to match the 
biological half-life of the antibody to the radionuclide it is delivering (Flynn et al, 2002). 
This has been illustrated by the rapidly cleared scFv, which is less efficient when paired 
with isotopes with long half-lives, as the majority of the isotope’s disintegration will occur 
after renal elimination (reviewed in Goldenberg, 2002).
The suitability of the HSAbody for carrying radiolabel to tumour cells has been
•  1demonstrated by the preliminary in vivo studies described in this chapter. In this case, I 
was used to monitor the pharmacokinetic properties of the molecule. Radiolabelling with 
iodine onto tyrosine residues of the HSAbody using the Iodogen method resulted in active 
protein, suggesting this method is suitable for the attachment of other iodine isotopes, for 
example, therapeutic levels of 131I (~8 day half-life) or imaging agents such as 123I (~13.2 h 
half-life) for single photon emission computed tomography (SPECT) and 124I (~4 day half- 
life) for positron emission tomography (PET).
Radiometals have a broader range of efficient emissions for imaging and do not 
dehalogenate, as often happen with radioiodine. Favourable localisation of radiometals has 
been shown for antibody fragments of intermediate MW comparable to the HSAbody (Wu 
et al, 2000; Yazaki et al, 2001; Goel et al, 2001; Tahtis et al, 2001). To test the feasibility 
of labelling with radiometals, trial labellings with 11’indium (~2 day half-life) were 
performed (data not shown). Preliminary studies using the bifunctional chelate DTPA 
attached to lysine residues on the HSAbody showed that this molecule was readily 
radiolabelled using this method. Furthermore, the HSAbody has significantly more lysine 
residues than tyrosine (83 versus 46) providing more attachment points for the radiolabel.
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Crucially, there is only one lysine residue located in the CDR loops (HI), compared to 
three tyrosine residues (two in H3, one in L3).
Labelling via lysine residues offers a variety of radiolabelling possibilities and 
provides access to a host of radiolabels. However, the choice of a stable chelate is 
important as high accumulation in bone can occur with radiometals (Williams et al, 1996; 
Govindan et al, 1998). Furthermore, increased uptake of radiometals associated with small 
antibody fragments catabolised by the kidney has been shown (Colcher et al, 1998; Arano 
et al, 1998; Colcher et al, 1999; Yazaki et al, 2001; Tsai et al, 2001). For example, in 
comparative studies substantially higher renal uptake was observed for 11'indium-labelled 
diabody (~55 kDa) compared to radioiodinated versions (Yazaki et al, 2001). This is 
believed to be the result of accumulation of the radiometal in the lysosomal compartment of 
the kidney tubule cells following degradation and recycling of the antibody constitutive 
amino acids. In the case of radioiodine attached to tyrosine residues, the radiolabel is able 
to be scavenged or cleared, but radiometals are not. Charge modification (Kim et al, 2002), 
blocking of renal reabsorption by administration of cationic amino acids (Behr et al, 1997; 
Rutherford et al, 1997; Yazaki et al, 2001), and the use of metabolising linkers (Arano, 
1998; Fujioka et al, 2001) have all been applied to reduce the renal uptake of radiolabelled 
antibody fragments. In addition, studies on both '"indium- and 64Copper-labelled 
minibody (~80 kDa) showed significantly higher hepatic uptake than the radioiodinated 
counterpart (Wu et al, 2000; Yazaki et al, 2001). The authors proposed, however, the 
possibility that dehalogenation of the radiolabel prevented accurate measurement of the 
protein when radiolabelled with iodine. In vivo studies on the HSAbody labelled with 
chelated radiometals may help to determine if the low liver, kidney and spleen doses seen 
for the HSAbody are a result of dehalogenation of the radioiodine label.
Another potential application of the HSAbody is to exploit the natural functions of 
HSA for therapeutic use. HSA, as a serum protein, shuttles small molecules and drugs 
around the body and may be an effective vehicle for delivery of drugs to tumour cells, 
directed via the antibody unit. Furthermore, the availability of lysine residues may be again 
exploited for conjugation of a variety of cytotoxic agents. For example, the anti-metabolite 
methotrexate (Bertino, 1993) has been coupled to HSA via lysine residues and studies have
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shown tumour responses in pre-clinical (Burger et al, 2001; Wosikowski et al, 2003) and 
clinical trials (Hartung et al, 1999) using this compound.
As the HSAbody is almost fully human, it is expected to have a significantly increased 
circulating half-life in humans compared to mice. Albumin has a long circulating half-life 
in humans (~19 days; Peters, 1985) but in other species this time is substantially less (e.g. ~ 
2 days in mice; Peters, 1985). This may be one reason why, despite the similarity in size 
and avidity to the murine IgG and the consensus between the human and mouse albumin 
molecules (> 80% conserved sequence), the HSAbody was rapidly cleared from circulation 
within 48 h. In anticipation of a reduction in the clearance rate of the HSAbody in humans, 
methods to modulate its pharmacokinetics were investigated in the next chapter.
S.4 Summary
The aim of this chapter was to design and construct a divalent MFE-23-based molecule 
and test its in vivo targeting potential. This was achieved by genetically linking HSA 
between two high affinity, humanised variants of MFE-23 (Ml 0b). Dimers of Ml0b were 
also generated using HSA sub-domains as linkers. The full-length HSAbody was produced 
in the methylatropic yeast P. pastoris by fermentation, followed by IMAC and CEA- 
affinity chromatography at yields of ~ 4 mg/L. Avidity of the molecule was confirmed by 
BIAcore sandwich assays. The in vivo behaviour of the HSAbody was investigated in 
mouse models. Pharmacokinetics of the molecule was first studied in non-tumour bearing 
mice, showing that the HSAbody was rapidly cleared in all tissues by 48 h. Subsequent 
studies in mice bearing CEA-positive LS174T tumour xenografts showed specific tumour 
uptake and rapid clearance from normal tissues, with a -4-fold increase in tumour: blood 
ratio at 24 h compared to the anti-CEA IgG, A5B7. In addition, overall dose to tumour was 
~8-fold higher for the HSAbody than MFE-23 alone and, with comparable tumour: blood 
ratios, this represents a more favourable in vivo performance for the HSAbody.
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Chapter 6
Investigation on the effect o f glycosylation on the pharmacokinetics
o f HSAbodies
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6.1 Introduction
The previous chapter demonstrated the tumour targeting potential of an engineered 
MFE-23-based dimer incorporating HSA as a linker. This resulted in the specific 
localisation of the molecule to tumour cells with a ~4-fold improvement in tumour: blood 
ratios at 24 h over the anti-CEA IgG A5B7 and ~8-fold higher tumour uptake compared to 
MFE-23 in mouse models, indicating an in vivo advantage. The aim of this chapter was to 
determine if the pharmacokinetics of the HSAbody could be further improved.
It has been shown that large recombinant antibodies have very long circulating half- 
lives in humans, which can lead to increased toxicity in normal tissues. Various methods to 
accelerate the clearance of engineered antibodies have therefore been employed. 
Administration of a second antibody reactive with the first (anti-antibodies) results in the 
formation of an immune complex and rapid clearance by the reticuloendothelial system via 
the liver and spleen (Keep et al, 1983; Sharkey et al, 1984; 1988; Pedley et al, 1989, 1994; 
Begent et al, 1982, 1987; Goldenberg et al, 1987). This approach has been further 
developed by clearing biotinylated antibodies using avidin and streptavidin (Marshall et al, 
1994; Paganelli et al, 1988, 1991,). Further improvements to the clearance of antibodies 
can be achieved by galactosylation of the clearing antibody (Sharma et al, 1990, 1991,
1994; Marshall et al, 1995; Napier et al, 2000). With advances in protein engineering, 
direct modification of the antibody molecules themselves has been performed for optimal 
clearance. For example, the manipulation of molecular size has shown significant effect on 
the clearance pattern of recombinant antibodies (see Chapters 1,4, 5). More recently, 
direct glycosylation of the antibody molecule itself resulted in improved tumour: tissue 
ratios (Medzihradszky et al, 2003).
It was hypothesised that the incorporation of branched mannose residues onto the 
HSAbody would result in its accelerated clearance from circulation via mannose-binding 
proteins present in the circulation (Opanasopit et al, 2001). To achieve this, Asn-linked 
glycosylation tripeptide (Asn-X-Ser/ Thr) sites were engineered into the HSA primary 
sequence, and the mutated constructs were expressed in P. pastoris. The effect of 
glycosylation on the pharmacokinetics and tumour targeting properties of the 
‘glycoHSAbody’ were then studied in vivo.
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6.2 Results
6.2.1 Design strategy for glvcoHSAbodies
Wild-type HSA does not contain any Asn-linked glycosylation recognition sequences 
(Asn-X-Ser/Thr) and so the x-ray crystallography structure (He & Carter, 1992) was 
studied to determine suitable regions for mutagenesis. The criteria for choosing these 
amino acid regions were based on surface charge, exposed residues, side-chain interactions 
and areas which were predicted would not affect proper protein folding or interfere with 
antigen binding. Six potential sites were identified for mutagenesis at residues Thr83, Tyr84 
and Gly85, Val^o, Aspm and Vali22 , Leu305, Ala3o6 and Ala307, Asn3i8, Tyr3]9 and Ala32o, 
Ala36 2 , Ala363 and Ala36 4 , and Gln397, Leu398 and Gly399. Their placement in the HSA 
structure is shown in Figure 6.1a. These regions all appeared to be solvent-exposed and on 
or near the surface of the protein, as judged by inspection of the crystal structure. In 
addition, several of the amino acids selected constituted a base point mutation change if 
replaced with one of the constituent amino acids in the tripeptide sequence (Thr83-Asn; 
Gly8s- Ser; Ala32o-Thr; Ala364 -  Ser/Thr; and Gln397-Asn).
Along with potential sites predicted from structural investigations, three naturally 
occurring Asn-linked glycosylation sites based on the Malmo-95 (Sakamoto et al, 1995), 
Redhill (Brennan et al, 1990), and Casebrook (Peach & Brennan, 1991; Haynes et al, 1992) 
alloalbumin mutations, were investigated in the HSA structure (Figure 6. lb). These 
introduce oligosaccharide chains at Asn residues 63, 318, and 494, respectively and have 
been shown to be readily glycosylated.
For practical reasons, N-linked glycosylation recognition sequences (Asn-X-Ser/Thr) 
were initially introduced into the HSA primary sequence based on the three naturally 
occurring mutations (Casebrook, Redhill, Malmo-95). These sites are formed by a single 
amino acid mutation, created by a point mutation in the DNA sequence and require 
minimal genetic manipulation to generate. Furthermore, each site is located in one of the 
three discrete domains of HSA, decreasing the likelihood of steric interactions between the 
oligosaccharide chains. For glycosylation at position Asn 63 this constituted a point
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Asn318
F igure 6.1. Structural representation o f HSA showing potential regions for incorporation o f glycosylation 
recognition sites, (a) Structure-based predictions for regions on the HSA structure where mutagenesis may be 
possible for the addition o f  glycosylation recognition sequences (Asn-X-Ser/Thr) are indicated and their 
amino acid sequences are given. Domain 1 is shown in red, domain 2 in pink, domain 3 in purple, (b) Sites 
o f  naturally-occurring Asn-linked glycosylation as a result o f mutation o f the HSA sequence. Asp 63 (shown 
in blue) is mutated to an Asn. Ala 320 is mutated to a Thr to produce a recognition sequence at Asn 318 
(shown in green). Asp 494 (red) is mutated to an Asn. The HSA structure is shown in grey.
P rim e r  nam e Sequence 5 ’-3’
Casebrook sense GCTGATGAGTCAGCTGAAAATTGTAACAAATCACTTCATACCC
Casebrook anti-sense GGGTATGAAGTGATTTGTTACAATTTTCAGCTGACTCATCAGC
Redhill sense GGATGTTTGCAAAAACTATACTGAGGCAAAGGATGTCTTCCTG
Redhill anti-sense C AGG AAGAC ATCCTTTGC CTC A G T AT AGTTTTTGC A A AC ATCC
M almo-95 sense CCATGCTTTTCAGCTCTGGAAGTCAATGAAACATACGTTCCC
M almo-95 anti-sense GGGAACGTATGTTTCATTGACTTCCAGAGCTGAAAAGCATGG
T able  6.1. O ligonucleotide primers for insertion o f  glycosylation sites into HSA. Point mutations are shown 
in red. M utagenesis primers are fully complementary to the template sequence. Experimental conditions are 
described in Chapter 2.
mutation from an Asp to Asn; for that at position 318, an Ala to Thr change at residue 320; 
and for that at position 494, an Asp to Asn. Each of these sites required only one base 
mutation to create the recognition sequence of Asn-X-Ser/Thr. Mutations were introduced 
by site-directed mutagenesis to the pPICHSAl primer incorporating the HSAbody coding 
sequence (,see 5.2.2) using a set of complementary primers annealing to both strands of 
DNA at the region to be mutated (Table 6.1). Three successive rounds of mutagenesis were 
performed, with one glycosylation site inserted during each round. Successful mutagenesis 
was confirmed by DNA sequencing, and mutation efficiency was calculated to be > 90%. 
This resulted in a series of constructs with varying glycosylation placement and extent.
The full set of mutated constructs generated is listed in Table 6.2.
T able 6.2. L ist o f H SA body constructs contain ing Asn-linked glycosylation sites
C o n s tru c t nam e__________________ G lycosylation site____________ P red icted  M W  (kDa)
G lyco(D l)HSA body Asn 63 -1 2 2
Glyco(D2)HSAbody Asn 318 -1 2 2
Glyco(D3)HSAbody A sn 494 -1 2 2
G lyco(D l D2)HSAbody Asn 63, Asn 318 -1 2 4
Glyco(Dl D3)HSAbody Asn 63, Asn 494 -1 2 4
Glyco(D2D3)HSAbody Asn 318, Asn 494 -1 2 4
G lyco(D l D2D3)HSAbody Asn 63, Asn 318, Asn 494 -1 2 6
(glycoHSAbody)
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250 kDa
148 kDa
-120 kDa
60  kDa 
42 kDa
30 kDa 
22 kDa 
17 kDa 
4 /6  kDa
M l  2 3 4 5  6 7 8  9
Figure 6.2. SDS-PAGE analysis o f P. pastoris expression for first round mutagenesis o f  HSAbodies 
incorporating one glycosylation site. Four transformants for each construct were tested and culture 
supernatants (96 h) were subjected to SDS-PAGE (8% Tris-Glycine). Expressed proteins were detected by 
coomassie staining. Samples were loaded as follows: MW marker (Multimark; lane M), unmodified 
HSAbody supernatant (lane 1), glyco(Dl)HSAbody (clones D l.1-4; lane 2-5), glyco(D3)HSAbody (clones 
D3.1-4; lane 6-9).
6.2.2 Test expressions of glycosylated HSAbodies in Pichia pastoris
Test expressions (96 h) of several transformants for each round of mutategenesis were 
performed to determine the effect of glycosylation on protein expression and 
immunoreactivity. Culture supernatants were subjected to SDS-PAGE and the presence of 
full-length protein was confirmed by Western blot analysis using anti-HIS, anti-MFE-23 
and anti-HSA antibodies to detect the COOH-terminal hexahistidine tag, scFv and HSA 
subunits, respectively. Analysis of expressed proteins from first round mutagenesis 
(glycosylation in D1 or D3; repeated attempts to transform P. pastoris wild-type cells with 
the glyco(D2)HSAbody construct were unsuccessful) by coomassie staining resulted in a 
visible protein band for all but one of the transformants (clone D1.4; Figure 6.2). In 
addition, a smear of protein, generally attributed to heterogeneously glycosylated material, 
was detected for the glycoHSAbody but not the unmodified version. Figure 6.3 show the 
results of Western blot analysis of 3 of the 4 transformants expressed for both constructs 
(D1.1-3, D3.1-3). Protein bands at the predicted MW (~>120kDa) were detected for both 
constructs, although the glyco(D3)HSAbody was expressed at a very low level, and 
transformants of this construct were not detectable by anti-HIS antibodies. The protein
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Figure 6.3. Western blot analysis o f P. pastor is-expressed transformants from first round mutagenesis o f HSAbodies. Three o f the four transformants for each construct 
were tested and culture supernatants (96 h) were subjected to SDS-PAGE (8% Tris-Glycine). Expressed proteins were detected by (a) anti-HIS, (b) anti-MFE-23, and (c) 
anti-HSA antibodies. Samples were loaded as follows: MW marker (Multimark; lane M), HSA (2 pg; lane 1), unmodified HSAbody supernatant (lane 2), 
glyco(Dl)HSAbody (clones D1,1-3; lane 3-5), glyco(D3)HSAbody (clones D3.1-3; lane 6-8).
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Figure 6.4. Irnmunoreactivity o f  P. pastoris-expressed transformants from first round mutagenesis o f  the 
HSAbody. The culture supernatants from the three transformants tested by Western blot analysis were 
applied to CEA-coated wells. Following washing, bound proteins were detected by anti-HIS and anti-HSA 
antibodies. CEA-binding proteins were detected in both glyco(Dl)HSAbody transformants (clones D 1 .1 -3) 
and glyco(D3)HSAbody transformants (clones D 3 .1 -3) for both antibodies used. Culture medium (negative 
control) or supernatant containing expressed HSAbody were applied as controls. All samples were tested in 
duplicate and their averages were subtracted from control wells coated in PBS. Data represents several 
experiments.
bands for both expressed glycoHSAbodies appeared at a very slightly higher MW that the 
unmodified HSAbody, probably due to the addition of carbohydrates. Blotting with 
concanavilin A lectin resulted in a large smear of protein in which no discrete bands were 
observed (data not shown), suggesting the presence of glycosylated material in the 
supernatants. The addition of carbohydrates to the HSAbody did not affect its 
irnmunoreactivity, as determined by CEA ELISA using anti-HIS and anti-HSA antibodies 
to detect the bound protein (Figure 6.4).
Test expressions for second round mutagens containing two putative glycosylation 
sites were conducted on two transformants for each construct. Figure 6.5 shows the SDS- 
PAGE and Western blot evaluation of the expressions. Smears of protein were again 
detected for the expressed transformants with very faint protein bands detected in the 
coomassie-stained gel and anti-HIS blot. Stronger bands for the glycoproteins were 
observed in the blots probed with anti-MFE-23 and anti-HSA polyclonal antibodies.
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17/22 kDa_
Figure 6.5. Evaluation o f P. pastoris expression for second round mutagenesis o f HSAbodies incorporating two glycosylation sites. Several transformants for each 
construct were tested and culture supernatants (96 h) were subjected to SDS-PAGE (8% Tris-Glycine). Expressed proteins were detected by (a) Coomassie blue, (b) anti 
HIS, (b) anti-MFE-23, and (c) anti-HSA antibodies. Samples were loaded as follows: MW marker (Multimark; lane M), glyc(Dl)HSAbody (clone D l. l ;  lane 1), 
glyc(D 1 D2)HSAbody (clones D1-D2.1-2; lane 2-3), glyc(DlD3)HSAbody (clones D1-D3.1-2; lane 4-5), glyc(D2D3)HSAbody (clones D2-D3.1-3; lane 6-8).
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Figure 6.6. Irnmunoreactivity o f P. pastoris -expressed transformants from second round mutagenesis o f the 
HSAbody. The culture supernatants from all three constructs were applied to CEA-coated wells. Following 
washing, bound proteins were detected by anti-HIS and anti-HSA antibodies. CEA-binding proteins were 
detected for all three constructs, corresponding to glyco(DlD2)HSAbody transformants (clones D1-D2.1-2), 
glyco(DlD3)HSAbody transformants (clones D1D3.1-2), and glyco(D2D3)HSAbody transformants (clones 
D 2-D3.1 -2). Culture medium (negative control) or supernatant containing expressed HSAbody were applied 
as controls. All samples were tested in duplicate and their averages were subtracted from control wells coated 
in PBS. Data represents several experiments.
However, when culture supernatants were tested for irnmunoreactivity, all transformants 
exhibited anti-CEA activity, as evidenced by high absorbance readings for the anti-HSA 
antibody and to a lesser extent, for the monoclonal anti-HIS antibody (Figure 6.6).
Expression of third round mutagens, in which glycosylation sites were inserted into all 
three HSA domains, was tested using six yeast transformants. Evaluation of the expression 
pattern for this construct by SDS-PAGE and coomassie staining showed all six clones 
exhibited heavily smeared protein bands, with no discrete bands detected at the predicted 
MW (Figure 6.7a). Furthermore, Western blot analysis using anti-HIS, anti-MFE-23 and 
antibody-HS A antibodies were also inconclusive, with bands at the predicted MW only 
visible by anti-HSA antibodies (Figure 6.7b, c, d). However, CEA activity was confirmed 
for all transformants by ELISA (Figure 6.8). Two transformants (clones D1D2D3.2 and 
D1D2D3.3) showed reduced anti-HSA activity when this antibody was used to detect
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Figure 6.7. Evaluation o f  P. pastoris expression for third round mutagenesis o f  HSAbodies incorporating three glycosylation sites. Six transformants were tested and 
culture supernatants (96 h) were subjected to SDS-PAGE (8% Tris-Glycine). Expressed proteins were detected by (a) Coomassie blue, (b) anti-HIS, (b) anti-MFE-23, 
and (c) anti-HSA antibodies. Samples were loaded as follows: MW marker (Multimark; lane M), unmodified HSAbody (1 pg; lane 1), glyc(DlD2D3)HSAbody (clones 
D1-D2-D3.1-6; lane 2-7), HSA (5 pg; lane 8).
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Figure 6.8. Irnmunoreactivity o f  P. pastoris -expressed transformants from third round mutagenesis o f the 
HSAbody. Six transformants for this round o f  mutagenesis were applied to CEA-coated wells. Following 
washing, bound proteins were detected by anti-HIS and anti-HSA antibodies. CEA-binding proteins were 
detected for all expressed transformants (clones D1D2D3.1-6). Clones D1D2D3.1 and D1D2D3.3 showed 
reduced anti-HSA activity, although their anti-HIS signals were comparable to the other four clones. Culture 
medium (negative control) or HSA were applied as negative controls. All samples were tested in duplicate 
and their averages were subtracted from control wells coated in PBS. Data represents several experiments.
bound protein, although their anti-HIS levels were similar to the four other clones. Both of 
these clones also contained strong, aberrant low MW bands as detected by anti-MFE-23 
Western blot. The best overall clone in terms of ELIS A from this round of mutagenesis 
was chosen for large-scale production, characterisation and in vivo studies.
6.2.3 Large-scale production of the glvcoHSAbodv
Fermentation of the glycoHSAbody and its subsequent two-step purification by 
IMAC (via the COOH-terminal hexahistidine tag) and CEA-affinity purification resulted in 
yields of ~ 4 mg/L. This is comparable to the yields recovered for the unmodified protein 
using the same purification protocol. Figure 6.9 shows the UV profile monitoring the 
IMAC purification. Following application of copper ions to the matrix, a large sample load
198
Sample load
I Column strip
Copper
M '
W a « K
1
Elution
1 I I I I H l l n i  I I I !
hiiriI hhuii
1 I H I l i  i l l l M I  Hi l l
1 1
Si!
1 S J I
Elution volume (ml)
Figure 6.9. UV trace showing EMAC purification o f  glycoHSAbody from P. pastoris fermentation 
supernatant Chelating Fast-flow Sepharose was charged with copper ions, washed with dHjO and 
equilibrated with PBS containing 1 M  NaCl. The supernatant containing expressed protein was loaded onto 
file column (in the presence o f  1 M  NaCl) and non-specific proteins were washed off with PBS and 40 mM 
imidazole in PBS/ 1 M  NaCl. The hexahistidine-tagged glycoHSAbody was specifically recovered by 
competitive elution with 200 mM imidazole/ PBS/ 1 M  NaCl in 7 ml fractions (red dotted lines). Copper was 
striped from the matrix using EDTA.
peak was observed, followed by a peak corresponding to non-specifically bound proteins 
washed off using 40 mM imidazole. Competitive elution with 200 mM imidazole resulted 
in a broad peak representing hexahistidine-tagged proteins. The CE A-binding portion of the 
eluted product was obtained by immediate purification on an affinity column, as described 
in Chapter 5. The purity of the final protein, as analysed by SDS-PAGE and Western blot 
analysis, is shown in Figure 6.10. The glycoHSAbody appeared as a smear of protein, 
although a distinct band was visible at the predicted MW (>-120 kDa). As expected, the 
breakdown products identified in Chapter 5 (-94 kDa, -27 kDa) corresponding to cleavage 
at the N-terminus of the HS A linker were detected for the glycoHSAbody.
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F igure 6.10. Evaluation o f  glycoHSAbody following fermentation, IMAC and CEA-affinity purification. 
The final product was subjected to SDS-PAGE (8% Tris-Glycine) and proteins were detected by (a) 
coomassie staining, (b) anti-HIS, (c) anti-MFE-23, and (d) anti-HSA antibodies. Protein bands at the 
predicted MW (>~120 kD) were detected, as well as bands corresponding to breakdown products from 
cleavage o f the HSA linker (94 kD, 27 kD).
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6.2.4 Characterisation of N-linked glvcans
To determine to what extent the HSAbody was glycosylated, die MW of the 
glycoHSAbody was compared to die unmodified protein by size-exclusion 
chromatography. Figure 6.11 shows the overlay UV traces for both proteins. Three broad 
peaks were observed, corresponding to MW ranges of > -600 kDa, -120 kDa, and -  27 
kDa when compared to protein standards of known MW. A slight shift in the MW peak for 
the glycoHSAbody at the predicted size for the HSAbody (-120 kDa) indicated that the 
glycoHSAbody was of a higher MW. The presence of the smaller MW species peak (-27 
kDa), relating to breakdown product, and higher MW aggregates (~ >600 kDa) are in good 
agreement with the profile seen for the unmodified protein.
670 kD 158 kD 44 kD 17 kD 1.35 kD
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Figure 6.11. UV trace showing comparison o f gel filtration chromatography profiles for glycoHSAbody (red 
line) and HSAbody (blue line). IMAC and CEA-purified proteins (1 mg) were applied to a Sepharose 200 
column at a flow-rate o f  1.5 ml/m in in PBS. Three broad peaks were observed, corresponding to high MW 
proteins (Peak 1), predicted MW for HSAbodies (Peak 2), and low M W  proteins (Peak 3). A peak shift 
corresponding to a gain in M W  was observed for the glycoHSAbody when compared to the unmodified 
protein (Peak 2). Elution volumes o f M W  calibrants are indicated at top o f  figure, along with their MW.
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Figure 6.12. Comparison o f SELDI-MS profiles for glycoHSAbody and HSAbody. Purified proteins (100 
ng) were spotted onto a NP20 normal phase chip, washed with dH20, and laser desorbed following application 
o f SPA. Peaks were calibrated externally. M W  of peaks are indicated.
The gain in MW for the glycoHSAbody was further characterised by mass 
spectrometry using SELDI-MS. A broad peak at 127.1 +H kDa was detected for the 
glycoHSAbody, as compared to 120.8 +H kDa for the unglycosylated version (Figure 
6.12). A very low resolution peak was observed for the glycoHSAbody, which may be a 
result of the addition of carbohydrates as they are sometimes difficult to detect by mass 
spectrometry.
The presence of mannose residues was confirmed by lectin blot assay. Purified protein 
was subjected to SDS-PAGE and mannose residues blotted with Concanavalin A 
conjugated to peroxidase. Concanavalin A recognises a-D-mannopyranosyl units, which 
correspond to the high-mannose linkages typically found on proteins expressed in yeast 
(Bretthauer & Castellino, 1999). Figure 6.13 shows that a band at the predicted MW was 
detected for the glycoHSAbody, but not the unmodified protein when incubated with this 
lectin. Faint bands were also detected at -94 kDa, and -67 kDa, corresponding to the 
breakdown products identified in Chapter 5. This is another indication that these lower 
MW species contain the HS A unit of the protein, as this is the only portion of the protein 
which contains N-linked glycosylation recognition sequences. These results established 
that the incorporation of glycosylation sites into the HSAbody sequence resulted in the 
addition of mannose residues following expression in P. pastoris.
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Figure 6.13. Detection o f  glycosylation by lectin blot analysis. Purified glycoHSAbody (2 p.g; lane 4) and 
glycosylated control (2 |ig; lane 6), but not HSAbody (2 pg; lane 2), were detected by Concanavalin A HRP 
blotting following separation by SDS-PAGE (8% Tris-Glycine) under reducing conditions. Lanes M l 
(Multimark) and M2 (Seeblue Plus2) contain molecular weight markers, and lanes 1, 3, 5, 7 are blank.
To study the glycosylations further, the affect of de-glycosylation on the MW of the 
glycoHSAbody was tested. Purified protein was digested with PNGase F under native or 
denaturing conditions to account for poor digestion when in a folded state. Treatment with 
PNGase F under both conditions resulted in a fractional MW decrease, as assessed by SDS- 
PAGE and Western blot analysis (Figure 6.14). A large MW difference between the 
unmodified and glycoHSAbody has not been observed by SDS-PAGE, and changes to the 
glycoHSAbody due to de-glycosylation may not be visible using this technique. 
Alternatively, the poor resolution difference seen between the PNGase F-treated and non­
treated samples may be a result o f incomplete removal of the N-linked glycans.
To further determine the extent of glycosylation, the N-linked glycans of the 
glycoHSAbody were profiled by DSA-FACE. This technique involves the de- 
glycosylation of N-linked mannose residues by proteolytic cleavage, followed by their 
flourescense labelling and profiling using standard automated DNA sequencing techniques.
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Figure 6.14. Assessment o f PNGase F treatment o f  glycoHSAbody. Native or denatured glycoHSAbody was 
treated with PNGase F and the extent o f  de-glycosylation was evaluated by SDS-PAGE (8% Tris-Glycine) 
and Western blot analysis. Proteins were detected by (a) coomassie staining, (b) anti-HIS, (c) anti-MFE-23, 
and (d) anti-HSA antibodies. Gels were loaded as follows: MW marker (Multimark; lane M); unmodified 
HSAbody (lane 1); PNGase-treated native glycoHSAbody (lane 2); PNGase-treated denatured 
glycoHSAbody (lane 3); un-treated glycoHSAbody (1 \ig, lane 4; 2jtg, lane 6); blank (lane 5).
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Application of DSA-FACE confirmed the presence of fluorescently-labelled carbohydrates 
(Figure 6.15). Several distinct peaks were observed at intensities just above background 
when compared to internal standards and references. Comparison of the two predominant 
peaks obtained from digestion of the N-linked glycans of the glycoHSAbody (at positions 
4300 and 4900 glucose units, respectively; Figure 6.15b) to the RNAse B reference control 
(which contains branched Mans-9GlcNAc2 ; Figure 6.15c) shows that they are positioned 
closely to the Man<5GlcNAc2 and Man8GlcNAc2 peaks in the standard. Smaller intensity 
peaks were also observed at both lower (3800 and 4100) and higher (5000) glucose units. 
These were assigned to mannose residues of less than Man5GlcNAc2 and greater than 
Man9GlcNAc2 , respectively. Taken together, these results indicate that the glycoHSAbody 
contains N-linked glycans consisting predominantly of Mari6GlcNAc2 and MangGlcNAc2 
species.
6.2.5 Characterisation of avidity
The effect of glycosylation of the avidity of the HSAbody was tested by BIAcore 
sandwich assays. First, purified glycoHSAbody (100 nM) was passed over the surface of a 
sensor chip displaying immobilised antigen (1200 RU CEA (N-Al)). A large binding curve 
was observed for the glycoHSAbody, and its retention on the surface following the end of 
injection as a result of its strong association with antigen immobilised on the chip surface 
(Figure 6.16 a, b). The magnitude of the curve is consistent with that seen for the 
unmodified protein and the observed on and off-rates of the glycoHSAbody were not 
affected when compared to the unmodified HSAbody in overlay BIAcore sensorgrams. 
Following capture of the glycoHSAbody by the immobilised antigen, the availability of the 
second Ml0b unit in the molecule was tested by challenge with antigen in solution (100 
mM CEA). This resulted in a second, small binding curve and retention of the antigen in 
solution following the end of injection (Figure 6.16c, d). The scale of binding is better 
visualised when the interaction is enlarged (Figure 6.17). The glycoHSAbody shows a 
reduction in dissociation compared to the unmodified protein. Control experiments with 
monomer (Ml0b) did not result in a binding interaction with CEA in solution. The 
experimental data for binding of the glycoHSAbody to the immobilised antigen was fit to a
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Figure 6.15. N-linked glycan profiling o f glycoHSAbody by DSA-FACE. Electropherogram obtained from electrophoresis o f PNGase F digest o f  ghb. Blue peaks 
represent APTS-derivatised carbohydrates, red peaks represent the rhodamine-labelled oligonucleotides used as internal standards. The x-axis is measured in glucose 
units and represents the electrophoretic mobility o f the oligosaccharide chains. The y-axis is a measure o f the relative fluorescent intensity. The malto-oligosaccharide 
(a-1,4-glucose) reference is shown in (a) with two glucose units indicated beside peaks (5,10). In (b), the oligosaccharide profile derived from PNGase F treatment o f 
the glycoHSAbody is shown. Note the magnitude o f the y-axis. A second reference is given in (c), showing the profile o f RNAse B N-glycans. Peaks representing 
branched Man5GlcNAc2 (M5), M an^GlcNA^ (M6), Man7GlcNAc2 (M7), MangGlcNAc^ (M8), and Man9GlcNAc2 (M9) are indicated.
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Figure 6.16. BIAcore sensorgram showing glycoHSAbody binding to antigen. 100 mM of glycoHSAbody (red line), HSAbody (blue line) and M l Ob (green line) were 
(a) passed over a CEA (N -A l) chip (1200 RU immobilised) at 10 ml/min (association 1), and (b) monitored for retained binding to antigen on chip surface (dissociation 
1) before washing, (c) CEA was then passed over captured glycoHSAbody, HSAbody or M l 0b (association 2) and (d) monitored for retained binding to antigen in 
solution (dissociation 2) for retained binding.
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Figure 6.17. BIAcore sensorgram showing magnified view of glycoHSAbody binding to CEA in solution. The glycoHSAbody (red line), HSAbody (blue line) and 
MlOb (green line) were captured by CEA (N -A l) immobilised to the chip surface (see Figure 6.16) and then challenged with CEA in solution. The two curves were 
aligned for comparison purposes, (a) Response units o f CEA passed over captured glycoHSAbody, HSAbody or MlOb and (b) response units o f retained antigen during 
dissociation. Note the low response units on the y-axis.
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Figure 6.18. Bivalent binding model o f glycoHSAbody binding to antigen, (a) The glycoHSAbody binding 
data (red line) was fit to a bivalent analyte model (black line) in BLAevaluation software, (b) Residuals o f the 
curve fit are shown for the association and dissociation phases in the panel insert. The circles represent the 
experimental data along the fit, represented at a line across zero. The predicted individual components o f  the 
modelled binding curve are shown in (c). The total binding curve is shown as a black line, the contribution o f 
a monovalent binding (AB) interaction at the chip surface is shown as a green line and that for a bivalent 
binding (AB2) interaction is shown as a blue line. The contribution o f  buffer (bulk and drift) is shown as a 
red line.
bivalent binding model. Figure 5.18 shows the results of the fit. Residual of +/-1.5 for the 
association and dissociation phases indicated this was a reasonable fit to the model, as did 
the Chi2 value of 0.146. The individual components of the model curve were similar as 
those seen for the unmodified protein, returning models showing that predominantly 
divalent binding was occurring at the immobilised surface.
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6.2.6 Assessment of radiolabelled glycoHSAbody
The glycoHSAbody labelled well with Na-125I. Greater than 97% of the total 
radioactivity was associated with protein and evaluation by size-exclusion chromatography 
demonstrated that the glycosylated protein eluted with a similar radioactive profile to the 
unmodified, radiolabelled HSAbody (Figure 6.19). The majority of the radioactivity eluted 
at the predicted MW for the glycoHSAbody, with a very slight shoulder and smaller peak 
corresponding to the smaller MW co-purifying protein (-27 kD). No discemable MW shift 
was detected for the glycoHSAbody, which was attributed to the poor resolution of the 
column (Superose 12) for proteins of this size. The radiolabelled glycoHSAbody was 
reactive with CEA (>67%), as demonstrated by affinity chromatography. Furthermore,
—♦—HSAbody 
» glycoHSAbody
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Figure 6.19. Radioactive profile showing gel filtration chromatography o f  125I-labelled glycoHSAbody. 
Radiolabelled glycoHSAbody (pink line) or HSAbody (blue line) were injected onto a Superose 12 size- 
exclusion chromatography column and the radioactivity for each fraction (1 ml) was plotted against the 
elution volume. The elution volumes o f  the molecular weight standards are indicated at the top o f the figure.
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analysis of the fractions from the affinity column by digitised SDS-PAGE indicated that the 
majority of the radioactivity was associated with the full-length protein (Figure 6.20). 
Although radiolabelled breakdown products were visible, quantitation of the bands 
indicated that they accounted for <25 % of the total radioactivity. These results are in good 
agreement with those seen for the unmodified protein and indicated that glycosylation did 
not block the radiolabelling potential of the HSAbody.
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F igure 6.20. Digitised SDS-PAGE analysis o f  125I-radiolabelled glycoHSAbody. The final radiolabelled 
product was loaded onto a CEA-affinity chromatography column (lane 1), non-specific proteins were washed 
o ff (lanes 2-4), and CEA-reactive proteins were eluted from the column (lanes 5-7). Radiolabelled HSAbody 
was applied as a control (lane 9). Lane 8 is blank. Samples were subjected to SDS-PAGE (8% Tris-Glycine) 
and exposed to a phosphor storage plate for 1 week. Radioactivity was detected on a Phosphorlmager and 
quantified.
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Table 6.3. Biodistribution o f  I25I-labelled glycoH SAbody (% ID/g) in non-tumour bearing m ice
1 h 4 h 24 h 48 h
Blood 6.56 ± 0.86 2.65 ± 0.83 0.12 ± 0 .01 0.03 ± 0.00
Liver 5.41 ± 0.63 1.93 ± 0 .3 0 0.32 ± 0.05 0.25 ± 0.05
Kidney 5.70 ± 0.60 2.62 ± 0.58 0.62 ± 0 .1 4 0.39 ± 0 .1 4
Lung 3.26 ± 0.31 1.47 ± 0 .3 0 0.06 ± 0.00 0.04 ± 0.01
Spleen 6.13 ± 0 .5 4 2.78 ± 0.96 0.73 ± 0.25 0.32 ± 0 .1 2
Colon 1.29 ± 0 .1 7 0.94 ± 0.38 0.04 ± 0.00 0.03 ± 0.00
Muscle 0.52 ± 0 .1 5 0.36 ± 0 .1 0 0.01 ± 0 .0 0 0.01 ± 0.00
6.2.7 In vivo pharmacokinetic, biodistribution and tumour localisation studies
The effect of glycosylation on the in vivo properties of the HSAbody was investigated 
in mouse models. Pharmacokinetic studies were first performed in non-tumour bearing 
mice to determine the overall clearance patterns of the glycoHSAbody. Biodistribution 
data is given in Table 6.3. Figure 6.21 shows the mean values (n=4) of biodistribution in 
tissues at 1,4, 24, and 48 h post intravenous injection with 125I-labelled glycoHSAbody. A 
marked increase in clearance was seen for the glycosylated molecule, with a 2-fold 
decrease of radioactivity in blood within lh(6 .56±0.86  %ID/g) compared to the 
HSAbody (13.85 ± 4.15 %ID/g). Elevated levels in the liver (5.41 ± 0.63 %ID/g; 3.53 ± 
0.64 %ID/g for unmodified) and spleen (6.13 ± 0.54 %ID/g; 2.69 ± 0.64 %ID/g for 
unmodified) at this time point are indicative of rapid clearance of the glycosylated molecule 
through these organs. The dose in the kidney for the glycosylated protein was comparable 
to the unmodified version, with 5.70 ± 0.60 %ID/g (5.64 ± 0.44 %ID/g for unmodified) at 1 
h, dropping to less than 1 %ID/g for both proteins by 24 h.
To better illustrate the differences in circulating antibody, a direct comparison of blood 
clearance for the two molecules is shown in Figure 6.22. At 4 h the %ID/g in blood for the 
glycosylated protein was 2.65 ± 0.83, as compared to 11.06 ± 1.02 for Ihe unmodified 
HSAbody. By 24 h, the level of glycoHSAbody in the blood was 0.12 ± 0.01 %ID/g (2.31 
± 0.74 %ID/g for unmodified), dropping to 0.03 ± 0.00 %ID/g (1.09 ± 0.19 %ID/g for
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unmodified) by 48 h. These results indicate that the glycoHSAbody has an accelerated 
clearance compared to the unmodified protein.
Next, the tumour localisation properties of the glycoHSAbody were investigated in 
LS-174T xenograft-bearing nude mice. Because of the degree of variation between mice, 
individual data within each group (n=4) is given (see Table A2.1). Figures 6.23-6.26 show 
the biodistribution data represented as %ID/g and tissue: blood ratios at 1,4, 24, and 48 h 
post intravenous administration with 125I-labelled glycoHSAbody. For comparison, the 
biodistribution data for the HSAbody is shown. A significant decrease in blood levels 
(p=0.021) at 1 h (Figure 6.23) was observed for the glycoHSAbody (3.98, 5.54, 6.68, 8.48 
%ID/g; see Table A2.1) compared to the unglycosylated protein (25.28, 26.19, 26.44,38.13 
%ID/g; see Table A2.1). This constitutes a ~5-fold reduction in circulating antibody within 
1 h following glycosylation. Tumour levels at this time point were also much reduced for 
the glycoHSAbody, at 1.83,4.31, 5.81 and 15.47 %ID/g (compared to 6.11,17.99, 18.19 
and 63.57 %ID/g for the HSAbody), resulting in tumour: blood ratios of 0.33, 0.64, 0.68, 
and 3.88:1.
At 4 h (Figure 6.24) blood levels remained constant for the glycoHSAbody at 6.01, 
6.47, 6.73 and 8.91 %ID/g (compared to 4.88, 7.23, 15.12, and 16.40 %ID/g for the 
unmodified protein). An increase in tumour levels at this time point was detected, with 
%ID/g levels similar to those seen for the unglycosylated HSAbody (7.73, 10.85, 13.10 and 
20.1 %ID/g compared to 6.82, 8.42, 9.03 and 26.02 %ID/g; p=0.686). Liver (5.40, 6.19, 
6.79 and 8.24 %ID/g), kidney (5.59, 6.45, 6.46, and 9.23 %ID/g) and spleen (3.34,4.13, 
4.55, and 6.28 %ID/g) levels were also comparable to those for the unmodified protein at 
this time point (liver: 8.59, 9.25, 11.04, 13.77 %ID/g; kidney: 1.91, 4.48,6.59, 6.80 %ID/g; 
spleen: 3.89,4.85, 5.27, 6.19%ID/g). Tumour: blood ratios were slightly elevated at 1.14, 
1.67,2.17, and 2.25:1.
By 24 h (Figure 6.25) a marked drop (p=0.02) in blood levels was observed for the 
glycoHSAbody (0.09, 0.10, 0.11, 0.31 %ID/g), as compared to the unmodified protein 
(0.47, 3.02,4.96, 5.76 %ID/g), resulting in a ~23-fold reduction in circulating antibody. 
Tumour levels were also much lower for the glycosylated protein, with 1.41, 1.72, 4.02 and 
7.02 %ID/g remaining (compared to 8.97, 21.46, 28.81, and 38.80 %ID/g). The tumour:
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Figure 6.23. Comparison o f  biodistributions for 125I-labelled glycoH SAbody and H SAbody in LS174T
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blood ratios, however, reached their consistently highest values at 24 h for the 
glycoHSAbody, with ratios of 13.02, 17.99, 22.36 and 34.76 (compared to 3.72, 5.80, 12.82 
and 18.91 for the HSAbody). This represents a ~2-fold higher tumour localisation for the 
glycoHSAbody that the HSAbody 24 h after administration. The liver: blood ratios at 24 h 
were 9.89, 3.80,4.02, and 2.31; kidney: blood ratios were 13.65, 6.06, 7.95, and 21.94, and 
spleen: blood ratios were 2.93, 3.90,2.38, and 1.61 (see Table A2.2). These are higher than 
those found for the HSAbody (0.52,0.44, 1.89, 0.27 for liver; 0.59, 0.64, 2.36, 0.38 for 
kidney; 0.31, 0.57, 1.34, 0.25 for spleen) at the same time point. Tumour: liver (3.51,4.46, 
5.86 and 5.63 compared to 9.99, 13.37, 13.10 and 24.41 for the HSAbody), kidney (0.59, 
2.26,2.54 and 3.68 compared to 7.97, 9.02, 9.56, and 21.72 for the HSAbody), and spleen 
(5.71, 7.53, 8.07 and 11.84 compared to 10.15, 14.08, 14.73 and 40.76 for the HSAbody) 
ratios were also highest at this time point, although they were lower than those achieved for 
the unmodified protein (see Table A2.3).
Forty-eight hour cohorts for the glycoHSAbody showed wide deviation in their tumour 
%ID/g, with levels of 6.46 and 10.2 %ID/g in two mice, compared to 0.17 %ID/g in both of 
the other two mice (Figure 6.26). Levels in other tissues in this group were similar 
however, with blood (0.03, 0.03, 0.05, 0.06 %ID/g), liver (0.48, 0.59, 0.66, 0.71 %ID/g), 
kidney (0.62, 0.72, 0.85, 0.95 %ID/g) and spleen (0.21, 0.27, 0.40, 0.44 %ID/g) all under 1 
%ID/g. As expected, the two mice with high %ID/g values in tumour showed extremely 
high ratios for all tissues with 95.00 and 201.7 in the blood, 9.09 and 17.01 in the liver,
7.52 and 10.64 in the kidney and 15.30 and 25.22 in the spleen. The remaining two 
exhibited much lower ratios in these organs, with 5.28 and 5.54 in the blood, 0.26 and 0.36 
in the liver, 0.24 and 0.28 in the kidney and 0.63 and 0.82 in the spleen.
Overall, higher tumour: blood ratios can be seen for the glycoHSAbody when 
compared to the HSAbody and A5B7 at 24 h. However, liver, kidney and spleen ratios 
were all lower for the glycoHSAbody, with the highest ratios at the earliest time point (24 
h) for these organs associated with the unmodified HSAbody (see Table A2.3).
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6.3 Discussion
This chapter describes the effect of glycosylation on the pharmacokinetics and tumour 
localisation of HSAbodies. A series of molecules was developed in P. pastoris, varying in 
amount and position of glycosylation sites. A HSAbody glycosylated in all three HSA sub- 
domains was chosen to study the affect of glycosylation on the in vivo performance of 
HSAbodies. This molecule was predicted to have the most pronounced effect on the 
pharmacokinetics of the unmodified molecule.
Protein engineering has enabled the direct manipulation of antibodies to modulate their 
pharmacokinetic properties. This has been illustrated using a variety of techniques 
including the progressive humanisation of murine antibodies (Clark, 2000), the 
manipulation of antibody size and charge (Chapman et al, 1999; Pavlinkova et al, 1999; 
Kim et al, 1999; Onda et al, 2001; Yang et al, 2003), and the direct glycosylation of 
antibody fragments (Medzihraszky et al, 2003). Glycosylation of antibodies results in their 
rapid clearance from circulation through identification of carbohydrate chains by specific 
receptors and their removal from circulation via endocytosis and lysosomal degradation. 
These receptors are present in soluble form in circulation or on the cell surface of 
macrophages, dendritic cells and hepatic endothelial cells (Fraser et al, 1998; East &
Isacke, 2002; Gordon, 2002). It was predicted therefore, that the addition of branched 
mannose residues onto the HSAbody would result in its specific uptake by these receptor- 
bearing cells for faster clearance and ultimately, more favourable tumour: tissue ratios 
compared to its unglycosylated counterpart. Furthermore, the exploitation of glycosylation 
as a means of removing the antibody from the circulation was predicted to allow the 
controllable clearance of these molecules which would be directly comparable in humans.
HSA is unique among major plasma proteins in that its primary structure lacks the 
Asn-X-Ser/Thr recognition sequence required for Asn-linked glycosylation. However,
HSA is subject to inherited point mutations that produce genetic variants (Arai et al, 1990; 
Watkins et al, 1991; Madison et al, 1991; Galliano et al, 1990; Carlson et al, 1992;
Madison et al, 1994). These mutations have resulted in several identified glycoforms of 
HSA (Nielsen et al, 1997). The three most comprehensively studied include the Malmo- 
95, Redhill, and Casebrook mutations which contain glycosylation sites at Asn 63, 318, and
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494, respectively (Peach & Brennan, 1991; Hayes et al, 1992; Brennan et al, 1990; Carlson 
et al, 1992; Sakamoto et al, 1995). Although structure-based regions predicted to be 
suitable for mutagenesis were considered, the naturally-occurring sites were chosen for 
practical reasons. First, changes at these sites involved a single nucleotide replacement, 
simplifying the molecular biology involved in their construction. Second, these sites have 
been shown to be readily glycosylated in humans, suggesting they are surface exposed and 
accessible for the addition of N-glycans. Studies have shown that in humans, mutation at 
Ala32o-Thr and Asp494-Asn leads to glycosylation on all variant molecules (Peach & 
Brennan, 1991; Hayes et al, 1992) whereas mutation at Asp63-Asn results in only partial 
glycosylation of variant molecules. This is believed to be due to the placement of this 
mutant near to a disulphide bond pair (Cyss3-Cys62). Third, these mutations account for a 
decreased concentration in HSA serum levels and result in albumin derivatives with altered 
ligand properties and clearance rates (Peach & Brennan, 1991; Nielsen et al, 1997; Kragh- 
Hansen et al, 1996). Finally, a previous study on the mutagenesis of albumin showed that 
glycosylation at Asp494-Asn led to accelerated clearance in animals but glycosylation at a 
site chosen by structure-based design did not (Sheffield et al, 2000).
Asn-linked glycosylation of the HSAbody was achieved by site-directed mutagenesis 
of the HSA unit and expression in the methalylotropic yeast, P. pastoris. P. pastoris 
attaches high-molecular weight mannose residues (Bretthauer & Castellino, 1999) with 
posttranslationally added oligosaccharide chains averaging 8-14 mannose residues per side 
chain (Grinna & Tschopp, 1989; Tschopp, 1987). These are not typically 
hyperglycosylated, although longer oligomannose structures have been reported, as well as 
shorter (Montesino et al, 1998; Bretthauer and Castellino, 1999). This is an advantage over 
S. cerevisiae, which can add 50-150 mannose residues (Grinna & Tschopp, 1989; Tschopp, 
1987). In addition, S. cerevisiae core oligosaccharides have terminal a-1, 3 glycan linkages 
whereas P. pastoris does not. This may be more favourable for clinically-relevant reagents 
and may be supported by an ongoing Phase 1 clinical trial of a glycosylated scFv-enzyme 
fusion protein for ADEPT therapy (Bagshawe, 1988) which has shown no adverse affects 
as a result of the P. pastoris-produced fusion protein in the 27 patients treated so far (A. 
Mayer, Dept, of Oncology, personal communication). These results indicate that P. 
pastoris-expressed proteins containing glycosylation are able to provide viable clinical- 
grade products.
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Glycosylation of the HSAbody did not affect expression levels, purification or 
immunoreactivity. Proteins reactive with CEA were expressed for each round of 
mutagenesis, with the exception of the glyco(D2)HSAbody, which was not tested as it was 
not successfully transformed into yeast cells. This may be due to unforeseen mutations in 
the plasmid which affect its homologous recombination with the host genome. 
Comprehensive analysis of the plasmid or re-cloning will be needed to determine the cause 
of its failure to recombine. It was also noticed that protein bands for the glycoHS Abodies 
were very faint when analysed by SDS-PAGE and Western blots and the intensity of the 
bands decreased with each round of mutagenesis. These results suggest that an increase in 
glycosylation may result in a decrease in detectable protein by electrophoresis. It is 
possible that glycosylation affects the mobility and detection of glycoproteins due to their 
heterogeneous nature.
The glycoHSAbody containing glycosylation sites in all three HSA domains was 
successfully expressed by large-scale fermentation, with final yields after the two-step 
affinity purification comparable to the unmodified protein. Furthermore, the avidity of the 
molecule for CEA was maintained, as evidenced by binding curves detected for antigen 
immobilised to the chip surface and in solution. As discussed in Chapter 5, the 
experimental protocol used to determine avidity must be further optimised to obtain a more 
convincing binding curve for the antigen in solution. Further kinetic analysis of the 
glycoHSAbody will also be needed to determine whether the affinity was affected.
The extent of glycosylation on the glycoHSAbody was assessed in several ways. 
Visualisation of the glycoHSAbody separated on SDS-PAGE showed a discrete band at the 
expected MW (and slightly higher than the HSAbody) as well as a smear of protein below, 
which is indicative of a heterogeneous product (i.e. as a result of glycosylation). Gel 
filtration chromatography and MS also confirmed a slight increase in size for the 
glycoHSAbody compared to the unmodified protein. Lectin blot assay using Concanavalin 
A confirmed that mannose residues were present on the glycoHSAbody and not the 
unmodified protein. However, further characterisation by PNGase F digestion was 
inconclusive, as the change in MW due to de-glycosylation was minimal. This may be a 
result of poor separation on SDS-PAGE, as the change in MW between glycosylated and 
non-glycosylated HSAbodies has been difficult to determine by electrophoresis.
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Assessment of the PNGase F-treated glycoHSAbody by mass spectrometry may produce a 
clearer result.
More sensitive analysis of the N-linked glycans by DSA-FACE profiling resulted in 
the identification of branched mannose residues on the glycoHSAbody corresponding to 
predominantly Mari6GlcNAc2 and MangGlcNAc2 species. This is in good agreement with 
the oligosaccharide chain lengths usually seen for proteins expressed in P. pastoris 
(Montesino et al, 1998; Bretthauer & Castellino, 1999). However, the overall resolution of 
the data obtained using this technique was low, suggesting either low levels of 
carbohydrates or inefficient removal of the N-linked glycans, as this technique relies on the 
removal of the N-linked glycans through enzymatic digestion. This may be due to 
inaccessibility of the glycans, resulting in poor digestion. A study on the glycan structure 
of the Casebrook mutation reported that the carbohydrates at this position were not able to 
be released using proteolytic cleavage (Brennan et al, 1990). The authors proposed that the 
molecular environment surrounding the Asn3 ig residue inhibited enzymatic attack. 
Alternative enzymes may be more successful and have been used in DSA-FACE 
(Callewaert et al, 2001). An alternative to enzymatic digestion is to use anhydrous 
hydrazine, which is a small molecule capable of hydrolysing both N and O-linked glycans 
(Patel et al, 1993). This was successfully applied to release the oligosaccharide at position 
Asn3 ig (Kragh-Hansen et al, 2001). For a more comprehensive analysis of the N-linked 
glycans, tandem MS may be applied to enable the direct sequencing of mannose residues 
without the need for glycan release (Medzihradszky et al, 2003). This will allow the 
confirmation of their precise length and position on the HSAbody.
The addition of N-linked glycans to the HSAbody produced a marked reduction in 
circulating antibody within 1 h compared to the unmodified protein. As the 
immunoreactivity, radiolabelling efficiency and protein integrity were similar for both 
proteins, the pharmacokinetic differences were predicted to be a direct result of 
glycosylation. Furthermore, the increased levels in liver and spleen at this time point are 
indicative of clearance through these organs. This implicates the involvement of mannose- 
binding proteins as the mode of accelerated clearance, as elimination through these organs 
has been associated with glycosylated proteins bound to mannose receptors (Lee et al, 
2002). Studies with mannosylated albumin showed that the serum half-life was greatly
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reduced in mice compared to wild-type (6.4 min compared to >60 min) and increased levels 
were found in the liver and spleen. Rapid removal from circulation of P. pastoris - 
glycosylated scFv (Wang et al, 1998) and scFv fusion proteins (Powers et al, 2001; 
Medzihradszky et al, 2003) has also been reported. Of these studies, only one group 
included data on dose to normal tissues and this showed increased levels in the liver 
(Medzihradszky et al, 2003).
The accelerated clearance exhibited by the glycoHSAbody resulted in tumour: blood 
ratios ~2-fold higher that the unmodified protein at 24 h. This corresponds to a ~7-fold 
increase in tumour: blood ratios over the IgG A5B7 at this time point. Due to its rapid 
clearance however, the overall uptake was lower in the tumour for the glycoHSAbody with 
~7-fold less accumulation than the unmodified HSAbody at 24 h. Overall uptake in liver, 
kidney and spleen was relatively high, resulting in decreased tumour: tissue ratios in these 
organs compared to the unmodified protein. The liver and spleen are the major organs for 
catabolism of large molecules such as IgG (Henderson et al, 1982; Mattes et al, 1994). The 
glycoHSAbody is close in size to an IgG (—127 kDa versus 150 kDa) and is glycosylated, 
which further directs its clearance through these organs. Although normal liver cells are 
not overly radiosensitive, the elevated uptake of the glycoHSAbody in this tissue may limit 
its therapeutic potential. These results indicate that the glycoHSAbody may be suitable as 
an imaging agent.
Imaging with monoclonal antibodies (such as A5B7) typically occurs 4-10 days after 
administration due to their persistence in blood and normal organs which give high 
background activities (Begent et al, 1989; Lane et al, 1994; Britton, 1990). Smaller 
antibody fragments such as Fab and scFv exhibit superior tumour penetration and faster 
clearance with imaging typically occurring 4-6 h post administration (Fjeld et al, 1992; 
Moffat et al, 1994; Behr et al, 1995; Larson et al, 1997; Pavlinkova et al, 1999). However, 
images are not optimal due to the low uptake of the antibody fragments in the tumour. In 
two imaging trials with MFE-23, it was demonstrated that the most favourable tumour: 
tissue ratios (allowing tumour images to be taken) occurred after 22 h (Begent et al, 1996; 
Mayer et al, 2000). In fact, for radioimmunoguided surgery using MFE-23, the optimal 
times for imaging was predicted to be between 72 and 96 h (Mayer et al, 2000). With the
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ability to control the clearance of the HSAbody by glycosylation, the imaging times in 
patients can potentially be much reduced in comparison with MFE-23.
Tumour heterogeneity (e.g. viable: necrotic areas) influences the effectiveness of 
antibody localisation (Yokota et al, 1993) and it has been demonstrated using mathematical 
models based on in vivo biodistribution data that optimal viable: necrotic ratios occur at 
early time points (Flynn et al, 2001,2002). Furthermore, multimeric antibodies are 
retained in the viable, sensitive areas of tumour longer than monomeric forms (Flynn et al, 
2001, 2002). Therefore, for effective tumour localisation, an ideal molecule would 
combine high overall dose to viable tumour tissue and high tumour: tissue ratios at early 
time points to be most effective. The glycoHSAbody described here exhibits the fast 
localisation to tumour and rapid clearance from normal tissues seen with scFv, but higher 
overall dose and longer retention times in the tumour. This represents a substantial 
improvement over MFE-23 and MFE-23 derivatives, which showed lower tumour: blood 
ratios at 24 h in vivo. Studies in mouse models on humanised MFE-23 (hMFE; Graff, 2002) 
and a stabilised, higher affinity variant of Ml0b (sm3E; Graff, 2002) showed tumour: blood 
ratios of 10:1 at 24 h (data not shown), compared to ratios of 13.02, 17.99, 22.36, and 
34.76:1 for the glycoHSAbody. At 24 h, tumour levels for hMFE and sm3E were 0.63 ± 
0.22 and 1.00 ± 1.09, respectively. Tumour accumulation for HSAbody at the same time 
point was 1.41, 1.72,4.02, and 7.01. Blood levels for hMFE and sm3E were 0.06 ± 0.04 
and 0.10 ± 0.11, respectively, with similar amounts seen for the glycoHSAbody (0.09, 0.10, 
0.11, and 0.31). The considerable improvements seen with the glycoHSAbody compared to 
MFE-23 and MFE-23 derivatives are predicted to be a result of the gain in functional 
affinity for the glycoHSAbody. However, where high renal uptake limits the further 
application of scFv, elevated liver activity may limit the use of the glycoHSAbody in the 
detection of hepatic deposits. However, with tumour: liver ratios of greater than 3.5:1 (3.51, 
4.46, 5.63, and 5.86), it was predicted that this would allow reasonable detection of 
metastases ~1 cm (A. Green, Dept, of Oncology, personal communication).
The application of multivalent scFv-based molecules of intermediate MW for imaging 
may result in rapid acquisition of higher-quality images because of the balance between 
optimum pharmacokinetics and prolonged tumour retention. No clinical evidence has yet 
been reported for these molecules, but pre-clinical studies have been encouraging. In one
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study using 123I-labelled T84.66 minibody (Hu et al, 1996), rapid tumour accretion and 
favourable xenograft images could be clearly visualised 19 h post administration. Further 
imaging studies with this molecule using the radiometals H1Indium and 64Copper also 
showed high tumour uptake and specificity (Wu et al, 2000; Yazaki et al, 2001). However, 
high hepatic and renal retention of this molecule limits its use in RAIT. Another scFv- 
based molecule with potential as an imaging agent is the anti-TAG 72 antibody CC49 
tandem scFv (Beresford et al, 1999). Tumour localisation at 6 h after administration with 
" mTc-labelled divalent and tetravalent tandem scFv resulted in high tumour localisation 
(Goel et al, 2001). As with the minibody, activity in kidney and liver were found to be 
high. However, these molecules have also been investigated as therapeutic agents and 
showed a significant reduction in tumour progression and prolonged median survival times, 
with negligible normal tissue toxicity (Pavlinkova et al, 1999; Goel et al, 2001).
Unfortunately, significant variation in the experimental data acquired for each group 
made it difficult to assess the molecules further (e.g. calculating the area under the curve to 
determine tm  a  and X\a P clearances). Further in vivo experiments will be needed to 
validate the effectiveness of these molecules. In addition, earlier time points may be 
evaluated to determine if higher ratios are achievable at earlier times. With maximum 
levels (based on the time points studied) in tumour at 24 h, the pharmacokinetics of the 
glycoHSAbody may be better suited to radionuclides with shorter half-lives, such as those 
found with the radiometals. The unmodified HSAbody has shown it is readily 
radiolabelled with U1lndium. Test labellings of the glycoHSAbody will show if it is 
similarly amenable to this method. In vivo studies can then be performed to determine the 
suitability of using these radionuclides for further imaging. The preliminary study 
described in this chapter indicates that glycosylation can modulate the clearance of 
HSAbodies, resulting in favourable tumour: blood ratios. Glycosylation on all three 
domains of HSA was chosen for preliminary in vivo investigations as it was hypothesised 
that this would result in the most pronounced difference in clearance. The next step will be 
to investigate all glycosylated constructs, as it is predicted that molecules with less 
glycosylation or different sites of glycosylation will have different rates of clearance.
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6.4 Summary
The aim of this chapter was to test the effect of glycosylation on the pharmacokinetic 
properties of the engineered dimeric HSAbody described in Chapter 5. To accomplish this, 
site-directed mutagenesis was performed on the HSAbody to introduce Asn-linked 
glycosylation recognition sequences into each of the three HS A sub-domains. A series of 
constructs was produced, ranging in placement and amount of glycosylation. For pilot 
studies, the HSAbody potentially glycosylated in all three domains was expressed in P. 
pastoris by large-scale fermentation and the expressed product was purified by IMAC and 
CEA-affinity chromatography at yields comparable to the unmodified protein. N-linked 
glycans of Man5.gGlcNAc2 structure were confirmed to be attached to the glycoHSAbody 
and their presence did not change the immunoreactivity or avidity of the HSAbody for 
CEA. Preliminary in vivo experiments on the glycoHSAbody indicated that glycosylation 
of the HSAbody resulted in a ~2-fold decrease in circulating antibody within 1 h with a 
concomitant reduction in tumour localisation. Maximum tumour: blood ratios were 
achieved at 24 h, with a ~2-fold increase over the unglycosylated HSAbody and a ~7-fold 
over the currently-used anti-CEA IgG A5B7. These preliminary results show that 
glycosylation of the HSAbody results in favourable tumour localisation and 
pharmacokinetics and that this molecule may be suitable as a diagnostic in RAID.
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Chapter 7
Final summary and conclusions
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7.1 Thesis summary
This thesis is concerned with the design and cancer-targeting potential of novel 
antibody-based molecules directed against CEA. CEA is one of the most widely-used 
serum tumour markers and has been recognised as a target for antibody delivery for over 20 
years. The antibody unit used in this thesis was the phage-derived anti-CEA scFv MFE-23, 
which has successfully targeted CEA-positive colorectal carcinoma in two imaging trials 
and is currently being used as the targeting arm of ADEPT in a Phase I clinical trial. Based 
on the knowledge that multivalent molecules have superior tumour retention than those 
with monovalent binding it was hypothesised that MFE-23-based molecules could be 
designed with favourable pharmacokinetics and tumour retention.
The first set of experiments focused on defining the interaction between MFE-23 and 
its cognate antigen CEA. SELDI-AMS was applied to partially map the MFE-23 binding 
site on recombinant domains of CEA. A novel approach was taken to accomplish this, 
exploiting IMAC technology for the direct characterisation of the immune complex. The 
technology developed may be further applied to study other antibody/antigen complexes. In 
particular, for the characterisation of novel antibody fragments selected from phage-display 
libraries as many of these proteins contain a hexahistidine tag for detection and purification 
purposes. These experimental techniques resulted in detailed sequence information on the 
putative region where MFE-23 binds to CEA, substantiating structural predictions. The 
identification of the N-Al domains of CEA as the MFE-23 binding region and the 
characterisation of its potential MFE-23 epitope was consequently applied to guide the 
design of subsequent MFE-23 dimers. Further work on defining the MFE-23 binding 
epitope by alanine scanning across the predicted region or by co-crystallisation of the 
antibody/antigen complex would confirm the epitope.
The first divalent molecules designed used a flexible polypeptide linker to join two 
MFE-23 together in tandem. This format was also expected to facilitate the development of 
chelating versions of MFE-23, with the two scFv binding to adjacent, non-overlapping 
epitopes on CEA. A bacterial expression vector was developed by cloning a ‘reversed’ 
version of MFE-23 (V l- V h)  downstream of the linker and restriction sites for insertion of a 
second anti-CEA scFv. To test the tandem scFv format, MFE-23 was cloned into the 
plasmid to produce a divalent molecule. However, bacterial expression resulted in very
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low protein yields and purification of the molecule by IMAC produced a heterogenous 
product, with the bulk of the purified material associated with two contaminating proteins.
A more successful approach to creating divalent MFE-23-based molecules was then 
taken in which the constructs were produced in the methylatropic yeast P. pastoris. P. 
pastoris allows expression of larger levels of complex molecules and has the advantage of 
post-translational modifications such as glycosylation with mannose residues. This 
facilitated the development of more sophisticated divalent molecules incorporating 
humanised, high affinity versions of MFE-23 linked together using HSA and HSA 
domains. This novel class of antibody-based molecules were termed HSAbodies. The 
largest molecule, using the entire HSA protein as a linker, was selected as a lead candidate 
for further investigation. The HSAbody performed more favourably than MFE-23 in vivo, 
with ~ 8-fold higher dose delivered to tumour at 24 h and comparable tumour: blood ratios. 
In addition, the HSAbody exhibited --4-fold higher tumour: blood ratios compared to the 
anti-CEA IgG, A5B7. These results suggest that the design features implemented into this 
novel molecule, namely higher affinity, avidity and size, were correctly hypothesised as 
characteristics which would improve the in vivo performance of MFE-23.
It was reasoned that the addition of glycosylation to the HSAbody would improve its 
pharmacokinetics further and enable the ‘controllable’ clearance of the HSAbody. A series 
of ‘glycoHSAbodies’ were engineered, ranging in site and amount of glycosylation. The 
lead candidate, which had three glycosylation sites, showed a marked difference in its 
pharmacokinetics compared to the unmodified HSAbody when tested in vivo, with ~5-fold 
reduction in circulating antibody within 1 h. Crucially, comparison of tumour: tissue ratios 
at 24 h showed a ~2-fold improvement for the glycosylated HSAbody compared to the 
unmodified protein and MFE-23 and -4-fold improvement over the clinically-used IgG 
A5B7.
Taken together, these in vivo results indicate that the constructs developed in this 
thesis represent a set of molecules of varying circulating half-life whilst maintaining 
prolonged tumour retention. The next step will be to investigate all glycosylated constructs 
and MFE-23-based dimers linked by HSA sub-domains. It is predicted that molecules with 
less than three sites of glycosylation will clear less rapidly from blood than the 
glycoHSAbody tested in this thesis. In addition, glycoHSAbodies varying in attachment
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site of glycosylation may have different rates of clearance. Furthermore, the smaller, 
domain-linked dimers will offer another method to modulate the pharmacokinetics of MFE- 
23-based molecules. Therefore, the entire range of constructs developed in this thesis 
should be tested in vivo to gain an insight into the importance of glycosylation and size on 
the pharmacokinetics of HSAbodies. This data can then be used to provide a method of 
‘controlling’ the systemic clearance of antibody-based molecules and direct future work 
towards the development of personalised therapeutics based on individual patient profiles.
The HSAbody format is not limited to CEA targets and could potentially be applied to 
other cancer markers. Coding sequences for scFv or peptides may be easily cloned into the 
HSAbody plasmid to produce divalent molecules against a given antigen. A number of 
well-characterised tumour-associated antigens have been described which may be suitable 
for HSAbody-directed imaging or therapy. For example, the well-characterised anti-HER-2 
neu scFv C6.5 (Adams et al, 1998) or the LI9 scFv directed against the ED-B domain of 
fibronectin (Pini et al, 1998) would be ideal candidates to study the compatibility of the 
HSAbody format against breast and vascular target systems, respectively.
The HSAbodies were designed to incorporate characteristics ideal for RAIT. These 
include target specificity, avidity, high affinity, human sequences, controllable 
pharmacokinetics, optional size, target flexibility, and easy production. Further pre-clinical 
studies using HSAbodies radiolabelled with therapeutic radionuclides (e.g. 1311,90Y) will 
indicate if these features were correctly hypothesised as being advantageous for therapy.
7.2 Conclusions
The work described in this thesis has shown that the combination of bioinformatics 
and protein engineering can be applied to optimise the in vivo performance of anti-CEA 
antibodies. These techniques have been used to 1) define the antibody/antigen interface in 
order to guide the design of optimised molecules: 2) increase the functional affinity of 
antibody fragments for prolonged residence times in tumour; and 3) control the clearance of 
antibody-based molecules from normal tissues for improved tumour: tissue ratios. The 
molecules generated in this thesis form a platform for development of new antibody-HSA 
molecules for cancer targeting which are almost fully human and have favourable 
pharmacokinetics.
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Appendix 1
PCR and restriction digestion reactions
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A1.1. Construction of pUC119 HIS/MFE-23 (VL-Vh)
Al.1.1 PCR of MFE-23 to reverse Vh and Vrdomains
pUCl 19/MFE-23HIS (6 ng) 6 pi
V h  (or VL) sense primer 2pi
V h  (or V l)  anti-sense primer (10 pM) 2 pi
10 x PCR buffer 10 pi
dNTPs (2 mM) 10 pi
AmpliTaq® (5 U/ pi) 0.5 pi
dHzO 69.5 pi
A master mix was made up containing 10 x PCR buffer, dNTPs, AmpliTaq® and dH20  and 
90 pi was aliquoted to individual tubes. Oligonucleotide primers were added, followed by 
DNA template or dUzO (6 pi) and die reactions were amplified for 30 cycles as follows: 
94°C, 1 min; 67°C, 1 min; 72°C, 1 min.
PCR products were purified (see 2.2.1.4) and overhangs were filled in as follows:
V h  product (-15 ng/pl) 3 pi
V l  product (-15 ng/pl) 3 pi
10 x PCR buffer 5 pi
dNTP(2mM) 5 pi
Klenow enzyme (0.5 U/ pi; Roche) 1 pi
dHzO 33 pi
Reaction was incubated at room temperature for 20 min, then healed at 94°C for 1 min. 
Following addition of 0.25 pi AmpliTaq®, reaction was amplified for 15 cycles as follows: 
94°C, 1 min; 65°C, 1 min; 72°C, 1 min. At this time, the reaction was heated at 940C for 2 
min during the addition of the following PCR mix to amplify ‘reversed’ MFE-23 product:
V l sense (10 pM) 2 pi
V h  anti-sense (10 pM) 2 pi
10 x PCR buffer 5 pi
dNTP (2mM) 5 pi
AmpliTaq® 0.25 pi
dH20  35.75 nl
and the reaction was further amplified for 20 cycles as follows: 94°C, 1 min; 67°C, 1 min; 
72°C, 1 min. PCR products were analysed on 1% agarose gels and purified.
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Figure A l.l  Analysis o f  MFE-23 (Vl-Vh) PCR product. Agarose gel (1%) showing final PCR product o f 
MFE-23 ( V l- V h). Gel was loaded as follows: q>xl74 Hae III marker, PCR product o f  d H ^  as template, PCR 
product o f  MFE-23 ( V l- V h).
A l. 1.2 Digestion of MFE-23 (V t -V h) and pUCl 19HIS vector with Nco V Not I
MFE-23 (V l-V h)  PCR product 40 pi (~1 pg)
10 x Buffer H (Roche) 6 pi
Nco I (Roche) (10 U/pl) 1.5 pi
Not I (Roche) (10 U/pl) 1.5 pi
dH20  11 pi
pUC119fflS 5 pi (~5 pg)
10 x buffer H 7 pi
Nco I 2.5 pi
Not I 2.5 pi
dH20  53 pi
Reactions were incubated at 37°C for 2 h. Following electrophoresis on a 1% agarose gel, 
the bands were excised and purified (see see 2.2.1.4). Ligation reactions were set up and 
incubated at 16°C for 4 h as follows:
pUC 119fflS Nco V Not I 2 pi (~ 50 ng)
MFE-23 (V l -V h )  N co V N o t  I 0.5 pi/ 1.5 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dH20 15 pl/14 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, ligations were used to transform TGI electro-competent cells as described in
2.2.1.8. Colonies were screened by M l3 PCR (see 2.2.1.2).
Figure A1.2. Screening o f  MFE-23 (Vl-Vh) inserts by PCR. Eighteen individual colonies o f TG I cells 
transformed with pUC MFE-23 (VL-VH) were screened for positive inserts by PCR using M13 sense and anti 
sense primers (lane 1-18). <pxl74 Hae III (lane M). As a negative control, no colony was added to reaction 
mixture (lane 19).
A1.2 Construction of vector for chelating and divalent MFE-23
Al .2.1 PCR of MFE-23 (Vr-VtA for append flexible linker and restriction sites
pUCl 19fflS/ MFE-23 (V L-V H) (1 ng/pl) 6 pi
Tandem 1 sense (10 pM) 2 pi
Tandem 2 anti-sense (10 pM) 2 pi
10 x PCR buffer 10 pi
dNTP (2 mM) 10 pi
AmpliTaq® 0.5 pi
dH20  69.5 pi
A master mix was made up containing oligonuclides, 10 x PCR buffer, dNTPs, AmpliTaq® 
and dH20  and 94 pi was aliquoted to individual tubes. DNA template or dH20  (6 pi) were 
added and the reactions were amplified for 30 cycles as follows: 94°C, 1 min; 67°C, 1 min; 
72°C, 1 min.
PCR products were purified (see 2.2.1.4) and overhangs were filled in as follows:
Linker-MFE-23 (V L-V H) PCR product (-50 ng/pl) 1 pi
Tandem 3 anti-sense (10 pM) 5 pi
10 x PCR buffer 5 pi
dNTP (2mM) 5 pi
Klenow enzyme (0.5 U/ pi; Roche) 1 pi
dH20  33 pi
Reaction was incubated at room temperature for 20 min, and then heated at 94°C for 1 min 
Following addition of 0.25 pi AmpliTaq®, reaction was amplified for 15 cycles as follows. 
94°C, 1 min; 65PC, 1 min; 72°C, 1 min. At this time, the reaction was heated at 94°C for 2 
min during the addition of the following PCR mix to amplify ‘reversed’ MFE-23 product:
Tandem 3 anti-sense (10 pM) 2 pi
10 x PCR buffer 5 pi
dNTP (2mM) 5 pi
AmpliTaq® 0.25 pi
dH20  37.75 pi
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and the reaction was further amplified for 20 cycles as follows: 94°C, 1 min; 67°C, 1 min; 
72°C, 1 min. PCR products were analysed on 1% agarose gels and purified.
M l  2 3
Figure A 13 . Agarose gel (1%) showing final PCR product o f Linker-MFE-23 (VL-VH) insert. Gel was 
loaded as follows: lane M, 9x174 Hae IE marker, lane 1, PCR product o f  MFE-23 (Vl-Vh); lane 2, PCR 
product o f Linker-MFE-23 (Vl-Vh); lane 3 PCR product o f dH20 as template.
Al .2.2 Digestion of Linker-MFE-23 (V l - V h )  and pUCl 19H1S/MFE-23 vector with Not V 
EcoRI
Linker-MFE-23 (Vl-Vh) PCR product 40 pi (-0.5 pg)
10 x Buffer H (Roche) 5 pi
Not I (Roche) (10 U/pl) 1 pi
Eco RI (Roche) (10 U/pl) 1 pi
dHzO 3 pi
pUC 119HIS/MFE-23 5 pi (-5 pg)
10 x buffer H 10 pi
Not I 5 pi
Eco RI 5 pi
dH20  75 pi
Reactions were incubated at 37°C for 2 h. Following electrophoresis on a 1% agarose gel, 
the bands were excised and purified (see 2.2.1.4). Ligation reactions were set up and 
incubated at 16°C for-16 h as follows:
pUC 119HIS/MFE-23 Not V Eco RI 1 pi
Linker-MFE-23 (VL-VH) Not V Eco RI 2 pi/ 4 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dH20 14.5 pl/12.5 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, ligations were used to transform TGI electro-competent cells as described in
2.2.1.8. Colonies were screened by M l3 PCR (see 2.2.1.2).
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Figure A1.4. Screening o f MFE-23-MFE-23 (Vl-V h) inserts by PCR. Twenty individual colonies o f  TGI 
cells transformed with pUC MFE-23-MFE-23 (VL-VH) were screened for positive inserts by PCR using M l 3 
sense and anti-sense primers (lane 1-20). <pxl74 Hae III (lane M). As a negative control, no colony was added 
to reaction mixture (lane 2 1 ).
Al .2.3 Screening of MFE-23-MFE-23 (Vr-VV) bv Nco V Eco RI digestion
Plasmid preparations were performed on clones 6,14,17 and 18 (see above) and digested 
as follows:
Plasmid DNA 6,14,17,18 or pUCl 19/MFE-23 (1 pg/pl) 2 pi
10 x buffer H (Roche) 2 pi
Nco I 1 pi
Eco RI 1 pi
dH20 14 pi
Reactions were incubated at 37°C for 2 h and digestions were analysed by electrophoresis.
Ml  1 2 3 4 5 6 M2
Figure A1.5. Screening o f MFE-23-MFE-23 (VL-VH) inserts by restriction digestion. Agarose gel (1%) 
showing Nco I/E cor RI digestion screening o f  pUC 119HIS/MFE-23-MFE-23 (VL-VH). Gel was loaded as 
follows: lane M l, A Hind III marker; lane 1, undigested clone 6 ; lane 2, digested pU C l 19HIS/MFE-23; lane 
3, digested clone 6 ; lane 4, digested clone 14; lane 5, digested clone 17; lane 6 , digested clone 18; lane M, 
<pxl74 Hae III.
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A1.3 Construction of pPIC/MFE-23/HSA D1/D2/D3
Al .3.1 PCR to append restriction sites onto MFE-23. MIOb. HSA D l/ D2/ D3
pUC 119HIS/MFE-23 (1 ng/pl) 5 pi
pPIC MFE-23 sense (10 pM) 2 pi
pPIC MFE-23 anti-sense (10 pM) 2 pi
10 x PCR buffer 10 pi
dNTP (2mM) 10 pi
MgCl2 (25 mM) 6 pi
AmpliTaq® (5 U/pl) 0.5 pi
(fflbO 64.5 pi
For Ml0b, pUCl 19HIS/MFE-23 was replaced with pRSMlOb and Ml0b sense and anti­
sense primers were used. For HSA products, pUCl 19HIS/MFE-23 was replaced with HSA 
cDNA (5 pi, diluted 1:500 in dH20) and primers were as follows: HSA sense and HSA anti­
sense for whole HSA; HSA sense and Dl anti-sense for D l; D2 sense and D2 anti-sense for 
D2; D3 sense and HSA anti-sense for D3.
®A master mix was made up containing oligonuclides, 10 x PCR buffer, dNTPs, AmpliTaq 
and dH:zO and 95 pi was aliquoted to individual tubes. DNA template or dH20  (5 pi) were 
added and the reactions were amplified for 30 cycles as follows: 95°C, 1 min; 65°C, 1 min; 
72°C, 2 min, followed by a 70°C extension for 5 min. For Ml 0b amplification the 
following conditions were used: 95°C, 1 min; 70°C, 1 min; 72°C, 1 min. PCR products 
were then analysed by electrophoresis and purified (see 2.2.1.4).
F igure A1.6. Agarose gel (1%) showing PCR products o f MFE-23, HSA & D1/D2/D3. Gel was loaded as 
follows: lane 1, HSA; lane 2, dH20 with HSA primers; lane 3, MFE-23; lane 4, D l ; lane 5, D2; lane 6 , D3; 
lane 7, PCR product using dH20 as template and MFE-23 primers; lane 8 , PCR product using dH20 as 
template and HSA primers; lane 9 PCR product using d H ^  as template and MIOb primers; lane 10, MIOb; 
lane M l , A Hind III marker; lane M2, tpx 174 Hae III.
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Al .3 .2 Digestion of MFE-23 PCR product and pPICZaA to create pPICOl
MFE-23 PCR product 
10 x Buffer H 
Xho I (40 U/pl; Roche) 
Xba I (10 U/pl; Roche) 
dHzO
pPICZaA 
10 x Buffer H 
Xho I 
Xba I 
dH20
50 pi (-0.5 pg) 
10 pi 
2 pi 
5 pi 
33 pi
10 pi (5 pg)
20 pi 
5 pi 
10 pi 
155 pi
Digestion reactions were incubated at 37°C for 2h, followed by phenol/chloroform 
extraction (see 2.2.1.4) and electrophoresis. Following electrophoresis on a 1% agarose 
gel, the bands were excised and purified (see 2.2.1.4). Ligation reactions were set up and 
incubated at 16°C for-16 h as follows:
pPICZaA Xho V Xba I 
MFE-23 Xho V Xba I 
10 x ligase buffer 
T4 DNA ligase 
dH20
5 pi (-50 ng) 
2.5 pi/ 5 pi 
2 pi 
0.5 pi
10 pl/7.5 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, 2.5pl of ligation mixtures were used to transform TOP10F’ electro-competent 
cells as described in 2.2.1.8. Minipreps of individual colonies were screened by Xho V Xba 
I digestion (see 2.2.1.5).
M il 2 3 > 1 8  M2
~ 900 bp
1 ft
*
u
F igure A1.7. Agarose gel (1%) showing Xho UXbal digestion screeing o f pPICOl/MFE-23. Sixteen 
individual colonies o f TOP 10F’ cells transformed with pPICOl/MFE-23 were screened for positive inserts by 
Xho VXba I (lanes 3-18), and compared to similarly digested pU Cl 19HIS/MFE-23 (lane 2) and uncut 
pPIC01/MFE-23 DNA (lane 1). Molecular weight markers were A Hind III (lane M l)  and 9x174 Hae III (lane
M2).
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Al.3.3 Digestion of MIOb. HSA. Dl. D2. D3 and dPIC01/MFE-23 with SUV Not I
Template 10 x Buffer M 
(Roche)
Sfi I (10 U/pl; Roche) dH20
MIOb PCR 
product
50 pi 10 pi 2.5 pi 37.5 pi
HSA PCR product 50 pi 20 pi 4 pi 86 pi
Dl PCR product 50 pi 10 pi 5 pi 35 pi
D2 PCR product 50 pi 10 pi 5 pi 35 pi
D3 PCR product 50 pi 10 pi 5 pi 35 pi
pPIC 01/MFE-23 30 pi 20 pi 4 pi 106 pi
Reactions were incubated at 50°C for -16 h, and then the following was added:
Template
reaction
10 x
Buffer H
1 M NaCl 400 mM 
Tris-HCl, 
pH 7.4
/Vo/1 (10 U/pl; 
Roche)
dH20
MIOb 15 pi - - 5 pi 80 pi
HSA - 10 pi 20 pi 5 pi 5 pi
Dl 10 pi - - iMi __________ 85 pi
D2 10 pi - - 5 pi 85 pi
D3 10 pi - - 5 pi 85 pi
pPIC 01/MFE-23 - 10 pi 20 pi __________ 5 pi
Reactions were incubated at 37°C for 2 h. Following electrophoresis on a 1% agarose gel, 
the bands were excised and purified (see 2.2.1.4). Ligation reactions were set up and 
incubated at 16°C for -16 h as follows:
pPIC 01 /MFE-23 
Sfi V Not I
Insert
SfiVNotl
10 x Ligase buffer T4 DNA
Ligase
dH20
lp l MIOb 8 pi 2 pi 0.5 pi 8.5 pi
HSA
3 pi Dl 5 pi 2 pi 0.5 pi 9.5 pi
3 pi D2 5 pi 2 pi 0.5 pi 9.5 pi
3 pi D3 5 pi 2 pi 0.5 pi 9.5 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, ligations were used to transform TOP 10F’ electro-competent cells as described 
in 2.2.1.8. Minipreps of individual colonies were screened by Xho V Not I digestion (see
2.2.1.5).
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Figure A1.8. Agarose gels (1%) showing Xho 1/ Not I restriction screening o f pPICOl/MlOb, D l , D2, D3, 
HSA. Gels were loaded as follows: lane M l , X. Hind HI; lane 1 pPICOl /D l uncut vector; lane 2 ,Xho 1/ N ot I- 
digested pPIC O l/D l; lane 3, Xho V Not I-digested pPICOl/MFE-23; lanes 4-8, pPICOl/MlOb clones; lane 
M l, X. Hind IE; M2, <p 174 Hae III; lane 9, pPICOl/Dl uncut; lane 10,Xho I/N o t  I-digested pPICZaA; lanes 
1 l-14,pPIC 01/D l clones; lanes 15-22, pPIC01/D2 clones; lanes 23-26,pPICOl/D3 clones; lane M l, X. Hind 
HI; lane 27, pPIC01/MFE-23 uncut; lane 28, Xho V Not I-digested pPICOl/MFE-23; lanes 29-34, 
pPICO 1 /HSA clones.
A 1.4 Construction of pPICHSAl
AI.4.1 PCR to append restriction sites onto MIOb to create dimer
pPICOl/MlOb (1 ng/pl) 5 pi
Ml Ob Xho I sense (10 pM) 2 pi
Ml Ob Sfi I anti-sense (10 pM) 2 pi
10 x PCR buffer 10 pi
dNTP (2 mM) 10 pi
MgC12 (25 mM) 6 pi
t n  i u .  i \  n  «  i
For ‘C-terminal’ Ml 0b the primers were replaced with MIOb Not I sense and MIOb Xba I 
anti-sense primers. A master mix was made up containing everything but template DNA 
and oligonucleotides and 91 pi was aliquoted to tubes. DNA template or dt^O (5 pi) was 
added to tubes, followed by oligonucleotides and the reactions were amplified for 35 cycles 
as follows: 94°C, 1 min; 71 °C, 1 min; 72°C, 1 min. A 5 min extension at 70°C was added
AmpliTaq (5 U/pl) 
dH20
0.5 pi 
64.5 pi
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at the end of the last cycle. PCR products were then analysed by electrophoresis and 
purified (see 2.2.1.4).
Ml 1 2 3 4 5 6 M2
Figure A1.9. Agarose gel (1%) showing MIOb dimer insert PCR products. Gel was loaded as follows: lane 
M l, X Hind ID marker; lane 2, PCR product using dH20  as template with MlOb-ATro I sense and SJi I anti­
sense primers; lanes 2-3 PCR product for ‘N-terminaT MIOb; lane 4, PCR product using d H ^  as template 
with MIOb Not I sense and Xba  I anti-sense primers; lanes 5-6, PCR product for ‘C-terminal’ MIOb; lane M2, 
<px!74 Hae III marker.
Al .4.2 Digestion of ‘C-terminaT Ml Ob PCR product and pPICOl/Dl and D3
C-terminal MIOb PCR product 50 pi
10 x buffer H 12 pi
AfofI(10U/pl) 5 pi
Xbal{\0V /\A ) 5 pi
dH20  28 pi
pPICOl/Dl 20 pi (-10 pg)
10 x buffer H 12 pi
No* I (10 U/pl) 5 pi
X bal(\0  U/pl) 5 pi
dH20  78 pi
pPIC01/D3 25 pi (-10 pg)
10 x buffer H 12 pi
Not I (10 U/pl) 5 pi
Xba I (10 U/pl) 5 pi
dH20  73 pi
Digestion reactions were incubated at 37°C for 2 h, followed by phenol/chloroform 
extraction (see 2.2.1.4) and electrophoresis on 1% agarose gels. Following electrophoresis, 
the relevant bands were excised, purified (see 2.2.1.4) and concentrations estimated. 
Ligation reactions were set up and incubated at 16°C for -  16 h as follows:
pPICOl/Dl Not VXba I 2.5 pi
MIOb Not VXbal 5 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dH20  10 pi
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pPIC01/D3 Not VXba I 2.5 pi
MIOb Not VXba I 5 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dHzO 10 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, 1.5 pi of ligation mixture was used to transform 50 pi TOP10F’ electro- 
competent cells as described in 2.2.1. 8 . Minipreps of individual colonies were screened by 
Xho VXba I digestion (see 2.2.1.5).
M 1 2---------------► 7 8----------------► 13
-1400 bp
Figure A1.10. Agarose gel (1%) showing Xho \1 Xba  I digestion screening o f pP IC H SA l/D lor D3-M10b. 
Six colonies o f TOP 10F’ cells transformed with pPIC H SA l/D l-M lO b (lanes 2-8) orpPICH SA l/D3-M 10b 
(lanes 8-13) were screened for positive inserts by Xho VX ba  I digestion and compared to similarly digested 
pPIC01/D3 (lane 1) and uncut pPIC01/D3 spiked with X Hind III marker (lane M).
Al.4.3 Digestion of ‘N-terminaP MIOb PCR product and pPICOl/Dl or D3-M10b
N-terminal Ml0b PCR product 50 pi
lOxBSA 10 pi
10 x buffer 2 10 pi
Sfi I (20 U/pl) 2.5 pi
cfflhO 27.5 pi
pPICOl/Dl-MlOb 15 pi (-10 pg)
lOxBSA 5 pi
10 x buffer 2 5 pi
Sfi I (20 U/pl) 2.5 pi
dH20  22.5 pi
pPIC01/D3 15 pi (-10 pg)
lOxBSA 5 pi
10 x buffer 2 5 pi
Sfi I (20 U/pl) 2.5 pi
dH20  22.5 pi
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Digestion reactions were incubated at 50°C overnight (-16 h), and the following digestion 
mix was added to each reaction:
lOxBSA 5 pi
10 x buffer 2 5 pi
Xho I (20 U/pl) 2.5 pi
dH20  37.5 pi
Reactions were incubated at 37°C for 2 h. Following electrophoresis on 1% agarose gels, 
the relevant bands were excised, purified (see 2.2.1.4) and concentrations estimated. 
Ligation reactions were set up and incubated at 16°C for -  16 h as follows:
pPICOl/Dl-MlOb ATio V Sfi I 2 pi
Ml Ob Xho V SJi I 2 pi
10 x ligase buffer 2 pi
T4 DNA ligase 1 pi
dH20  13 pi
pPIC01/D3-M10b^/io VSfi I 1 pi
M\0bXhoVSfi l  2 pi
10 x ligase buffer 2 pi
T4 DNA ligase 1 pi
dH20  14 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, 1.5 pi of ligation mixture was used to transform 50 pi TOPI OF’ electro- 
competent cells as described in 2.2.1.8. Minipreps of individual colonies were screened by 
Xho VXba I digestion (see 2.2.1.5).
M U 2 3  ► 8  9 -----------------------► 18 M2
| j E H 9 ~ 2 1 0 0  bp
-1400
Figure A l . l l .  Agarose gel (1%) showing Xho VXba  I digestion screening o f pPIC H SA l/M lO b-D lor D3- 
MlOb. Colonies o f TOP 10F’ cells transformed with pPICHSAl/M lOb-Dl-M lOb (lanes 3-8) or 
pPICHSAl/M 10b-D3-M 10b (lanes 9-18) were screened for positive inserts by Xho UXba  I digestion and 
compared to similarly digested pPICOl/Dl-M lOb (lane 2) and uncut pPICOl/Dl-M lOb (lane 1). Lane M l 
contains X Hind III marker and lane M2 contains <pxl 74 Hae III marker.
Al.4.4 Digestion of pPICHSAl/MlOb-Dl-MlOb for insertion of HSA and D2
pPICHSAl/MlOb-Dl-MlOb 15 pi (-10 pg)
10 x buffer 2 5 pi
lOxBSA 5 pi
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Sfi I (20 U/fj.1) 2.5 pi
dH20  22.5 pi
Incubate at 50°C for 2 h and add the following:
10 x buffer 3 15 pi
lOxBSA 10 pi
Notl (10 U/pl) 5 nl
dH20  70 pi
Reactions were incubated at 37°C for 2 h. Following electrophoresis on 1% agarose gels, 
the relevant bands were excised, purified (see 2.2.1.4) and concentrations estimated. 
Ligation reactions were set up and incubated at 16°C for ~ 16 h as follows:
pPICHSAl/MlOb-Dl-MlOb Sfi VNot I 2 pi
D2 Sfi V Not I 6 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dH20  9.5 pi
pPICHSAl/MlOb-Dl-MlOb Sfi \JNot I 2 pi
HSA Sfi V Not I 2 pi
10 x ligase buffer 2 pi
T4 DNA ligase 0.5 pi
dH20  13.5 pi
A ligation reaction was set up omitting insert to control for re-ligated vector. Following 
incubation, 1.5 pi of ligation mixture was used to transform 50 pi TOPI OF’ electro- 
competent cells as described in 2.2.1.8. Minipreps of individual colonies were screened by 
Xho V Not I digestion (see 2.2.1.5).
> 18 M2
Figure A1.12. Agarose gel (1%) showing Xho V Not I digestion screening o f  pPICHSAl/M 10b-D2 or HSA- 
MlOb. Colonies o f TOP 10F’ cells transformed with pPICHSAl/M 10b-D2-M 10b (lanes 3-10) or 
pPICHSAl/MlOb-HSA-MlOb (lanes 11-18) were screened for positive inserts by Xho V Not I digestion and 
compared to similarly digested pPICOl/M lOb-Dl-M lOb (lane 1) and uncut pPICOl/M lOb-Dl-M lOb (lane 2). 
Lane M l contains X Hind III marker and lane M2 contains 9 x 1 74 Hae III marker.
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Table A2.1. B iodistribution o f  125I-labelled H SA body, glycoH SA body and A 5B7 IgG in LS-174T xenograft-bearing mice
Tumour Blood Liver Kidney Lung Spleen Colon Muscle
Time A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco
(h) body HSA body HSA body HSA body HSA body HSA body HSA body HSA body HSA
body body body body body body body body
1 1 64.39 18.19 5.81 49.88 25.28 8.48 17.32 8.55 7.68 11.98 10.03 13.42 13.67 8.29 4.64 9.80 5.38 3.91 1.45 16.23 2.27 1.05 1.04 1.13
2 59.25 17.99 1.83 48.14 26.44 5.54 14.17 24.92 2.54 8.12 10.68 4.97 12.01 8.43 2.13 7.51 7.15 4.02 1.23 2.38 1.33 0.89 1.85 0.96
3 8.74 63.57 15.47 54.83 26.19 3.98 16.50 16.36 23.80 11.42 12.82 9.09 14.00 10.89 3.95 10.43 7.09 8.75 1.98 2.29 1.98 1.6 1.26 1.38
4 42.39 6.11 4.31 53.91 38.13 6.68 17.28 14.65 8.46 10.83 15.14 8.87 14.36 10.79 3.47 12.11 7.76 3.56 2.21 3.05 2.24 1.39 1.56 0.91
5 4 28.39 26.02 13.10 29.42 16.40 6.01 25.44 9.25 5.40 11.22 6.59 5.59 9.71 5.31 3.63 8.48 5.27 3.34 2.76 1.95 2.34 1.27 1.07 0.99
6 16.10 9.03 7.73 40.33 4.88 6.73 25.35 11.04 8.24 9.26 4.48 6.45 14.11 3.30 4.75 10.47 4.85 6.28 3.76 2.25 3.45 1.53 0.99 1.37
7 55.66 8.42 10.85 35.43 15.12 6.47 25.33 13.77 6.19 11.65 6.80 6.46 17.50 6.31 4.35 9.55 6.19 4.13 2.78 2.85 3.06 1.59 1.07 1.37
8 28.31 6.82 20.10 46.00 7.23 8.91 15.33 8.59 6.79 13.66 1.91 9.23 30.36 5.05 6.22 11.66 3.89 4.55 4.67 1.64 2.93 1.33 1.04 1.63
9 24 49.93 38.80 4.02 12.33 3.02 0.11 5.25 1.58 1.14 3.39 1.78 1.58 4.97 1.41 0.09 2.21 0.95 0.33 1.39 0.44 0.04 0.91 0.31 0.03
10 33.88 28.81 7.01 14.74 4.96 0.31 4.66 2.19 1.19 4.53 3.19 1.90 9.37 2.37 0.16 3.01 2.83 1.22 1.50 1.04 0.14 0.62 0.42 0.06
11 39.28 8.97 1.72 21.36 0.47 0.09 6.40 0.89 0.38 5.14 1.12 0.76 10.66 0.28 0.07 4.06 0.63 0.22 2.03 0.11 0.03 1.24 0.09 0.02
12 44.78 21.46 1.41 17.42 5.76 0.10 9.17 1.60 0.25 5.79 2.24 2.38 7.40 1.74 0.08 3.80 1.45 0.17 2.17 0.49 0.08 2.22 0.25 0.01
13 48 18.94 0.49 0.17 3.16 0.22 0.03 2.29 0.29 0.66 1.11 0.49 0.72 1.22 0.09 0.05 0.83 0.17 0.27 0.34 0.03 0.03 0.28 0.02 0.01
14 35.85 0.50 6.46 19.45 0.08 0.06 7.23 0.42 0.71 6.11 0.51 0.85 9.65 0.07 0.04 2.89 0.32 0.42 2.33 0.02 0.03 1.69 0.02 0.01
15 45.02 0.21 10.20 4.52 0.08 0.05 2.58 0.14 0.59 1.17 0.21 0.95 1.91 0.03 0.06 0.75 0.21 0.40 0.43 0.01 0.03 0.47 0.01 0.01
16 50.03 6.01 0.17 8.84 0.13 0.03 6.96 0.33 0.48 2.83 0.55 0.62 3.01 0.06 0.04 1.95 0.26 0.21 1.39 0.03 0.02 0.80 0.02 0.01
Biodistribution results are represented as percent injected dose per gram tissue (%ID/g)
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T able A 2.2. C om parative Tissue: Blood ratios o f  12SI-labelled H SA body, glycoH SAbody and A 5B7 IgG in LS-174T xenograft-bearing mice
Tumour Liver Kidney Lung Spleen Colon Muscle
Host Time A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco
(h) body HSA body HSA body HSA body HSA body HSA body HSA body HSA
body body body body body body body
1 1 1.29 0.71 0.68 0.34 0.33 0.90 0.24 0.39 1.58 0.27 0.32 0.54 0.19 0.21 0.46 0.02 0.64 0.26 0.02 0.04 0.13
2 1.23 0.68 0.33 0.29 0.94 0.45 0.16 0.40 0.89 0.24 0.31 0.38 0.15 0.27 0.72 0.02 0.09 0.24 0.01 0.07 0.17
3 0.15 2.42 3.88 0.30 0.62 5.97 0.20 0.48 2.28 0.25 0.41 0.99 0.19 0.27 2.20 0.03 0.08 0.49 0.03 0.04 0.34
4 0.78 0.16 0.64 0.32 0.38 1.26 0.20 0.39 1.32 0.26 0.28 0.52 0.22 0.20 0.53 0.04 0.07 0.33 0.02 0.04 0.13
5 4 0.96 1.58 2.17 0.86 0.56 0.89 0.38 0.40 0.93 0.33 0.32 0.60 0.28 0.32 0.55 0.09 0.11 0.38 0.04 0.06 0.16
6 0.39 1.84 1.14 0.62 2.26 1.22 0.22 0.91 0.95 0.34 0.67 0.70 0.25 0.99 0.93 0.09 0.46 0.51 0.03 0.20 0.20
7 1.57 0.55 1.67 0.71 0.91 0.95 0.32 0.44 0.99 0.49 0.41 0.67 0.26 0.40 0.63 0.07 0.18 0.47 0.04 0.07 0.21
8 0.61 0.94 2.25 0.33 1.18 0.76 0.29 0.26 1.03 0.66 0.69 0.69 0.25 0.53 0.51 0.10 0.22 0.32 0.02 0.14 0.18
9 24 4.04 12.82 34.76 0.42 0.52 9.89 0.27 0.59 13.65 0.40 0.46 0.80 0.17 0.31 2.93 0.11 0.14 0.40 0.07 0.10 0.26
10 2.29 5.80 22.36 0.31 0.44 3.80 0.30 0.64 6.06 0.63 0.47 0.53 0.20 0.57 3.90 0.10 0.21 0.45 0.04 0.08 0.21
11 1.83 18.91 17.99 0.29 1.89 4.02 0.24 2.36 7.95 0.49 0.60 0.75 0.19 1.34 2.38 0.09 0.23 0.36 0.05 0.19 0.24
12 2.56 3.72 13.02 0.52 0.27 2.31 0.33 0.38 21.94 0.42 0.30 0.80 0.21 0.25 1.61 0.12 0.08 0.77 0.12 0.04 0.18
13 48 5.99 2.20 5.28 0.72 1.30 20.19 0.35 2.20 21.79 0.38 0.44 1.58 0.26 0.78 8.38 0.10 0.17 0.97 0.08 0.12 0.36
14 1.84 6.25 94.00 0.37 5.21 10.33 0.31 6.36 12.49 0.49 0.87 0.67 0.14 4.05 6.14 0.11 0.34 0.46 0.08 0.26 0.21
15 9.93 2.44 201.7 0.57 1.57 11.85 0.25 2.42 18.94 0.42 0.42 1.24 0.16 2.36 7.99 0.09 0.20 0.65 0.10 0.13 0.37
16 1.29 0.71 5.54 0.30 0.62 15.00 0.20 0.48 19.49 0.25 0.41 1.47 0.19 0.27 6.69 0.03 0.08 0.68 0.03 0.04 0.49
Biodistribution results are represented as tissue: blood ratios
249
Table A 2.3. C om parative Tum our: T issue ratios o f  125I-labelled H SA body, glycoH SAbody, and A 5B7 IgG in LS-174T xenograft-bearing mice
Blood Liver Kidney Lung Spleen Colon Muscle
Host Time A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco A5B7 HSA Glyco
(h) body HSA body HSA body HSA body HSA body HSA body HSA body HSA
body body body body body body body
1 1 1.29 0.71 0.68 3.71 2.12 0.75 5.37 1.81 0.43 4.70 2.19 1.25 6.56 3.38 1.48 44.24 1.12 2.55 61.17 17.36 5.14
2 1.23 0.68 0.33 4.18 0.72 0.71 7.29 1.68 0.36 4.93 2.13 0.85 7.88 2.51 0.45 48.09 7.54 1.37 66.40 9.71 1.90
3 0.15 2.42 3.88 0.53 3.88 0.65 0.76 4.95 1.70 0.62 5.83 3.91 0.83 8.95 1.76 4.40 27.76 7.77 5.26 50.31 11.16
4 0.78 0.16 0.64 2.45 0.41 0.50 3.91 0.40 0.48 2.95 0.56 1.24 3.49 0.78 1.21 19.12 2.00 1.92 30.38 3.90 4.70
5 4 0.96 1.58 2.17 1.11 2.81 2.42 2.53 3.94 2.34 2.92 4.89 3.60 3.34 4.92 3.91 10.28 13.34 5.59 22.26 24.29 13.20
6 0.39 1.84 1.14 0.63 0.81 0.93 1.73 2.01 1.19 1.14 2.73 1.62 1.53 1.86 1.22 4.28 4.01 2.24 10.50 9.11 5.60
7 1.57 0.55 1.67 2.19 0.61 1.75 4.77 1.23 1.67 3.17 1.33 2.49 5.82 1.35 2.62 19.99 2.95 3.53 35.00 7.81 7.90
8 0.61 0.94 2.25 1.84 0.79 2.95 2.07 3.56 2.17 0.93 1.35 3.22 2.42 1.75 4.41 6.05 4.15 6.84 21.22 6.54 12.28
9 24 4.04 12.82 34.76 9.50 24.41 3.51 14.70 21.72 2.54 10.03 27.41 43.04 22.58 40.76 11.84 35.69 87.01 85.64 54.42 124.5 132.8
10 2.29 5.80 22.36 7.25 13.10 5.86 7.47 9.02 3.68 3.61 12.13 42.05 11.22 10.15 5.71 22.56 27.64 49.14 53.90 67.98 105.6
11 1.83 18.91 17.99 6.13 9.99 4.46 7.63 7.97 2.26 3.68 31.30 23.94 9.65 14.08 7.53 19.34 79.67 49.31 31.59 95.16 74.03
12 2.56 3.72 13.02 4.88 13.37 5.63 7.73 9.56 0.59 6.04 12.31 16.10 11.77 14.73 8.07 20.56 43.53 16.77 20.15 85.64 71.11
13 48 5.99 2.20 5.28 8.25 1.68 0.26 16.98 1.00 0.24 15.50 4.93 3.32 22.71 2.83 0.63 54.74 12.64 5.42 66.90 18.23 14.36
14 1.84 6.25 94.00 4.95 1.19 9.09 5.86 0.98 7.52 3.71 7.13 140.2 12.38 1.54 15.30 15.38 18.25 203.0 21.12 24.05 427.8
15 9.93 2.44 201.7 17.38 1.55 17.01 38.30 1.00 10.64 23.55 5.78 161.5 59.28 1.03 25.22 103.4 12.22 308.0 93.95 18.02 537.2
16 5.65 44.85 5.54 7.18 17.87 0.36 17.63 10.86 0.28 16.59 87.86 3.76 25.55 22.87 0.82 35.77 198.0 8.07 62.19 255.4 11.28
Biodistribution results are represented as tumour: tissue ratios
250
Appendix 3
References
251
Abraham, R., Buxbaum, S., Link, J., Smith, R., Venti, C., and Darsley, M. (1995) Screening and kinetic 
analysis o f recombinant anti-CEA antibody fragments. J  Immunol Methods (183), 119-125.
Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., Ill, Bookman, M. 
A., Fand, I., Houston, L. L., and Weiner, L. M. (1993) Highly specific in vivo tumor targeting by 
monovalent and divalent forms of741F8 anti-c-erbB-2 single-chain Fv. Cancer Res (53), 4026-4034.
Adams, G. P., McCartney, J. E., Wolf, E. J., Eisenberg, J., Huston, J. S., Bookman, M. A., Moldofsky, P.,
Stafford, W. F., Ill, Houston, L. L., and Weiner, L. M. (1995) Enhanced tumor specificity of 741F8- 
1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. JNucl 
Med (36), 2276-2281.
Adams, G. P., McCartney, J. E., Wolf, E. J., Eisenberg, J., Tai, M. S., Huston, J. S., Stafford, W. F., Ill,
Bookman, M. A., Houston, L. L., and Weiner, L. M. (1995) Optimization o f in vivo tumor targeting 
in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects o f dose escalation 
and repeated i.v. administration. Cancer Immunol Immunother (40), 299-306.
Adams, G. P. (1998) Improving the tumor specificity and retention o f antibody-based molecules. In Vivo (12), 
11- 21 .
Adams, G. P., Schier, R., McCall, A. M., Crawford, R. S., Wolf, E. J., Weiner, L. M., and Marks, J. D. (1998) 
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain o f human 
HER2/neu. Br J  Cancer (77), 1405-1412.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., and Weiner, L. M. (1998) 
Increased affinity leads to improved selective tumor delivery o f single-chain Fv antibodies. Cancer 
Res (58), 485-490.
Adams, G. P., Shaller, C. C., Chappell, L. L., Wu, C., Horak, E. M., Simmons, H. H., Litwin, S., Marks, J. D., 
Weiner, L. M., and Brechbiel, M. W. (2000) Delivery o f the alpha-emitting radioisotope bismuth- 
213 to solid tumors via single-chain Fv and diabody molecules. Nucl M ed Biol (27), 339-346.
Afanasieva, T. A., Wittmer, M., Vitaliti, A., Ajmo, M., Neri, D., and Klemenz, R. (2003) Single-chain 
antibody and its derivatives directed against vascular endothelial growth factor: application for 
antiangiogenic gene therapy. Gene Ther (10), 1850-1859.
Ahnen, D. J., Nakane, P. K., and Brown, W. R. (1982) Ultrastructural localization o f carcinoembryonic
antigen in normal intestine and colon cancer: abnormal distribution o f CEA on the surfaces o f colon 
cancer cells. Cancer (49), 2077-2090.
252
Albers, G. H., Fleuren, G., Escribano, M. J., and Nap, M. (1988) Immunohistochemistry o f CEA in the human 
pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. Am 
J  Clin Pathol (90), 17-22.
Allen, T. M. (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2), 750-763.
Alt, M., Muller, R., and Kontermann, R. E. (1999) Novel tetravalent and bispecific IgG-like antibody
molecules combining single-chain diabodies with the immunoglobulin gamma 1 Fc or CH3 region. 
FEBS Lett (454), 90-94.
Amit, A. G., Mariuzza, R. A., Phillips, S. E., and Poljak, R. J. (1986) Three-dimensional structure of an 
antigen-antibody complex at 2.8 A resolution. Science (233), 747-753.
Andersson, C. E., Lonnroth, I. C., Gelin, L. J., Moldawer, L. L., and Lundholm, K. G. (1991) Pretranslational 
regulation o f albumin synthesis in tumor-bearing mice. The role o f anorexia and undemutrition. 
Gastroenterology (100), 938-945.
Arai, K., Madison, J., Shimizu, A., and Putnam, F. W. (1990) Point substitutions in albumin genetic variants 
from Asia. Proc Natl Acad Sci U SA  (87), 497-501.
Arakawa, F., Kuroki, M., Misumi, Y., Oikawa, S., Nakazato, H., and Matsuoka, Y. (1990) Characterization of  
a cDNA clone encoding a new species of the nonspecific cross-reacting antigen (NCA), a member of 
the CEA gene family. Biochem Biophys Res Commun (166), 1063-1071.
Arano, Y. (1998) Strategies to reduce renal radioactivity levels o f antibody fragments. Q JN ucl Med (42), 
262-270.
Arano, Y., Wakisaka, K., Akizawa, H., Ono, M., Kawai, K., Nakayama, M., Sakahara, H., Konishi, J., and 
Saji, H. (1998) Assessment o f the radiochemical design o f antibodies with a metabolizable linkage 
for target-selective radioactivity delivery. Bioconjug Chem (9), 497-506.
Athanassiadou, P., Athanassiades, P., Lazaris, D., Kyrkou, K., Petrakakou, E., and Aravantinos, D. (1994)
Immunocytochemical differentiation o f reactive mesothelial cells and adenocarcinoma cells in serous 
effusions with the use of carcinoembryonic antigen and fibronectin. Acta Cytol (38), 718-722.
Atwell, J. L., Pearce, L. A., Lah, M., Gruen, L. C., Kortt, A. A., and Hudson, P. J. (1996) Design and 
expression o f a stable bispecific scFv dimer with affinity for both glycophorin and N9 
neuraminidase. Mol Immunol (33), 1301-1312.
Atwell, J. L., Breheney, K. A., Lawrence, L. J., McCoy, A. J., Kortt, A. A., and Hudson, P. J. (1999) scFv 
multimers o f the anti-neuraminidase antibody NC10: length o f the linker between VH and VL 
domains dictates precisely the transition between diabodies and triabodies. Protein Eng (12), 597- 
604.
253
Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F.,
Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure o f human carcinoma xenografts by 
a single dose o f pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U SA  (97), 
1802-1807.
Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F.
(1988) A cytotoxic agent can be generated selectively at cancer sites. B rJ  Cancer (58), 700-703.
Baker, P. J., Hraba, T., Taylor, C. E., Stashak, P. W., Fauntleroy, M. B., Zahringer, U., Takayama, K.,
Sievert, T. R., Hronowski, X., Cotter, R. J., and . (1994) Molecular structures that influence the 
immunomodulatory properties o f the lipid A and inner core region oligosaccharides of bacterial 
lipopolysaccharides. Infect Immun (62), 2257-2269.
Baluna, R. and Vitetta, E. S. (1997) Vascular leak syndrome: a side effect o f immunotherapy. 
Immunopharmacology (37), 117-132.
Banfleld, M. J., King, D. J., Mountain, A., and Brady, R. L. (1997) VL:VH domain rotations in engineered 
antibodies: crystal structures o f the Fab fragments from two murine antitumor antibodies and their 
engineered human constructs. Proteins (29), 161-171.
Banks, E. R. and Cooper, P. H. (1991) Adenosquamous carcinoma o f the skin: a report o f 10 cases. JCutan 
Pathol (18), 227-234.
Barbet, J., Kraeber-Bodere, F., Vuillez, J. P., Gautherot, E., Rouvier, E., and Chatal, J. F. (1999) Pretargeting 
with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm (14), 
153-166.
Bardies, M., Bardet, S., Faivre-Chauvet, A., Peltier, P., Douillard, J. Y., Mahe, M., Fiche, M., Lisbona, A., 
Giacalone, F., Meyer, P., Gautherot, E., Rouvier, E., Barbet, J., and Chatal, J. F. (1996) Bispecific 
antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or 
small-cell lung cancer. JN uclM ed  (37), 1853-1859.
Barnett, T., Goebel, S. J., Nothdurft, M. A., and Elting, J. J. (1988) Carcinoembryonic antigen family: 
characterization of cDNAs coding for NCA and CEA and suggestion o f nonrandom sequence 
variation in their conserved loop-domains. Genomics (3), 59-66.
Barnett, T. R., Kretschmer, A., Austen, D. A., Goebel, S. J., Hart, J. T., Elting, J. J., and Kamarck, M. E.
(1989) Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code 
for novel members o f the carcinoembryonic antigen family. J  Cell Biol (108), 267-276.
Barnett, T. R., Drake, L., and Pickle, W. (1993) Human biliary glycoprotein gene: characterization o f a family 
of novel alternatively spliced RNAs and their expressed proteins. Mol Cell Biol (13), 1273-1282.
254
Barr, K.A., Hopkins, S. A., and Sreekrishna, K. (1992) Protocol for efficient secretion o f HSA developed from 
Pichia pastoris. Pharm Eng (12), 48-51.
Baselga, J. (2001) Phase I and II clinical trials o f trastuzumab. Ann Oncol (12 Suppl 1), S49-S55.
Baselga, J. and Albanell, J. (2001) Mechanism of action o f anti-HER2 monoclonal antibodies. Ann Oncol (12 
Suppl 1), S35-S41.
Bates, P. A., Luo, J., and Sternberg, M. J. (1992) A predicted three-dimensional structure for the 
carcinoembryonic antigen (CEA). FEBS Lett (301), 207-214.
Batra, S. K., Jain, M., Wittel, U. A., Chauhan, S. C., and Colcher, D. (2002) Pharmacokinetics and 
biodistribution o f genetically engineered antibodies. Curr Opin Biotechnol (13), 603-608.
Baxter, L. T. and Jain, R. K. (1988) Vascular permeability and interstitial diffusion in superfused tissues: a 
two-dimensional model. Microvasc Res (36), 108-115.
Bayly, A.M., Kortt, A.A., Hudson, P.J., Power, B.E. (2002) Large-scale bacterial fermentation and isolation 
of scFv multimers using a heat-inducible bacterial expression vector. J  Immunol Meth (262), 217- 
227.
Beauchemin, N., Benchimol, S., Coumoyer, D., Fuks, A., and Stanners, C. P. (1987) Isolation and
characterization of full-length functional cDNA clones for human carcinoembryonic antigen. Mol 
Cell Biol (7), 3221-3230.
Begent, R. H., Keep, P. A., Green, A. J., Searle, F., Bagshawe, K. D., Jewkes, R. F., Jones, B. E., Barratt, G. 
M., and Ryman, B. E. (1982) Liposomally entrapped second antibody improves tumour imaging 
with radiolabelled (first) antitumour antibody. Lancet (2), 739-742.
Begent, R. H., Bagshawe, K. D., Pedley, R. B., Searle, F., Ledermann, J. A., Green, A. J., Keep, P. A., 
Chester, K. A., Glaser, M. G., and Dale, R. G. (1987) Use o f second antibody in 
radioimmunotherapy. NCI Monogr, 59-61.
Begent, R. H., Ledermann, J. A., Green, A. J., Bagshawe, K. D., Riggs, S. J., Searle, F., Keep, P. A., Adam, 
T., Dale, R. G., and Glaser, M. G. (1989) Antibody distribution and dosimetry in patients receiving 
radiolabelled antibody therapy for colorectal cancer. B rJ  Cancer (60), 406-412.
Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., 
Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. (1996) 
Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a 
combinatorial library. Nat Med (2), 979-984.
255
Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., 
Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. (1996) 
Clinical evidence o f efficient tumor targeting based on single-chain Fv antibody selected from a 
combinatorial library. Nat Med (2), 979-984.
Behr, T. M., Sharkey, R. M., Sgouros, G., Blumenthal, R. D., Dunn, R. M., Kolbert, K., Griffiths, G. L., 
Siegel, J. A., Becker, W. S., and Goldenberg, D. M. (1997) Overcoming the nephrotoxicity of  
radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse 
model in relation to the internal radiation dosimetry. Cancer (80), 2591-2610.
Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Ying, Z., Zhang, C. H., Swayne, L. C., 
Vardi, Y., Siegel, J. A., and Goldenberg, D. M. (1997) Phase I/II clinical radioimmunotherapy with 
an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. JNucl Med 
(38), 858-870.
Behr, T. M., Memtsoudis, S., Vougioukas, V., Liersch, T., Gratz, S., Schmidt, F., Lorf, T., Post, S.,
Wormann, B., Hiddemann, W., Ringe, B., and Becker, W. (1999) Radioimmunotherapy of colorectal 
cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to 
equitoxic chemotherapy and initial results o f an ongoing phase-I/II clinical trial. Anticancer Res (19), 
2427-2432.
Behr, T. M., Blumenthal, R. D., Memtsoudis, S., Sharkey, R. M., Gratz, S., Becker, W., and Goldenberg, D. 
M. (2000) Cure o f metastatic human colonic cancer in mice with radiolabeled monoclonal antibody 
fragments. Clin Cancer Res (6), 4900-4907.
Benchimol, S., Fuks, A., Jothy, S., Beauchemin, N., Shirota, K., and Stanners, C. P. (1989) Carcinoembryonic 
antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell (57), 327-334.
Behr, T., Becker, W., Hannappel, E., Goldenberg, D. M., and Wolf, F. (1995) Targeting o f liver metastases of 
colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 
99mTc: the role o f metabolism and kinetics. Cancer Res (55), 5777s-5785s.
Benjamin, D. C., Berzofsky, J. A., East, I. J., Gurd, F. R., Hannum, C., Leach, S. J., Margoliash, E., Michael, 
J. G., Miller, A., Prager, E. M., and . (1984) The antigenic structure o f proteins: a reappraisal. Annu 
Rev Immunol (2), 67-101.
Berek, C. and Milstein, C. (1987) Mutation drift and repertoire shift in the maturation of the immune 
response. Immunol Rev (96), 23-41.
Beresford, G. W., Pavlinkova, G., Booth, B. J., Batra, S. K., and Colcher, D. (1999) Binding characteristics 
and tumor targeting o f a covalently linked divalent CC49 single-chain antibody. In tJ  Cancer (81), 
911-917.
256
Berling, B., Kolbinger, F., Grunert, F., Thompson, J. A., Brombacher, F., Buchegger, F., von Kleist, S., and 
Zimmermann, W. (1990) Cloning of a carcinoembryonic antigen gene family member expressed in 
leukocytes o f chronic myeloid leukemia patients and bone marrow. Cancer Res (50), 6534-6539.
Bertino, J. R. (1993) Kamofsky memorial lecture. Ode to methotrexate. J  Clin Oncol (11), 5-14.
Berzofsky, J. A. (1985) Intrinsic and extrinsic factors in protein antigenic structure. Science (229), 932-940.
Bessette, P. H., Qiu, J., Bardwell, J. C., Swartz, J. R., and Georgiou, G. (2001) Effect o f sequences of the
active-site dipeptides o f DsbA and DsbC on in vivo folding o f multidisulfide proteins in Escherichia 
coli. JBacteriol (183), 980-988.
Better, M., Chang, C. P., Robinson, R. R., and Horwitz, A. H. (1988) Escherichia coli secretion o f an active 
chimeric antibody fragment. Science (240), 1041-1043.
Bhat, T. N., Bentley, G. A., Boulot, G., Greene, M. I., Tello, D., Dall'Acqua, W., Souchon, H., Schwarz, F. P., 
Mariuzza, R. A., and Poljak, R. J. (1994) Bound water molecules and conformational stabilization 
help mediate an antigen-antibody association. Proc Natl Acad Sci U S A  (91), 1089-1093.
Bhatia, J., Sharma, S. K., Chester, K. A., Pedley, R. B., Boden, R. W., Read, D. A., Boxer, G. M., Michael, N. 
P., and Begent, R. H. (2000) Catalytic activity o f an in vivo tumor targeted anti-CEA 
scFv::carboxypeptidase G2 fusion protein. In tJ  Cancer (85), 571-577.
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., 
Riordan, G. S., and Whitlow, M. (1988) Single-chain antigen-binding proteins. Science (242), 423- 
426.
Bjemer, J., Lebedin, Y., Bellanger, L., Kuroki, M., Shively, J. E., Varaas, T., Nustad, K., Hammarstrom, S., 
and Bormer, O. P. (2002) Protein epitopes in carcinoembryonic antigen. Report o f the ISOBM TD8 
workshop. Tumour Biol (23), 249-262.
Boado, R. J., Ji, A., and Pardridge, W. M. (2000) Cloning and expression in Pichia pastoris o f a genetically 
engineered single chain antibody against the rat transferrin receptor. J  Drug Target (8), 403-412.
Boder, E. T. and Wittrup, K. D. (1997) Yeast surface display for screening combinatorial polypeptide 
libraries. Nat Biotechnol (15), 553-557.
Boehm, M. K., Mayans, M. O., Thornton, J. D., Begent, R. H., Keep, P. A., and Perkins, S. J. (1996)
Extended glycoprotein structure of the seven domains in human carcinoembryonic antigen by X-ray 
and neutron solution scattering and an automated curve fitting procedure: implications for cellular 
adhesion. J  Mol Biol (259), 718-736.
257
Boehm, M. K. and Perkins, S. J. (2000) Structural models for carcinoembryonic antigen and its complex with 
the single-chain Fv antibody molecule MFE23. FEBS Lett (475), 11-16.
Boehm, M. K., Corper, A. L., Wan, T., Sohi, M. K., Sutton, B. J., Thornton, J. D., Keep, P. A., Chester, K.
A., Begent, R. H., and Perkins, S. J. (2000) Crystal structure o f the anti-(carcinoembryonic antigen) 
single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. 
Biochem J  (346 Pt 2), 519-528.
Bordes, M., Michiels, R., and Martin, F. (1973) Detection by immunofluorescence o f carcinoembryonic 
antigen in colonic carcinoma, other malignant or benign tumours, and non-cancerous tissues. 
Digestion (9), 106-115.
Bos, E. S., Kuijpers, W. H., Meesters-Winters, M., Pham, D. T., de Haan, A. S., van Doommalen, A. M.,
Kaspersen, F. M., van Boeckel, C. A., and Gougeon-Bertrand, F. (1994) In vitro evaluation o f DNA- 
DNA hybridization as a two-step approach in radioimmunotherapy o f cancer. Cancer Res (54), 
3479-3486.
Bothmann, H. and Pluckthun, A. (2000) The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase 
FkpA. I. Increased functional expression o f antibody fragments with and without cis-prolines. J  Biol 
Chem (275), 17100-17105.
Boucher, D., Coumoyer, D., Stanners, C. P., and Fuks, A. (1989) Studies on the control o f gene expression of  
the carcinoembryonic antigen family in human tissue. Cancer Res (49), 847-852.
Braden, B. C., Goldman, E. R., Mariuzza, R. A., and Poljak, R. J. (1998) Anatomy o f an antibody molecule: 
structure, kinetics, thermodynamics and mutational studies o f the antilysozyme antibody D 1.3. 
Immunol Rev (163), 45-57.
Braisted, A. C. and Wells, J. A. (1996) Minimizing a binding domain from protein A. Proc Natl Acad Sci U S  
A (93), 5688-5692.
Brankamp, R. G., Sreekrishna, K., Smith, P. L., Blankenship, D. T., and Cardin, A. D. (1995) Expression o f a 
synthetic gene encoding the anticoagulant-antimetastatic protein ghilanten by the methylotropic 
yeast Pichia pastoris. Protein Expr Purif (6), 813-820.
Breitz, H. B., Fisher, D. R., Goris, M. L., Knox, S., Ratliff, B., Murtha, A. D., and Weiden, P. L. (1999)
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. 
Cancer Biother Radiopharm (14), 381-395.
Breitz, H. B., Weiden, P. L., Beaumier, P. L., Axworthy, D. B., Seiler, C., Su, F. M., Graves, S., Bryan, K., 
and Reno, J. M. (2000) Clinical optimization of pretargeted radioimmunotherapy with antibody- 
streptavidin conjugate and 90Y-DOTA-biotin. JNucl Med (41), 131-140.
258
Brekken, R. A., Huang, X., King, S. W., and Thorpe, P. E. (1998) Vascular endothelial growth factor as a 
marker o f tumor endothelium. Cancer Res (58), 1952-1959.
Brennan, S. O., Myles, T., Peach, R. J., Donaldson, D., and George, P. M. (1990) Albumin Redhill (-1 Arg, 
320 Ala— Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant 
signal peptidase cleavage site. Proc Natl Acad Sci U SA  (87), 26-30.
Bretthauer, R. K. and Castellino, F. J. (1999) Glycosylation of Pichia pastoris-derived proteins. Biotechnol 
Appl Biochem (30 ( Pt 3)), 193-200.
Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B., and Pastan, I. (1993) A recombinant immunotoxin containing 
a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U SA  (90), 7538-7542.
Britton, K. E. (1990) The development of new radiopharmaceuticals. EurJNucl Med (16), 373-385.
Brown, J. R. (1976) Structural origins o f mammalian albumin. Fed Proc (35), 2141-2144.
Buchegger, F., Pelegrin, A., Delaloye, B., Bischof-Delaloye, A., and Mach, J. P. (1990) Iodine-131-labeled 
MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in 
radioimmunotherapy o f large human colon carcinoma grafted in nude mice. JNucl M ed  (31), 1035- 
1044.
Buchegger, F., Mach, J. P., Folli, S., Delaloye, B., Bischof-Delaloye, A., and Pelegrin, A. (1996) Higher
efficiency o f 1311-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab')2 as compared 
to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude 
mice. Recent Results Cancer Res (141), 19-35.
Buchegger, F., Roth, A., Allal, A., Dupertuis, Y. M., Slosman, D. O., Delaloye, A. B., and Mach, J. P. (2000) 
Radioimmunotherapy o f colorectal cancer liver metastases: combination with radiotherapy. Ann N Y 
Acad Sci (910), 263-269.
Burger, A. M., Hartung, G., Stehle, G., Sinn, H., and Fiebig, H. H. (2001) Pre-clinical evaluation o f a
methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. In tJ  Cancer (92), 
718-724.
Burtin, P., Buffe, D., and von Kleist, S. (1972) The carcinoembryonic antigens o f human tumours. Triangle
(11), 123-129.
Cabilly, S., Riggs, A. D., Pande, H., Shively, J. E., Holmes, W. E., Rey, M., Perry, L. J., Wetzel, R., and 
Heyneker, H. L. (1984) Generation o f antibody activity from immunoglobulin polypeptide chains 
produced in Escherichia coli. Proc Natl Acad Sci U SA  (81), 3273-3277.
259
Callewaert, N., Gey sens, S., Molemans, F., and Contreras, R. (2001) Ultrasensitive profiling and sequencing 
of N-linked oligosaccharides using standard DNA-sequencing equipment. Glycobiology (11), 275- 
281.
Carlson, J., Sakamoto, Y., Laurell, C. B., Madison, J., Watkins, S., and Putnam, F. W. (1992)
Alloalbuminemia in Sweden: structural study and phenotypic distribution o f nine albumin variants. 
Proc Natl Acad Sci U SA  (89), 8225-8229.
Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T., Juan, T., Talvenheimo, J., Montestruque, S., 
Sun, J., Elliott, G., Thomas, J., Ferbas, J., Kern, B., Briddell, R., Leonard, J. P., and Cesano, A. 
(2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization o f in vitro 
properties. Clin Cancer Res (9), 3982S-3990S.
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L.,
Rowland, A. M., Kotts, C. E., Carver, M. E., and . (1992) High level Escherichia coli expression and 
production o f a bivalent humanized antibody fragment. Biotechnology (N Y )  (10), 163-167.
Casasnovas, J. M., Larvie, M., and Stehle, T. (1999) Crystal structure o f two CD46 domains reveals an 
extended measles virus-binding surface. EM BO J(18), 2911-2922.
Casellas, R., Nussenzweig, A., Wuerffel, R., Pelanda, R., Reichlin, A., Suh, H., Qin, X. F., Besmer, E., 
Renter, A., Rajewsky, K., and Nussenzweig, M. C. (1998) Ku80 is required for immunoglobulin 
isotype switching. EMBO J  (17), 2404-2411.
Casey, J. L., Keep, P. A., Chester, K. A., Robson, L., Hawkins, R. E., and Begent, R. H. (1995) Purification 
of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate 
chromatography. J  Immunol Methods (179), 105-116.
Casey, J. L., King, D. J., Pedley, R. B., Boden, J. A., Boden, R., Chaplin, L. C., Doming, M., and Begent, R. 
H. (1998) Clearance o f yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 
12N4 DOTA macrocycle. B rJ  Cancer (78), 1307-1312.
Casey, J. L., Napier, M. P., King, D. J., Pedley, R. B., Chaplin, L. C., Weir, N., Skelton, L., Green, A. J., 
Hope-Stone, L. D., Yarranton, G. T., and Begent, R. H. (2002) Tumour targeting o f humanised 
cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study. B rJ  Cancer (86), 1401- 
1410.
Cereghino, G. P., Cereghino, J. L., Ilgen, C., and Cregg, J. M. (2002) Production o f recombinant proteins in 
fermenter cultures o f the yeast Pichia pastoris. Curr Opin Biotechnol (13), 329-332.
Cereghino, J. L. and Cregg, J. M. (2000) Heterologous protein expression in the methylotrophic yeast Pichia 
pastoris. FEMS Microbiol Rev (24), 45-66.
260
Chadd, H. E. and Chamow, S. M. (2001) Therapeutic antibody expression technology. Curr Opin Biotechnol
(12), 188-194.
Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Morris, V. L., and Groom, A. C. (2000) Clinical targets 
for anti-metastasis therapy. Adv Cancer Res (79), 91-121.
Chambers A. F., Groom A. C. and MacDonald, I. C. (2002) Dissemination and growth o f cancer cells in 
metastatic sites. Nature Reviews Cancer (2), 563-572.
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., and King, D. J. (1999) Therapeutic antibody 
fragments with prolonged in vivo half-lives. Nat Biotechnol (17), 780-783.
Chapman, A. P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv 
Drug Deliv Rev (54), 531-545.
Chen, T., Grunert, F., Medina-Marino, A., and Gotschlich, E. C. (1997) Several carcinoembryonic antigens 
(CD66) serve as receptors for gonococcal opacity proteins. J  Exp Med (185), 1557-1564.
Chester, K. A., Begent, R. H., Robson, L., Keep, P., Pedley, R  B., Boden, J. A., Boxer, G., Green, A., Winter,
G., Cochet, O., and . (1994) Phage libraries for generation o f clinically useful antibodies. Lancet 
(343), 455-456.
Chisaka, H., Morita, E., Tada, K., Yaegashi, N., Okamura, K., and Sugamura, K. (2003) Establishment of
multifunctional monoclonal antibody to the nonstructural protein, NS1, o f  human parvovirus B19. J  
Infect (47), 236-242.
Choo, A. B., Dunn, R. D., Broady, K. W., and Raison, R  L. (2002) Soluble expression o f a functional 
recombinant cytolytic immunotoxin in insect cells. Protein Expr Purif (24), 338-347.
Clackson, T., Hoogenboom, H. R , Griffiths, A. D., and Winter, G. (1991) Making antibody fragments using 
phage display libraries. Nature (352), 624-628.
Clackson, T. and Wells, J. A. (1995) A hot spot of binding energy in a hormone-receptor interface. Science 
(267), 383-386.
Clark, M. (2000) Antibody humanisation: a case o f the ‘Emperor’s new clothes’? Immunology Today (21), 
397-402.
Clauser, K. R , Baker, P., and Burlingame, A. L. (1999) Role of accurate mass measurement (+/-10 ppm) in 
protein identification strategies employing MS or MS/MS and database searching. Anal Chem (71), 
2871-2882.
261
Clorius, J. H., Sinn, H., Manke, H. G., Schrenk, H. H., Blatter, J., Werling, C., Friedrich, E. A., Voges, J.,
Bahner, M., Sturm, V., and . (1995) Serum albumin (SA) accumulation by bronchogenic tumours: a 
tracer technique may help with patient selection for SA-delivered chemotherapy. EurJNucl Med 
(22), 989-996.
Cloutier, S. M., Couty, S., Terskikh, A., Marguerat, L., Crivelli, V., Pugnieres, M., Mani, J. C., Leisinger, H. 
J., Mach, J. P., and Deperthes, D. (2000) Streptabody, a high avidity molecule made by 
tetramerization o f in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol 
Immunol (37), 1067-1077.
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, 
V., Shak, S., Lieberman, G., and Slamon, D. J. (1999) Multinational study o f the efficacy and safety 
of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic 
breast cancer that has progressed after chemotherapy for metastatic disease. J  Clin Oncol (17), 2639- 
2648.
Coiffier, B., Pfreundschuh, M., Stahel, R., Vose, J., and Zinzani, P. L. (2002) Aggressive lymphoma: 
improving treatment outcome with rituximab. Anticancer Drugs (13 Suppl 2), S43-S50.
Colcher, D., Bird, R., Roselli, M., Hardman, K. D., Johnson, S., Pope, S., Dodd, S. W., Pantoliano, M. W.,
Milenic, D. E., and Schlom, J. (1990) In vivo tumor targeting o f a recombinant single-chain antigen- 
binding protein. J  Natl Cancer Inst (82), 1191-1197.
Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J., Choudhury, A., and Batra, S. K. (1998)
Pharmacokinetics and biodistribution o f genetically-engineered antibodies. Q JNucl Med (42), 225- 
241.
Colman, P. M., Deisenhofer, J., and Huber, R. (1976) Structure o f the human antibody molecule Kol 
(immunoglobulin Gl): an electron density map at 5 A resolution. JM ol Biol (100), 257-278.
Cook, G. P. and Tomlinson, I. M. (1995) The human immunoglobulin VH repertoire. Immunol Today (16), 
237-242.
Cooke, S. P., Pedley, R. B., Boden, R., Begent, R. H., and Chester, K. A. (2002) In vivo tumor delivery o f a 
recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction o f factor: a fusion] 
protein. Bioconjug Chem (13), 7-15.
Cregg, J. M., Vedvick, T. S., and Raschke, W. C. (1993) Recent advances in the expression of foreign genes 
in Pichia pastoris. Biotechnology (N Y )  (11), 905-910.
Cregg, J. M., Cereghino, J. L., Shi, J., and Higgins, D. R. (2000) Recombinant protein expression in Pichia 
pastoris. Mol Biotechnol (16), 23-52.
262
Cumber, A. and Wawrzynczak, E. (1992) Enhanced stability o f an immunotoxin made with abrin A chain and 
a hindered disulphide cross-linker. Biochem Soc Trans (20), 312S-
Curti, B. D., Urba, W. J., Alvord, W. G., Janik, J. E., Smith, J. W., Madara, K., and Longo, D. L. (1993)
Interstitial pressure o f subcutaneous nodules in melanoma and lymphoma patients: changes during 
treatment. Cancer Res (53), 2204-2207.
Darcy, P. K., Kershaw, M. H., Trapani, J. A., and Smyth, M. J. (1998) Expression in cytotoxic T lymphocytes 
o f a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis o f 
colon carcinoma. EurJImmunol (28), 1663-1672.
Daugherty, P. S., Chen, G., Olsen, M. J., Iverson, B. L., and Georgiou, G. (1998) Antibody affinity 
maturation using bacterial surface display. Protein Eng (11), 825-832.
Davies, J. and Riechmann, L. (1994) 'Camelising' human antibody fragments: NMR studies on VH domains. 
FEBS Lett (339), 285-290.
Davies, J. and Riechmann, L. (1996) Affinity improvement o f single antibody VH domains: residues in all 
three hypervariable regions affect antigen binding. Immunotechnology (2), 169-179.
Dawson, P. M., Blair, S. D., Begent, R. H., Kelly, A. M., Boxer, G. M., and Theodorou, N. A. (1991) The 
value o f radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Dis 
Colon Rectum (34), 217-222.
de Graaf, M., Boven, E., Oosterhoff, D., van der Meulen-Muileman IH, Huls, G. A., Gerritsen, W. R., 
Haisma, H. J., and Pinedo, H. M. (2002) A fully human anti-Ep-CAM scFv-beta-glucuronidase 
fusion protein for selective chemotherapy with a glucuronide prodrug. Br J  Cancer (86), 811-818.
de Graaf, M., van der Meulen-Muileman IH, Pinedo, H. M., and Haisma, H. J. (2002) Expression o f scFvs 
and scFv fusion proteins in eukaryotic cells. Methods Mol Biol (178), 379-387.
Decanniere, K., Desmyter, A., Lauwereys, M., Ghahroudi, M. A., Muyldermans, S., and Wyns, L. (1999) A 
single-domain antibody fragment in complex with RNase A: non-canonical loop structures and 
nanomolar affinity using two CDR loops. Structure FoldDes (7), 361-370.
Delves, P.J. and Roitt I.M. (2000) The Immune System N  Eng J  Med (343), 37-49.
DeNardo, S. J., DeNardo, G. L., Kukis, D. L., Shen, S., Kroger, L. A., DeNardo, D. A., Goldstein, D. S., 
Mirick, G. R., Salako, Q., Mausner, L. F., Srivastava, S. C., and Meares, C. F. (1999) 67Cu-2IT- 
BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with 
lymphoma. JNucl Med (40), 302-310.
263
Denton, G., Brady, K., Lo, B. K., Murray, A., Graves, C. R., Hughes, O. D., Tendler, S. J., Laughton, C. A., 
and Price, M. R. (1999) Production and characterization o f an anti-(MUCl mucin) recombinant 
diabody. Cancer Immunol Immunother (48), 29-38.
Deonarain, M. P., Rowlinson-Busza, G., George, A. J., and Epenetos, A. A. (1997) Redesigned anti-human 
placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo 
tumour targeting. Protein Eng (10), 89-98.
Deonarain, M. P., and Epenetos, A. A. (1998) Design, characterisation and anti-tumour cytotoxicity o f a panel 
of recombinant, mammalian ribonuclease-based immunotoxins. Brit J  Cancer (77), 537-546.
Desmyter, A., Transue, T. R., Ghahroudi, M. A., Thi, M. H., Poortmans, F., Hamers, R., Muyldermans, S., 
and Wyns, L. (1996) Crystal structure o f a camel single-domain VH antibody fragment in complex 
with lysozyme. Nat Struct Biol (3), 803-811.
Desplancq, D., King, D. J., Lawson, A. D., and Mountain, A. (1994) Multimerization behaviour of single 
chain Fv variants for the tumour-binding antibody B72.3. Protein Eng (7), 1027-1033.
Digane, M.E., Tschopp, J., Grinna L., Lair, S.V., Craig, W.S., Velicelebi, G., Siegel, R., Davis, G.R., Thill, G. 
P. (1988) Secretion o f heterologous proteins from the methylotrophic yeast, Pichia pastoris. In: G. 
Pierce (Ed.) Development in Industrial Microbiology (29), Elsevier Science, 59-65.
Di Paolo, C., Willuda, J., Kubetzko, S., Lauffer, I., Tschudi, D., Waibel, R., Pluckthun, A., Stahel, R. A., and 
Zangemeister-Wittke, U. (2003) A recombinant immunotoxin derived from a humanized epithelial 
cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor 
activity. Clin Cancer Res (9), 2837-2848.
Dinndorf, P., Krailo, M., Liu-Mares, W., Frierdich, S., Sondel, P., and Reaman, G. (2001) Phase I trial o f anti- 
B4-blocked ricin in pediatric patients with leukemia and lymphoma. J  Immunother (24), 511-516.
Dockal, M., Carter, D. C., and Ruker, F. (1999) The three recombinant domains of human serum albumin. 
Structural characterization and ligand binding properties. J  Biol Chem (274), 29303-29310.
Dolezal, O., Pearce, L. A., Lawrence, L. J., McCoy, A. J., Hudson, P. J., and Kortt, A. A. (2000) ScFv 
multimers o f  the anti-neuraminidase antibody NC10: shortening o f the linker in single-chain Fv 
fragment assembled in V(L) to V(H) orientation drives the formation o f dimers, trimers, tetramers 
and higher molecular mass multimers. Protein Eng (13), 565-574.
Domenech, N., Alvarez, B., Bullido, R., Alonso, F., Ezquerra, A., and Dominguez, J. (2003) A new epitope 
on swine CD5 molecule detected by monoclonal antibody 5F12/9. Hybrid Hybridomics (22), 179- 
182.
264
Donda, A., Cesson, V., Mach, J. P., Corradin, G., Primus, F. J., and Robert, B. (2003) In vivo targeting of an 
anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition 
and regression o f  established syngeneic tumor grafts. Cancer Immun (3), 11-
Dosio, F., Arpicco, S., Brusa, P., Stella, B., and Cattel, L. (2001) Poly(ethylene glycol)-human serum 
albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J  Control 
Release (76), 107-117.
Dreyer, W. J. and Bennett, J. C. (1965) The molecular basis o f antibody formation: a paradox. Proc Natl Acad 
Sci U S A  (54), 864-869.
Dubel, S., Breitling, F., Kontermann, R., Schmidt, T., Skerra, A., and Little, M. (1995) Bifunctional and 
multimeric complexes o f streptavidin fused to single chain antibodies (scFv). J  Immunol Methods 
(178), 201-209.
East, L. and Isacke, C. M. (2002) The mannose receptor family. Biochim Biophys Acta (1572),364-386.
Edelman, G. M. and POULIK, M. D. (1961) Studies on structural units o f the gamma-globulins. J  Exp Med 
(113), 861-884.
Edelman, G. M. (1973) Antibody structure and molecular immunology. Science (180), 830-840.
Ehrlich, P. (1913) Himmehveit, The Collected papers o f Paul Ehrlich. Oxford. Pergamon Press.
Eidelman, F. J., Fuks, A., DeMarte, L., Taheri, M., and Stanners, C. P. (1993) Human carcinoembryonic
antigen, an intercellular adhesion molecule, blocks fusion and differentiation o f rat myoblasts. J  Cell 
B iol(123), 467-475.
Eisenberg, R. J., Long, D., Pereira, L., Hampar, B., Zweig, M., and Cohen, G. H. (1982) Effect o f monoclonal 
antibodies on limited proteolysis o f native glycoprotein gD of herpes simplex virus type 1. J  Virol 
(41), 478-488.
Eldin, P., Pauza, M. E., Hieda, Y., Lin, G., Murtaugh, M. P., Pentel, P. R., and Pennell, C. A. (1997) High- 
level secretion o f  two antibody single chain Fv fragments by Pichia pastoris. J  Immunol Methods 
(201), 67-75.
Ellis, S. B., Brust, P. F., Koutz, P. J., Waters, A. F., Harpold, M. M., and Gingeras, T. R. (1985) Isolation of  
alcohol oxidase and two other methanol regulatable genes from the yeast Pichia pastoris. Mol Cell 
Biol (5), 1111-1121.
Emmanouilides, C. (2003) Radioimmunotherapy for non-Hodgkin’s Lymphoma. Semin Oncol (4), 531-544.
265
Epenetos, A. A., Snook, D., Durbin, H., Johnson, P. M., and Taylor-Papadimitriou, J. (1986) Limitations of 
radiolabeled monoclonal antibodies for localization o f human neoplasms. Cancer Res (46), 3183- 
3191.
Essig, N. Z., Wood, J. F., Howard, A. J., Raag, R., and Whitlow, M. (1993) Crystallization o f single-chain Fv 
proteins. J  Mol Biol (234), 897-901.
Eto, J., Suzuki, Y., Ohkawa, H., and Yamaguchi, I. (2003) Anti-herbicide single-chain antibody expression 
confers herbicide tolerance in transgenic plants. FEBS Lett (550), 179-184.
Fantini, J., Rognoni, J. B., Culouscou, J. M., Pommier, G., Marvaldi, J., and Tirard, A. (1989) Induction of 
polarized apical expression and vectorial release o f carcinoembryonic antigen (CEA) during the 
process o f differentiation o f HT29-D4 cells. JC ell Physiol (141), 126-134.
Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell (61), 759-767.
Feller, G., D'Amico, S., Benotmane, A. M., Joly, F., Van Beeumen, J., and Gerday, C. (1998)
Characterization o f the C-terminal propeptide involved in bacterial wall spanning o f alpha-amylase 
from the psychrophile Alteromonas haloplanctis. JB iol Chem (273), 12109-12115.
Ferrajoli, A., O'Brien, S., and Keating, M. J. (2001) Alemtuzumab: a novel monoclonal antibody. Expert Opin 
Biol Ther (1), 1059-1065.
Fidler, I. J. and Kripke, M. L. (1977) Metastasis results from preexisting variant cells within a malignant 
tumor. Science (197), 893-895.
Fidler, I. J. (1978) Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res (38), 
2651-2660.
Fidler, I. J. and Hart, I. R. (1982) Biological diversity in metastatic neoplasms: origins and implications. 
Science (217), 998-1003.
Fidler, I. J. and Hart, I. R. (1982) Recent observations on the pathogenesis o f cancer metastasis. Prog Clin 
Biol Res {8 5 P tB ), 601-619.
Fidler, I. J. and Hart, I. R. (1982) The development o f biological diversity and metastatic potential in 
malignant neoplasms. Oncodev Biol Med (4), 161-176.
Fischer, R., Drossard, J., Emans, N., Commandeur, U., and Hell wig, S. (1999) Towards molecular farming in 
the future: pichia pastoris-based production o f single-chain antibody fragments. Biotechnol Appl 
Biochem (30 ( Pt 2)), 117-120.
266
FitzGerald, K., Holliger, P., and Winter, G. (1997) Improved tumour targeting by disulphide stabilized 
diabodies expressed in Pichia pastoris. Protein Eng (10), 1221-1225.
Fjeld, J. G., Michaelsen, T. E., and Nustad, K. (1992) The binding parameters of radiolabelled monoclonal F 
(ab')2 and Fab' fragments relative to immunoglobulin G in reactions with surface-bound antigens. 
Eur JN ucl M ed (19), 402-408.
Flynn, A. A., Boxer, G. M., Begent, R. H., and Pedley, R. B. (2001) Relationship between tumour 
morphology, antigen and antibody distribution measured by fusion o f digital phosphor and 
photographic images. Cancer Immunol Immunother (50), 77-81.
Flynn, A. A., Pedley, R. B., Green, A. J., Boxer, G. M., Boden, R., Bhatia, J., Morris, R., and Begent, R. H. 
(2002) Antibody and radionuclide characteristics and the enhancement o f the effectiveness o f  
radioimmunotherapy by selective dose delivery to radiosensitive areas o f tumour. IntJRadiat Biol 
(78), 407-415.
Folkman, J. and Ingber, D. (1992) Inhibition o f angiogenesis. Semin Cancer Biol (3), 89-96.
Folkman, J. (1992) The role o f angiogenesis in tumor growth. Semin Cancer Biol (3), 65-71.
Folkman, J. and Shing, Y. (1992) Angiogenesis. J  Biol Chem (267), 10931-10934.
Frankel, A. E., Powell, B. L., and Lilly, M. B. (2002) Diphtheria toxin conjugate therapy o f cancer. Cancer 
Chemother Biol Response M odif (20), 301-313.
Fraser, I. P., Koziel, H., and Ezekowitz, R. A. (1998) The serum mannose-binding protein and the
macrophage mannose receptor are pattern recognition molecules that link innate and adaptive 
immunity. Semin Immunol (10), 363-372.
Freyre, F. M., Vazquez, J. E., Ayala, M., Canaan-Haden, L., Bell, H., Rodriguez, I., Gonzalez, A., Cintado,
A., and Gavilondo, J. V. (2000) Very high expression of an anti-carcinoembryonic antigen single 
chain Fv antibody fragment in the yeast Pichia pastoris. J  Biotechnol (76), 157-163.
Frisch, C., Kolmar, H., Schmidt, A., Kleemann, G., Reinhardt, A., Pohl, E., Uson, I., Schneider, T. R., and
Fritz, H. J. (1996) Contribution o f the intramolecular disulfide bridge to the folding stability o f REIv, 
the variable domain o f a human immunoglobulin kappa light chain. Fold Des (1), 431-440.
Fritsche, R. and Mach, J. P. (1977) Isolation and characterization o f carcinoembryonic antigen (CEA) 
extracted from normal human colon mucosa. Immunochemistry (14), 119-127.
Fromant, M., Blanquet, S., and Plateau, P. (1995) Direct random mutagenesis o f gene-sized DNA fragments 
using polymerase chain reaction. Anal Biochem (224), 347-353.
267
Fujioka, Y., Arano, Y., Ono, M., Uehara, T., Ogawa, K., Namba, S., Saga, T., Nakamoto, Y., Mukai, T., 
Konishi, J., and Saji, H. (2001) Renal metabolism o f 3-iodohippurylN(epsilon)-maleoyl-L-lysine 
(HML)-conjugated Fab fragments. Bioconjug Chem (12), 178-185.
Galliano, M., Minchiotti, L., Porta, F., Rossi, A., Ferri, G., Madison, J., Watkins, S., and Putnam, F. W.
(1990) Mutations in genetic variants o f human serum albumin found in Italy. Proc Natl Acad Sci U S 
A (87), 8721-8725.
Gangopadhyay, A., Lazure, D. A., Kelly, T. M., and Thomas, P. (1996) Purification and analysis o f an 80- 
kDa carcinoembryonic antigen-binding protein from Kupffer cells. Arch Biochem Biophys (328), 
151-157.
Garnett, M. C. (2001) Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev (53), 171-216.
Gautherot E., Rouvier E., Daniel L., Loucif E., Bouhou J., Manetti C., Martin M., Le Doussal J.M., and
Barbet J. (2000) Pre-targeted radioimmunotherapy o f human colorectal xenografts with bispecific 
antibody and 131 -I-labelled bivalent hapten, JNucl Med (41), 480-487.
Gay, D., Saunders T., Camper, S., Weigert, M. (1993) Receptor editing: an approach by autoreactive B cells 
to escape tolerance. JExp Med (177), 999-1008.
Gearhart, P. J., Johnson, N. D., Douglas, R., and Hood, L. (1981) IgG antibodies to phosphorylcholine exhibit 
more diversity than their IgM counterparts. Nature (291), 29-34.
Ghetie, M. A., Ghetie, V., and Vitetta, E. S. (1997) Immunotoxins for the treatment o f B-cell lymphomas.
Mol Med (3), 420-427.
Glennie, M. J. and van de Winkel, J. G. (2003) Renaissance o f cancer therapeutic antibodies. Drug Discov 
Today 503-510.
Goel, A., Colcher, D., Baranowska-Kortylewicz, J., Augustine, S., Booth, B. J., Pavlinkova, G., and Batra, S. 
K. (2000) Genetically engineered tetravalent single-chain Fv o f  the pancarcinoma monoclonal 
antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res (60), 
6964-6971.
Goel, A., Baranowska-Kortylewicz, J., Hinrichs, S. H., Wisecarver, J., Pavlinkova, G., Augustine, S.,
Colcher, D., Booth, B. J., and Batra, S. K. (2001) 99mTc-labeled divalent and tetravalent CC49 
single-chain Fv's: novel imaging agents for rapid in vivo localization o f human colon carcinoma. J  
Nucl Med (42), 1519-1527.
Gold, P. and Freedman, S. O. (1965) Specif c carcinoembryonic antigens o f the human digestive system. J  
Exp Med (122), 467-481.
268
Goldenberg, D. M., Sharkey, R. M., and Ford, E. (1987) Anti-antibody enhancement o f iodine-131 anti-CEA 
radioimmunodetection in experimental and clinical studies. JNucl Med (28), 1604-1610.
Goldenberg, D. M., Abdel-Nabi, H., Sullivan, C. L., Serafmi, A., Seldin, D., Barron, B., Lamki, L., Line, B., 
and Wegener, W. A. (2000) Carcinoembryonic antigen immunoscintigraphy complements 
mammography in the diagnosis o f breast carcinoma. Cancer (89), 104-115.
Goldenberg, D. M. (2001) The role of radiolabeled antibodies in the treatment o f non-Hodgkin's lymphoma: 
the coming o f age o f radioimmunotherapy. Crit Rev Oncol Hematol (39), 195-201.
Goldenberg, D. M. (2002) Targeted therapy o f cancer with radiolabeled antibodies. JNucl Med (43), 693-713.
Goodwin, D. A., Meares, C. F., McTigue, M., and David, G. S. (1986) Monoclonal antibody hapten 
radiopharmaceutical delivery. Nucl Med Commun (7), 569-580.
Goodwin, D.A., Meares, C.F., McCall, M.J., et al. (1988) Pre-targeted immunoscintigraphy o f murine tumors 
with indium-111-labeled bifunctional haptens. JNucl Med (29), 226-234.
Gordon, S. (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell (111), 927- 
930.
Govindan, S. V., Shih, L. B., Goldenberg, D. M., Sharkey, R. M., Karacay, H., Donnelly, J. E., Losman, M.
J., Hansen, H. J., and Griffiths, G. L. (1998) 90Yttrium-labeled complementarity-determining- 
region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal 
biodistribution studies. Bioconjug Chem (9), 773-782.
Graff, C.P. (2002) Antibody Engineering for Tumour Immunotherapy. PhD Thesis. Dept, o f Chemical 
Engineering, MIT.
Graham, R. A., Wang, S., Catalano, P. J., and Haller, D. G. (1998) Postsurgical surveillance o f colon cancer: 
preliminary cost analysis o f physician examination, carcinoembryonic antigen testing, chest x-ray, 
and colonoscopy. Ann Surg (228), 59-63.
Gray-Owen, S. D., Lorenzen, D. R., Haude, A., Meyer, T. F., and Dehio, C. (1997) Differential Opa
specificities for CD66 receptors influence tissue interactions and cellular response to Neisseria 
gonorrhoeae. Mol Microbiol (26), 971-980.
Grillo-Lopez, A. J. (2002) Zevalin: the first radioimmunotherapy approved for the treatment o f lymphoma. 
Expert Rev Anticancer Ther (2), 485-493.
Grinna, L. S. and Tschopp, J. F. (1989) Size distribution and general structural features of N-linked 
oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast (5), 107-115.
269
Grossbard, M. L., Multani, P. S., Freedman, A. S., O'Day, S., Gribben, J. G., Rhuda, C., Neuberg, D., and 
Nadler, L. M. (1999) A Phase II study o f adjuvant therapy with anti-B4-blocked ricin after 
autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. 
Clin Cancer Res (5), 2392-2398.
Gruber, M., Schodin, B. A., Wilson, E. R., and Kranz, D. M. (1994) Efficient tumor cell lysis mediated by a 
bispecific single chain antibody expressed in Escherichia coli. J  Immunol (152), 5368-5374.
Guerdoud, L. M., Ouellet, R., and Van Lier, J. E. (1994) Evaluation o f 99mTc-labeled modified serum 
albumin for tumor detection. Nucl Med Biol (21), 1101-1108.
Gurkan, C., Symeonides, S. N., and Ellar, D. J. (2003) High-level production in Pichia pastoris o f an anti- 
pi 85 HER-2 scFv using an alternative secretion expression vector. Biotechnol Appl Biochem
Gurkan, C. and Ellar, D. J. (2003) Expression in Pichia pastoris and purification o f a membrane-acting
immunotoxin based on a synthetic gene coding for the Bacillus thuringiensis Cyt2Aal toxin. Protein 
ExprPurif(29), 103-116.
Hale, G., Slavin, S., Goldman, J. M., Mackinnon, S., Giralt, S., and Waldmann, H. (2002) Alemtuzumab
(Campath-IH) for treatment o f lymphoid malignancies in the age o f nonmyeloablative conditioning? 
Bone Marrow Transplant (30), 797-804.
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B.,
Bendahman, N., and Hamers, R. (1993) Naturally occurring antibodies devoid o f light chains. Nature 
(363), 446-448.
Hammarstrom, S. (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and 
expression in normal and malignant tissues. Semin Cancer Biol (9), 67-81.
Hanes, J. and Pluckthun, A. (1999) In vitro selection methods for screening o f peptide and protein libraries. 
Curr Top Microbiol Immunol (243), 107-122.
Hanes, J., Schaffitzel, C., Knappik, A., and Pluckthun, A. (2000) Picomolar affinity antibodies from a fully 
synthetic naive library selected and evolved by ribosome display. Nat Biotechnol (18), 1287-1292.
Harper, M., Lema, F., Boulot, G., and Poljak, R. J. (1987) Antigen specificity and cross-reactivity of 
monoclonal anti-lysozyme antibodies. Mol Immunol (24), 97-108.
Harris, L. J., Larson, S. B., Hasel, K. W., Day, J., Greenwood, A., and McPherson, A. (1992) The three- 
dimensional structure o f an intact monoclonal antibody for canine lymphoma. Nature (360), 369- 
372.
270
Hartung, G., Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Heeger, S., Kranzle, M., Edler, L., Frei, E.,
Fiebig, H. H., Heene, D. L., Maier-Borst, W., and Queisser, W. (1999) Phase I trial o f methotrexate- 
albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the 
Association for Medical Oncology o f the German Cancer Society. Clin Cancer Res (5), 753-759.
Hartung, G., Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Heeger, S., Kranzle, M., Edler, L., Frei, E.,
Fiebig, H. H., Heene, D. L., Maier-Borst, W., and Queisser, W. (1999) Phase I trial o f methotrexate- 
albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group o f the 
Association for Medical Oncology of the German Cancer Society. Clin Cancer Res (5), 753-759.
Hass, G. M., Bolling, T. J., Kinders, R. J., Henslee, J. G., Mandecki, W., Dorwin, S. A., and Shively, J. E.
(1991) Preparation o f synthetic polypeptide domains o f carcinoembryonic antigen and their use in 
epitope mapping. Cancer Res (51), 1876-1882.
Hass, G. M., Bolling, T. J., Kinders, R. J., Henslee, J. G., Mandecki, W., Dorwin, S. A., and Shively, J. E.
(1991) Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in 
epitope mapping. Cancer Res (51), 1876-1882.
Hauck, W. and Stanners, C. P. (1991) Control o f carcinoembryonic antigen gene family expression in a 
differentiating colon carcinoma cell line, Caco-2. Cancer Res (51), 3526-3533.
Haunschild, J., Steiner, K., Faro, H. P., and Senekowitsch, R. (1995) Pharmacokinetics of reshaped MAb 425 
in three animal species. Cell Biophys (26), 167-182.
Hay, F. (1996) The Generation o f diversity. Mosby.
Haynes, P. A., Batley, M., Peach, R. J., Brennan, S. O., and Redmond, J. W. (1992) Characterisation of
oligosaccharides from a glycoprotein variant o f human serum albumin (albumin Casebrook) using 
high-performance anion-exchange chromatography and nuclear magnetic resonance spectroscopy. J  
Chromatogr(581), 187-193.
He, M. and Taussig, M. J. (1997) Antibody-ribosome-mRNA (ARM) complexes as efficient selection 
particles for in vitro display and evolution o f antibody combining sites. Nucleic Acids Res (25), 
5132-5134.
He, X. M. and Carter, D. C. (1992) Atomic structure and chemistry o f human serum albumin. Nature (358), 
209-215.
Hefta, L. J., Chen, F. S., Ronk, M., Sauter, S. L., Sarin, V., Oikawa, S., Nakazato, H., Hefta, S., and Shively, 
J. E. (1992) Expression o f carcinoembryonic antigen and its predicted immunoglobulin- like 
domains in HeLa cells for epitope analysis. Cancer Res (52), 5647-5655.
271
Hefta, L. J., Neumaier, M., and Shively, J. E. (1998) Kinetic and affinity constants o f epitope specific anti- 
carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain 
constructs. Immunotechnology (4), 49-57.
Hefta, S. A., Hefta, L. J., Lee, T. D., Paxton, R. J., and Shively, J. E. (1988) Carcinoembryonic antigen is 
anchored to membranes by covalent attachment to a glycosylphosphatidylinositol moiety: 
identification o f the ethanolamine linkage site. Proc Natl Acad Sci U SA  (85), 4648-4652.
Henderson, L. A., Baynes, J. W., and Thorpe, S. R. (1982) Identification o f the sites o f IgG catabolism in the 
rat. Arch Biochem Biophys (215), 1-11.
Hennecke, F., Krebber, C., and Pluckthun, A. (1998) Non-repetitive single-chain Fv linkers selected by 
selectively infective phage (SIP) technology. Protein Eng (11), 405-410.
Herron, J. N., He, X. M., Mason, M. L., Voss, E. W., Jr., and Edmundson, A. B. (1989) Three-dimensional 
structure o f a fluorescein-Fab complex crystallized in 2-methyl-2,4-pentanediol. Proteins (5), 271- 
280.
Heuser, C., Diehl, V., Abken, H., and Hombach, A. (2003) Anti-CD30-IL-12 antibody-cytokine fusion 
protein that induces IFN-gamma secretion o f T cells and NK cell-mediated lysis o f Hodgkin's 
lymphoma-derived tumor cells. In tJ  Cancer (106), 545-552.
Heuser, C., Ganser, M., Hombach, A., Brand, H., Denton, G., Hanisch, F. G., and Abken, H. (2003) An anti- 
MUCl-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis o f MUC1- 
positive tumour cells. B rJ  Cancer (89), 1130-1139.
Hilschmann, N. and Craig, L. C. (1965) Amino acid sequence studies with Bence-Jones proteins. Proc Natl 
Acad Sci U S A  (53), 1403-1409.
Hinoda, Y., Neumaier, M., Hefta, S. A., Drzeniek, Z., Wagener, C., Shively, L., Hefta, L. J., Shively, J. E., 
and Paxton, R. J. (1988) Molecular cloning o f a cDNA coding biliary glycoprotein I: primary 
structure o f a glycoprotein immunologically crossreactive with carcinoembryonic antigen. Proc Natl 
Acad Sci U S A  (85), 6959-6963.
Hinshelwood, J., Spencer, D. I., Edwards, Y. J., and Perkins, S. J. (1999) Identification o f the C3b binding
site in a recombinant vWF-A domain o f complement factor B by surface-enhanced laser desorption- 
ionisation affinity mass spectrometry and homology modelling: implications for the activity o f factor
B. JM ol Biol (294), 587-599.
Hnatowich, D. J., Virzi, F., and Rusckowski, M. (1987) Investigations o f avidin and biotin for imaging 
applications. JNucl M ed (28), 1294-1302.
272
Hnatowich, D. J. (1994) The in vivo uses of streptavidin and biotin: a short progress report. Nucl Med 
Commun (15), 575-577.
Holliger, P., Prospero, T., and Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody 
fragments. Proc Natl Acad Sci U SA  (90), 6444-6448.
Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., and Winter, G. (1996) Specific killing of
lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng (9), 299-305.
Holliger, P., Wing, M., Pound, J. D., Bohlen, H., and Winter, G. (1997) Retargeting serum immunoglobulin 
with bispecific diabodies. Nat Biotechnol (15), 632-636.
Holliger, P., Manzke, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua, L., Wolf, J., Diehl, V., Cochet, 
O., Winter, G., and Bohlen, H. (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in 
colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific 
fusion proteins. Cancer Res (59), 2909-2916.
Horn, U., Strittmatter, W., Krebber, A., Knupfer, U., Kujau, M., Wenderoth, R., Muller, K., Matzku, S., 
Pluckthun, A., and Riesenberg, D. (1996) High volumetric yields o f functional dimeric 
miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density 
fermentation under non-limited growth conditions. Appl Microbiol Biotechnol (46), 524-532.
Horwitz, A. H., Chang, C. P., Better, M., Hellstrom, K. E., and Robinson, R. R. (1988) Secretion o f functional 
antibody and Fab fragment from yeast cells. Proc Natl Acad Sci U S A  (85), 8678-8682.
Hostetter, R. B., Augustus, L. B., Mankarious, R., Chi, K. F., Fan, D., Toth, C., Thomas, P., and Jessup, J. M.
(1990) Carcinoembryonic antigen as a selective enhancer o f colorectal cancer metastasis. J  Natl 
Cancer Inst (82), 380-385.
Hsu, T. A., Eiden, J. J., Bourgarel, P., Meo, T., and Betenbaugh, M. J. (1994) Effects o f co-expressing
chaperone BiP on functional antibody production in the baculovirus system. Protein Expr Purif (5), 
595-603.
Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L. E., Wong, J. Y., Shively, J. E., and Wu, A.
M. (1996) Minibody: A novel engineered anti-carcinoembiyonic antigen antibody fragment (single­
chain Fv-CH3) which exhibits rapid, high-level targeting o f xenografts. Cancer Res (56), 3055-3061.
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., 
Bruccoleri, R. E., Haber, E., Crea, R., and . (1988) Protein engineering o f antibody binding sites: 
recovery o f specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia 
coli. Proc Natl Acad Sci U SA  (85), 5879-5883.
273
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., 
Bruccoleri, R. E., Haber, E., Crea, R., and . (1988) Protein engineering o f antibody binding sites: 
recovery o f specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia 
coli. Proc Natl Acad Sci U SA  (85), 5879-5883.
Huston, J. S., Mudgett-Hunter, M., Tai, M. S., McCartney, J., Warren, F., Haber, E., and Oppermann, H.
(1991) Protein engineering o f single-chain Fv analogs and fusion proteins. Methods Enzymol (203), 
46-88.
Huston, J. S., Mudgett-Hunter, M., Tai, M. S., McCartney, J., Warren, F., Haber, E., and Oppermann, H.
(1991) Protein engineering o f single-chain Fv analogs and fusion proteins. Methods Enzymol (203), 
46-88.
Ikeda, S., Kuroki, M., Haruno, M., Oikawa, S., Nakazato, H., Kosaki, G., and Matsuoka, Y. (1992) Epitope 
mapping o f the carcinoembryonic antigen with various related recombinant proteins expressed in 
Chinese hamster ovary cells and 25 distinct monoclonal antibodies. Mol Immunol (29), 229-240.
Iliades, P., Kortt, A. A., and Hudson, P. J. (1997) Triabodies: single chain Fv fragments without a linker form 
trivalent trimers. FEBS Lett (409), 437-441.
Illidge, T. M. and Johnson, P. W. (2000) The emerging role o f radioimmunotherapy in haematological 
malignancies. BrJHaematol (108), 679-688.
Inazawa, J., Abe, T., Inoue, K., Misawa, S., Oikawa, S., Nakazato, H., and Yoshida, M. C. (1989) Regional 
assignment o f  nonspecific cross-reacting antigen (NCA) o f the CEA gene family to chromosome 19 
at band q 13.2. Cytogenet Cell Genet (52), 28-31.
Itzkowitz, S. H., Shi, Z. R., and Kim, Y. S. (1986) Heterogeneous expression o f two oncodevelopmental 
antigens, CEA and SSEA-1, in colorectal cancer. H istochemJ(18), 155-163.
Jain, R. K. (1987) Transport o f molecules across tumor vasculature. Cancer Metastasis Rev (6), 559-593.
Jain, R. K. and Ward-Hartley, K. A. (1987) Dynamics o f cancer cell interactions with microvasculature and 
interstitium. Biorheology (24), 117-125.
Jain, R. K. and Baxter, L. T. (1988) Mechanisms of heterogeneous distribution o f monoclonal antibodies and 
other macromolecules in tumors: significance o f elevated interstitial pressure. Cancer Res (48), 
7022-7032.
Janin, J. and Chothia, C. (1990) The structure o f protein-protein recognition sites. JB iol Chem (265), 16027- 
16030.
274
Jean, F., Malapert, P., Rougon, G., and Barbet, J. (1988) Cell membrane, but not circulating,
carcinoembryonic antigen is linked to a phosphatidylinositol-containing hydrophobic domain. 
Biochem Biophys Res Commun (155), 794-800.
Jemmerson, R. and Paterson, Y. (1986) Mapping epitopes on a protein antigen by the proteolysis o f antigen- 
antibody complexes. Science (232), 1001-1004.
Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G., and Hoogenboom, H. R. (1994) Guiding the selection 
of human antibodies from phage display repertoires to a single epitope o f an antigen. Biotechnology 
(N Y) (12), 899-903.
Jessup, J. M., Petrick, A. T., Toth, C. A., Ford, R., Meterissian, S., O'Hara, C. J., Steele, G., Jr., and Thomas, 
P. (1993) Carcinoembryonic antigen: enhancement o f liver colonisation through retention of human 
colorectal carcinoma cells. B rJ  Cancer (67), 464-470.
Jin, L. and Wells, J. A. (1994) Dissecting the energetics o f an antibody-anti gen interface by alanine shaving 
and molecular grafting. Protein Sci (3), 2351-2357.
Jones, P. L., Gallagher, B. M., and Sands, H. (1986) Autoradiographic analysis o f monoclonal antibody
distribution in human colon and breast tumor xenografts. Cancer Immunol Immunother (22), 139- 
143.
Jung, S. and Pluckthun, A. (1997) Improving in vivo folding and stability o f  a single-chain Fv antibody 
fragment by loop grafting. Protein Eng (10), 959-966.
Jung, S., Honegger, A., and Pluckthun, A. (1999) Selection for improved protein stability by phage display. J  
Mol Biol (294), 163-180.
Juweid, M., Sharkey, R. M., Behr, T. M., Swayne, L. C., Dunn, R., Ying, Z., Siegel, J. A., Hansen, H. J., and 
Goldenberg, D. M. (1996) Clinical evaluation o f tumor targeting with the anticarcinoembryonic 
antigen murine monoclonal antibody fragment, MN-14 F(ab)2. Cancer (78), 157-168.
Juweid, M., Sharkey, R. M., Behr, T., Swayne, L. C., Herskovic, T., Pereira, M., Rubin, A. D., Hanley, D., 
Dunn, R., Siegel, J., and Goldenberg, D. M. (1996) Radioimmunotherapy o f medullary thyroid 
cancer with iodine-131 -labeled anti-CEA antibodies. JNucl Med (37), 905-911.
Juweid, M. E., Hajjar, G., Swayne, L. C., Sharkey, R. M., Suleiman, S., Herskovic, T., Pereira, M., Rubin, A. 
D., and Goldenberg, D. M. (1999) Phase I/n trial o f (131)I-MN-14F(ab)2 anti-carcinoembryonic 
antigen monoclonal antibody in the treatment o f patients with metastatic medullary thyroid 
carcinoma. Cancer (85), 1828-1842.
Kabat, E. A. and Wu, T. T. (1971) Attempts to locate complementarity-determining residues in the variable 
positions o f light and heavy chains. Ann N Y  Acad Sci (190), 382-393.
275
Kabat, E. A. and Wu, T. T. (1991) Identical V region amino acid sequences and segments o f sequences in 
antibodies o f different specificities. Relative contributions o f VH and VL genes, minigenes, and 
complementarity-determining regions to binding o f antibody-combining sites. J  Immunol (147), 
1709-1719.
Kamarck, M. E., Elting, J. J., Hart, J. T., Goebel, S. J., Rae, P. M., Nothdurft, M. A., Nedwin, J. J., and
Barnett, T. R. (1987) Carcinoembryonic antigen family: expression in a mouse L-cell transfectant 
and characterization o f a partial cDNA in bacteriophage lambda gtl 1. Proc Natl Acad Sci U SA  (84), 
5350-5354.
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S.,
Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., and Wahl, R. L. (2000) Radioimmunotherapy with 
iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results 
and long-term follow-up o f the University o f Michigan experience. Blood (96), 1259-1266.
Kang, A. S., Jones, T. M., and Burton, D. R. (1991) Antibody redesign by chain shuffling from random 
combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A  (88), 11120-11123.
Kantor, J., Tran, R., Greiner, J., Pestka, S., Fisher, P. B., Shively, J. E., and Schlom, J. (1989) Modulation o f  
carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant 
human gamma-interferon. Cancer Res (49), 2651-2655.
Karlsson, R. (1994) Real-time competitive kinetic analysis o f interactions between Iow-molecular-weight 
ligands in solution and surface-immobilized receptors. Anal Biochem (221), 142-151.
Karush, F. (1970) Affinity and the immune response. Ann N Y  Acad Sci (169), 56-64.
Kathuria, S., Sriraman, R., Nath, R., Sack, M., Pal, R., Artsaenko, O., Talwar, G. P., Fischer, R., and Finnem, 
R. (2002) Efficacy o f plant-produced recombinant antibodies against HCG. Hum Reprod (17), 2054- 
2061.
Keep, P. A., Leake, B. A., and Rogers, G. T. (1978) Extraction o f CEA from tumour tissue, foetal colon and 
patients' sera, and the effect o f perchloric acid. B rJ  Cancer (37), 171-189.
Keep, P. A., Searle, F., Begent, R. H., Barratt, G. M., Boden, J., Bagshawe, K. D., and Ryman, B. E. (1983) 
Clearance o f injected radioactively labelled antibodies to tumour products by liposome-bound 
second antibodies. Oncodev Biol Med (4), 273-280.
Khan, W. N., Frangsmyr, L., Teglund, S., Israelsson, A., Bremer, K., and Hammarstrom, S. (1992)
Identification o f  three new genes and estimation of the size o f the carcinoembryonic antigen family. 
Genomics (14), 384-390.
276
Khan, W. N., Teglund, S., Bremer, K., and Hammarstrom, S. (1992) The pregnancy-specific glycoprotein
family o f the immunoglobulin superfamily: identification o f new members and estimation of family 
size. Genomics (12), 780-787.
Khare, P. D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y., and Kuroki, M. 
(2001) Specifically targeted killing o f carcinoembryonic antigen (CEA)-expressing cells by a 
retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene 
for inducible nitric oxide synthase. Cancer Res (61), 370-375.
Khazaeli, M. B., Conry, R. M., and LoBuglio, A. F. (1994) Human immune response to monoclonal 
antibodies. J  Immunother (15), 42-52.
Kim, I. S., Yoo, T. M., Kobayashi, H., Kim, M. K., Le, N., Wang, Q. C., Pastan, I., Carrasquillo, J. A., and
Paik, C. H. (1999) Chemical modification to reduce renal uptake o f disulfide-bonded variable region 
fragment o f anti-Tac monoclonal antibody labeled with 99mTc. Bioconjug Chem (10), 447-453.
Kimball, P. M. and Brattain, M. G. (1978) A comparison o f methods for the isolation o f carcinoembryonic 
antigen. Cancer Res (38), 619-623.
King, D. J., Turner, A., Farnsworth, A. P., Adair, J. R., Owens, R. J., Pedley, R. B., Baldock, D., Proudfoot, 
K. A., Lawson, A. D., Beeley, N. R., and . (1994) Improved tumor targeting with chemically cross- 
linked recombinant antibody fragments. Cancer Res (54), 6176-6185.
Kipriyanov, S. M., Dubel, S., Breitling, F., Kontermann, R. E., and Little, M. (1994) Recombinant single­
chain Fv fragments carrying C-terminal cysteine residues: production o f bivalent and biotinylated 
miniantibodies. Mol Immunol (31), 1047-1058.
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., der Lieth, C. W., Matys, E. R., and 
Little, M. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and 
pharmacokinetics. J  Mol Biol (293), 41-56.
Kipriyanov, S. M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Le Gall, F., Kouprianova, 
O. A., der Lieth, C. W., and Little, M. (2003) Effect o f domain order on the activity o f bacterially 
produced bispecific single-chain Fv antibodies. J  Mol Biol (330), 99-111.
Kjeldsen, T., Pettersson, A. F., Drube, L., Kurtzhals, P., Jonassen, I., Havelund, S., Hansen, P. H., and
Markussen, J. (1998) Secretory expression of human albumin domains in Saccharomyces cerevisiae 
and their binding o f myristic acid and an acylated insulin analogue. Protein Expr Purif (13), 163- 
169.
Klohs, W. D. and Hamby, J. M. (1999) Antiangiogenic agents. Curr Opin Biotechnol (10), 544-549.
277
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., 
and Vimekas, B. (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on 
modular consensus frameworks and CDRs randomized with trinucleotides. J  Mol Biol (296), 57-86.
Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., 
Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. (2000) Phase II 
trial o f yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with 
metastatic colon cancer. Clin Cancer Res (6), 406-414.
Kohler, G. and Milstein, C. (1975) Continuous cultures o f fused cells secreting antibody o f predefined 
specificity. Nature (256), 495-497.
Konishi, H., Ochiya, T., Muto, T., Sugimura, T., and Terada, M. (1998) Toward targeted killing o f tumor- 
specific antigen-producing cancer cells by retrovirus displaying a single chain variable fragment 
antibody. Adv Exp Med Biol (451), 405-410.
Kontermann, R. E., Wing, M. G., and Winter, G. (1997) Complement recruitment using bispecific diabodies. 
Nat Biotechnol (15), 629-631.
Kortt, A. A., Guthrie, R. E., Hinds, M. G., Power, B. E., Ivancic, N., Caldwell, J. B., Gruen, L. C., Norton, R. 
S., and Hudson, P. J. (1995) Solution properties o f Escherichia coli-expressed VH domain o f anti­
neuraminidase antibody NC41. J  Protein Chem (14), 167-178.
Kortt, A. A., Lah, M., Oddie, G. W., Gruen, C. L., Bums, J. E., Pearce, L. A., Atwell, J. L., McCoy, A. J.,
Howlett, G. J., Metzger, D. W., Webster, R. G., and Hudson, P. J. (1997) Single-chain Fv fragments 
of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with 
zero-residue linker a trimer. Protein Eng (10), 423-433.
Kostelny, S. A., Cole, M. S., and Tso, J. Y. (1992) Formation o f a bispecific antibody by the use o f leucine 
zippers. J  Immunol (148), 1547-1553.
Kousparou, C. A., Epenetos, A. A., and Deonarain, M. P. (2002) Antibody-guided enzyme therapy of cancer 
producing cyanide results in necrosis o f targeted cells. In tJ  Cancer (99), 138-148.
Koutz, P., Davis, G. R., Stillman, C., Barringer, K., Cregg, J., and Thill, G. (1989) Structural comparison of  
the Pichia pastoris alcohol oxidase genes. Yeast (5), 167-177.
Kraeber-Bodere, F., Faivre-Chauvet, A., Ferrer, L., Vuillez, J. P., Brard, P. Y., Rousseau, C., Resche, I.,
Devillers, A., Laffont, S., Bardies, M., Chang, K., Sharkey, R. M., Goldenberg, D. M., Chatal, J. F., 
and Barbet, J. (2003) Pharmacokinetics and dosimetry studies for optimization o f anti- 
carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131- 
labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res (9), 3973S-3981S.
278
Kragh-Hansen, U., Pedersen, A. O., Galliano, M., Minchiotti, L., Brennan, S. O., Tamoky, A. L., Franco, M.
H., and Salzano, F. M. (1996) High-afFinity binding of laurate to naturally occurring mutants of 
human serum albumin and proalbumin. BiochemJ(320 ( Pt 3)), 911-916.
Kragh-Hansen, U., Donaldson, D., and Jensen, P. H. (2001) The glycan structure o f  albumin Redhill, a 
glycosylated variant o f human serum albumin. Biochim Biophys Acta (1550), 20-26.
Kreitman, R. J. and Pastan, I. (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer 
than 1000 molecules per cell are sufficient for complete responses. Cancer Res (58), 968-975.
Kreitman, R. J. (2000) Immunotoxins. Expert Opin Pharmacother (1), 1117-1129.
Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and 
Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- 
resistant hairy-cell leukemia. N  Engl JM ed  (345), 241-247.
Kretzschmar, T., Aoustin, L., Zingel, O., Marangi, M., Vonach, B., Towbin, H., and Geiser, M. (1996) High- 
level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J  
Immunol Methods (195), 93-101.
Krop-Watorek, A., Oikawa, S., Oyama, Y., and Nakazato, H. (1998) Oligomerization o f N-terminal domain 
of carcinoembryonic antigen (CEA) expressed in Escherichia coli. Biochem Biophys Res Commun 
(242), 79-83.
Kuroki, M., Murakami, M., Wakisaka, M., Ikeda, S., Oikawa, S., Oshima, T., Nakazato, H., Kosaki, G., and 
Matsuoka, Y. (1992) Immunoreactivity of recombinant carcinoembryonic antigen proteins expressed 
in Escherichia coli. Immunol Invest (21), 241-257.
Kurucz, I., Titus, J. A., Jost, C. R., Jacobus, C. M., and Segal, D. M. (1995) Retargeting o f CTL by an
efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J  Immunol (154), 4576- 
4582.
Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A.
(2000) Structures o f HIV-1 gpl20 envelope glycoproteins from laboratory-adapted and primary 
isolates. Structure Fold Des (8), 1329-1339.
Lamminmaki, U., Pauperio, S., Westerlund-Karlsson, A., Karvinen, J., Virtanen, P. L., Lovgren, T., and
Saviranta, P. (1999) Expanding the conformational diversity by random insertions to CDRH2 results 
in improved anti-estradiol antibodies. JM ol Biol (291), 589-602.
Lane, D. M., Eagle, K. F., Begent, R. H., Hope-Stone, L. D., Green, A. J., Casey, J. L., Keep, P. A., Kelly, A. 
M., Ledermann, J. A., Glaser, M. G., and . (1994) Radioimmunotherapy o f metastatic colorectal
279
tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with 
comparative biodistribution o f intact and F(ab')2 antibodies. B rJ  Cancer (70), 521-525.
Larson, S. M., El Shirbiny, A. M., Divgi, C. R., Sgouros, G., Finn, R. D., Tschmelitsch, J., Picon, A.,
Whitlow, M., Schlom, J., Zhang, J., and Cohen, A. M. (1997) Single chain antigen binding protein 
(sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer (80), 2458-2468.
Laroche, Y., Storme, V., De Meutter, J., Messens, J., Lauwereys, M. (1994) High-level secretion and very
efficient isotopic labelling o f tick anticoagulant peptide (TAP) expressed in the methylatorphic yeast, 
Pichia pastoris. Bio/Technology (12), 1119-1124.
Lee, B. and Richards, F. M. (1971) The interpretation o f protein structures: estimation o f static accessibility. J  
Mol Biol (55), 379-400.
Lee, S. J., Evers, S., Roeder, D., Parlow, A. F., Risteli, J., Risteli, L., Lee, Y. C., Feizi, T., Langen, H., and 
Nussenzweig, M. C. (2002) Mannose receptor-mediated regulation o f serum glycoprotein 
homeostasis. Science (295), 1898-1901.
Leusch, H. G., Hefta, S. A., Drzeniek, Z., Hummel, K., Markos-Pusztai, Z., and Wagener, C. (1990) 
Escherichia coli o f human origin binds to carcinoembryonic antigen (CEA) and non-specific 
crossreacting antigen (NCA). FEBS Lett (261), 405-409.
Leusch, H. G., Drzeniek, Z., Hefta, S. A., Markos-Pusztai, Z., and Wagener, C. (1991) The putative role of  
members o f the CEA-gene family (CEA, NCA an BGP) as ligands for the bacterial colonization of 
different human epithelial tissues. Zentralbl Bakteriol (275), 118-122.
Leusch, H. G., Drzeniek, Z., Markos-Pusztai, Z., and Wagener, C. (1991) Binding o f Escherichia coli and 
Salmonella strains to members o f the carcinoembryonic antigen family: differential binding 
inhibition by aromatic alpha-glycosides of mannose. Infect Immun (59), 2051-2057.
Levy, R., Weiss, R., Chen, G., Iverson, B. L., and Georgiou, G. (2001) Production o f correctly folded Fab 
antibody fragment in the cytoplasm o f Escherichia coli trxB gor mutants via the coexpression of 
molecular chaperones. Protein Expr Purif (23), 338-347.
Leyland-Jones, B. (2002) Trastuzumab: hopes and realities. Lancet Oncol (3), 137-144.
Lin, E., Lin, S. W., and Lin, A. (2001) The participation of 5S rRNA in the co-translational formation of a 
eukaryotic 5S ribonucleoprotein complex. Nucleic Acids Res (29), 2510-2516.
Linardou, H., Epenetos, A. A., and Deonarain, M. P. (2000) A recombinant cytotoxic chimera based on 
mammalian deoxyribonuclease-I. In tJ  Cancer {86), 561-569.
280
Lote, C. J., Wood, J. A., and Saunders, H. C. (1992) Renal filtration, reabsorption and excretion o f aluminium 
in the rat. Clin Sci (Lond) (82), 13-18.
Luo, D., Mah, N., Wishart, D., Zhang, Y., Jacobs, F., and Martin, L. (1996) Construction and expression of 
bi-functional proteins o f  single-chain Fv with effector domains. J  Biochem (Tokyo) (120), 229-232.
Luo, D., Geng, M., Noujaim, A. A., and Madiyalakan, R  (1997) An engineered bivalent single-chain 
antibody fragment that increases antigen binding activity. J  Biochem (Tokyo) (121), 831-834.
MacCallum, R. M., Martin, A. C., and Thornton, J. M. (1996) Antibody-antigen interactions: contact analysis 
and binding site topography. J  Mol Biol (262), 732-745.
Mach, J. P. and Pusztaszeri, G. (1972) Carcinoembryonic antigen (CEA): demonstration o f a partial identity 
between CEA and a normal glycoprotein. Immunochemistry (9), 1031-1034.
Mack, M., Riethmuller, G., and Kufer, P. (1995) A small bispecific antibody construct expressed as a
functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U SA  (92), 
7021-7025.
MACNALTY, A. S. (1954) Emil von Behring, bom March 15, 1854. B rM ed J {4863), 668-670.
Madison, J., Arai, K., Sakamoto, Y., Feld, R. D., Kyle, R. A., Watkins, S., Davis, E., Matsuda, Y., Amaki, I., 
and Putnam, F. W. (1991) Genetic variants o f serum albumin in Americans and Japanese. Proc Natl 
Acad Sci U SA  (88), 9853-9857.
Mallender, W. D. and Voss, E. W., Jr. (1994) Construction, expression, and activity o f a bivalent bispecific 
single-chain antibody. J  Biol Chem (269), 199-206.
Mallender, W. D., Ferreira, S. T., Voss, E. W., Jr., and Coelho-Sampaio, T. (1994) Inter-active-site distance 
and solution dynamics o f a bivalent-bispecific single-chain antibody molecule. Biochemistry (33), 
10100-10108.
Mao, G. D. and Poznansky, M. J. (1989) Superoxide dismutase: improving its pharmacological properties by 
conjugation with human serum albumin. Biomater Artif Cells Artif Organs (17), 229-244.
Marks, J. D., Griffiths, A. D., Malmqvist, M., Clackson, T. P., Bye, J. M., and Winter, G. (1992) By-passing 
immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y )  (10), 
779-783.
Marques, J. A., George, J. K., Smith, I. J., Bhakta, V., and Sheffield, W. P. (2001) A barbourin-albumin
fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. 
Thromb Haemost (86), 902-908.
281
Marshall, D., Pedley, R. B., Boden, J. A., Boden, R., and Begent, R. H. (1994) Clearance o f circulating radio­
antibodies using streptavidin or second antibodies in a xenograft model. Br J  Cancer (69), 502-507.
Marshall, D., Pedley, R. B., Melton, R. G., Boden, J. A., Boden, R., and Begent, R. H. (1995) Galactosylated 
streptavidin for improved clearance o f biotinylated intact and F(ab')2 fragments o f an anti-tumour 
antibody. Br J  Cancer (71), 18-24.
Mattes, M. J., Griffiths, G. L., Diril, H., Goldenberg, D. M., Ong, G. L., and Shih, L. B. (1994) Processing o f 
antibody-radioisotope conjugates after binding to the surface o f  tumor cells. Cancer (73), 787-793.
Mayer, A., Tsiompanou, E., O'Malley, D., Boxer, G. M., Bhatia, J., Flynn, A. A., Chester, K. A., Davidson,
B. R., Lewis, A. A., Winslet, M. C., Dhillon, A. P., Hilson, A. J., and Begent, R. H. (2000) 
Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single­
chain Fv antibody. Clin Cancer Res (6), 1711-1719.
Mayer, A., Tsiompanou, E., Flynn, A. A., Pedley, R. B., Dearling, J., Boden, R., and Begent, R. H. (2003) 
Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest (21), 
382-388.
Maynard, J. and Georgiou, G. (2000) Antibody Engineering. Annu Rev Biomed Eng (2), 339-376.
McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D. J. (1990) Phage antibodies: filamentous phage 
displaying antibody variable domains. Nature (348), 552-554.
McCartney, J. E., Tai, M. S., Hudziak, R. M., Adams, G. P., Weiner, L. M., Jin, D., Stafford, W. F., Ill, Liu,
S., Bookman, M. A., Laminet, A. A., and. (1995) Engineering disulfide-linked single-chain Fv 
dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti- 
c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides. 
Protein Eng (8), 301-314.
McCormick, A. A., Reinl, S. J., Cameron, T. I., Vojdani, F., Fronefield, M., Levy, R., and Tuse, D. (2003) 
Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in 
vaccinated mice confirm relevance to the tumor Ig. J  Immunol Methods (278), 95-104.
McGregor, D. P., Molloy, P. E., Cunningham, C., and Harris, W. J. (1994) Spontaneous assembly of bivalent 
single chain antibody fragments in Escherichia coli. Mol Immunol (31), 219-226.
McGrew, J. T., Leiske, D., Dell, B., Klinke, R., Krasts, D., Wee, S. F., Abbott, N., Armitage, R., and
Harrington, K. (1997) Expression o f trimeric CD40 ligand in Pichia pastoris: use o f a rapid method 
to detect high-level expressing transformants. Gene (187), 193-200.
McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M.
R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D.,
282
and Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed 
indolent lymphoma: half o f patients respond to a four-dose treatment program. J  Clin Oncol (16), 
2825-2833.
Medzihradszky, K. F., Spencer, D. I., Sharma, S. K., Bhatia, J., Pedley, R. B., Read, D. A., Begent, R. H., and 
Chester, K. A. (2003) Glycoforms obtained by expression in Pichia pastoris improve cancer targeting 
potential o f a recombinant antibody-enzyme fusion protein. Glycobiology (14), 27-37.
Mendez, M. J., Green, L. L., Corvalan, J. R., Jia, X. C., Maynard-Currie, C. E., Yang, X. D., Gallo, M. L., 
Louie, D. M., Lee, D. V., Erickson, K. L., Luna, J., Roy, C. M., Abderrahim, H., Kirschenbaum, F., 
Noguchi, M., Smith, D. H., Fukushima, A., Hales, J. F., Klapholz, S., Finer, M. H., Davis, C. G., 
Zsebo, K. M., and Jakobovits, A. (1997) Functional transplant o f megabase human immunoglobulin 
loci recapitulates human antibody response in mice. Nat Genet (15), 146-156.
Merchant, M. and Weinberger, S. R. (2000) Recent advancements in surface-enhanced laser
desorption/ionization-time of flight-mass spectrometry. Electrophoresis (21), 1164-1177.
Mian, I. S., Bradwell, A. R., and Olson, A. J. (1991) Structure, function and properties o f antibody binding 
sites. J  Mol Biol (217), 133-151.
Michael, N. P., Chester, K. A., Melton, R. G., Robson, L., Nicholas, W., Boden, J. A., Pedley, R. B., Begent, 
R. H., Sherwood, R. F., and Minton, N. P. (1996) In vitro and in vivo characterisation o f a 
recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology (2), 47-57.
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A., Dodd, S. W., Wood, J. F., Whitlow, M., Snoy,
P., and Schlom, J. (1991) Construction, binding properties, metabolism, and tumor targeting o f a 
single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res (51), 6363- 
6371.
Miller, R. A., Oseroff, A. R., Stratte, P. T., and Levy, R. (1983) Monoclonal antibody therapeutic trials in 
seven patients with T-cell lymphoma. Blood (62), 988-995.
Moelling, K., Scott, A., Dittmar, K. E., and Owada, M. (1980) Effect o f pl5-associated protease from an 
avian RNA tumor virus on avian virus-specific polyprotein precursors. J  Virol (33), 680-688.
Moffat, F. L., Jr., Vargas-Cuba, R. D., Serafini, A. N., Casillas, V. J., Morillo, G., Benedetto, P., Robinson, D.
S., Ardalan, B., Manten, H. D., Clark, K. C., and . (1994) Radioimmunodetection o f colorectal 
carcinoma using technetium-99m-labeled Fab' fragments o f the IMMU-4 anti-carcinoembryonic 
antigen monoclonal antibody. Cancer (73), 836-845.
Mogensen, C. E. and Soiling. (1977) Studies on renal tubular protein reabsorption: partial and near complete 
inhibition by certain amino acids. Scand J  Clin Lab Invest (37), 477-486.
283
Montesino, R., Garcia, R., Quintero, O., and Cremata, J. A. (1998) Variation in N-linked oligosaccharide 
structures on heterologous proteins secreted by the methylotrophic yeast Pichia pastoris. Protein 
Expr Purif (14), 197-207.
Mordenti, J., Thomsen, K., Licko, V., Chen, H., Meng, Y. G., and Ferrara, N. (1999) Efficacy and
concentration-response o f murine anti-VEGF monoclonal antibody in tumor-bearing mice and 
extrapolation to humans. Toxicol Pathol (27), 14-21.
Multani, P. S., O'Day, S., Nadler, L. M., and Grossbard, M. L. (1998) Phase II clinical trial o f bolus infusion 
anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. 
Clin Cancer Res (4), 2599-2604.
Muyldermans, S. (2001) Single domain camel antibodies: current status. JBiotechnol (74), 277-302.
Nadler, L. M., Stashenko, P., Hardy, R , and Schlossman, S. F. (1980) A monoclonal antibody defining a 
lymphoma-associated antigen in man. J  Immunol (125), 570-577.
Nagy, Z.A. et al. Fully human, HLA-DR specific monoclonal antibodies efficiently induce programmed death 
of malignant lymphoid cells. Nat Med (8), 801-807.
Napier, M. P., Sharma, S. K., Springer, C. J., Bagshawe, K. D., Green, A. J., Martin, J., Stribbling, S. M., 
Cushen, N., O'Malley, D., and Begent, R. H. (2000) Antibody-directed enzyme prodrug therapy: 
efficacy and mechanism o f action in colorectal carcinoma. Clin Cancer Res (6), 765-772.
Nasu, T., Fukuda, Y., Hashino, J., Nagahira, K., Kawashima, H., Noguchi, C., Oikawa, S., and Nakanishi, T. 
(1999) Epitope mapping o f monoclonal antibodies against N-domain o f carcinoembryonic antigen. 
Immunol Lett (67), 57-62.
Nemazee, D. and Hogquist, K. A. (2003) Antigen receptor selection by editing or downregulation o f V(D)J 
recombination. Curr Opin Immunol (15), 182-189.
Neri, D., Momo, M., Prospero, T., and Winter, G. (1995) High-affinity antigen binding by chelating 
recombinant antibodies (CRAbs). J  Mol Biol (246), 367-373.
Neri, D., Camemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., 
Zardi, L., and Winter, G. (1997) Targeting by affinity-matured recombinant antibody fragments of  
an angiogenesis associated fibronectin isoform. Nat Biotechnol (15), 1271-1275.
Neuberger, M. S., Ehrenstein, M. R., Klix, N., Jolly, C. J., Yelamos, J., Rada, C., and Milstein, C. (1998) 
Monitoring and interpreting the intrinsic features o f somatic hypermutation. Immunol Rev (162), 
107-116.
284
Neumaier, M., Zimmermann, W., Shively, L., Hinoda, Y., Riggs, A. D., and Shively, J. E. (1988) 
Characterization o f a cDNA clone for the nonspecific cross-reacting antigen (NCA) and a 
comparison o f NCA and carcinoembryonic antigen. JBiol Chem (263), 3202-3207.
Newton, D. L., Xue, Y., Olson, K. A., Fett, J. W., and Rybak, S. M. (1996) Angiogenin single-chain 
immunofusions: influence of peptide linkers and spacers between fusion protein domains. 
Biochemistry (35), 545-553.
Newton, D. L. and Ryback, S. M. (2001) Antibody targeted therapeutics for lymphoma: new focus on the 
CD22 antigen and RNA. Expert Opin Biol Ther (1), 995-1003.
Nieba, L., Krebber, A., and Pluckthun, A. (1996) Competition BIAcore for measuring true affinities: large 
differences from values determined from binding kinetics. Anal Biochem (234), 155-165.
Nielsen, H., Kragh-Hansen, U., Minchiotti, L., Galliano, M., Brennan, S. O., Tamoky, A. L., Franco, M. H., 
Salzano, F. M., and Sugita, O. (1997) Effect o f genetic variation on the fatty acid-binding properties 
o f human serum albumin and proalbumin. Biochim Biophys Acta (1342), 191-204.
Nielsen, U. B., Adams, G. P., Weiner, L. M., and Marks, J. D. (2000) Targeting o f bivalent anti-ErbB2
diabody antibody fragments to tumor cells is independent o f the intrinsic antibody affinity. Cancer 
Res (60), 6434-6440.
O’ Connell, D., Becerri, I.B., Roy-Burman, A., Daws, M., and Marks, J.D. Phage versus phagemid libraries 
for generation o f human monoclonal antibodies. J  Mol Biol (321), 49-56.
Oikawa, S., Kosaki, G., and Nakazato, H. (1987) Molecular cloning o f a gene for a member o f
carcinoembryonic antigen (CEA) gene family; signal peptide and N-terminal domain sequences of 
nonspecific crossreacting antigen (NCA). Biochem Biophys Res Commun (146), 464-469.
Oikawa, S., Nakazato, H., and Kosaki, G. (1987) Primary structure of human carcinoembryonic antigen 
(CEA) deduced from cDNA sequence. Biochem Biophys Res Commun (142), 511-518.
Oikawa, S., Imajo, S., Noguchi, T., Kosaki, G., and Nakazato, H. (1987) The carcinoembiyonic antigen
(CEA) contains multiple immunoglobulin-like domains. Biochem Biophys Res Commun (144), 634- 
642.
Onda, M., Nagata, S., Tsutsumi, Y., Vincent, J. J., Wang, Q., Kreitman, R. J., Lee, B., and Pastan, I. (2001) 
Lowering the isoelectric point o f the Fv portion of recombinant immunotoxins leads to decreased 
nonspecific animal toxicity without affecting antitumor activity. Cancer Res (61), 5070-5077.
Opanasopit, P., Shirashi, K., Nishikawa, M., Yamashita, F., Takakura, Y., and Hashida, M. (2001) In vivo
recognition o f mannosylated proteins by hepatic mannose receptors and mannan-binding protein. Am 
J  Physiol Gastrointest Liver Physiol (280), G879-G889.
285
Orlandi, R., Gussow, D. H., Jones, P. T., and Winter, G. (1992) Cloning immunoglobulin variable domains 
for expression by the polymerase chain reaction. 1989. Biotechnology (24), 527-531.
Osbourn, J. K., Field, A., Wilton, J., Derbyshire, E., Eamshaw, J. C., Jones, P. T., Allen, D., and McCafFerty, 
J. (1996) Generation o f a panel of related human scFv antibodies with high affinities for human 
CEA. Immunotechnology (2), 181-196.
Pack, P. and Pluckthun, A. (1992) Miniantibodies: use of amphipathic helices to produce functional, flexibly 
linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry (31), 1579-1584.
Pack, P., Kujau, M., Schroeckh, V., Knupfer, U., Wenderoth, R., Riesenberg, D., and Pluckthun, A. (1993) 
Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell 
density fermentation o f Escherichia coli. Biotechnology (N Y )  (11), 1271-1277.
Pack, P., Muller, K., Zahn, R., and Pluckthun, A. (1995) Tetravalent miniantibodies with high avidity 
assembling in Escherichia coli. JM ol Biol (246), 28-34.
Padlan, E. A., Silverton, E. W., Sheriff, S., Cohen, G. H., Smith-Gill, S. J., and Davies, D. R. (1989) Structure 
o f an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc 
Natl Acad Sci U S A  (86), 5938-5942.
Padlan, E. A. (1994) Anatomy of the antibody molecule. Mol Immunol (31), 169-217.
Paganelli, G., Riva, P., Deleide, G., Clivio, A., Chiolerio, F., Scassellati, G. A., Malcovati, M., and Siccardi, 
A. G. (1988) In vivo labelling o f biotinylated monoclonal antibodies by radioactive avidin: a strategy 
to increase tumor radiolocalization. Int J  Cancer Suppl (2), 121-125.
Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio,
F., Seccamani, E., and . (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic 
antigen-positive patients. Cancer Res (51), 5960-5966.
Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. (1996) Treatment o f advanced solid
tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med (2), 350- 
353.
Paige, A. G., Whitcomb, K. L., Liu, J., and Kinstler, O. (1995) Prolonged circulation o f recombinant human 
granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional 
polyethylene glycol. Pharm Res (12), 1883-1888.
Pantoliano, M. W., Bird, R. E., Johnson, S., Asel, E. D., Dodd, S. W., Wood, J. F., and Hardman, K. D.
(1991) Conformational stability, folding, and ligand-binding affinity o f single-chain Fv 
immunoglobulin fragments expressed in Escherichia coli. Biochemistry (30), 10117-10125.
286
Pastorino, F., Brignole, C., Marimpietri, D., Sapra, P., Moase, E. H., Allen, T. M., and Ponzoni, M. (2003) 
Doxorubicin-loaded Fab' fragments o f anti-disialoganglioside immunoliposomes selectively inhibit 
the growth and dissemination o f human neuroblastoma in nude mice. Cancer Res (63), 86-92.
Patel, T., Bruce, J., Merry, A., Bigge, C., Wormald, M., Jaques, A., and Parekh, R. (1993) Use o f hydrazine to 
release in intact and unreduced form both N- and O-linked oligosaccharides from glycoproteins. 
Biochemistry (32), 679-693.
Patrick, M. R., Chester, K. A., and Pietersz, G. A. (1998) In vitro characterization o f a recombinant 32P- 
phosphorylated anti-(carcinoembryonic antigen) single-chain antibody. Cancer Immunol 
Immunother (46), 229-237.
Pavlinkova, G., Beresford, G. W., Booth, B. J., Batra, S. K., and Colcher, D. (1999) Pharmacokinetics and 
biodistribution o f engineered single-chain antibody constructs o f MAb CC49 in colon carcinoma 
xenografts. JNucl Med (40), 1536-1546.
Pavlinkova, G., Beresford, G., Booth, B. J., Batra, S. K., and Colcher, D. (1999) Charge-modified single 
chain antibody constructs o f monoclonal antibody CC49: generation, characterization, 
pharmacokinetics, and biodistribution analysis. Nucl Med Biol (26), 27-34.
Paxton, R. J., Mooser, G., Pande, H., Lee, T. D., and Shively, J. E. (1987) Sequence analysis of  
carcinoembryonic antigen: identification o f glycosylation sites and homology with the 
immunoglobulin supergene family. Proc Natl Acad Sci U SA  (84), 920-924.
Peach, R. J. and Brennan, S. O. (1991) Structural characterization of a glycoprotein variant of human serum 
albumin: albumin Casebrook (494 Asp— Asn). Biochim Biophys Acta (1097), 49-54.
Pedersen, J. T., Henry, A. H., Searle, S. J., Guild, B. C., Roguska, M., and Rees, A. R. (1994) Comparison of 
surface accessible residues in human and murine immunoglobulin Fv domains. Implication for 
humanization o f  murine antibodies. JM ol Biol (235), 959-973.
Pedley, R. B., Dale, R., Boden, J. A., Begent, R. H., Keep, P. A., and Green, A. J. (1989) The effect o f second 
antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human 
colonic tumor xenograft model. In tJ  Cancer (43), 713-718.
Pedley, R. B., Boden, J. A., Boden, R., Begent, R. H., Turner, A., Haines, A. M., and King, D. J. (1994) The 
potential for enhanced tumour localisation by poly(ethylene glycol) modification o f anti-CEA 
antibody. Br J  Cancer (70), 1126-1130.
Pedley, R. B., El Emir, E., Flynn, A. A., Boxer, G. M., Dearling, J., Raleigh, J. A., Hill, S. A., Stuart, S., 
Motha, R., and Begent, R. H. (2002) Synergy between vascular targeting agents and antibody- 
directed therapy. In tJ  Radiat Oncol Biol Phys (54), 1524-1531.
287
Pei, X. Y., Holliger, P., Murzin, A. G., and Williams, R. L. (1997) The 2.0-A resolution crystal structure o f a 
trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement o f VH 
CDR3. Proc Natl Acad Sci U SA  (94), 9637-9642.
Perisic, O., Webb, P. A., Holliger, P., Winter, G., and Williams, R. L. (1994) Crystal structure of a diabody, a 
bivalent antibody fragment. Structure (2), 1217-1226.
Peters, T., Jr. (1985) Serum albumin. Adv Protein Chem (37), 161-245.
Philben, V. J., Jakowatz, J. G., Beatty, B. G., Vlahos, W. G., Paxton, R. J., Williams, L. E., Shively, J. E., and 
Beatty, J. D. (1986) The effect o f tumor CEA content and tumor size on tissue uptake of indium 111- 
labeled anti-CEA monoclonal antibody. Cancer (57), 571-576.
Piefer, A. J. and Jonsson, C. B. (2002) A comparative study o f the human T-cell leukemia virus type 2
integrase expressed in and purified from Escherichia coli and Pichia pastoris. Protein Expr Purif 
(25), 291-299.
Pietersz, G. A., Patrick, M. R., and Chester, K. A. (1998) Preclinical characterization and in vivo imaging 
studies o f an engineered recombinant technetium-99m-labeled metallothionein-containing anti- 
carcinoembryonic antigen single-chain antibody. JNucl Med (39), 47-56.
Pini, A., Viti, F., Santucci, A., Camemolla, B., Zardi, L., Neri, P., and Neri, D. (1998) Design and use o f a 
phage display library. Human antibodies with subnanomolar affinity against a marker of 
angiogenesis eluted from a two-dimensional gel. J  Biol Chem (273), 21769-21776.
Pluckthun, A. and Pack, P. (1997) New protein engineering approaches to multi valent and bispecific antibody 
fragments. Immunotechnology (3), 83-105.
Poljak, R. J., Amzel, L. M., Avey, H. P., Chen, B. L., Phizackerley, R. P., and Saul, F. (1973) Three-
dimensional structure o f the Fab' fragment o f a human immunoglobulin at 2,8-A resolution. Proc 
Natl Acad Sci U S A  (70), 3305-3310.
Poljak, R. J. (1973) X-ray crystallographic studies o f immunoglobulins. Contemp Top Mol Immunol (2), 1-26.
Porath, J., Carlsson, J., Olsson, I., and Belfrage, G. (1975) Metal chelate affinity chromatography, a new 
approach to protein fractionation. Nature (258), 598-599.
Porath, J. (1992) Immobilized metal ion affinity chromatography. Protein Expr Purif (3), 263-281.
Porter, R. J. (1962) Prolonged suppression by x-ray o f adaptation for the secondary antibody response. Proc 
Soc Exp Biol M ed (111), 583-584.
288
Porter, R. R. (1958) Separation and isolation o f fractions of rabbit gamma-globulin containing the antibody 
and antigenic combining sites. Nature (182), 670-671.
Poste, G. and Fidler, I. J. (1980) The pathogenesis o f cancer metastasis. Nature (283), 139-146.
Postema, E. J., Raemaekers, J. M., Oyen, W. J., Boerman, O. C., Mandigers, C. M., Goldenberg, D. M., van 
Dongen, G. A., and Corstens, F. H. (2003) Final results o f  a phase I radioimmunotherapy trial using 
(186)Re-epratuzumab for the treatment o f patients with non-Hodgkin's lymphoma. Clin Cancer Res 
(9), 3995S-4002S
Potter, K. N., Li, Y., and Capra, J. D. (1993) Antibody production in the baculovirus expression system. Int 
Rev Immunol (10), 103-112.
Porter, RR. (1973) Structural studies of immunoglobulins. Science (180), 713-716.
Power, B. E., Caine, J. M., Bums, J. E., Shapira, D. R., Hattarki, M. K., Tahtis, K., Lee, F. T., Smyth, F. E., 
Scott, A. M., Kortt, A. A., and Hudson, P. J. (2001) Construction, expression and characterisation o f  
a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a 
heat-inducible bacterial secretion vector. Cancer Immunol Immunother (50), 241-250.
Powers, D. B., Amersdorfer, P., Poul, M., Nielsen, U. B., Shalaby, M. R., Adams, G. P., Weiner, L. M., and 
Marks, J. D. (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J  Immunol Methods 
(251), 123-135.
Poznansky, M. J. (1988) Soluble enzyme—albumin conjugates: new possibilities for enzyme replacement 
therapy. Methods Enzymol (137), 566-574.
Poznansky, M. J., Halford, J., and Taylor, D. (1988) Growth hormone-albumin conjugates. Reduced renal 
toxicity and altered plasma clearance. FEBS Lett (239), 18-22.
Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., 
Bush, S. A., Durack, L. D., Martin, P. J., Fisher, D. R., Wood, B., Borrow, J. W., Porter, B., Smith, J. 
P., Matthews, D. C., Appelbaum, F. R., and Bernstein, I. D. (2000) A phase I/II trial o f iodine-131- 
tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation 
for relapsed B-cell lymphomas. Blood (96), 2934-2942.
Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., 
Bush, S. A., Durack, L. D., Martin, P. J., Fisher, D. R., Wood, B., Borrow, J. W., Porter, B., Smith, J. 
P., Matthews, D. C., Appelbaum, F. R., and Bernstein, I. D. (2000) A phase I/II trial o f iodine-131- 
tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation 
for relapsed B-cell lymphomas. Blood (96), 2934-2942.
289
Radic, M.Z., Erikson, J., Litwin, S., Weigert, M. (1993) B lymphocytes may escape tolerance by revising 
their antigen receptors. J  Exp Med (177), 1163-1173.
Ran, S., Huang, X., Downes, A., and Thorpe, P. E. (2003) Evaluation o f novel antimouse VEGFR2 antibodies 
as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia (5), 297-307.
Read, D. A. (1995) B rJ  Cancer (71) Suppl. XIV:abstr.P132, 57.
Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P.,
Bartholomew, R. M., and Frincke, J. M. (1985) Antibodies against metal chelates. Nature (316), 
265-268.
Reid, G., Gan, B. S., She, Y. M., Ens, W., Weinberger, S., and Howard, J. C. (2002) Rapid identification of  
probiotic lactobacillus biosurfactant proteins by ProteinChip tandem mass spectrometry tryptic 
peptide sequencing. Appl Environ Microbiol (68), 977-980.
Reiter, Y., Pai, L. H., Brinkmann, U., Wang, Q. C., and Pastan, I. (1994) Antitumor activity and
pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv 
fragment. Cancer Res (54), 2714-2718.
Reiter, Y., Brinkmann, U., Kreitman, R. J., Jung, S. H., Lee, B., and Pastan, I. (1994) Stabilization o f the Fv 
fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework 
regions. Biochemistry (33), 5451-5459.
Reiter, Y., Schuck, P., Boyd, L. F., and Plaksin, D. (1999) An antibody single-domain phage display library 
of a native heavy chain variable region: isolation of functional single-domain VH molecules with a 
unique interface. J  Mol Biol (290), 685-698.
Richards, F. M. (1974) The interpretation of protein structures: total volume, group volume distributions and 
packing density. JM ol Biol (82), 1-14.
Ridder, R., Schmitz, R., Legay, F., and Gram, H. (1995) Generation o f rabbit monoclonal antibody fragments 
from a combinatorial phage display library and their production in the yeast Pichia pastoris. 
Biotechnology (N Y )  (13), 255-260.
Ritz, J., Pesando, J. M., Notis-McConarty, J., Clavell, L. A., Sallan, S. E., and Schlossman, S. F. (1981) Use 
o f monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. 
Cancer Res (41), 4771-4775.
Riva, P., Marangolo, M., Tison, V., Armaroli, L., Moscatelli, G., Franceschi, G., Spinelli, A., Vecchietti, G., 
Morigi, P., Tassini, R., and. (1991) Treatment o f metastatic colorectal cancer by means o f specific 
monoclonal antibodies conjugated with iodine-131: a phase II study. In tJ  Rad Appl Instrum B (18), 
109-119.
290
Roberts, R. W. (1999) Totally in vitro protein selection using mRNA-protein fusions and ribosome display. 
Curr Opin Chem Biol (3), 268-273.
Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., 
Blattler, W. A., Rees, A. R., and Guild, B. C. (1994) Humanization o f murine monoclonal antibodies 
through variable domain resurfacing. Proc Natl Acad Sci U S A  (91), 969-973.
Romanos, M. A., Scorer, C. A., and Clare, J. J. (1992) Foreign gene expression in yeast: a review. Yeast (8), 
423-488.
Rosenfeld, S. A., Nadeau, D., Tirado, J., Hollis, G. F., Knabb, R. M., and Jia, S. (1996) Production and
purification o f recombinant hirudin expressed in the methylotrophic yeast Pichia pastoris. Protein 
Expr Purif (8), 476-482.
Ruan, B., Hoskins, J., Wang, L., and Bryan, P. N. (1998) Stabilizing the subtilisin BPl^ T pro-domain by phage 
display selection: how restrictive is the amino acid code for maximum protein stability? Protein Sci 
(7), 2345-2353.
Rutherford, R. A., Smith, A., Waibel, R., and Schubiger, P. A. (1997) Differential inhibitory effect o f L-lysine 
on renal accumulation o f 67Cu-labelled F(ab')2 fragments in mice. In tJ  Cancer (72), 522-529.
Sack, T. L., Gum, J. R., Low, M. G., and Kim, Y. S. (1988) Release of carcinoembryonic antigen from human 
colon cancer cells by phosphatidylinositol-specific phospholipase C . J  Clin Invest (82), 586-593.
Sagar, V. V. and Meckelnburg, R. L. (1983) What's new in nuclear medicine? Del Med J  (55), 39-40.
Sakamoto, Y., Kitamura, K., Madison, J., Watkins, S., Laurell, C. B., Nomura, M., Higashiyama, T., and 
Putnam, F. W. (1995) Structural study o f the glycosylated and unglycosylated forms o f a genetic 
variant o f  human serum albumin (63 Asp—>Asn). Biochim Biophys Acta (1252), 209-216.
Sali, A. and Blundell, T. L. (1990) Definition o f general topological equivalence in protein structures. A 
procedure involving comparison o f properties and relationships through simulated annealing and 
dynamic programming. J  Mol Biol (212), 403-428.
Sanders, D. S., Ferryman, S. R., Bryant, F. J., and Rollason, T. P. (1993) Patterns o f CEA-related antigen 
expression in invasive squamous carcinoma o f the cervix. J  Pathol (171), 21-26.
Sarma, V. R., Silverton, E. W., Davies, D. R., and Terry, W. D. (1971) The three-dimensional structure at 6 A 
resolution o f a human gamma G1 immunoglobulin molecule. J  Biol Chem (246), 3753-3759.
Sayle, R. A. and Milner-White, E. J. (1995) RASMOL: biomolecular graphics for all. Trends Biochem Sci 
(20), 374-
291
Searle, S.J., Pedersen, J.T., Henry, A.H., Webster, D.M., and Rees, A.T. (1995) Antibody Structure and
Function. In: Antibody Engineering 2nd Edition (Borrebaeck, C.A.K., Ed.), Oxford University Press, 
3-51.
Scherf, U., Benhar, I., Webber, K. O., Pastan, I., and Brinkmann, U. (1996) Cytotoxic and antitumor activity 
o f a recombinant tumor necrosis factor-Bl(Fv) fusion protein on LeY antigen-expressing human 
cancer cells. Clin Cancer Res (2), 1523-1531.
Schier, R., Bye, J., Apell, G., McCall, A., Adams, G. P., Malmqvist, M., Weiner, L. M., and Marks, J. D. 
(1996) Isolation o f high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity- 
driven selection. J  Mol Biol (255), 28-43.
Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., 
Marks, C., and Marks, J. D. (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by 
molecular evolution o f the complementarity determining regions in the center o f the antibody 
binding site. J  Mol Biol (263), 551-567.
Schindler, J., Sausville, E., Messmann, R., Uhr, J. W., and Vitetta, E. S. (2001) The toxicity o f deglycosylated 
ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by 
prior radiotherapy: a retrospective analysis o f patients in five clinical trials. Clin Cancer Res (7), 
255-258.
Schmiedl, A., Breitling, F., and Dubel, S. (2000) Expression o f a bispecific dsFv-dsFv' antibody fragment in 
Escherichia coli. Protein Eng (13), 725-734.
Schnell, R., Vitetta, E., Schindler, J., Borchmann, P., Barth, S., Ghetie, V., Hell, K., Drillich, S., Diehl, V.,
and Engert, A. (2000) Treatment o f refractory Hodgkin's lymphoma patients with an anti-CD25 ricin 
A-chain immunotoxin. Leukemia (14), 129-135.
Schodin, B. A. and Kranz, D. M. (1993) Binding affinity and inhibitory properties o f a single-chain anti-T cell 
receptor antibody. JB iol Chem (268), 25722-25727.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., and Morgan, A. C., Jr. (1985) Human anti-murine 
immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res (45), 879- 
885.
Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S., and Axworthy, D. (2000) A 
tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. 
Cancer Res (60), 6663-6669.
292
Schwyzer, M., Weil, R., Frank, G., and Zuber, H. (1980) Amino acid sequence analysis o f fragments
generated by partial proteolysis from large simian virus 40 tumor antigen. J  Biol Chem (255), 5627- 
5634.
Scorer, C. A., Buckholz, R. G., Clare, J. J., and Romanos, M. A. (1993) The intracellular production and 
secretion o f HTV-1 envelope protein in the methylotrophic yeast Pichia pastoris. Gene (136), 111- 
119.
Screaton, R. A., Penn, L. Z., and Stanners, C. P. (1997) Carcinoembryonic antigen, a human tumor marker, 
cooperates with Myc and Bcl-2 in cellular transformation. J  Cell Biol (137), 939-952.
Segal, D. M., Weiner, G. J., and Weiner, L. M. (2001) Introduction: bispecific antibodies. J  Immunol Methods 
(248), 1-6.
Seitz, U., Neumaier, B., Glatting, G., Kotzerke, J., Bunjes, D., and Reske, S. N. (1999) Preparation and 
evaluation o f the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for 
radioimmunotherapy o f leukaemia. EurJNucl Med (26), 1265-1273.
Seregni, E., Bombardieri, E., Bogni, A., Crippa, F., De Jager, E., and Buraggi, G. L. (1992) The role of serum 
carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the 
experience o f  the Istituto Tumori o f Milan. In tJ  Biol Markers (7), 167-170.
Sharkey, R. M., Primus, F. J., and Goldenberg, D. M. (1984) Second antibody clearance o f radiolabeled 
antibody in cancer radioimmunodetection. Proc Natl Acad Sci U S A  (81), 2843-2846.
Sharkey, R. M., Mabus, J., and Goldenberg, D. M. (1988) Factors influencing anti-antibody enhancement of 
tumor targeting with antibodies in hamsters with human colonic tumor xenografts. Cancer Res (48), 
2005-2009.
Sharkey, R. M., Karacay, H., Griffiths, G. L., Behr, T. M., Blumenthal, R. D., Mattes, M. J., Hansen, H. J., 
and Goldenberg, D. M. (1997) Development o f a streptavidin-anti-carcinoembryonic antigen 
antibody, radiolabeled biotin pretargeting method for radioimmunotherapy o f colorectal cancer. 
Studies in a human colon cancer xenograft model. Bioconjug Chem (8), 595-604.
Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, R. W., and Rogers, G. T. (1990) Inactivation and
clearance o f an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft 
model. Br J  Cancer (61), 659-662.
Sharma, S. K., Bagshawe, K. D., Springer, C. J., Burke, P. J., Rogers, G. T., Boden, J. A., Antoniw, P.,
Melton, R. G., and Sherwood, R. F. (1991) Antibody directed enzyme prodrug therapy (ADEPT): a 
three phase system. Dis Markers (9), 225-231.
293
Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, J. A., Rogers, G. T., Springer, C. J., Melton, R. G., and 
Sherwood, R. F. (1994) Galactosylated antibodies and antibody-enzyme conjugates in antibody- 
directed enzyme prodrug therapy. Cancer (73), 1114-1120.
Shawler, D. L., Bartholomew, R. M., Smith, L. M., and Dillman, R. O. (1985) Human immune response to 
multiple injections o f murine monoclonal IgG. J  Immunol (135), 1530-1535.
Sheahan, K., O'Brien, M. J., Burke, B., Dervan, P. A., O'Keane, J. C., Gottlieb, L. S., and Zamcheck, N.
(1990) Differential reactivities o f carcinoembryonic antigen (CEA) and CEA-related monoclonal and 
polyclonal antibodies in common epithelial malignancies. Am J  Clin Pathol (94), 157-164.
Sheffield, W. P., Smith, I. J., Syed, S., and Bhakta, V. (2001) Prolonged in vivo anticoagulant activity o f a 
hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis (12), 433- 
443.
Sheibani, K., Battifora, H., and Burke, J. S. (1986) Antigenic phenotype o f  malignant mesotheliomas and 
pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value o f Leu Ml 
antigen. Am J  Pathol (123), 212-219.
Sheshberadaran, H. and Payne, L. G. (1988) Protein antigen-monoclonal antibody contact sites investigated
by limited proteolysis o f monoclonal antibody-bound antigen: protein "footprinting". Proc Natl Acad 
Sci U S A  (85), 1-5.
Shi, M., Xie, Z., Feng, J., Sun, Y., Yu, M., Shen, B., and Guo, N. (2003) A recombinant anti-erbB2, scFv-Fc- 
IL-2 fusion protein retains antigen specificity and cytokine function. Biotechnol Lett (25), 815-819.
Sievers, E. L. and Linenberger, M. (2001) Mylotarg: antibody-targeted chemotherapy comes o f age. Curr 
Opin Oncol (13), 522-527.
Silbemagl, S. (1988) The renal handling o f amino acids and oligopeptides. Physiol Rev (68), 911-1007.
Sinn, H., Schrenk, H. H., Friedrich, E. A., Schilling, U., and Maier-Borst, W. (1990) Design o f compounds 
having an enhanced tumour uptake, using serum albumin as a carrier. Part I. In tJ  Rad Appl Instrum 
B (17), 819-827.
Skerra, A. and Pluckthun, A. (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia 
coli. Science (240), 1038-1041.
Skerra, A. (1994) Use o f the tetracycline promoter for the tightly regulated production o f a murine antibody 
fragment in Escherichia coli. Gene (151), 131-135.
Smith-Gill, S. J., Lavoie, T. B., and Mainhart, C. R. (1984) Antigenic regions defined by monoclonal 
antibodies correspond to structural domains o f avian lysozyme. J  Immunol (133), 384-393.
294
Smith, B. J., Popplewell, A., Athwal, D., Chapman, A. P., Heywood, S., West, S. M., Carrington, B., Nesbitt, 
A., Lawson, A. D., Antoniw, P., Eddelston, A., and Suitters, A. (2001) Prolonged in vivo residence 
times o f antibody fragments associated with albumin. Bioconjug Chem (12), 750-756.
Sondermann, P., Huber, R., and Jacob, U. (1999) Crystal structure o f the soluble form o f the human
fcgamma-receptor lib: a new member of the immunoglobulin superfamily at 1.7 A resolution. 
E M B O J(18), 1095-1103.
Spencer, D. I., Robson, L., Purdy, D., Whitelegg, N. R., Michael, N. P., Bhatia, J., Sharma, S. K., Rees, A. R., 
Minton, N. P., Begent, R. H., and Chester, K. A. (2002) A strategy for mapping and neutralizing 
conformational immunogenic sites on protein therapeutics. Proteomics (2), 271-279.
Stanfield, R. L., Fieser, T. M., Lemer, R. A., and Wilson, I. A. (1990) Crystal structures o f an antibody to a 
peptide and its complex with peptide antigen at 2.8 A. Science (248), 712-719.
Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C., Hartung, G., Maier-Borst, W., and Heene, D. 
L. (1997) Plasma protein (albumin) catabolism by the tumor itself—implications for tumor 
metabolism and the genesis o f cachexia. Crit Rev Oncol Hematol (26), 77-100.
Stehle, G., Wunder, A., Sinn, H., Schrenk, H. H., Schutt, S., Frei, E., Hartung, G., Maier-Borst, W., and
Heene, D. L. (1997) Pharmacokinetics o f methotrexate-albumin conjugates in tumor-bearing rats. 
Anticancer Drugs (8), 835-844.
Stehle, G., Wunder, A., Schrenk, H. H., Hartung, G., Heene, D. L., and Sinn, H. (1999) Albumin-based drug 
carriers: comparison between serum albumins of different species on pharmacokinetics and tumor 
uptake o f the conjugate. Anticancer Drugs (10), 785-790.
Stehle, G., Wunder, A., Schrenk, H. H., Hartung, G., Heene, D. L., and Sinn, H. (1999) Methotrexate-albumin 
conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer 
Drugs {10), 405-411.
Steipe, B., Schiller, B., Pluckthun, A., and Steinbacher, S. (1994) Sequence statistics reliably predict 
stabilizing mutations in a protein domain. J  Mol Biol (240), 188-192.
Stemmer, W. P. (1994) DNA shuffling by random fragmentation and reassembly: in vitro recombination for 
molecular evolution. Proc Natl Acad Sci U SA  (91), 10747-10751.
Suckau, D., Kohl, J., Karwath, G., Schneider, K., Casaretto, M., Bitter-Suermann, D., and Przybylski, M.
(1990) Molecular epitope identification by limited proteolysis o f an immobilized antigen-antibody 
complex and mass spectrometric peptide mapping. Proc Natl Acad Sci U S A  (87), 9848-9852.
Sumpio, B. E. and Hayslett, J. P. (1985) Renal handling o f proteins in normal and disease states. Q JM ed  
(57), 611-635.
295
Sun, C., Wirsching, P., and Janda, K. D. (2003) Enabling ScFvs as multi-drug carriers: a dendritic approach. 
Bioorg Med Chem (11), 1761-1768.
Syed, S., Schuyler, P. D., Kulczycky, M., and Sheffield, W. P. (1997) Potent antithrombin activity and 
delayed clearance from the circulation characterize recombinant hirudin genetically fused to 
albumin. Blood {89), 3243-3252.
Taheri, M., Saragovi, U., Fuks, A., Makkerh, J., Mort, J., and Stanners, C. P. (2000) Self recognition in the Ig 
superfamily. Identification o f precise subdomains in carcinoembryonic antigen required for 
intercellular adhesion. JB iol Chem (275), 26935-26943.
Tahtis, K., Lee, F. T., Smyth, F. E., Power, B. E., Renner, C., Brechbiel, M. W., Old, L. J., Hudson, P. J., and 
Scott, A. M. (2001) Biodistribution properties o f (11 l)indium-labeled C-functionalized trans- 
cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in 
a breast carcinoma xenograft model. Clin Cancer Res (7), 1061-1072.
Takahashi, H., Okai, Y., Paxton, R. J., Hefta, L. J., and Shively, J. E. (1993) Differential regulation o f
carcinoembryonic antigen and biliary glycoprotein by gamma-interferon. Cancer Res (53), 1612- 
1619.
Tan, K., Zelus, B. D., Meijers, R., Liu, J. H., Bergelson, J. M., Duke, N., Zhang, R., Joachimiak, A., Holmes, 
K. V., and Wang, J. H. (2002) Crystal structure of murine sCEACAMla[l,4]: a coronavirus receptor 
in the CEA family. EMBOJ (21), 2076-2086.
Tan, P. H., Sandmaier, B. M., and Stayton, P. S. (1998) Contributions o f a highly conserved VH/VL hydrogen 
bonding interaction to scFv folding stability and refolding efficiency. Biophys J (75), 1473-1482.
Tang, Y., Jiang, N., Parakh, C., and Hilvert, D. (1996) Selection o f linkers for a catalytic single-chain 
antibody using phage display technology. JB iol Chem (271), 15682-15686.
Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Bemdorff, D., Dinkelborg, L., Neri, D., and Zardi, L. 
(1999) A high-affinity human antibody that targets tumoral blood vessels. Blood (94), 192-198.
Tawaragi, Y., Oikawa, S., Matsuoka, Y., Kosaki, G., and Nakazato, H. (1988) Primary structure of
nonspecific crossreacting antigen (NCA), a member of carcinoembryonic antigen (CEA) gene 
family, deduced from cDNA sequence. Biochem Biophys Res Commun (150), 89-96.
Thomas, P., Toth, C. A., Saini, K. S., Jessup, J. M., and Steele, G., Jr. (1990) The structure, metabolism and 
function o f the carcinoembryonic antigen gene family. Biochim Biophys Acta (1032), 177-189.
Thomas, P. and Toth, C. A. (1990) Carcinoembryonic antigen binding to Kupffer cells is via a peptide located 
at the junction o f the N-terminal and first loop domains. Biochem Biophys Res Commun (170), 391- 
396.
296
Thomas, P., Petrick, A. T., Toth, C. A., Fox, E. S., Elting, J. J., and Steele, G., Jr. (1992) A peptide sequence 
on carcinoembryonic antigen binds to a 80kD protein on KupfFer cells. Biochem Biophys Res 
Commun (188), 671-677.
Tibbetts, L. M., Doremus, C. M., Tzanakakis, G. N., and Vezeridis, M. P. (1993) Liver metastases with 10 
human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen 
production. Cancer (71), 315-321.
Tom, B. H., Rutzky, L. P., Jakstys, M. M., Oyasu, R., Kaye, C. I., and Kahan, B. D. (1976) Human colonic 
adenocarcinoma cells. I. Establishment and description o f a new line. In Vitro (12), 180-191.
Tonegawa, S. (1983) Somatic generation of antibody diversity. Nature (302), 575-581.
Toth, C. A., Thomas, P., Broitman, S. A., and Zamcheck, N. (1982) A new KupfFer cell receptor mediating 
plasma clearance o f carcinoembryonic antigen by the rat. Biochem J  (204), 377-381.
Toth, C. A., Thomas, P., Broitman, S. A., and Zamcheck, N. (1985) Receptor-mediated endocytosis of 
carcinoembryonic antigen by rat liver KupfFer cells. Cancer Res (45), 392-397.
Toth, C. A., Rapoza, A., Zamcheck, N., Steele, G., and Thomas, P. (1989) Receptor-mediated endocytosis of 
carcinoembryonic antigen by rat alveolar macrophages in vitro. JLeukoc Biol (45), 370-376.
Trikha, M., Yan, L., and Nakada, M. T. (2002) Monoclonal antibodies as therapeutics in oncology. Curr Opin 
Biotechnol (13), 609-614.
Tsai, S. W., Li, L., Williams, L. E., Anderson, A. L., Raubitschek, A. A., and Shively, J. E. (2001)
Metabolism and renal clearance o f 111 In-labeled DOTA-conjugated antibody fragments. Bioconjug 
Chem (12), 264-270.
Tschopp, J. F., Brust, P. F., Cregg, J. M., Stillman, C. A., and Gingeras, T. R. (1987) Expression o f the lacZ 
gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res (15), 3859-3876.
Urban, J. L. and Schreiber, H. (1992) Tumor antigens. Annu Rev Immunol (10), 617-644.
Van de, Water J., Deininger, S. O., Macht, M., Przybylski, M., and Gershwin, M. E. (1997) Detection of
molecular determinants and epitope mapping using MALDI-TOF mass spectrometry. Clin Immunol 
Immunopathol (85), 229-235.
Verhaar, M. J., Chester, K. A., Keep, P. A., Robson, L., Pedley, R. B., Boden, J. A., Hawkins, R. E., and
Begent, R. H. (1995) A single chain Fv derived from a filamentous phage library has distinct tumor 
targeting advantages over one derived from a hybridoma. In tJ  Cancer (61), 497-501.
297
Virji, M., Makepeace, K., Ferguson, D. J., and Watt, S. M. (1996) Carcinoembryonic antigens (CD66) on 
epithelial cells and neutrophils are receptors for Opa proteins o f pathogenic neisseriae. Mol 
Microbiol (22), 941-950.
Virji, M., Evans, D., Hadfield, A., Grunert, F., Teixeira, A. M., and Watt, S. M. (1999) Critical determinants 
o f host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: identification o f Opa 
adhesiotopes on the N-domain o f CD66 molecules. Mol Microbiol (34), 538-551.
Viiji, M., Evans, D., Griffith, J., Hill, D., Serino, L., Hadfield, A., and Watt, S. M. (2000) Carcinoembryonic 
antigens are targeted by diverse strains of typable and non-typable Haemophilus influenzae. Mol 
Microbiol (36), 784-795.
Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999) Increased binding affinity and valence of 
recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 
(59), 347-352.
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh,
G. F., Stagg, R. J., and Kaminski, M. S. (2000) Multicenter phase II study o f iodine-131 
tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell 
non-Hodgkin's lymphomas. J  Clin Oncol (18), 1316-1323.
Wabl, M., Cascalho, M., and Steinberg, C. (1999) Hypermutation in antibody affinity maturation. Curr Opin 
Immunol (11), 186-189.
Waldmann, T. A. and Strober, W. (1969) Metabolism o f immunoglobulins. Prog Allergy (13), 1-110.
Wang, D., Liao, J., Mitra, D., Akolkar, P. N., Gruezo, F., and Kabat, E. A. (1991) The repertoire o f antibodies 
to a single antigenic determinant. Mol Immunol (28), 1387-1397.
Wang, M., Lee, L. S., Nepomich, A., Yang, J. D., Conover, C., Whitlow, M., and Filpula, D. (1998) Single­
chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Eng (11), 
1277-1283.
Watkins, S., Madison, J., Davis, E., Sakamoto, Y., Galliano, M., Minchiotti, L., and Putnam, F. W. (1991) A 
donor splice mutation and a single-base deletion produce two carboxyl-terminal variants o f human 
serum albumin. Proc Natl Acad Sci U SA  (88), 5959-5963.
Watkins, S., Madison, J., Galliano, M., Minchiotti, L., and Putnam, F. W. (1994) Analbuminemia: three cases 
resulting from different point mutations in the albumin gene. Proc Natl Acad Sci U SA  (91), 9417- 
9421.
298
Webber, K. O., Reiter, Y., Brinkmann, U., Kreitman, R., and Pastan, I. (1995) Preparation and
characterization o f a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its 
single-chain analog. Mol Immunol (32), 249-258.
Webster, D. M., Pedersen, J., Staunton, D., Jones, A., and Rees, A. R. (1994) Antibody-combining sites. 
Extending the natural limits. Appl Biochem Biotechnol (47), 119-132.
Weigert, M., Perry, R., Kelley, D., Hunkapiller, T., Schilling, J., and Hood, L. (1980) The joining o f V and J 
gene segments creates antibody diversity. Nature (283), 497-499.
White, C. A. (2003) Rituxan immunotherapy and Zevalin radioimmunotherapy in the treatment o f non- 
Hodgkin's lymphoma. Curr Pharm Biotechnol (4), 221-238.
Whitlow, M., Bell, B. A., Feng, S. L., Filpula, D., Hardman, K. D., Hubert, S. L., Rollence, M. L., Wood, J. 
F., Schott, M. E., Milenic, D. E., and . (1993) An improved linker for single-chain Fv with reduced 
aggregation and enhanced proteolytic stability. Protein Eng (6), 989-995.
Whitlow, M., Filpula, D., Rollence, M. L., Feng, S. L., and Wood, J. F. (1994) Multivalent Fvs:
characterization o f single-chain Fv oligomers and preparation o f a bispecific Fv. Protein Eng (7), 
1017-1026.
Williams, A. F. and Barclay, A. N. (1988) The immunoglobulin superfamily-domains for cell surface 
recognition. Annu Rev Immunol (6), 381-405.
Williams, L.E. and Primus, E.J. (1996) Biodistribution of an 11 lln  or 90Y-labelled dimeric anti-CEA 
monoclonal antibody (CT84.66) following its large scale production in a bioreactor. Tumour 
Targeting (2), 116-124.
Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R., Zangemeister-Wittke, U., and Pluckthun, 
A. (1999) High thermal stability is essential for tumor targeting o f antibody fragments: engineering 
o f a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv 
fragment. Cancer Res (59), 5758-5767.
Willuda, J., Kubetzko, S., Waibel, R., Schubiger, P. A., Zangemeister-Wittke, U., and Pluckthun, A. (2001) 
Tumor targeting o f mono-, di-, and tetravalent anti-pl85(HER-2) miniantibodies multimerized by 
self-associating peptides. JB iol Chem (276), 14385-14392.
Wirtz, P. and Steipe, B. (1999) Intrabody construction and expression III: engineering hyperstable V(H) 
domains. Protein Sci (8), 2245-2250.
Wiseman, G. A., White, C. A., Stabin, M., Dunn, W. L., Erwin, W., Dahlbom, M., Raubitschek, A., Karvelis, 
K., Schultheiss, T., Witzig, T. E., Belanger, R., Spies, S., Silverman, D. H., Berlfein, J. R., Ding, E., 
and Grillo-Lopez, A. J. (2000) Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-
299
Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. 
Eur JN ucl M ed (27), 766-777.
Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., PodolofF, D. A., Lamonica, D., Bartlett, N. L., 
Parker, J. A., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., and Leigh, B. R. (2001) 
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of 
Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's 
lymphoma. Crit Rev Oncol Hematol (39), 181-194.
Witzig, T. E. (2000) The use o f ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell 
non-Hodgkin's lymphoma. Semin Oncol (27), 74-78.
Wong, J. Y., Somlo, G., Odom-Maryon, T., Williams, L. E., Liu, A., Yamauchi, D., Wu, A. M., Yazaki, P., 
Wilczynski, S., Shively, J. E., Forman, S., Doroshow, J. H., and Raubitschek, A. A. (1999) Initial 
clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody 
and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing 
metastatic breast cancer. Clin Cancer Res (5), 3224s-3231s.
Woodhouse, E. C., Chuaqui, R. F., and Liotta, L. A. (1997) General mechanisms o f metastasis. Cancer (80), 
1529-1537.
Worn, A., Auf der, Maur A., Escher, D., Honegger, A., Barberis, A., and Pluckthun, A. (2000) Correlation 
between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic 
inhibitors. J  Biol Chem (275), 2795-2803.
Worn, A. and Pluckthun, A. (2001) Stability engineering o f antibody single-chain Fv fragments. J  Mol Biol 
(305), 989-1010.
Wosikowski, K., Biedermann, E., Rattel, B., Breiter, N., Jank, P., Loser, R., Jansen, G., and Peters, G. J.
(2003) In vitro and in vivo antitumor activity o f methotrexate conjugated to human serum albumin in 
human cancer cells. Clin Cancer Res (9), 1917-1926.
Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer, R., Hu, S. Z., Odom-Maryon, 
T., Wong, J. Y., and Shively, J. E. (1996) Tumor localization o f anti-CEA single-chain Fvs: 
improved targeting by non-covalent dimers. Immunotechnology (2), 21-36.
Wu, A. M., Yazaki, P. J., Tsai, S., Nguyen, K., Anderson, A. L., McCarthy, D. W., Welch, M. J., Shively, J. 
E., Williams, L. E., Raubitschek, A. A., Wong, J. Y., Toyokuni, T., Phelps, M. E., and Gambhir, S.
S. (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by 
using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A  (97), 8495-8500.
300
Wu, T. T. and Kabat, E. A. (1970) An analysis o f the sequences o f the variable regions o f Bence Jones
proteins and myeloma light chains and their implications for antibody complementarity. J  Exp Med 
(132), 211-250.
Wunder, A., Stehle, G., Schrenk, H. H., Hartung, G., Heene, D. L., Maier-Borst, W., and Sinn, H. (1998)
Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. In tJ  
Cancer (76), 884-890.
Wunder, A., Muller-Ladner, U., Stelzer, E. H., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S., 
and Fiehn, C. (2003) Albumin-based drug delivery as novel therapeutic approach for rheumatoid 
arthritis. J  Immunol (170), 4793-4801.
Wyckoff, J. B., Jones, J. G., Condeelis, J. S., and Segall, J. E. (2000) A critical step in metastasis: in vivo 
analysis o f intravasation at the primary tumor. Cancer Res (60), 2504-2511.
Wyss, D. F. and Wagner, G. (1996) The structural role of sugars in glycoproteins. Curr Opin Biotechnol (7), 
409-416.
Yamashita, K., Totani, K., Kuroki, M., Matsuoka, Y., Ueda, I., and Kobata, A. (1987) Structural studies of the 
carbohydrate moieties of carcinoembryonic antigens. Cancer Res (47), 3451-3459.
Yamashita, K., Totani, K., Iwaki, Y., Kuroki, M., Matsuoka, Y., Endo, T., and Kobata, A. (1989)
Carbohydrate structures o f nonspecific cross-reacting antigen-2, a glycoprotein purified from 
meconium as an antigen cross-reacting with anticarcinoembryonic antigen antibody. Occurrence of 
complex-type sugar chains with the Gal beta 1— 3GlcNAc beta 1— 3Gal beta 1— 4GlcNAc beta 1- 
—outer chains. JB iol Chem (264), 17873-17881.
Yang, J., Moyana, T., and Xiang, J. (1995) A genetically engineered single-chain FV/TNF molecule
possesses the anti-tumor immunoreactivity o f FV as well as the cytotoxic activity of tumor necrosis 
factor. Mol Immunol (32), 873-881.
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., 
Chen, H. X., and Rosenberg, S. A. (2003) A randomized trial o f bevacizumab, an anti-vascular 
endothelial growth factor antibody, for metastatic renal cancer. N  Engl J  Med (349), 427-434.
Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M. C., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu,
H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C., Borowski, V., Mehlig, M., and Filpula, 
D. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by 
site-specific PEGylation. Protein Eng (16), 761-770.
301
Yang, W. D., Li, B., Zhu, C. M., He, H. J., Yang, G. Z., and Wu, X. F. (2000) Fused Expression of Anti-CEA 
Single-chain Antibody Gene with Core-streptavidin Gene in Insect Cells. Sheng Wu Hua Xue Yu 
Sheng Wu Wu Li Xue Bao (Shanghai) (32), 669-671.
Yang, W. P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., and Barbas, C. F., III. (1995) CDR 
walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the 
picomolar range. J  Mol Biol (254), 392-403.
Yazaki, P. J., Wu, A. M., Tsai, S. W., Williams, L. E., Ikler, D. N., Wong, J. Y., Shively, J. E., and
Raubitschek, A. A. (2001) Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 
diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem (12), 220- 
228.
Yazaki, P. J., Shively, L., Clark, C., Cheung, C. W., Le, W., Szpikowska, B., Shively, J. E., Raubitschek, A. 
A., and Wu, A. M. (2001) Mammalian expression and hollow fiber bioreactor production of 
recombinant anti-CEA diabody and minibody for clinical applications. J  Immunol Methods (253), 
195-208.
Yeh, P., Landais, D., Lemaitre, M., Maury, I., Crenne, J. Y., Becquart, J., Murry-Brelier, A., Boucher, F.,
Montay, G., et al. (1992) Design o f yeast-secreted albumin derivatives for human therapy: biological 
and antiviral properties o f a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci U SA  (89), 
1904-1908.
Yi, J. and Skalka, A. M. (2000) Mapping epitopes of monoclonal antibodies against HTV-1 integrase with
limited proteolysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 
Biopolymers (55), 308-318.
Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. (1992) Rapid tumor penetration o f a single-chain Fv 
and comparison with other immunoglobulin forms. Cancer Res (52), 3402-3408.
Yokota, T., Milenic, D. E., Whitlow, M., Wood, J. F., Hubert, S. L., and Schlom, J. (1993)
Microautoradiographic analysis o f the normal organ distribution o f radioiodinated single-chain Fv 
and other immunoglobulin forms. Cancer Res (53), 3776-3783.
You, Y. H., Hefta, L. J., Yazaki, P. J., Wu, A. M., and Shively, J. E. (1998) Expression, purification, and
characterization o f a two domain carcinoembryonic antigen minigene (N-A3) in pichia pastoris. The 
essential role o f the N-domain. Anticancer Res (18), 3193-3201.
Zhang, W., Ran, S., Sambade, M., Huang, X., and Thorpe, P. E. (2002) A monoclonal antibody that blocks 
VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression o f Flk-1 and tumor growth in 
an orthotopic human breast cancer model. Angiogenesis (5), 35-44.
302
Zhou, H., Fuks, A., and Stanners, C. P. (1990) Specificity o f intercellular adhesion mediated by various 
members o f the immunoglobulin supergene family. Cell Growth Differ (1), 209-215.
Zhou, H., Fuks, A., Alcaraz, G., Bolling, T. J., and Stanners, C. P. (1993) Homophilic adhesion between Ig 
superfamily carcinoembryonic antigen molecules involves double reciprocal bonds. J  Cell Biol 
(122), 951-960.
Zhou, H., Stanners, C. P., and Fuks, A. (1993) Specificity o f anti-carcinoembryonic antigen monoclonal 
antibodies and their effects on CEA-mediated adhesion. Cancer Res (53), 3817-3822.
Zhu, Z., Zapata, G., Shalaby, R., Snedecor, B., Chen, H., and Carter, P. (1996) High level secretion o f a 
humanized bispecific diabody from Escherichia coli. Biotechnology ( NY)  (14), 192-196.
Zhu, Z., Lu, D., Kotanides, H., Santiago, A., Jimenez, X., Simcox, T., Hicklin, D. J., Bohlen, P., and Witte, L. 
(1999) Inhibition o f vascular endothelial growth factor induced mitogenesis o f human endothelial 
cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett (136), 203- 
213.
Zimmermann, W., Ortlieb, B., Friedrich, R , and von Kleist, S. (1987) Isolation and characterization o f cDNA 
clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure. 
Proc Natl Acad Sci U S A  (84), 2960-2964.
303
Appendix 4
Publications and presentations
304
Published
Huhalov, A., Spencer, D.I.R. and Chester K.A. (2003) A Strategy for 
Characterising Antibody/Antigen Interactions using Proteinchip Arrays. In: 
Handbook o f  Proteomic Methods, Humana Press.
Huhalov, A., Spencer D.I.R. and Chester K.A. (2003) Mapping 
AntibodyiAntigen Interactions by Mass Spectrometry and Bioinformatics.
In: B. Lo (Ed.) Antibody Engineering Protocols, 2nd Edition. Humana Press.
Huhalov, A., Robson, L., Perkins, S.J., Begent, R.H.J., Chester, K.A. (1999) 
A vector for expression of dimeric and chelating forms of anti-CEA scFvs. 
British Journal o f  Cancer (80), s. 2, p. 51.
In preparation
Huhalov, A., Spencer D.I.R., Hawkins, R.E., Perkins, S.J., Begent, R.H.J., 
and Chester, K. A. Capture and analysis of interacting tagged-proteins 
(CAIT): An application to map the carcinoembryonic antigen-binding site of 
the single chain Fv molecule MFE-23.
Huhalov, A., Tolner, B., Pedley, R.B., Begent, R.H.J., and Chester, K.A. 
HSAbodies: A new group of antibody-based molecules for targeting cancers 
expressing carcinoembryonic antigen (CEA).
305
Presented posters
th th11 International Antibody Engineering Conference, 3-6 December 2000, 
San Diego, USA. Towards Epitope Mapping an anti-CEA sFv for Improved 
Tumor Targeting. Winner of Best Poster Prize.
The Cancer Research Campaign National Cancer Symposium, 11-14th 
February 2001, Manchester, UK. Towards Epitope Mapping an anti-CEA 
sFv for Improved Tumor Targeting. Winner of Best Poster Prize.
11th International CEA Workshop, 10-13th August 2000, Bristol, UK.
British Cancer Research Meeting, 11-14* July, 1999, Edinburgh, UK.
306
